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ABSTRACT 
 
Fewer than half of depressed patients who take antidepressants experience complete 
remission of symptoms after 4-6 weeks of daily administration. The reason for this clinically 
observed heterogeneity in antidepressant response is still unclear. The majority of antidepressant 
drugs today are designed to enhance the brain’s production of one or more of the monoaminergic 
neurotransmitters (serotonin [5HT], norepinephrine [NE], and dopamine [DA]). In order to better 
understand how the brain adapts to chronic antidepressant administration, we developed a 
computational model that represents the known interactions of the neurobiology of depression. 
This model was expanded with further knowledge extraction, and also re-structured as 
computational tools were improved. Our model is based on the neuroadaptation hypothesis, 
whereby the brain homeostatically adapts to chronic antidepressant administration by adjusting the 
strengths of transmitter-system components (TSCs) in order to return brain-region activity levels 
back toward their pre-drug baselines. The main finding was that the model can adapt through many 
different pathways, arriving at many different TSC-strength configurations but not all of the 
adapted configurations are also associated with therapeutic elevations in the monoamines. These 
results provide insight into the heterogeneity among individuals in response to chronic 
antidepressants. We expanded this model to incorporate the stress-hormone response and the male 
sex-steroid system, and postulated that if only a subset of adapted configurations to chronic 
antidepressant are therapeutic, then it is possible that individual, pairs, or subsets of TSCs are 
responsible for mediating the therapeutic state. Through several modes of analyses, including 
sensitivity, correlation, and linear temporal-logic, we found that therapeutic neuroadaptation to 
chronic antidepressant is an overdetermined process that depends on multiple TSCs, providing a 
potential explanation for the clinical finding that no single antidepressant alleviates depressive 
symptoms in all patients. Our models can be used to systematically facilitate the clinical practice 
of antidepressant augmentation by providing the means to computationally screen for 
antidepressant drug/hormone combinations that could potentially be more therapeutic than single 
drugs by themselves. 
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CHAPTER 1: INTRODUCTION 
 
“Because the [people] that don’t know [about drugs], they talk about drug use as being simply like 
a, b, and c…that’s like saying people are simply a, b, and c.”  
–Carl Hart, Professor of Psychology, Columbia University.  
Carl Hart is known for his research in drug abuse and addiction, and was the first 
 tenured African American science professor at Columbia University.  
 
Our relationship with psychoactive drugs is undeniably highly intertwined with social 
conventions and personal situations and is hardly a simple subject. The duality of alcohol, for 
example, as both the staple of celebrations and the pitfall of alcoholics, illustrates the diversity of 
outcomes that drugs can have on different people who take them for varying lengths of time and 
under distinct circumstances. It is therefore essential to push the boundaries of our current 
understanding of how our brains respond and adapt to acute and chronic drug use. As chemicals 
or compounds that are taken into the body with the intention to produce some desired effect, most 
psychoactive drugs affect the brain by mimicking or displacing naturally occurring 
neurotransmitters. They can agonize or antagonize receptors, inhibit or enhance the release of 
neurotransmitters, or affect the activity of proteins that synthesize or break down 
neurotransmitters. Drugs that alter neurotransmitter levels or activity can alter neuronal 
interactions mediated by synapses, leading to detectable changes in the pre-drug firing-rates of 
neurons. 
The brain responds to chronic drug use by adjusting the strengths of its neuron-specific 
receptors to restore neural activity to pre-drug levels. At the heart of the response to chronic drug 
use is the body’s homeostatic adaptation to the persistent presence of the drug. But does everyone 
who takes a drug have the same pattern of homeostatic responses? Can different people adapt to 
the same drug by altering the expression or sensitivity of different receptors? Could this be why 
different people can be affected by chronic use of the same drug in different ways?  
Heterogeneity in neuroadaptive pathways may underlie the large variability that is 
observed in chronic antidepressant drug effects. Although antidepressant drugs can cause changes 
in neurotransmission almost immediately after acute administration, it takes weeks to months for 
most of them to achieve therapeutic effects in depressed patients. This suggests that the acute 
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actions of antidepressant drugs on neurotransmission are not responsible for antidepressant effects. 
Instead, the therapeutic effect results from adaptation to chronic administration of the 
antidepressant, where the persistent adapted state is presumably different from the pre-drug state. 
Unfortunately, not everyone who takes an antidepressant chronically has a therapeutic 
response. This leads us to speculate how some individuals neuroadapt to the same drug with 
therapeutic outcomes but not others. What neuroadaptive changes might be taking place in 
someone who neuroadapts therapeutically, versus someone who does not? Are there key proteins 
or receptors that could be mediating therapeutic neuroadaptation? Identification of key 
neuroadaptive factors could go a long way in designing antidepressant regimens that could result 
in more favorable (therapeutic) outcomes in more people. One of the largest challenges we face in 
answering these questions is the fact that neurobiological systems consist of a vast number of 
interacting elements that can neuroadapt in an immense number of possible ways.  
In order to better understand the complicated process of neuroadaptation to chronic 
antidepressant, I used computational modeling to simulate and analyze possible interactions and 
processes that are involved in mediating antidepressant drug effects. This work resulted in two 
main findings. The first result of this work is the finding that different brains can neuroadapt to the 
same drug in many different ways, resulting in heterogeneous outcomes on neurotransmitter levels. 
This translates to the clinical finding that different depressed patients can have different outcomes 
with chronic administration of the same antidepressant.  
The second result of this study was obtained from close analysis of therapeutic 
neuroadaption, which found that therapeutic outcomes following chronic antidepressant 
administration relies on contributions from all (not individual or pairs or subsets of) adaptable 
model units. The overdetermined nature of therapeutic neuroadaptation to chronic antidepressant 
supports a polypharmacy approach that targets multiple adaptable neurobiological elements to treat 
depression more effectively.  
By computationally representing, simulating, and analyzing neuroadaptation to chronic 
antidepressants, this work is the first of its kind in depression neurobiology and provides a unique 
perspective that can markedly change the way we understand antidepressant pharmacology. The 
ideal outcome would be that this work leads to experimental verifications that in turn lead to the 
design of more effective pharmacological treatment options for the over 350 million people 
worldwide who are depressed (Kessler, Berglund et al. 2003). 
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1.1 BIOLOGICAL BACKGROUND ON DEPRESSION 
Depression is a debilitating psychiatric disorder and a leading cause of physical disability 
and social strife (Greenberg, Stiglin et al. 1993, Cole and Dendukuri 2003, Kessler, Berglund et 
al. 2003, Holahan, Pahl et al. 2010, Greenberg, Fournier et al. 2015). Risk factors for depression 
include a family history of depression, past episodes of depression, female sex, and stress or 
trauma, among others (Kendler, Karkowski et al. 1999, Cole and Dendukuri 2003, Strine, Mokdad 
et al. 2008, Bravo, Dinan et al. 2014). Decades of research have amassed a huge dataset of 
neurobiological facts on the neurobiology of depression. It is known to involve disparate neural 
types located in various brain regions that release scores of different neurotransmitters onto a host 
of different receptor types. Despite this huge accumulation of facts, we still do not understand the 
neurobiology of depression. In consequence, we still do not know how to treat it effectively. 
The monoamine hypothesis of depression has prevailed since the 1960s. According to the 
monoamine hypothesis, depression results from deficiency in one or more of the monoamines: 
dopamine (DA), norepinephrine (NE), and/or serotonin (5HT). Clinical observation in the 1960s 
showed that drugs known as tricyclic antidepressants (TCAs), which increase brain levels of DA, 
NE, and 5HT acutely, had antidepressant effects (Schildkraut 1965, Coppen 1967). The 
observation that the administration of Reserpine, a monoamine depleting drug, coincided with the 
onset of depressive symptoms, supported this view (Stein 1960). Antidepressant drug design since 
then has predominantly been based on this hypothesis. The monoamine hypothesis is consistent 
with findings that effective antidepressant drugs enhance monoamine neurotransmission (Scuvee-
Moreau and Dresse 1979, Waldmeier 1982). 
Unacceptable side effects of TCAs led to the development of antidepressant drugs targeting 
the monoamine neurotransmitter systems with greater selectivity. Antidepressant medications 
known as selective serotonin reuptake inhibitors (SSRIs) are currently the first-line 
pharmacological treatments for depression and are used by millions of people worldwide (Koenig 
and Thase 2009). Experiments on animals indicate that the main neurobiological effect of chronic 
SSRI administration is to increase brain levels of 5HT (Blier, Pineyro et al. 1998). However, 
evidence in humans suggest that there is considerable heterogeneity in the antidepressant response 
(Cunningham, Borison et al. 1994, Corrigan, Denahan et al. 2000).  
SSRIs have fewer side effects than TCAs but still take weeks to months to produce any 
therapeutic effect and even then only provide relief in 35-50% of patients (Li, Li et al. 2014). SSRI-
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nonresponders are usually treated either by switching them to another SSRI, or by prescribing a 
second drug (such as an antipsychotic, like Asenapine, or an atypical antidepressant, like 
Bupropion) to augment SSRI action on the monoamines (Fava and Rush 2006, Trivedi, Fava et al. 
2006). Although these strategies have been shown to increase the proportion of depressed patients 
who respond to pharmacotherapy, an effective antidepressant combination unfortunately is never 
found in the 10-30% of depressed patients who are classified as treatment-resistant (Souery, 
Papakostas et al. 2006).     
The low efficacy rate of SSRIs has sparked a high-profile controversy over whether or not 
SSRIs are reasonably more effective than placebo (Moncrieff and Kirsch 2015). Kirsch and 
colleagues conducted a meta-analysis that compared antidepressants with psychotherapy in 
placebo-controlled studies (Kirsch 2017). They found that members of the placebo group improved 
almost as much as the treatment group, and the authors concluded that the true drug effect (over 
placebo) was only 25% (Kirsch 2010). The authors posited that one factor that may be affecting 
the findings is the diversity of antidepressants in the clinical trials analyzed.  
Kirsch and coworkers then conducted a meta-analysis that compared four different groups 
of antidepressants. However, the results across all four groups illustrated that no one group of 
antidepressants, including SSRIs, had a greater than 25% true drug effect (Kirsch 2009). 
Interestingly, it was observed that subjects who experienced negative side effects associated with 
antidepressant use had improved therapeutic outcomes over subjects who did not experience 
negative side effects. Kirsch and colleagues suggested that those subjects had a greater expectancy 
effect with antidepressant drugs because they experienced psychosomatic effects similar to the 
stated side-effects and subsequently anticipated an antidepressant effect (Moncrieff 2007, Kirsch, 
Deacon et al. 2008). 
Other groups have proposed a different interpretation of this finding, namely that subjects 
who experience negative side-effects have increased sensitivity to the drugs over those who do 
not. This would correspond to a greater antidepressant effect in subjects who also experience 
negative side-effects. Kirsch and colleagues then combined both published and unpublished data 
from the Food and Drug Administration (FDA) for another meta-analysis, but only found less than 
a two-point difference between placebo and antidepressant using the Hamilton Depression Rating 
Scale, a questionnaire commonly used in clinical practice to evaluate depression severity. They 
found that the placebo was about 82% as effective as the real drug (Kirsch, Deacon et al. 2008, 
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Kirsch 2009). Kirsch and colleagues concluded by suggesting that alternative therapies, such as 
cognitive behavioral therapy and exercise, could be a better treatment choice for depression than 
antidepressant drugs (Kirsch 2010, Moncrieff and Kirsch 2015). 
Interestingly, several groups have attempted to reproduce Kirsch’s findings and have been 
unsuccessful. Statistical analyses conducted on the same data used in the Kirsch group’s studies 
by other groups have not come to the same conclusions (Turner, Matthews et al. 2008, 
Fountoulakis and Moller 2011, Horder, Matthews et al. 2011). Still, the topic remains controversial 
and has led to several high-profile challenges against antidepressant efficacy (Fountoulakis, 
Hoschl et al. 2013). 
Another controversy challenging current views on antidepressant pharmacology concerns 
Reboxetine, a selective norepinephrine reuptake inhibitor (NERI). Reboxetine is believed to bind 
the norepinephrine transporter protein (NET) and block the reuptake of extracellular 
norepinephrine into terminals, with low affinity for other reuptake blockers or receptors. A large 
number of studies have supported the belief that chronic administration of Reboxetine has 
antidepressant effects that are similar to or as effective as other antidepressants (Papakostas, 
Nelson et al. 2008). One report found that a combination of Reboxetine and exercise was an 
effective antidepressant intervention (Russo-Neustadt, Alejandre et al. 2004).  
A recent meta-analysis challenges these findings and even suggests that in addition to being 
ineffective in the treatment of depression, Reboxetine can in fact be harmful for depressed patients 
(Eyding, Lelgemann et al. 2010). A recent survey combining data from several meta-analyses on 
Reboxetine concluded that different meta-analyses use idiosynchratic criteria for study inclusion, 
leading to divergent interpretations (Sepede, Corbo et al. 2012).  
Many controversies surrounding the efficacy of current antidepressant drugs have led to 
rethinking of the monoamine hypothesis and motivated research into antidepressant drug design 
involving targets in addition to and beyond the monoamines (Berton and Nestler 2006). 
Importantly, controversies concerning antidepressant efficacy demonstrate the need to better 
understand antidepressant mechanism of action and design more effective interventions. 
Chronic SSRI remains the first-line treatment for depression. Current understanding of 
SSRI mechanism of action is derived primarily from rodent studies, as similar acute and chronic 
pharmacological effects of antidepressants have been observed in both rodents and humans (Nord, 
Finnema et al. 2013). Acutely, SSRIs inhibit the 5HT transporter protein (5HTT) and increase 5HT 
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in the extracellular space as measured in rodents (Bymaster, Zhang et al. 2002, Koch, Perry et al. 
2002). This activates somatodendritic 5HT1A autoreceptors on dorsal raphe nucleus (DR) 5HT-
producing neurons. A decreased firing rate of 5HT neurons results, causing a subsequent decrease 
in 5HT release. The net effect of decreased reuptake due to SSRI and decreased DR firing-rate due 
to inhibition via 5HT1A autoreceptors is an increase in extracellular 5HT of 200% or more, 
depending on the SSRI (de Montigny, Chaput et al. 1990, Malagie, Trillat et al. 1995, Ceglia, 
Acconcia et al. 2004). This acute rise in 5HT is not enough to cause relief from depressive 
symptomology. Four to six weeks of maintained SSRI is required to achieve an antidepressant 
effect (Plenge and Mellerup 2003).  
Under chronic SSRI in rats, 5HT neuron firing-rate returns to normal following 
desensitization of DR 5HT1A autoreceptors (Blier, Pineyro et al. 1998, Naudon, El Yacoubi et al. 
2002, Gray, Milak et al. 2013). The consensus interpretation of this finding is that 5HT1A 
autoreceptors simply “tire out” with sustained exposure to elevated (200%) 5HT levels. The 
restoration of DR 5HT neuron firing activity (due to 5HT1A autoreceptor desensitization) coupled 
with 5HT reuptake inhibition (due to maintained SSRI) leads to greatly increased 5HT release. 
With chronic SSRI, extracellular 5HT rises above 400% of baseline in rats and is associated with 
depression relief (Ceglia, Acconcia et al. 2004). These findings led to the view that chronic SSRIs 
work by blocking 5HT reuptake and by causing desensitization of DR 5HT1A autoreceptors, 
which greatly elevates 5HT levels, which in turn results in an antidepressant effect (de Montigny, 
Chaput et al. 1990). There are a number of questions that remain unanswered by the current view.  
Importantly, this perspective does not adequately explain why 5HT1A autoreceptors (on 
DR neurons) and 5HT1A heteroreceptors (on postsynaptic neurons) respond differently to chronic 
SSRI administration.  Although 5HT1A autoreceptors have been found to desensitize with chronic 
SSRI, 5HT1A heteroreceptors in brain regions including the hippocampus do not, despite the fact 
that SSRI blocks 5HT reuptake and should elevate 5HT at all 5HT synapses (El Mansari, Sanchez 
et al. 2005). Why don’t all 5HT receptors “tire out”? It also should follow from the current view 
that adding a 5HT1A receptor agonist would accelerate the antidepressant effect by enhancing the 
rate at which presynaptic 5HT1A autoreceptors desensitize, but current attempts at accelerating 
SSRI action through coupling with a 5HT1A receptor agonist have been ineffective (Blier and 
Ward 2003). 
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Figure 1 helps illustrate these unanswered questions and can be used to support an 
alternative neuroadaptation hypothesis of antidepressant response. It shows DR neurons inhibiting 
themselves through 5HT1A autoreceptors, inhibiting hippocampal CA3 neurons through 5HT 
binding to inhibitory hippocampal 5HT1A heteroreceptors, and activating prefrontal cortex (PFC) 
neurons through excitatory 5HT2A heteroreceptors (Azmitia, Gannon et al. 1996, Celada, Puig et 
al. 2013). When SSRIs inhibit 5HT reuptake and increase extracellular 5HT at all 5HT synapses 
including those onto hippocampal CA3 neurons, CA3 5HT1A heteroreceptors do not desensitize 
but DR 5HT1A autoreceptors do (de Montigny, Chaput et al. 1990, El Mansari, Sanchez et al. 
2005). If 5HT1A receptors desensitized or “tire out” when exposed to sustained elevation in 5HT, 
then all 5HT1A receptors should desensitize equally, but that is not the case. 
By inhibiting itself with its own 5HT via inhibitory 5HT1A autoreceptors, the DR regulates 
the 5HT level via negative feedback. When SSRIs are given acutely, the increase in 5HT in the 
extracellular space results in increased activation of the DR 5HT1A autoreceptor, decreasing the 
firing-rate of DR neurons and subsequently decreasing 5HT release through this negative feedback 
mechanism. However, single DR neurons also co-release glutamate along with 5HT (Johnson 
1994, Gagnon and Parent 2014). Even if 5HT1A autoreceptor activation prevents chronic SSRI 
administration from unbalancing the system through large changes in 5HT levels, the decreased 
DR firing-rate would decrease the glutamatergic input from DR neurons to the CA3 and the PFC, 
changing their firing rates.  
Because the PFC neurons do not receive as much glutamate from DR neurons as they did 
before SSRI administration, the PFC neuron firing-rate decreases, which in turn decreases the 
glutamatergic input from the PFC to the DR (de Montigny, Chaput et al. 1990). These changes 
disrupt the normal balance of activity between brain regions. My work suggests that DR 5HT1A 
autoreceptors may desensitize as part of a larger neuroadaptive process to restore unbalanced 
neuron firing-rates that result from SSRI administration, rather than through a “tiring out” effect 
from increased 5HT binding as suggested by the current view. My computational simulations and 
analyses show that the neuroadaptation hypothesis is also viable (see Chapter 3). 
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Figure 1: Simplified representation of SSRI effects in the DR and interacting brain regions. This 
schematic shows the DR projecting to the hippocampal CA3 region and the prefrontal cortex (PFC) with 
5HT binding to inhibitory 5HT1A and excitatory 5HT2A heteroreceptors, respectively. Connections can 
represent synapses or other functional relationships. Arrows represent excitatory synaptic projections while 
tees represent inhibitory interactions between drugs and protein molecules, protein molecules and 
transmitters, or brain regions at synapses. In addition to 5HT, the DR also releases glutamate into CA3 and 
the PFC. Feedback inhibition onto the DR is mediated by 5HT binding to inhibitory 5HT1A autoreceptors. 
The PFC sends a glutamatergic projection back to the DR. The effect of an SSRI antagonizing the 5HT 
transporter (5HTT) molecule is indicated using blunt red arrows, which opposes the inhibitory action of 
5HTT onto 5HT levels in the synapse. When SSRIs are administered acutely, 5HT levels increase and bind 
to the 5HT1A autoreceptor on DR neurons and decrease DR neuron firing rate, thereby reducing 5HT 
release. The figure shows that although 5HT elevations due to SSRI action are opposed by the decrease in 
DR firing rate, the glutamate levels in the CA3 and PFC are decreased with the reduced DR firing rate. As 
a result of the decreased glutamatergic drive of the DR onto the PFC the PFC sends less glutamate back to 
the DR, illustrating the disruption in the activity levels of all these brain regions. The schematic shows that 
the DR is central to the SSRI effect, and suggests that desensitization of the DR 5HT1A autoreceptor would 
be more effective in restoring neural system balance than desensitization of the DR CA3 heteroreceptor. It 
motivates an alternative explanation for DR 5HT1A autoreceptor desensitization with chronic SSRI 
administration as part of a process of neuroadaptation to restore neural-system activity levels rather than a 
“tiring out” process due to sustained elevation in 5HT. 
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1.2 BIOLOGICAL BACKGROUND ON STRESS AND DEPRESSION 
Our current understanding of SSRI action is incomplete at best and likely involves 
interactions between the monoaminergic neurotransmitter system and other neurotransmitter or 
hormone systems. The most commonly observed risk factors for depression are stressful life 
events. Stress perturbs the physiological and psychological balance of an individual and leads to 
activation of the hypothalamic-pituitary-adrenal (HPA) axis and elevated cortisol production (A.1: 
Overview of Stress, HPA Axis, and Cortisol). The relationship between the steroid hormone 
cortisol and depression has been studied extensively.  
There is a large literature suggesting that cortisol is involved in both depression and the 
antidepressant response (Seckl and Fink 1992). The majority of depressed patients report a 
stressful life event precipitating their depression (Kendler, Karkowski et al. 1999, Caspi, Sugden 
et al. 2003). Although cortisol in the short-term may be adaptive and produce resiliency, chronic 
elevations in blood cortisol levels are related to depressive symptomology (Johnson, Kamilaris et 
al. 1992, Wong, Kling et al. 2000). 
The serotonergic neurotransmitter system and the stress steroid system interact in many 
ways. For example, cortisol can alter expression of proteins involved in serotonergic synaptic 
transmission. Specifically, cortisol has been shown to decrease the expression of the 5HT1A 
autoreceptor on DR neurons and increase the activity of the tryptophan hydroxylase-2 enzyme 
(TPH2, 5HT synthesis enzyme), thereby increasing serotonergic tone (Fumagalli, Jones et al. 1996, 
Fairchild, Leitch et al. 2003, Manoli, Le et al. 2005). Also, activation of 5HT receptors in the 
paraventricular nucleus (PVN) of the hypothalamus can enhance HPA axis activity by inducing 
CRF release, but chronic antidepressant administration can reverse elevated cortisol levels due to 
stress (Pan and Gilbert 1992, Jensen, Jessop et al. 1999). A full understanding of antidepressant 
mechanism of action will require taking account of the interactions between the monoaminergic 
neurotransmitter and stress hormone systems (A.1: Overview of Stress, HPA Axis, and Cortisol). 
 
1.3 BIOLOGICAL BACKGROUND ON SEX STEROIDS AND DEPRESSION 
The stress- as well as the sex-steroids play a role in the etiology of depression. Women 
have twice the rate of depression as men, and there is a large body of evidence to suggest that 
women and men respond differently to antidepressant treatments (Young, Kornstein et al. 2009). 
Men and women differ in the pathophysiology of depression due to differences in the production 
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of gonadal hormones, specifically in the cyclical nature of estrogen and progesterone secretion in 
females and the more stable production of testosterone in males. Importantly, both men and women  
are at greater risk of depression following menopause and andropause, respectively (Rubinow, 
Schmidt et al. 1998, Rocha, Fleischer et al. 2005). 
The sex hormones have been shown to be involved in monoaminergic (especially 
serotonergic) neurotransmission and the antidepressant response. For example, premenstrual 
syndrome (PMS) and perimenopausal depression involve interactions between estrogen and 5HT 
neurotransmission (Rubinow, Schmidt et al. 1998). Furthermore, estrogen is believed to affect 
monoamine neurotransmission so that the response to drugs that target the monoamines is altered 
in response to fluctuations in estrogen levels (Rubinow, Schmidt et al. 1998, Young, Kornstein et 
al. 2009). Testosterone supplementation has been found to alleviate depressive symptoms in both 
males and females in clinical settings (Orengo, Fullerton et al. 2005). Estrogen, progesterone, and 
testosterone receptors have been found in DR neurons, affecting the expression of genes involved 
in 5HT neurotransmission in both male and female rodents (Alves, Weiland et al. 1998, Robichaud 
and Debonnel 2005).  
The results of several recent studies suggest that oral contraceptives may be causing 
depression in young women (Ross and Kaiser 2016). However, data from controlled clinical 
studies on the relationship between sex steroids and depression are limited and results have 
historically been inconsistent (Bottcher, Radenbach et al. 2012). For more details on the 
relationship between the sex steroids and depression, see A.2: Overview of the HPG Axis and 
Depression. The relationship between depression, the monoaminergic neurotransmitter system, 
and the stress- and sex- steroid hormone systems is incompletely understood and involves 
complicated interactions that should be taken into account in any framework designed to represent 
antidepressant action. 
 
1.4 QUESTIONS WE WOULD LIKE TO ADDRESS 
Why is the clinical antidepressant response so variable? How can we treat depression more 
effectively? Are there key factors mediating therapeutic responses to antidepressants? What is the 
relationship between depression and the stress and sex hormones? Would drug combinations, or 
combinations of drugs and hormones, be more effective than single drugs? Answers to these 
questions would go a long way toward alleviating depression in the 350 million people worldwide 
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who suffer from it every year, but this disorder defies easy answers. Due to its complexity, 
depression neurobiology cannot be understood without computational simulation and analysis. 
 The purpose of my dissertation work was to develop and use computational models of 
depression neurobiology to understand antidepressant action and the role of stress and sex 
hormones to suggest potentially more effective treatment strategies. We have created 
computational models of the known interactions between the monoaminergic nuclei, the stress-
steroid system, and the sex-steroid system, and some related neurotransmitter systems associated 
with antidepressant action. These models differ in computational structure, and subsequent models 
are more neurobiologically extensive. With this work, we have provided potential answers to some 
of the questions we asked above. Our approach to answering all of these questions involves a 
combination of two computational modalities. 
 
1.5 BACKGROUND ON COMPUTATIONAL MODELING IN NEUROBIOLOGY 
Computer science has developed two different computational modalities by which to 
represent, simulate, and analyze systems (A.3: Difference between Imperative and Declarative 
Programming). They take the forms of imperative and declarative programming languages. In an 
imperative language a statement is a command (“do this”), while in a declarative language a 
statement is a fact (“this is true”). Imperative languages execute statements in a specified order 
whereas declarative languages can execute statements in all possible orders, thereby determining 
all possible consequences of the available facts. By elaborating the entire space of possible system 
states without limitations imposed by the order of commands, declarative languages can be used 
to provide a view of the range of model-system behavior much larger than what could be produced 
with imperative programming tools alone. Through their unique execution methods and 
capabilities, imperative and declarative languages can each provide unique contributions to our 
understanding of the outcomes of complicated neurobiological processes (Anastasio 2015). 
The majority of computational models in neuroscience have been implemented using 
imperative programming languages, but declarative programming approaches have recently 
entered the realm of computational neuroscience. Maude is an example of a declarative language, 
developed at the University of Illinois at Urbana-Champaign, that has recently been used in 
computational models of normal and pathological neurobiological processes (Anastasio 2011, 
Anastasio 2013, Camacho and Anastasio 2017). Declarative processes can also be implemented in 
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imperative languages for computational efficiency. I have applied both imperative and declarative 
programming approaches in computational modeling of the monoaminergic neurotransmitter-
producing system and important related neurotransmitter and neurohormone systems to expand 
our understanding of neuroadaptation to chronic antidepressant administration.  
I have developed three computational models: the Monoamine-model (M-model), the 
Monoamine-Stress-model (MS-model), and the Monoamine-Stress-Sex-model (MSS-model). 
These models differ in extent: the M-model represents the interactions between the three 
monoaminergic transmitter systems and three non-monoaminergic transmitter systems; the MS-
model includes these interactions but also incorporates the brain regions, hormones, and receptors 
involved in the stress response in addition to other transmitter systems; and the MSS-model 
includes the elements of the MS-model but also incorporates the hormones, receptors, and brain 
regions involved in the male sex-steroid system. There was not enough experimental data available 
to develop an analogous MSS-model of the female MSS system (see 4.6).  
The models also differ in structure in that they took one of two structural forms: Region 
structure (M-model) or System structure (MS- and MSS-model). Briefly, the Region structure 
represents brain regions and transmitter systems as units, while the System structure represents all 
elements in the network (brain regions, transmitters, hormones, enzymes, etc.) as units. These 
different structural forms will be described in greater detail in Methods (see subsection 2.1). 
Analysis of these three models has provided insight into our understanding of chronic 
antidepressant response heterogeneity and proposes new pharmacological treatment options for 
depressed patients. 
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CHAPTER 2: METHODS 
 
2.1 MODEL STRUCTURE AND FUNCTION 
My thesis work involves elaboration of three computational models of depression 
neurobiology: the Monoamine-model (M-model), the Monoamine-Stress-model (MS-model), and 
the Monoamine-Stress-Sex-model (MSS-model). The models differ in extent (subsequent models 
incorporate more neurobiology) and take one of two different structures: Region structure or 
System structure. The models are nonlinear neural networks composed of interacting transmitter-
system components (TSCs) representing the neurobiological elements of the transmitter and/or 
hormone systems they embody. In all cases, the same model is implemented in two programming 
modalities to exploit their complementary capabilities. One programming language is imperative 
(MATLAB®), while the other is declarative (Maude). PythonTM is an imperative language that 
was used to implement declarative procedures in the MS- and MSS-model analyses. We used 
MATLAB to set model parameters and bring model behavior in line with experimental 
observation, to generate large sets of configurations of TSC strength adjustments, and to conduct 
sensitivity and pairwise correlation analyses. We used Maude for exhaustive search of adjusted 
TSC-strength configurations, and adapted Maude temporal-logic analysis into Python to study 
temporal relationships between TSC-strength configurations. 
 
2.1.1 DESCRIPTION OF M-MODEL REGION STRUCTURE 
The M-model has the Region structure. This structure takes the form of a recurrent neural 
network composed of six non-linear units that represent the three monoaminergic brain regions 
(DR, LC and VTA), as well as three non-monoaminergic neurotransmitter systems. The three non-
monoaminergic neurotransmitter systems represented in this structure are the corticotropin-
releasing factor (CRF), galanin, and glutamate systems. They are represented as tCRF, tGal, and 
Tglu, where t or T stands for “transmitter.” Each unit projects to every other unit including itself. 
The monoaminergic units release their respective monoamines (DR releases 5HT, LC 
releases NE, and VTA releases DA) as well as other transmitters that they are known to co-release 
onto the other monoaminergic neurons. The non-monoaminergic units release only the one 
transmitter that they represent (e.g., the tCRF region only releases CRF) in this structure. The 
strengths of the projections of the non-monoaminergic units onto themselves, between each other, 
and from the monoaminergic units are represented as generic neural-network connection weights. 
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 Unlike conventional units, the monoaminergic units can not only release more than one 
transmitter, but monoaminergic units can also have receptors specific for each transmitter they 
receive. Rather than having conventional connection weights, the connections onto the 
monoaminergic units in the model are implemented using the predominant receptors specific for 
each of the different transmitters released onto them. We define the predominant receptor as the 
receptor that mediates the main effect of a specific transmitter onto a specific neural type (e.g., the 
predominant receptor type for NE on DR neurons is the α1-adrenergic receptor (AR1)) (Baraban 
and Aghajanian 1980).   
The connections onto the non-monoaminergic units in this structure are implemented using 
generic weights, because each non-monoaminergic unit represents a heterogenous set of neural 
types that have in common only that they all release the corresponding non-monoaminergic 
transmitter, and so the idea of a predominant receptor type on a specific neural type does not apply. 
Figure 2 is a schematic representation of the M-model, which has the Region structure. Table 1 
shows all of the transmitters, receptors, and connection weights mediating the interactions between 
units in this model. 
Each monoaminergic unit releases its transmitter(s) in an amount proportional to its 
activation level minus the transporter level for that transmitter. In addition to its receptor or generic  
weight strengths, each unit also has a bias parameter. The units in the Region structure 
update by calculating their net inputs and “squashing” them; i.e., each unit computes the sum of 
its inputs (whether due to receptors [monoaminergic units] or generic weights [non-
monoaminergic units]), adds its bias, and passes the result through the sigmoidal squashing 
function. Recurrent neural networks with a continuous squashing function are considered to be 
universal approximators and are widely used to simulate biological processes (Thomas R 1990, de 
Jong 2002). The squashing function bounds the activations of the 6 units between 0 and 1. 
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To evaluate unit activity with or without drugs, the activity of all units is set to 0, and the 
units are allowed to influence each other’s activity for 150 time steps. Because the activities of the 
units in the model are prone to alternate and oscillate, activation of any unit is taken as the running 
average of its activity over the second half of the time step range (between time steps 75 and 150 
inclusive). The running average of the oscillations of all units settles down to a constant value 
within 50 time steps. The alternating and oscillating behavior apparent for some of the units is 
expected due to the inhibitory self-connections of the monoaminergic units and asymmetrical 
Figure 2: Schematic representation of the monoaminergic neurotransmitter M-model. The M-model 
has the Region structure. Each rectangle denotes a unit in the model that represents either a monoaminergic 
brain region or a set of regions that secrete a non-monoaminergic transmitter. DR, LC, and VTA 
(monoaminergic) refer to the dorsal raphe nucleus, locus coeruleus, and ventral tegmental area, 
respectively. tCRF, Tgal, and Tglu (non-monoaminergic) refer to corticotrophin releasing factor (CRF), 
galanin, and glutamate transmitter systems, respectively (t or T denotes “transmitter”). Connections 
between model elements can be excitatory or inhibitory and take the form either of the strengths of 
neurotransmitter-specific receptors (onto monoaminergic units) or of generic connection weights 
(connections onto non-monoaminergic units). Receptors mediating the predominant effect of each 
transmitter on the monoaminergic brain regions appear in their respective rectangles. Adjustable receptors 
(transmitter-system components, TSCs) are represented in red. 
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connections between the monoaminergic units (Luenberger 1979) and is in line with experimental 
observation (see B.1: Details on M-model Structure and Function). 
Drugs affect their targets through drug strength parameters. Agonist drugs add a 
contribution from a receptor equal to the product of the receptor strength and the drug strength. 
Antagonist drugs subtract a component equal to the product of the receptor strength, the drug 
strength, and the level of the cognate transmitter. Transporter blocking drugs reduce the level of a 
Table 1: Transmitters, receptors, and connection weights mediating interactions between 
monoaminergic units in the M-model. Interactions between the monoaminergic units (DR, LC, and VTA) 
are mediated by both excitatory (+) and inhibitory (−) receptors. A given monoaminergic unit is assigned 
one or at most two receptors for each transmitter it receives, which are the predominant receptors for the 
corresponding transmitter as determined through a comprehensive literature search (see text). Each 
monoaminergic unit may release more than one neurotransmitter onto another unit (listed in column 
headers), again as described in the literature. The non-monoaminergic units each release only one 
transmitter. They do not have receptors. Instead, the connections onto non-monoaminergic units from 
themselves, from each other, and from the monoaminergic units have generic connection weights. These 
weights are denoted by the letter “w” followed by a name associated with the sending unit (e.g., wDR is a 
connection weight from the DR unit while wGal is a connection weight from the Tgal unit). Note that all 
receptors and weights are unit specific (e.g., wDR takes different values onto tCRF, Tgal, and Tglu). The 
sign in parenthesis (+ or −) denotes the fixed polarity of a receptor or of a generic self-connection weight, 
while +/− means that the polarity of the corresponding connection weight is not fixed but can be set positive 
or negative during the parameter optimization process.  
 
From 
(across)  
DR 
5HT 
gal 
glu 
LC 
NE 
gal 
VTA 
DA 
tCRF 
CRF 
Tgal 
gal 
Tglu 
glu To 
(down) 
DR 5HT1AR(−) 
AR1(+) 
galR1(−) 
galR2(+) 
D2R(+) 
CRF1R(−) 
CRF2R(+) 
galR1(−) 
galR2(+) 
AMPAR(+) 
LC 
AMPAR(+) 
5HT2AR(−) 
galR1(−) 
AR2(−) 
D1R(−) 
D2R(+) 
CRF1R(+) galR1(−) AMPAR(+) 
VTA 
AMPAR(+) 
5HT2AR(+) 
5HT2CR(−) 
AR1(+) 
AR2(−) 
galR1(−) 
D2R(−) CRF1R(+) galR1(−) AMPAR(+) 
tCRF wDR(+/−) wLC(+/−) wVTA(+/−) wCRF(+) wGal(+/−) wGlu(+/−) 
Tgal wDR(+/−) wLC(+/−) wVTA(+/−) wCRF(+/−) wGal(+) wGlu(+/−) 
Tglu wDR(+/−) wLC(+/−) wVTA(+/−) wCRF(+/−) wGal(+/−) wGlu(+) 
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transporter by an amount equal to the product of the transporter strength and the drug strength. 
Transmitter releasing drugs add a contribution of neurotransmitter to the unit activation level equal 
to the product of the amount of released transmitter (which is equal to the unit activation) and the 
drug strength. Drug strengths were limited to the range from 0 to 1 which appropriately limited 
their effects (see B.1: Details on M-Model Structure and Function). 
 
2.1.2 DESCRIPTION OF MS- AND MSS-MODEL SYSTEM STRUCTURE 
The MS- and MSS-models have the System structure. The System structure also takes the 
form of a recurrent network of non-linear elements. Importantly, in the System structure the units 
represent not only neurotransmitter-producing regions but also represent precursors, enzymes, 
transmitters, transporters, hormones, and receptors. The net input to each unit is passed through 
the sigmoidal squashing function to produce a squashed output state (as with the Region structure). 
Distinct from the Region structure, all parameters in the System structure are conventional neural-
network weights, so all unit net-inputs can be updated efficiently via matrix multiplication of the 
unit state-vector and the weight matrix. The state vector represents the squashed output or state of 
each unit and the weight matrix consists of the weights of the interactions between the units. 
Units could be categorized into input, output, and “hidden units.” Input units do not receive 
connections from other units and can take on assigned values. Hidden and output units receive 
connections from input units and from each other. Output units are distinguished from hidden units 
in having targets (desired outputs). Hidden units have neither assigned nor desired values. 
The connections between the elements represent the interactions between them. Findings 
on the interactions between the units were compiled via a comprehensive literature search. There 
are three classes of connection weights in the MS- and MSS- models: canonical, structure, and 
non-structure. Canonical weights are the weights of the connections between units representing 
key components of the MS or MSS systems, such as the weight from the DR to 5HT, representing 
the effectiveness of the DR in producing 5HT. There were 23 canonical weights in the MS-model 
and 36 canonical weights in the MSS-model (see B.2: MS- and MSS-model Canonical Weights). 
Structure weights are the weights of the connections between units representing neurobiological 
entities that are known to interact empirically, such as the weight from DR to galanin, representing 
the effectiveness of the DR in co-releasing galanin. Non-structure weights denote all other 
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connection weights; they may or may not represent as yet unidentified interactions that actually do 
occur neurobiologically. The three classes of weights are treated differently during model training.    
Drugs in the System structure are represented as input units with connections to the model 
units that they interact with. For example, an SSRI is an input unit that sends an inhibitory 
projection to the 5HTT unit (because SSRIs inhibit the serotonin transporter). Figure 3 shows a 
highly simplified version of the MS-model, which has the System structure. The full diagram of 
Figure 3: Simplified schematic representation of the MS-model. The MS-model takes the form of a 
recurrent neural network of non-linear elements (units) that represent neurotransmitter-producing regions, 
enzymes, neurotransmitters, hormones, and receptors. Each unit type in the model is represented using a 
different shape in this highly simplified model diagram, in which only one or two of each unit type is 
shown. Neurotransmitter and hormone producing regions are represented as triangles, neurotransmitters 
and hormones are represented as circles, protein molecules are represented as rectangles, and inputs are 
represented as rounded rectangles. Connections between model units can be excitatory (arrow) or 
inhibitory (tee). Abbreviations: dorsal raphe, DR; adrenal gland, AG; serotonin, 5HT; cortisol, CORT; 
serotonin transporter, 5HTT; 5HT1A receptor, 5HT1AR; and glucocorticoid receptor, GCR. 
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the MS-model can be viewed in the Supplemental Material of our MS-model paper (Camacho, 
Vijitbenjaronk et al. 2018). For more information on inclusion of specific units as structure or non-
structure connections in the MS-model, see B.3: Details on MS-model Structure and Function.  
The MSS-model, which also has the System structure, extends the MS-model to include 
the elements of the Hypothalamic-Pituitary-Gonadal (HPG) axis as units. Figure 4 is a highly 
simplified schematic of the MSS-model. The complete structure of the MSS-model can be found 
in the Supplemental Material of our MSS-model paper, and details on MSS-model structure 
connections can be found in B.4: Details on MSS-model Structure and Function (Camacho, 
Vijitbenjaronk et al. 2018). 
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2.2 IMPERATIVE MODEL TRAINING METHODS 
2.2.1 IMPERATIVE TRAINING METHODS 
2.2.1.1 GENETIC ALGORITHM 
The M-model was trained using the genetic algorithm (GA) as implemented in MATLAB 
(see B.5: Details on GA Optimization of M-model). The GA essentially “evolved” the model 
parameter values so that model behavior “fit” with experimental observations. The parameters of 
the M-model are the receptor strengths, generic weights, bias levels, and drug strength parameters 
already mentioned, and also the efficacies of the monoaminergic transmitter transporters. Rather 
than maximize a fitness function, the GA was used to minimize an error function. The error 
function provided a measure of the difference between the behavior of the monoaminergic units 
in the model and that of real monoaminergic neurons in their responses to acute administration of 
various drugs. For the purposes of training the model the training data were assembled into an 
input/desired-output table or “truth table.” The truth table is an array of input/desired-output 
Figure 4: Simplified schematic representation of the MSS-model. The MSS-model takes the form of a 
recurrent network of non-linear elements (units) representing neurotransmitter and hormone producing 
brain regions, as well as key molecular species including enzymes, transmitters, hormones, and receptors. 
Each unit type is represented in this schematic representation using a different shape. Only one or two of 
each unit type from each system (monoamine, stress, or sex system) is shown for simplicity. 
Neurotransmitter and hormone producing regions, neurotransmitters and hormones, protein molecules, or 
inputs are represented respectively as triangles, circles, rectangles, or rounded rectangles. Connections 
between model units are represented with arrows or tees, representing excitatory and inhibitory 
connections, respectively. Abbreviations: dorsal raphe, DR; adrenal gland, AG; testes, TS; serotonin, 5HT; 
cortisol, CORT; testosterone, TEST; serotonin transporter, 5HTT; 5HT receptor, 5HTR; glucocorticoid 
receptor, GCR; and androgen receptor, AR.     
Table 2: M-model truth-table.  This table shows the input/desired-output relationships obtained by the 
Blier lab for M-model training. Acute (2-day) administration of each drug or combination studied by the 
Blier group is present down the rows, and the corresponding percent changes in the firing activities of the 
monoaminergic nuclei (DR, LC, and VTA) are across the columns. The percent changes are represented 
as either increases (+) or decreases (−) from baseline activity. Cells with a 0 represent instances where no 
change was observed with acute administration of the input(s). In cases where experimental data was 
unavailable, the cell was labeled N/A. 
Drug or 
Combination 
 
Change in firing activity (%) 
DR LC VTA 
Escitalopram −44 −45 −41 
Nomifensine +50 −71 −39 
Reboxetine 0 −70 −31 
Trazodone −40 25 0 
Asenapine +17 0 0 
Aripiprazole +48 0 0 
Bupropion +100 −46 0 
Quetiapine −43 +40 0 
Escitalopram+Aripiprazole 0 −26 N/A 
Escitalopram+Quetiapine −65 +27 N/A 
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training patterns that specifies how specific experimental manipulations, which are represented as 
patterns of desired network outputs, are known to affect specific neurobiological endpoints, which 
are represented as patterns of desired network outputs. In the M-model truth-table, the inputs are 
acute drug administrations, and the outputs are changes from baseline firing-rate of the 
monoaminergic neurons expressed as a percentage. The M-model truth-table was relatively simple 
and is represented below in Table 2 and graphically in Results. 
Data used as the targets of optimizations (i.e., truth-table values) were derived from the 
work of Pierre Blier. The Blier lab studied acute (2-day) and chronic (14-day) antidepressant drug 
effects in male Sprague-Dawley rats using subcutaneous osmotic mini-pumps. Single-unit 
recordings from presumed 5HT, NE, and DA neurons in the DR, LC, and VTA, respectively, and 
others such as hippocampal CA3 neurons were made after 2 and 14 days. The error function 
includes data on eight drugs and two drug combinations as studied by the Blier lab using this 
protocol. The eight drugs and drug pairs are: Escitalopram, Nomifensine, Reboxetine, Trazodone, 
Asenapine, Aripiprazole, Bupropion, Quetiapine, Escitalopram/Aripiprazole, and 
Escitalopram/Quetiapine. The acute (2-day) effects of these drugs were used for model parameter 
optimization. For consistency in the M-model, only the drugs studied by the Blier lab under this 
specific protocol were included. 
Descriptions of these drugs and their targets, along with references to the primary literature, 
are provided in B.6: Summary of Drugs and Drug Combinations Considered in the M-model. 
Through reduction of error, the GA optimized several criteria in addition to the agreement in the 
percentage changes in monoaminergic neuron activation levels due to acute drugs. These other 
criteria include the activation levels of the units in the absence of drugs, and the levels of the 
monoaminergic neurotransmitters in the absence of drugs or in the presence of the transporter 
blocking drugs Escitalopram and Reboxetine (See B.5: Details on GA Optimization of M-model). 
Of the 200 GA searches we ran, we selected the 10 lowest-error (i.e., most fit) parameter sets for 
further consideration (see 3.1.1). 
 
2.2.1.2 GRADIENT-BASED MACHINE LEARNING  
Due to the computationally intensive nature of the GA, the MS- and MSS-models were 
trained using a more efficient, gradient-based machine learning method (abbreviated GD, for 
gradient-descent). We were able to use GD to parameterize the MS- and MSS-models but not the 
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M-model because all elements in the MS- and MSS- models were represented as units. In the M-
model, however, only the 6 transmitter regions were represented as units (see 2.1.1). The MS- and 
MSS-models were trained on baseline values and to reproduce data on the effects on neuron 
activations, transmitter, enzyme, and hormone levels of receptor blockade, lesions, and other 
experimental manipulations. All of the manipulations (drug or hormone administration, chemical 
lesioning, etc.) will be referred to as “inputs.” 
       Data on the effects of inputs on model unit activations were obtained through an 
extensive literature search that compiled findings from multiple groups using a broad range of 
experimental methods. As for the M-model, the training data in the MS- and MSS-models were 
  Desired output 
Row Input DR AG 5HT CORT 
1 Baseline 0.50 0.50 0.50 0.50 
2 SSRI 0.40  0.60 0.70 
3 Dexamethasone   0.60 0.30 
4 Stress 0.60 0.70 0.60 0.70 
5 Adrenalectomy  0.30  0.30 
  Desired output 
Row Input DR Testosteroneend 5HT CORT 
1 Baseline 0.50 0.60 0.50 0.50 
2 SSRI 0.40 0.60 0.60 0.70 
3 Stress 0.60 0.50 0.60 0.70 
4 Testosteroneex 0.60 0.70 0.60  
5 Stress+Castration   0.60 0.70 
Table 4: Simplified example input/desired-output dataset for MSS-model. This table shows examples 
of the input/desired-output relationships obtained from the literature for model training. Each row 
represents the consensus of the results of one or more experiments in which output responses were 
recorded with each input. The output values range from 0.30 to 0.70, where 0.30 represents maximal 
decrease, 0.40 represents moderate decrease, 0.50 represents the baseline value, 0.60 represents moderate 
increase, and 0.70 represents maximal increase. The baseline endogenous Testosterone desired-output 
was set to 0.60 (instead of 0.50) to account for the higher Testosterone level in males than in females.    
Table 3: Simplified example input/desired-output dataset for MS-model. The relationships 
represented in this truth table are based on the simplified diagram in Figure 3. Each row represents the 
consensus of the results of one or more experiments in which output levels were measured in response to 
each input. Row 1 is the baseline where there is no input. In rows 2 and 3 the inputs are drugs: SSRI or 
dexamethasone (glucocorticoid receptor agonist). In rows 4 and 5 the input is stress or adrenalectomy. 
The output values range from 0.30 to 0.70, where 0.30 represents maximal decrease, 0.40 represents 
moderate decrease, 0.50 represents the baseline value, 0.60 represents moderate increase, and 0.70 
represents maximal increase. 
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assembled into a truth table. Desired-output behavior was set using the findings of one or more 
different experiments from one or more different labs. The majority of the findings were derived 
from rodent studies but some were obtained from human, cow, or primate studies. Inputs are either 
present or absent (1 or 0) and outputs are assigned discrete levels between 0.30 and 0.70. Outputs 
could either decrease maximally, decrease moderately, have no change, increase moderately, or 
increase maximally, corresponding to desired-output values of 0.30, 0.40, 0.50, 0.60, and 0.70, 
respectively (see B.7: MS-model Truth-table Justification and B.10: MSS-model Truth-table 
Justification for a summary of the experiments included in the MS- and MSS-model truth-tables 
and corresponding references).  
 When more than one finding was available on a particular input-output relationship, a 
consensus agreement was found based on the available data. The MS- and MSS-model truth table 
was assigned discrete levels (distinct from the M-model truth-table, which used raw percentages 
obtained by the Blier group) in order to account for the differences in quantitative results obtained 
from a diverse range of experimental methods and research labs. It also allowed for consistency 
over the whole truth table. Table 3 and Table 4 are condensed, example MS- and MSS-model 
input/desired-output tables (i.e., truth table). For the complete truth tables, see B.9: Complete MS-
model Truth-table and B.10: Complete MSS-model Truth-table. 
The training procedure is an efficient, gradient-based machine-learning algorithm known 
as recurrent back-propagation (Pineda 1987). Briefly, the learning procedure begins by 
constructing a matrix of random initial weights. Then an input pattern (such as a drug or hormone 
administration, or a lesion) is chosen at random and presented to the network. The randomized 
matrix of initial weights and random order of training pattern presentation represent the two 
sources of randomness in the training procedure. The steady-state network response to the input is 
then found after 100 iterations of unit updating (state-vector/weight-matrix multiplication followed 
by net-input squashing). The Piñeda algorithm requires steady-state behavior and tends to train 
networks away from oscillatory behavior. The steady-state actual outputs are compared with the 
desired outputs specified by the truth table for the selected training pattern. 
The differences between the desired and actual outputs of the units in the MS- and MSS-
models are used to compute an error signal. Weight changes are calculated by propagating the 
error signal back through the network and through time for as many iterations as the network was 
updated to compute the output. Weight changes are scaled by a learning rate term. The learning 
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rates were set to 1 for the canonical and structure weights, and to 0.10 for the non-structure weights, 
in order to disadvantage the non-structure connections because they are not known for certain to 
be involved in the behavior being modeled. All weights had an upper-bound at absolute value 10. 
All weights had a lower bound of 0 except for the canonical weights, which had a lower bound of 
1 to ensure they exerted an influence on overall network performance. For more details on training 
of the MS-model, see B.11: Details on Training the MS- and MSS-models Using GD. 
After training, we pruned the networks in order to eliminate unneeded non-structure 
connections. This was intended both to minimize the number of non-structure connections and 
improve generalizability of model behavior. Generalizability was assessed by training the model 
on all single-manipulation inputs (e.g., single drug) and testing on all combination inputs (e.g., 
drug combinations). The process of optimizing the pruning method is discussed in detail in B.12: 
Pruning Methods. All further networks were trained using the following procedure: Networks with 
the full weight matrix (i.e. all canonical, structure, and non-structure connection weights) were 
trained on the full truth table (all single and combination inputs). Non-structure connections were 
pruned at the sensitivity cutoff optimized for generalizability, and the pruned networks were then 
retrained on the full truth-table.  
 
2.2.2 NEUROADAPTATION PROCEDURES 
2.2.2.1 BACKGROUND ON TSC ADJUSTMENTS 
Most antidepressants are administered chronically, so models designed to represent the 
neurobiology of depression must represent the responses to chronic-drug as well as to acute-drug 
administration. All three models reproduce the effects of acute drug administration because they 
are included in the input/desired-output sets used in the training procedures of each model. 
 Additional computational procedures must be implemented to simulate the 
neuroadaptation that occurs in response to chronic drug administration. Neuroadaptation can occur 
in biological systems through changes in the “activities” (expression, sensitivity, cellular/synaptic 
localization, etc.) of key proteins (ion channels, transmitter receptors, etc.)(Turrigiano, Leslie et 
al. 1998, Desai, Rutherford et al. 1999, Turrigiano 1999, Turrigiano and Nelson 2000, Turrigiano 
2008, Turrigiano 2012). It is the process by which the overall activity levels (specifically the 
resting or spontaneous activity levels) of neurons in key brain structures are brought back to their 
normative baselines under conditions of chronic perturbation. 
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The baseline, or normative, activity level of each unit in a non-adjusted (i.e. normative) 
network is its response when network input is 0 (no drug, hormone, lesion, or other input).  
Simulated administration of a drug alters the activation levels of the units in a model. Figure 5 
compares baseline activity levels (dashed blue lines) of the units representing the 3 monoaminergic 
regions (DR, LC, and VTA), and the units representing 5HT and cortisol (CORT), with their 
responses to acute SSRI administration (orange lines). This figure was constructed using an MSS-
model network, but is representative of the neuroadaptive principle as implemented in all three of 
our models. From the homeostatic viewpoint, drug-induced deviations from baseline activity can 
be interpreted as errors. We define the “activation error” as the sum of the absolute differences of 
the running average (M-model) or steady-state (MS- and MSS-models) neural-region unit 
activations (the 3 monoaminergic regions only (M-model and MSS-models) and the 3 
monoaminergic regions as well as the paraventricular nucleus of the hypothalamus (MS-model)) 
from their baseline activations.  
Neuroadaptation was simulated by allowing the model to adjust the strengths of a subset 
of transmitter-system components (TSCs) known to adjust with chronic administration of 
antidepressants (M-, MS-, and MSS-models) or stress (MS- and MSS-model only). These 
adjustments can be neuroadaptive under chronic antidepressant or stress in that they can bring the 
Figure 5: Representative comparison of model unit responses at baseline (no-drug), with acute (no-
adaptation) SSRI administration, and with chronic (adaptation) SSRI administration in the MSS-
model. The responses of the 3 key monoaminergic brain regions (DR, LC, and VTA), as well as 5HT and 
CORT, are shown in the subplots as labeled. In each subplot, the blue dashed line represents the baseline 
(no-drug) activity level of each unit. The red line in each subplot represents the responses of the units with 
acute (no-adaptation) SSRI administration. Note that the responses of the 3 key brain regions all decrease 
and the levels of 5HT and CORT both increase in the acute SSRI condition. The yellow line in each plot 
shows the adapted activity levels of each unit in one example adapted configuration with chronic SSRI 
administration. In this adapted configuration, the DR and VTA responses return closer to baseline, and 
5HT and CORT responses increase and decrease, respectively.  
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activation levels of the units back toward their normative, no-drug or no-stress baselines. The 
neuroadaptation process is distinct from the neural network training procedure because in 
neuroadaptation, only a subset of the weights (specifically the 11, 10, and 13 adjustable TSCs in 
the M-, MS-, and MSS-models) are changing, and because the weights are not changing to produce 
agreement with the truth table but instead are adjusting to produce a more general overall 
restoration of the baseline activity of the neural brain regions. 
In the M-model, which had the Region structure, all adjustable TSCs were receptors. 
Receptors were represented in the M-model explicitly as receptor-strength parameters that were 
receptor-type and neuron-type specific (e.g., the 5HT1A autoreceptor on DR). In the MS- and 
Full ternary tree, 
mathcove.net 
 
Figure 6: Elaboration of a state transition tree. This figure is a visual representation of the full set of 
adjustment pathways for a model with 3 receptors, any 1 of which can adjust on each adjustment step, 
and each receptor can make 3 adjustments total. The “depth” of the tree corresponds to the number of 
adjustments each receptor has made. Thus, all 3 receptors have adjusted once at depth 1, twice at depth 
2, and so on. This tree has depth 3. The start state is depth 0. The number of adjusted states (receptor 
configurations) grows geometrically with depth. This relatively small “ternary tree” nevertheless 
illustrates how rapidly a tree of TSC adjustment pathways can grow. The M-model has 11 adjustable 
TSCs, each of which can increase or decrease by an increment at each adjustment step, for a total of 22 
possible adjustments at each of 3 adjustment steps (depth 3). The MS-model has 10 adjustable TSCs, 
each of which can increase or decrease by an increment at each adjustment step, for a total of 20 possible 
adjustments at each of 6 adjustment steps (depth 6). The MSS-model has 13 adjustable TSCs, each of 
which can increase or decrease by an increment at each adjustment step, for a total of 26 possible 
adjustments at each of 6 adjustments steps. 
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MSS-models, which had the System structure, the adjustable TSCs were individual connection 
weights of cell-type specific TSCs (e.g., the weight of the connection from the 5HT1AR unit to 
the DR unit). Both representations will be referred to as “TSC strength.” With each adjustment 
step, each of the adjustable TSCs can adjust by increasing or decreasing its strength by a specified 
increment (1 in the M and MSS-models, 0.50 in the MS-model) within the predetermined TSC 
strength minimum of 0 and maximum of |10| for the M- and MS-models and |5| for the MSS-
model. These TSCs will be referred to as “adjustable TSCs.” The models are agonistic as to 
whether TSC-strength adjustments are due to changes in expression, sensitivity, localization or a 
combination of these. 
We define “initial error” as the adaptation error of a trained network subjected to chronic 
administration of a drug (or combination) in the absence of any adjustments of the strengths of the 
weights representing the adjustable TSCs. An “adapted network” was any network that, due to one 
or more adjustments in TSC weights, had an adaptation error lower than initial error. The responses 
of the canonical units in an example MSS-model network adapted to chronic SSRI are shown in 
Figure 5 as yellow lines. This figure shows that adaptation to an SSRI can return the responses of 
DR and VTA back toward normal while also increasing 5HT levels and decreasing CORT levels, 
which is in agreement with clinically observed chronic SSRI effects (de Montigny, Chaput et al. 
1990, Ceglia, Acconcia et al. 2004, Dremencov, El Mansari et al. 2009, Ghanbari, El Mansari et 
al. 2010, Ruhe, Khoenkhoen et al. 2015).   
Many other adapted networks, however, did not also have this pattern of adapted behavior. 
Transmitter and hormone responses to chronic drug administration, therefore, must be evaluated 
in many different TSC-strength configurations. We generated large sets of adjusted TSC-strength 
configurations for the M-, MS-, and MSS-models. Each model, depending on its number of 
adjustable TSCs and number of possible adjustments, had computed a different number of 
adjustable TSC-strength configurations. 
Figure 6 is a visual representation of the tree of all possible TSC-adjustment sequences 
(pathways) for a model having only 3 adjustable TSCs. With only 3 adjustable TSCs and just 3 
total adjustments for each TSC, this “full ternary tree” illustrates how large a fully elaborated tree 
with many adjustable TSCs and many allowed adjustments can become. 
The number of possible TSC-strength configurations at any depth can be computed as 
(2n)d, where n is the number of adjustable TSCs and d is the depth of the tree (or number of steps 
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in each adjustment pathway). The factor of 2 is included because each TSC can either increment 
or decrement at each level. We enumerated all possible configurations of the adjustable TSC 
weights that were reachable by increasing or decreasing any single TSC by a specified increment 
within predetermined bounds, for a present number of allowed adjustments (3 in the M-model, 6 
in the MS- and MSS-models) that was the same for all weights.  
Due to the randomness inherent in the GD neural-network training-method (see 2.2.1.2), 
equally well-trained networks can have very different network connection weights. This variability 
nicely corresponds to the natural variability in neurobiological properties that are known to occur 
between individuals (see 4.3). To account for this inter-individual variability, the MS- and MSS-
models generated large sets of TSC-strength configuration starting from three representative 
networks, each trained from a different random initial weight matrix according to a different 
random order of input/desired-output presentations. In each of the 3 networks we made all possible 
combinations of 6 increments and 6 decrements in each of 10 (MS-model) or 13 (MSS-model) 
TSCs. Neuroadaptation in these models was studied by analyzing these large sets of adjusted TSC 
configurations (382,747 in the MS-model and 579,125 in the MSS-model). The inclusion of three 
representative networks in the MS- and MSS-models represents an advance over the M-model, 
which had only one representative case.       
We explored TSC adjustment configurations in four principle ways. Two of these were 
implemented in MATLAB: we either followed single pathways through the tree, where the TSC 
adjustment at each step was chosen at random, or we computed the TSC-strength configuration at 
each step without following any adjustment pathways. The other was implemented in Maude or 
Python, where we exhaustively elaborated every possible pathway (full tree). Explicitly following 
TSC-adjustment pathways, whether singly or exhaustively, was useful for exploring the 
neuroadaptation process, but was computationally expensive. Computation of all possible TSC-
strength configurations reachable in a set number of adjustments without explicitly following TSC-
adjustment pathways was computationally cheaper and was useful for exploring the range of 
possible model behaviors. 
The 11 adjustable TSCs in the M-model were the three monoaminergic autoreceptors: 
5HT1A on DR neurons, α2-adrenergic receptor (AR2) on LC neurons, and dopamine receptor D2 
(D2R) on VTA neurons; and specific receptors for CRF, galanin, and glutamate: galanin 1 
receptors (galR1) on DR and LC neurons, galanin 2 receptors (galR2) on DR neurons, CRF1R on 
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DR, LC, and VTA neurons, CRF2R on DR neurons, and α-amino-3hydroxy-5-methyl-4-
isoxazolepropionic acid receptors (AMPAR) on VTA neurons. The Blier lab (and others) found 
that these receptors adjust under chronic antidepressant treatment (Blier and de Montigny 1985, 
Blier and de Montigny 1987, Blier, de Montigny et al. 1990, de Montigny, Chaput et al. 1990, 
Haddjeri, de Montigny et al. 1997, Blier, Pineyro et al. 1998, Haddjeri, Blier et al. 1998, Dong and 
Blier 2001, Szabo and Blier 2001, Hawes and Picciotto 2004, Hawes, Brunzell et al. 2005, El 
Mansari, Ghanbari et al. 2008, Chernoloz, El Mansari et al. 2009, Chernoloz, El Mansari et al. 
2009, Ghanbari, El Mansari et al. 2009, Borroto-Escuela, Narvaez et al. 2010, Ghanbari, El 
Mansari et al. 2010, Katz, Guiard et al. 2010, Ghanbari, El Mansari et al. 2012, El Iskandrani, 
Oosterhof et al. 2015, El Mansari, Manta et al. 2015, Wang, Li et al. 2016). The 10 adjustable 
TSCs in the MS-model and the 13 adjustable TSCs in the MSS-model correspond to actual TSC 
proteins that are known empirically to undergo adaptive changes under conditions of chronic 
manipulations within the purview of the model truth-table (see B.13: MS-model Adjustable TSCs 
and B.14: MSS-model Adjustable TSCs). The adjustable TSCs in both models are real TSCs that 
are known to play critical roles in the interactions between the three monoaminergic-transmitter 
systems and the stress hormone (MS- and MSS-model) and male sex hormone (MSS-model) 
systems. 
 
2.2.2.2 IMPERATIVE PROGRAMMING NEUROADAPTATION EXPERIMENTS 
2.2.2.2.1 M-MODEL 
In the M-model, any 1 of the 11 adjustable TSCs could be adjusted up or down by 1.00 on 
each adjustment step. For example, one adjustment to desensitize the inhibitory 5HT1A receptor 
on DR neurons would bring the weight of the 5HT1A receptor on DR (3.10) closer to 0 by an 
increment of 1 (2.20) (TSC polarity was implemented in the unit update statements in the Region 
structure). The MATLAB version was used for making TSC-strength adjustments along single 
sequences (i.e., pathways) in which the TSC to be adjusted at any step was chosen at random. The 
adjustment was retained only if it resulted in a homeostatic reduction in activation error. 
In separate computer experiments, 1,000,000 randomly ordered, strictly error-reducing 
sequences of adjustments (any 1 of 11 TSCs, adjusted either up or down by 1) were allowed to 
continue until further TSC strength adjustment produced no further reduction in activation error 
with chronic Escitalopram. We found that the majority of sequences (mode of the dataset) took 7 
adjustment steps to reach “terminal” adaptation. The number of adjustments ranged between 2 and 
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26 with an average of 7.90 (see B.15: M-model Strictly Error-reducing Adjustments). Because 
these experiments continued until error could not be further reduced, they produced “terminally 
adapted” TSC strength configurations. We plotted 1000 configurations terminally adapted to 
chronic Escitalopram in B.15: M-model Strictly Error-Reducing Adjustments. This figure shows 
that there is not a single, unique, terminally adapted TSC strength configuration; in fact, there 
appear to be a multitude of heterogeneous configurations. To make definitive statements about 
neuroadaptation in the models it is necessary to examine sets of TSC-strength configurations that 
are complete in that every possible configuration is included. Technical limitations certainly did 
not allow examination of complete sets out to 26 adjustments. We were therefore limited to 
complete sets out to fewer adjustments which included terminally and non-terminally adapted 
TSC-strength configurations. We explored complete sets of non-terminally adapted TSC strength 
configurations using MATLAB, Maude, and Python.  
 
2.2.2.2.2 MS- AND MSS-MODELS 
Whereas representative adaptation pathways are important to simulate and analyze, it is 
also useful to precompute all possible TSC-strength configurations reachable along all possible 
pathways without explicitly following each pathway. The MS-model has 10 adjustable TSCs that 
can each adjust their strengths by an increment of 0.50 and the MSS-model has 13 adjustable TSCs 
that can each adjust their strengths by an increment of 1.  
To find all possible adjusted configurations independent of adaptation pathway, we found 
all possible adjustments for all of the 10 (MS-model) or 13 (MSS-model) adjustable TSCs at each 
adjustment step, up to a total of 6 adjustments. Generation of the full set of TSC-strength 
configurations for a total of 7 adjustments was not possible due to computer memory limitations. 
 Note that the adjustable TSCs constitute a small number of the MS- and MSS-model 
parameters, but they are the only parameters whose values can change during neuroadaptation. 
Thus, an “adjusted network” was one in which the weights corresponding to the adjustable TSCs 
are replaced with adjusted values. Recall that the activation levels of the neural units change when 
a drug is administered. Different drugs or combinations will each impose different changes in the 
activation levels of network units, resulting in unique activation errors associated with acute 
administration of each drug or combination. Adjusted MS-model networks were considered 
adapted if their activation error was lower than their initial error, and adjusted MSS-model 
networks were considered adapted if their activation error was at least 25% lower than their initial 
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error. The MSS-model had a more stringent criterion because with 13 adjustable TSCs (versus 10 
in the MS-model) the MSS-model had a much larger number of adjusted configurations. The 
monoamine and CORT levels due to administration of each drug, hormone, or combination were 
found for each adapted network and pooled and plotted in Results. 
 
2.2.2.2.3 FULL-RANGE INDIVIDUAL-WEIGHT ADJUSTMENT (FRIWA) 
We assume that all normal individuals will adapt to chronic antidepressant but we further 
assume that different individuals will adapt in different ways, and not all of them will achieve 
“therapeutic” levels of the monoamines, defined as the levels necessary to achieve remission of 
depressive symptoms (see 4.3). It is also possible that some adjustable TSCs contribute more to 
the attainment of therapeutic monoamine levels than others. We define “therapeuticity” as the 
ability of a TSC to contribute to the attainment of therapeutic monoamine levels through 
adjustments in its strength. We conducted full-range individual-weight adjustment (FRIWA) 
analysis (a kind of sensitivity analysis) to gauge the therapeuticity of single TSCs.  
The starting configurations for FRIWA analysis were all of the configurations adapted to 
chronic SSRI that were also therapeutic, extracted from the exhaustive set of configurations of 
adjustments in all TSCs up to a total of 6 adjustments. Of the 382,747 (MS-model) and 579,125 
(MSS-model) total TSC-strength configurations, the total number of adapted and therapeutic 
configurations over all 3 representative networks was 5598 (MS-model) and 12,351 (MSS-model). 
Therapeutic configurations were those that increased 5HT above the 5HT therapeutic floor 
(>=0.70) and decreased CORT below the therapeutic CORT ceiling (<=0.70). For more detail on 
therapeutic criteria, see B.16: Setting Therapeutic Criteria.   
FRIWA analysis involved adjustment of the weight of a single adaptable TSC across its 
full range (0 to |10| (MS-model) or 0 to |5| (MSS-model); note that individual TSCs are either 
positive or negative), while the weights for the 9 (MS-model) or 12 (MSS-model) other adaptable 
TSCs remained frozen at their starting values, in each of the 5598 (MS-model) or 12,351 (MSS-
model) adapted and therapeutic starting configurations. FRIWA occurred in steps, where each 
individual weight adjustment (IWA) was an increment of |0.50| (MS-model) or |1| (MSS-model). 
Thus, FRIWA generated a set of 200 new configurations (20 IWA adjustments for each of 10 TSC 
weights) starting from each of the 5598 adapted and therapeutic configurations for a total of 
980,193 new configurations in the MS-model. FRIWA generated a set of 78 new configurations 
32 
 
(6 FRIWA adjustments for each of the 13 TSC weights) starting from each of the 12,351 adapted 
and therapeutic configurations for a total of 963,378 new configurations in the MSS-model. 
 All configurations that were no longer adapted after a step of IWA were excluded from 
further analysis, leaving 493,564 adapted TSC-strength configurations in the MS-model and 
377,939 adapted TSC-strength configurations in the MSS-model. Of the 493,564 adapted MS-
model configurations, 285,635 configurations were designated “resistant,” because they remained 
therapeutic despite a step of IWA, while the remaining 207,929 configurations were designated 
“sensitive” because there were rendered non-therapeutic by a step of IWA. Of the 377,939 adapted 
MSS-model configurations, 354,462 configurations were classified as “resistant,” because they 
remained therapeutic despite a step of IWA, while the remaining 23,477 configurations were 
classified as “sensitive” because they were no longer therapeutic following a step of IWA.   
The weights of each of the 10 (MS-model) or 13 (MSS-model) adjustable TSCs in all of 
the post-IWA configurations were pooled over each representative network, and separated on the 
basis of resistance and sensitivity, excluding the weights that were manipulated by FRIWA. The 
mean weight of each adjustable TSC was computed for both the resistant and sensitive 
configurations of each network and compared (see 3.2.4). Further FRIWA analysis involved 
computing the pairwise correlations between all TSC weights over all the resistant, or over all the 
sensitive, configurations in each network (separately for each model). Only pairwise correlations 
that were statistically significant (p < 0.05) over all 3 representative networks of each model would 
have been reported in Results. Again for correlation analysis, the TSC weights that were 
manipulated by FRIWA were excluded.  
 
2.3 DECLARATIVE PROGRAMMING METHODS 
2.3.1 EXHAUSTIVE SEARCH IN MAUDE 
Maude elaboration of adjusted TSC pathways was used in M-model analysis. Maude can 
generate the full set of possible TSC-strength adjustment pathways by making every possible 
sequence of TSC-strength adjustments (i.e., Maude elaborates the full tree of possible receptor-
strength adjustment pathways) with simulated chronic drug administration. Maude can then search 
the space of all possible TSC-strength configurations by searching over the tree of all TSC-
adjustment sequences (i.e., pathways). Each of the adjustable TSCs can either increase or decrease 
its strength by a specified increment. Because each adjustable TSC can potentially increase or 
decrease its strength at any adjustment step (increase or decrease is not allowed for TSCs at an 
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absolute strength of 10 or 0 for the M-model), there are potentially 22 different adjustments that 
can be made at any point along any pathway (i.e., at any depth in the sequence tree).  
In Maude searches, TSC adjustments were allowed whether or not they reduced activation 
error. This allowed for the possibility that certain low error configurations could be reached only 
after passing through higher error configurations. Exhaustive search in Maude was limited to 
sequences of 3 adjustment steps in the M-model due to computational overhead. The Maude 
version of the M-model was used to characterize neuroadapted states with chronic drug or 
combination administration. All activation error values below the lowest activation error at depth 
1 were considered to be “adapted” at all depths deeper than depth 1 with the M-model. Among the 
adapted TSC-strength configurations, we searched for configurations that achieved certain 
“therapeutic” levels of the monoaminergic transmitters. Therapeutic levels were based on clinical 
evidence concerning the therapeutic action of antidepressants (see B.16: Setting Therapeutic 
Criteria). Of primary interest are the monoamine levels associated with the adapted states of the 
model. In the MS- and MSS-models, monoamine levels were determined for TSC-strength 
configurations down to depth 6 by precomputation in MATLAB of all possible configurations. 
 
2.3.2 TEMPORAL-LOGIC MODEL-CHECKING 
2.3.2.1 THERAPEUTIC PATHWAY ANALYSIS 
Elaborating actual adaptive pathways allows adaptation to be analyzed as a process. We 
studied the process of neuroadaptation by making allowed TSC weight adjustments (increments 
of 0.50 (MS-model) or 1 (MSS-model) up or down, within bounds of 0 and |10| (MS-model) or 0 
and |5| (MSS-model)) in all possible sequences. Linear temporal logic (LTL) is a type of modal 
temporal logic which allows for reasoning about sequences of discrete states evolving in time. 
LTL analysis allows the evaluation of temporally specified logical propositions such as whether a 
specific state is always maintained or eventually reached; whether a specific state pertains only 
until another state pertains; or whether a specific state always leads to another specific state. 
Temporal-logic model-checking allows us to determine such temporal relationships between TSC-
strength configurations (i.e. states).  
We used LTL model checking to determine if specific degrees of neuroadaptation (e.g. a 
configuration in which a specific TSC has been adjusted down 3 times) always leads to an adapted 
and therapeutic configuration (for all possible sequences of adjustments proceeding from that 
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configuration up to a total of 6 adjustments) (see B.17: Details on Temporal-logic Model-checking 
Procedure for details on model-checking statements).  
In order to evaluate model-checks in the MS- and MSS-models, it was necessary to define 
a set of logical predicates to be tested. The following predicates were used in the temporal-logic 
analysis: fht_high, 5HT is above the 5HT therapeutic floor (>=0.70); cort_low, CORT is 
below the therapeutic CORT ceiling (<=0.70); TSC_sens_gt_3, the adjustable TSC has 
sensitized by at least 3 steps; and TSC_desens_gt_3, the adjustable TSC has desensitized by 
at least 3 steps.  Note that TSC in the last two predicates is a placeholder for any specific, adjustable 
TSC (e.g. 5HT1AR).  
Then we evaluated the following propositions for each of the 10 (MS-model) or 13 (MSS-
model) adjustable TSCs, where |-> and /\ are the LTL “LEADS TO” and “AND” operators, 
respectively:  
 
TSC_sens_gt_3 |-> fht_high /\ cort_low  
TSC_desens_gt_3 |-> fht_high /\ cort_low  
 
These are equivalent to the LTL propositions that if at any point in the trajectory of TSC 
strength adjustments, the TSC sensitizes or desensitizes by at least 3 increments, then 5HT is high 
and CORT is low at some subsequent point in time. We found that both of these propositions were 
false for all of the tested TSCs in all 3 representative networks of both the MS- and MSS-models 
(see 3.2.6).  
Next, we evaluated the following more-easily-satisfiable propositions, where \/ and ~ are 
the LTL “OR” and “NOT” operators, respectively: 
 
TSC_sens_gt_3 |-> (fht_high /\ cort_low) \/ ~TSC_sens_gt_3 
TSC_desens_gt_3 |-> (fht_high /\ cort_low) \/ ~TSC_desens_gt_3 
 
These are equivalent to the LTL propositions that if at any point in the trajectory of TSC 
strength adjustments, the TSC sensitizes or desensitizes by at least 3 adjustments, then either 5HT 
is high and CORT is low at some subsequent point in time, or the TSC is no longer sensitized or 
desensitized. If 1 adjustable TSC was solely responsible for modulating the 5HT and CORT levels, 
then the model check for either of those 2 propositions for that specific, adjustable TSC should 
return True. Each LTL model check was carried out using each of the 3 representative networks 
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of the MS- and MSS-models for up to 6 adjustments, and only model-checking results that were 
consistent over all 3 networks are reported in Results.   
Temporal-logic model-checking in Maude is ideal for these purposes because it allows us 
to determine temporal relationships between TSC-strength configurations (i.e., states). As a 
declarative programming language, Maude allows TSC adjustments to execute in all possible 
orders (see A.3: Difference between Imperative and Declarative Programming). For computational 
efficiency, we implemented Maude linear temporal-logic (LTL) model-checking procedures in 
Python and conducted a cross-check to confirm agreement between the two languages. Temporal-
logic model-checking allows us to explore the temporal relationships between different adjustable 
TSC-strength configurations in a manner that is independent of the order of TSC adjustments 
(Monin and Hinchey 2003, Huth and Ryan 2004). 
 
2.3.2.2 THERAPEUTIC CLUSTER ANALYSIS 
We also used a form of LTL in the MSS-model analysis to examine the space of 
incrementally-adjusted TSC-strength configurations. If there are single or subsets of TSCs whose 
sensitization or desensitization is determinative of therapeutic states, then we would expect large 
and completely connected regions of adapted and therapeutic TSC-strength configurations within 
the space of incrementally changing TSC-strength configurations. However, if multiple TSCs 
contribute to the achievement of the therapeutic state, then we would expect there to be scattered 
or irregular regions of adapted and therapeutic states. We used the Henceforth LTL operator to 
search for connected regions of adapted and therapeutic states in which incremental adjustments 
of specific TSCs from therapeutic states always lead to subsequent therapeutic states. Each LTL 
and state-space analysis was conducted using each of the 3 representative networks for up to 6 
adjustment steps, and only results that were consistent over all 3 networks are reported in MSS-
model Results. 
 
All hardware considerations are reported in B.18: Hardware Considerations. 
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CHAPTER 3: RESULTS 
 
Although the M-model had a different structure and was trained using different methods 
than the MS- and MSS-models, all three models are based on a homeostatic hypothesis whereby 
the neural-region units in the network adjust the strengths of a subset of their TSCs in order to 
restore activity levels closer to no-drug, baseline levels with chronic drug administration. All three 
are models of the antidepressant response and are analyzed using both imperative and declarative 
programming methods. Results of the M-model are reported using one representative parameter 
set but the more efficient training method of the MS- and MSS- models allowed for reporting the 
results of three representative networks for each model. Overall, all three models illustrate that the 
clinically observed heterogeneity in the antidepressant response could reflect heterogeneity in 
adapted TSC-strength configurations that are usually associated with widely divergent monoamine 
levels. All three models provide predictions concerning the efficacy of drug or drug and hormone 
combinations that could potentially be more therapeutic than single antidepressants. Results from 
the MS- and MSS- models also provide insight into the therapeuticity (i.e., the ability to contribute 
to a therapeutic state) of different TSC types, through analysis of large sets of adapted 
configurations and temporal relationships between configurations that occur during the process of 
neuroadaptation. 
 
3.1 M-MODEL (REGION STRUCTURE) 
3.1.1 CHOOSING A PARAMETER VECTOR 
Before the M-model can be used for analysis of adapted TSC strength configurations, its 
parameters must be set so that model behavior agrees with experimental observations on the acute 
effects of antidepressants (i.e., before any TSC adjustments take place). The GA was used to obtain 
200 sets of M-model parameters that achieve this agreement with acute data by minimizing the 
RMS value of an error function (see 2.2.1.1). From the full set of 200 parameterizations, we 
selected the 10 best (lowest error) for further evaluation. We found that all elevated 5HT with 
acute Escitalopram administration (de Montigny, Chaput et al. 1990, El Mansari, Sanchez et al. 
2005), all responded to acute Escitalopram with decreased DR unit activity (de Montigny, Chaput 
et al. 1990), and all elevated 5HT to an even higher level after adaptation to Escitalopram (de 
Montigny, Chaput et al. 1990, Invernizzi, Belli et al. 1992, El Mansari, Sanchez et al. 2005). When 
only the 5HT1A autoreceptor on DR was allowed to adapt, all desensitized this receptor to reduce 
activation error (de Montigny, Chaput et al. 1990, Naudon, El Yacoubi et al. 2002). One 
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parameterization was eliminated due to its aberrant adaptive behavior. The fit with the RMS error 
of 9.93 was selected for further analysis. It was considered to be a representative parameterization 
of the M-model because it had an error near the top of the error range (5.66 to 9.94 for the ten best) 
but still displayed the required adaptive capability (for more detail and figures on the GA 
parameterizations and selection of a representative parameterization, see C.1: Analysis of M-
model Optimized Parameter Vectors). 
 
3.1.2 CHARACTERIZING BASELINE (NO-DRUG) BEHAVIOR 
Baseline activity of M-model units instantiated with the representative parameter set is 
shown in Figure 7A. All units settle into a stable oscillation about a constant offset following an 
initial transient. Such complex oscillation is in qualitative agreement with observation. Neurons in 
the monoaminergic nuclei, and in the non-monoaminergic regions with which they interact, can 
oscillate at multiple frequencies (Chergui, Suaud-Chagny et al. 1994, Gao, Liu et al. 2007, Zhang, 
Yang et al. 2008, Puig, Watakabe et al. 2010). The Blier lab also observed bursting behavior for 
some monoaminergic neurons depending on the neurons examined and the duration of drug 
administration (Katz, Guiard et al. 2010, Ghanbari, El Mansari et al. 2012, El Iskandrani, 
Oosterhof et al. 2015). We did not attempt to match real oscillation frequencies or bursting 
quantitatively with any of the three models because we were interested only in average unit 
activations (with the M-model) and steady-state neural-region unit activations (with the MS- and 
MSS-model) representing the overall activity level of each neural unit.  
The responses of this network to acute Escitalopram administration are shown in Figure 
7B. As with all drug conditions, the Escitalopram level is maintained over the course of the 
evaluation. Administration of Escitalopram changes the activation levels of the units including 
DR, LC, and VTA. This is consistent with experimental findings showing that acute administration 
of antidepressants can change the firing rates of neurons in those nuclei (reviewed in (Blier and El 
Mansari 2013)).   
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The activation levels of the monoaminergic units in the M-model instantiated with the 
representative parameter set with acute administration of all the drugs and combinations, expressed 
as percentage changes from baseline, are shown in Figure 8A (blue bars). The percentage changes 
Figure 7: M-model element activities in the baseline (no-drug) condition and acute (no-adaptation) 
Escitalopram condition. (A) The blue line in each plot shows the activity of a different model unit across 
150 time steps in the normal (no-drug) baseline condition. The superimposed red line is the average 
activity computed over the second half of the time series for the corresponding unit. These constant values 
for the normal condition are the baseline activations that define the normative activation of the network. 
(B) The blue line in each plot shows the activity of a different model unit across 150 time steps in the 
acute (no-adaptation) Escitalopram condition. The red line represents the average activity of each unit at 
baseline, plotting the same constant value as in (A). Of interest are the sustained levels of monoamine 
release, which is proportional to the average activity level of the monoaminergic units (DR, LC, and 
VTA). Oscillations apparent in the activities of some units are consistent with observation but are not 
relevant to model performance. Note that Escitalopram changes the average activity level of all of the 
units, and especially of the DR unit. 
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of actual DR, LC, and VTA units observed by the Blier lab under the acute influence of the same 
drugs and combinations (red bars) are shown for comparison. These plots, which are essentially 
graphical representations of the M-model truth table, demonstrate the M-model’s ability to 
reproduce the data concerning the acute effects of antidepressant drugs on neurons of the 
monoaminergic neurotransmitter regions. This rather coarse level of agreement with the data or 
“fitness” is typical of GA parameterizations. Agreement between MS- and MSS-model 
performance and data using GD is closer by orders of magnitude. 
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Figure 8: Agreement between observed and simulated percentage activation changes 
following acute or chronic drug administration in the M-model (A) Each row shows the 
percentage change from normal activation of the DR, LC, and VTA units, respectively, due to acute 
administration of the drug(s) in each column. The red bar represents the empirical value observed 
by the Blier lab, while the blue bar represents the computational value produced by the model. The 
model is parameterized using the representative parameterization (RMS error is 9.93, see text). (B) 
Each row shows the percentage change from normal activation of the DR, LC, and VTA units, 
respectively, in response to chronic administration of the drug(s) in each column. The red bar 
represents the value observed by the Blier lab. The blue bar represents the computational value 
produced by the model, each selected from among many adaptation runs for its agreement with the 
data (different runs produced different activation patterns; see text). The RMS error between the 
observed and computational values at the chronic stage is 9.58. Abbreviations: Escitalopram, Esc; 
Nomifensine, Nom; Reboxetine, Reb; Trazodone, Trz; Asenapine, Asn; Aripiprazole, Arp; 
Bupropion, Bup; Quetiapine, hQuet; Escitalopram + Aripiprazole, EsArp; Escitalopram + 
Quetiapine, EsQuet. 
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3.1.3 VERIFYING AGREEMENT BETWEEN THE MATLAB AND MAUDE VERSIONS OF 
THE M-MODEL 
In addition to being used to optimize M-model parameters and for preliminary adaptation 
runs, the MATLAB program was used as a crosscheck for the Maude specification. Extensive 
crosschecking assured that the Maude and MATLAB versions of the M-model computed the same 
unit activations and transmitter levels in the no-drug and in all acute drug conditions. This 
validation step ensures that both versions of the M-model are consistent with each other and with 
the data on the acute effects of drugs on the activity of neural regions and the levels of 
neurotransmitters. Details on this validation step can be found in C.2: Verifying Agreement 
between the MATLAB and Maude Versions of the M-model. 
 
3.1.4 CHARACTERIZING ADAPTIVE BEHAVIOR 
To obtain a preliminary view of the adaptive capability of the M-model, only the DR 
5HT1A autoreceptor was allowed to make adaptive adjustments. This preliminary evaluation was 
carried out using MATLAB, in which TSC-strength adjustments are made along a single pathway 
(i.e., a single sequence of TSC-strength adjustments). The DR 5HT1A could be adjusted up or 
down by 1 (or by a fraction, if its value was near the absolute-value limits of 0 or 10), and the 
adjustment direction on any adjustment step was chosen at random. An adjustment was retained 
only if it reduced activation error. These single-pathway adaptation runs show that desensitization 
of the DR 5HT1A autoreceptor decreases activation error and brings the monoaminergic unit 
activations back toward baseline (See C.3: Single-pathway Adaptation Runs in MATLAB). 
In subsequent MATLAB adaptation runs, all 11 M-model adjustable TSCs were allowed 
to adjust (see Figure 8B) but did so one at a time along a single adaptive pathway. Both the TSC 
and the direction of adjustment (up or down by 1, or less to reach a TSC-strength limit) were 
chosen at random at each adjustment step, and an adjustment was retained only if it reduced 
activation error. The fully adjustable model was allowed to make 100 adjustment steps (only a 
small number of these actually reduced activation error). Each column in Figure 8B shows one 
specific adaptation run that was chosen for its agreement with the data. These runs show that 
agreement between M-model (blue bars) and observation (red bars) on changes in DR, LC, and 
VTA activation due to chronic antidepressant administration can be obtained with a TSC strength 
adjustment scheme based on neuroadaptation. 
3.1.5 EXHAUSTIVE SEARCH OF ADAPTED STATES 
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We used exhaustive search in Maude to evaluate activation error and monoaminergic 
transmitter levels over all possible sequences of 3 TSC-strength adjustments, including pathways 
over which error could increase, producing all possible configurations of TSC strengths reachable 
within 3 adjustment steps with the M-model. Due to limitations in computational resources, 
exhaustive searches in Maude were limited to sequences of 3 TSC strength adjustments. The 
average number of adjustments to reach terminal adaptation (states in which further TSC-strength 
adjustments cannot further reduce activation error) with Escitalopram was found to be 7.90 (see 
Methods and B.15: M-model Strictly Error-reducing Adjustments). With 11 adjustable TSCs each 
able to increase or decrease its strength at each adjustment step, there would be 228, or over 54 
billion, possible configurations reachable in 8 adjustment steps (see Methods). Exhaustive search 
on this order in Maude was not possible but search to level 3, which was possible, is highly 
instructive for three reasons.  
First, it is unknown whether a state corresponding to terminal adaptation occurs in all 
rodents receiving chronic antidepressant treatment for 14 days (see 2.2.1.1), or in all humans over 
the course of a clinical trial (typically 6–8 weeks). Second, the GA-determined value of the DR 
5HT1A autoreceptor (as well as the other 2 autoreceptors) in all of the 10 best parameter vectors 
in the M-model was just over 3, so exhaustive search to level 3 includes the 3-step, almost-
complete desensitization of the DR 5HT1A autoreceptor (C.3: Single-pathway Adaptation Runs 
in MATLAB). Exhaustive search to level 3 is therefore appropriate for comparison of other 
adapted configurations to the configuration characterized by almost-complete DR 5HT1A 
autoreceptor desensitization, which is currently considered to be the main mechanism of SSRI 
effect (Blier, Pineyro et al. 1998, Gray, Milak et al. 2013). Third, exhaustive search avoids bias 
inherent in any kind of sampling of the configuration space, such as the sampling we did for 
illustrative purposes in MATLAB described in the previous subsection. 
The results of the exhaustive searches in Maude with the M-model are reported in Table 5 
in terms of the percentages of adapted TSC-strength configurations (i.e., states) that are also 
associated with therapeutic elevation in one or more of the monoamines. The percentages of 
adapted configurations that are also associated with therapeutic elevations in one or more 
monoamines are taken as M-model estimates of the percentage efficacies of the corresponding 
drug or combination. Although there are many adapted TSC-strength configurations, not all of 
these configurations are also associated with therapeutic elevations in the monoamines. Because 
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these percentages are considerably less than 100% in most cases, these results mirror the unideal 
antidepressant efficacies and heterogeneity between individuals in patterns of monoamine release 
following adaptation to the same chronic drug or combination that are observed in the clinic. The 
computational demonstration that the multiplicity of adaptable TSCs implies heterogeneity in 
monoamine levels in adapted configurations constitutes my proposed explanation for the low 
efficacy rates of antidepressants in depressed patients. 
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Row 
number 
Drug(s) 
Adap 
state 
Number (percentage) of adapted states with therapeutic monoamine elevation 
5HT DA NE 5HT/DA 5HT/NE DA/NE 5HT/DA/NE 
1 Escitalopram 655 192(29%) 0 0 0 0 0 0 
2 Nomifensine 2463 2267(92%) 2463(100%) 1628(66%) 2267(92%) 1531(62%) 1628(66%) 1531(62%) 
3 Reboxetine 1185 0 0 1185(100%) 0 0 0 0 
4 Trazodone 296 0 30(10%) 54(18%) 0 0 6(2%) 0 
5 Asenapine 63 0 0 0 0 0 0 0 
6 Aripiprazole 706 0 0 0 0 0 0 0 
7 Bupropion 1972 469(24%) 1972(100%) 1895(96%) 469(24%) 469(24%) 1895(96%) 469(24%) 
8 Quetiapine 662 0 60(9%) 662(100%) 0 0 60(9%) 0 
9 
Nomifensine 
+ 
Escitalopram 
2462 2265(92%) 2462(100%) 1628(66%) 2265(92%) 1531(62%) 1628(66%) 1531(62%) 
10 
Reboxetine + 
Escitalopram 
1218 355(29%) 1049(86%) 1023(84%) 309(25%) 294(24%) 889(73%) 260(21%) 
11 
Trazodone + 
Escitalopram 
431 0 175(41%) 162(38%) 0 0 73(17%) 0 
12 
Asenapine + 
Escitalopram 
132 2(2%) 0 74(56%) 0 0 0 0 
13 
Aripiprazole 
+ 
Escitalopram 
179 65(36%) 47(26%) 45(25%) 31(17%) 0 0 0 
14 
Bupropion + 
Escitalopram 
2388 2308(97%) 2388(100%) 1760(74%) 2308(97%) 1717(72%) 1760(74%) 1717(72%) 
15 
Quetiapine + 
Escitalopram 
586 66(11%) 204(34%) 586(100%) 0 66(11%) 204(34%) 0 
 
Table 5: Exhaustive searches of adapted TSC-strength configurations with the M-model. The M-model 
was subjected to chronic administration of 8 drugs either alone or in combination with Escitalopram, and 
made every possible sequence of 3 allowed TSC strength adjustments. Initial error is the activation error due 
to the drug(s) before any TSC adjustments have been made. Adapted states (Adap state) expresses the number 
of TSC strength configurations (i.e., states) at depth 2 or 3 (i.e., after 2 or 3 TSC adjustments) that have 
activation error lower than the lowest depth 1 error. The other columns show the number of adapted TSC 
strength configurations (also expressed as a percentage of the total number of adapted configurations) that are 
associated with therapeutic elevations in one or more of the monoaminergic neurotransmitters. The 
therapeutic levels are >400%, >200%, and >200% of baseline for 5HT, NE and DA, respectively. 
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3.1.6 COMPUTATIONAL PREDICTION: AUGMENTING ESCITALOPRAM ACTION WITH 
SCH-202596, A GALANIN RECEPTOR BLOCKER 
My hypothesis concerning the reason for the clinically observed heterogeneity in 
antidepressant response admits many options for experimental verification, including predictions 
involving specific combinations of compounds. Studies using pharmacological and genetic 
techniques have suggested that stimulation of the inhibitory galanin 1 receptor (galR1) results in a 
depression-like phenotype, while activation of the excitatory galanin 2 receptor (galR2) attenuates 
depression-like behavior (Lu, Barr et al. 2005, Rovin, Boss-Williams et al. 2012). These findings 
suggest that novel antidepressant drugs that target galanin receptor subtypes may be of potential 
therapeutic benefit. 
We used exhaustive Maude search to take a closer look at the 5HT levels in adapted 
configurations to chronic Escitalopram, SCH-202596 (SCH, a drug that blocks galR1s), and the 
combination of both drugs. We found an increase in the percentage of adapted configurations also 
having therapeutically elevated levels of 5HT going from 29% (Escitalopram alone) to 78% when 
the SSRI and SCH were administered together. SCH by itself did not produce any adapted states 
with therapeutic 5HT levels. Recognition of the possibility that the brain has many ways to adapt 
to chronic antidepressant leads to the conjecture that certain combinations of drugs (particularly 
of receptor-blocking drugs such as SCH) could reduce the number of adapted configurations and, 
further, could channel the brain into a higher percentage of therapeutic states. Consistent with this 
conjecture, compared with Escitalopram by itself, the model shows that combining Escitalopram 
and SCH decreases the number of adapted states but increases the proportion of states with high 
5HT. 
Histograms of the number of TSC-strength configurations under chronic Escitalopram or 
Escitalopram/SCH that achieve different 5HT levels are shown in Figure 9A and Figure 9B, 
respectively. When the M-model was allowed to adapt to Escitalopram, the adapted configurations 
with therapeutically elevated 5HT were found across a fairly widespread distribution (Figure 9A). 
A visual comparison of the distribution of Escitalopram/SCH configurations to the M-model 
shows fewer adapted states with a smaller range that is pushed to the right toward high 5HT states 
(Figure 9B). Combining these two drugs not only increased the proportion of high 5HT states, but 
narrowed the 5HT-level distribution. The M-model predicts that the combination of Escitalopram 
and SCH could have higher percent efficacy for depressed patients than Escitalopram by itself. 
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Figure 9: Raw 5HT values of adapted configurations to (A) Escitalopram (Esc) and (B) Esc and 
SCH-202596 (SCH) using the M-model. The 5HT levels are labeled along the x-axis and the number 
of configurations corresponding to each 5HT level are labeled on the y-axis. Total number of adapted 
configurations are labeled as “Total configs” in each case. Note the wide spread in the distribution of 
5HT levels with Esc using the M-model. This figure illustrates that combining Esc with SCH not only 
decreases the number of adapted states (Total configs decreases from 1586 to 1359), but also shifts the 
distribution to the right with more therapeutic (high-5HT) states.  
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3.2 MS- AND MSS-MODEL RESULTS (SYSTEM STRUCTURE) 
3.2.1 TRAINING AND PRUNING 
MS- and MSS-model networks were trained, pruned on the basis of sensitivity, and then 
retrained as described in Methods. The results of the training method can be viewed in Figure 10 
for the MS-model and Figure 11 for the MSS-model. Each plot in each of these two figures (Figure 
10 and Figure 11) shows all of the actual and desired outputs for one brain-region, transmitter or 
hormone output unit (DR, LC, VTA, paraventricular nucleus (PVN) of the hypothalamus, 5HT, 
NE, DA, or CORT in the MS-model; testes and testosterone (TEST) were also included in the 
MSS-model figure). Each actual output response and desired output response is plotted as a solid 
line and a dashed line, respectively. Correspondence between steady-state actual responses and 
desired responses is nearly exact in both figures. The RMS errors over the networks shown in 
Figure 10 and Figure 11 was 5.10x10-5 and 1.84x10-4, respectively. Comparison of these two 
values with the RMS error of 9.93 for the representative M-model parameterization indicates that 
the GD improves model agreement with data by many orders of magnitude (see 4.1). 
Figure 10: MS-model agreement between desired (i.e., target) and actual outputs after pruning 
and re-training. All of the desired and actual outputs, collected over all input/desired-output patterns, 
are represented in a single plot for each of the brain region and transmitter or hormone output units (DR, 
LC, VTA, PVN, 5HT, NE, DA, and CORT). Each output response is plotted as a solid line and each 
target (i.e. desired) output is plotted as a dashed line. Each of the outputs reach a steady-state value within 
25 time steps. The RMS error of this network is 5.10x10
−5
. Note that the solid line (actual output) is 
superimposed on the dashed line (desired or target output), illustrating the accuracy of the training 
method.  
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The heatmaps in C.4 illustrate the extent of MS- and MSS-model agreement for all output 
units over the whole training set both before (A-C of each figure) and after pruning (D-F of each 
figure). 
  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 11: MSS-model agreement between actual model outputs and desired outputs after pruning 
and retraining. Single plots compare the desired (i.e., target) outputs with the actual responses of model 
output units representing monoamine or hormone producing regions, or the monoamines or hormones 
themselves (DR, LC, VTA, PVN, Testes, 5HT, NE, DA, CORT, and TEST). Actual or desired outputs 
are plotted as solid or dashed lines, respectively. All of the outputs reach steady-state within 25 time 
steps. The RMS error of this network is 1.84 x 10-4. Note that the solid lines, representing actual outputs, 
reach steady-states that overlie the dashed lines, representing corresponding desired outputs, illustrating 
the accuracy of the training procedure.   
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3.2.2 MATLAB ENUMERATION OF ADJUSTABLE TSC-STRENGTH CONFIGURATIONS  
To determine the possible effects of chronic administration of drug/hormone combinations 
on a patient population, all of the configurations, starting from each of the 3 different, 
representative networks that could be generated by up to 6 adjustments at an increment of 0.50 
(MS-model) or 1 (MSS-model) were analyzed. The number of adjustments was limited to 6 due 
to computational overhead (see B.20: Hardware Considerations). Instead of choosing one 
representantive parameter set for neuroadaptation experiments as with the M-model, this analysis 
was repeated for each drug or combination using all 3 networks of each of the MS- and MSS-
models and the adapted monoamine levels of each was pooled for each model. While the M-model 
demonstrated the neuroadaptive pathways available to a single individual with chronic 
administration of an antidepressant or combination, the MS- and MSS-models demonstrate the 
compiled adaptive pathways available to 3 individuals. The distributions of monoamine and CORT 
levels over all of the networks that are adapted to spcific drug/hormone combinations are shown 
as histograms.   
 
3.2.2.1 MS-MODEL SINGLE DRUG, DRUG COMBINATION, AND DRUG/HORMONE 
COMBINATION HISTOGRAM ANALYSES 
A central goal of this study was to use the trained network models to evaluate the possibility 
that combinations of antidepressant drugs, or combinations of drugs and hormones, could be more 
therapeutically effective that single SSRIs. Configurations adapted to chronic administration of 
select drugs and hormones in combination with SSRI were analyzed. We use the term “SSRI” 
rather than “Escitalopram” in the MS- and MSS-model analyses because the MS- and MSS-models 
were trained on more than one SSRI (e.g., Citalopram, Escitalopram, Fluoxetine, etc.). The results 
of some specific drug and hormone combinations are shown in Figures 12 and 13. The rows of 
these 2 sets of histograms (Figures 12 and 13) show the monoamine and CORT distributions of all 
configurations starting from all 3 representative networks that were adapted to SSRI alone, to SSRI 
paired with another drug or hormone, and SSRI combined with the two other drugs or a drug and 
a hormone. Each column of these 2 sets of histograms (Figures 12 and 13) corresponds to a specific 
transmitter or hormone unit (5HT, NE, DA or CORT). Viewing the histograms down the columns 
shows how the distributions of monoamine and CORT levels are affected by the different drugs 
and combinations. In this histogram figure and in all subsequent histogram figures the baseline, 
average, and therapeutic levels of each transmitter or hormone will be represented with a blue, 
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green, or magenta line, respectively. Although “therapeutic” monoamine levels have not been 
quantified, we set the therapeutic 5HT, NE, and DA floors and the therapeutic CORT ceiling to 
0.70 using estimates based on experimental findings described in B.16: Setting Therapeutic 
Criteria. 
Figure 12A shows the results of adaptation to SSRI alone, 12B shows SSRI paired with 
Asenapine (an antipsychotic drug), 12C shows SSRI paired with Oxytocin (a peptide 
neurohormone), and 12D shows SSRI combined with both Asenapine and Oxytocin. Figure 12B 
shows that combining SSRI with Asenapine not only increases the proportion of adapted states 
with therapeutically elevated (toward the right) 5HT, but also shifts the NE histogram to the right 
as well increasing the proportion of adapted states with elevated NE. Figure 12B also shows that 
the combination of SSRI and Asenapine can decrease CORT levels in a higher proportion of 
adapted configurations below the therapeutic ceiling (toward the left). In Figure 12C, the 
combination of an SSRI and Oxytocin also shifts the 5HT distribution to the right and increases 
Figure 12: MS-model histograms showing number of adapted configurations expressing different 
monoamine and CORT levels with combinations of SSRI, Asenapine, and Oxytocin. Networks were 
adapted to SSRI alone (A), SSRI+Asenapine (Asn, an antipsychotic drug) (B), SSRI+Oxytocin (Oxt, a 
hormone) (C), and SSRI+Asn+Oxt (D). (B) and (C) show that combining an SSRI with either Asn or 
Oxt increases the proportion of high monoamine and low CORT states over the SSRI by itself. (D) shows 
that combining an SSRI with both Oxt and Asn further increases the proportion of high monoamine and 
low CORT states. These histograms suggest that combining an SSRI with either Oxt, Asn, or both may 
be therapeutic for a greater proportion of patients than an SSRI administered alone. 
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the proportion of adapted states with low CORT. The combination of all 3 factors (SSRI, 
Asenapine, and Oxytocin) in Figure 5D increases the proportion of adapted states with high 
monoamine levels for all 3 monoamines, and also increases the proportion of adapted states with 
low CORT beyond the levels observed with SSRI by itself. 
 
 
Figure 13A shows the results of adaptation to SSRI alone, 13B shows SSRI paired with 
Bupropion (an atypical antidepressant), 13C shows SSRI paired with Olanzapine (an antipsychotic 
drug), and 13D shows SSRI combined with both Bupropion and Olanzapine. Figure 13B shows 
that adaptation to the combination of SSRI and Bupropion can increase the proportion of adapted 
states with high NE and DA levels over that observed with the SSRI by itself. It also shows that 
this combination decreases CORT levels in a higher proportion of adapted states than the SSRI by 
itself. Figure 13C shows that the combination of SSRI and Olanzapine can increase the proportion 
of adapted states with therapeutic 5HT over the SSRI by itself. The combination of all 3 (SSRI, 
Figure 13: MS-model histograms showing number of adapted configurations expressing different 
monoamine and CORT levels with combinations of SSRI, Bupropion, and Olanzapine. Networks 
were adapted to SSRI alone (A), SSRI+Bupropion (Bup, a NET and DAT blocker) (B), 
SSRI+Olanzapine (Olan, an antipsychotic drug) (C), and SSRI+Bup+Olan (D). (B) and (C) show that 
combining an SSRI with either Bup or Olan increases the proportion of high monoamine and low CORT 
states over the SSRI by itself. (D) shows that combining an SSRI with both Bup and Olan further 
increases the proportion of high monoamine and low CORT states. The histograms in (D) illustrate that 
the combination of SSRI+Bup+Olan shifts the monoamine and CORT histograms, especially those of 
NE and DA, toward more therapeutic states, suggesting that this combination can be therapeutic for a 
greater proportion of patients than an SSRI administered alone.  
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Bupropion, and Olanzapine) in Figure 13D was found to shift all 3 of the monoamine (5HT, NE 
and DA) histograms to the right (toward high monoamine levels) and increase the proportion of 
adapted states that reduce CORT below its therapeutic ceiling. Overall, these histograms illustrate 
how combinations of chronic drugs (or of drugs and hormones) can increase the proportion of 
adapted states with elevated monoamines and reduced CORT levels (see 4.5). 
 
3.2.2.2 MSS-MODEL SINGLE DRUG, DRUG COMBINATION, AND DRUG/HORMONE 
COMBINATION HISTOGRAM ANALYSES 
Each MSS-model histogram in Figures 14 and 15 shows the numbers of adjusted TSC-
strength configurations adapted to each drug/hormone combination that had levels of 5HT, NE, 
DA, and CORT falling within discrete bins as indicated. Comparison of Figure 14A (SSRI alone) 
with 14B shows that combining SSRI with Quetiapine not only increases the proportion of adapted 
states with therapeutically elevated (toward the right) 5HT, NE, and DA, but also increases the 
proportion of adapted states with therapeutically decreased (toward the left) CORT. Figure 14C 
shows that combining an SSRI with Oxytocin increases the proportion of adapted states with 
therapeutically elevated 5HT and DA as well as the proportion of states with low CORT. Figure 
14D shows that the combination of all 3 factors (SSRI, Quetiapine, and Oxytocin) also increases 
the proportion of adapted states with therapeutically elevated 5HT and DA and low CORT. Figure 
14D also shows an interesting bi-modal distribution of NE, where one peak of adapted states is at 
or below baseline NE levels and the second peak is shifted to the right above the NE therapeutic 
floor.  
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Comparison of Figure 15A and Figure 15B shows that combining SSRI with Asenapine 
increases the proportion of adapted states with therapeutically elevated levels of all 3 monoamines 
and low CORT. Figure 15C shows that combining an SSRI with TEST increases the proportion of 
adapted states with therapeutically high 5HT and DA and low CORT. Figure 15D shows that the 
combination of SSRI, Asenapine, and TEST further increases the proportion of adapted states with 
therapeutically elevated monoamines and low CORT, and shifts all 4 of these distributions further 
toward their respective therapeutic poles. These histograms illustrate how the MSS-model can be 
used to identify drug or drug and hormone combinations that could potentially be therapeutic for 
a higher proportion of male depressed patients than SSRIs by themselves (see Discussion). 
Figure 14: MSS-model histograms showing number of adapted configurations associated with 
different monoamine and cortisol levels with combinations of SSRI, Quetiapine, and Oxytocin. 
Networks were adapted to SSRI alone (A), SSRI+Quetiapine (hQuet, an antipsychotic drug) (B), 
SSRI+Oxytocin (Oxt, a hormone) (C), and SSRI+hQuet+Oxt (D). (B) and (C) show that combining an 
SSRI with either hQuet or Oxt increases the proportion of high monoamine and low CORT states over 
the SSRI by itself. (D) shows that combining an SSRI with both hQuet and Oxt further increases the 
proportion of high monoamine and low CORT states.  
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3.2.3 PREDICTING THE EFFICACY OF DRUG AND HORMONE COMBINATIONS 
3.2.3.1 MS-MODEL DRUG/HORMONE COMBINATION SCREEN 
The monoamine levels for the 3 networks adapted to each of a set of clinically reasonable 
drug or hormone pairs and triples were compiled and the average monoamine levels were 
computed. The average levels of each of the 3 monoamines for each chronic drug or hormone 
combination are shown as rows in the heatmap in Figure 7. Each column represents the level of 
one monoamine (5HT, NE, or DA, moving across the columns). For purposes of illustration, 
quantification, and ordering, the 3 monoamine levels can be combined into a monoamine vector: 
[5HT NE DA]. Baseline, therapeutic, and excess monoamine reference vectors can then be 
defined.  The baseline reference vector consists of the baseline monoamine levels [0.50 0.50 0.50], 
the therapeutic reference vector consists of the therapeutic monoamine levels [0.70 0.70 0.70], and 
the excess monoamine reference vector consists of excessively high monoamine levels [0.80 0.80 
0.80]. The excess monoamine reference vector represents a tripling of the acute level and is 
Figure 15: MSS-model histograms showing number of adapted configurations associated with 
different monoamine and cortisol levels with combinations of SSRI, Asenapine, and Testosterone. 
Networks were adapted to SSRI alone (A), SSRI+Asenapine (an antipsychotic drug) (B), 
SSRI+Testosterone (TEST, a hormone) (C), and SSRI+Asn+TEST (D). (B) and (C) show that combining 
an SSRI with either Asn or TEST increases the proportion of high monoamine and low CORT states 
over the SSRI administered alone. (D) shows that combining an SSRI with both Asn and TEST further 
increases the proportion of high monoamine and low CORT states. 
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included in order to identify drug pairs and triples that may elevate the monoamines high enough 
to produce unwanted side effects (Shrier, Diaz et al. 2000, Boyer and Shannon 2005). 
All adapted monoamine vectors [5HT NE DA] that had any monoamine elevated above 
0.80 were ordered by their vector distance from the excess monoamine vector; all remaining 
adapted monoamine vectors were ordered by their vector distance from the therapeutic reference 
vector. This figure can be used as a tool to help predict monoamine levels following adaptation to 
chronic administration of each of the selected drug combinations, and to identify potentially 
effective interventions for the different subtypes of depression that are believed to respond to 
elevations in different monoamines (Malhi, Parker et al. 2002, Malhi, Parker et al. 2005)(see 4.5).  
The MS-model was used to evaluate the configurations adapted to chronic administration 
of 60 drug or drug/hormone pairs and triples. The 27 pairs consisted of SSRI paired with each of 
the 27 drugs and hormones that were used as individual (single) inputs in model training. The 33 
triples consisted of the subset of those pairs that have been used to augment SSRI action clinically 
(or experimentally in 1 case), combined with a third substance that was either Oxytocin (a 
hormone), Antalarmin (a CRF1 receptor antagonist), or Olanzapine (an antipsychotic). These 3 
substances were selected due to recent preliminary evidence suggesting that Oxytocin, Antalarmin, 
and Olanzapine could potentially have antidepressant effects either by themselves or in 
combination with another antidepressant (Corya, Andersen et al. 2003, Ducottet, Griebel et al. 
2003, Jutkiewicz, Wood et al. 2005, Parker, Buckmaster et al. 2005, Mathews, Garcia et al. 2006, 
Yoshida, Takayanagi et al. 2009). Figure 16 below shows the results of this analysis with the MS-
model.  
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Figure 16: Heatmap of MS-model adapted monoamine levels with SSRI, all other drugs paired 
with SSRI, and selected 3-drug combinations. Adapted monoamine levels were averaged over the 3 
networks and expressed as a vector [5HT NE DA]. The excess monoamine reference vector, representing 
levels high enough that they could be associated with unwanted side effects, was set to [0.80 0.80 0.80]. 
All drug combinations that resulted in 1 or more excess monoamine levels were ordered by vector 
distance from the excess monoamine reference vector. The therapeutic and the baseline reference vectors 
were set to [0.70 0.70 0.70] and [0.50 0.50 0.50], respectively. The baseline reference vector and all 
remaining drug pair and triple vectors were ordered by vector distance from the therapeutic reference 
vector. Abbreviations: GBR-12909, GBR; WAY-100635, WAY; Pramipexole, PPX; RU-28362, RU; 
Org-34850, Org; CP-96345, CP; Monoamine oxidase inhibitor, MAOI.  
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The MSS-model was used to evaluate networks adapted to chronic administration of SSRI, 
SSRI paired with 24 clinically relevant drugs or hormones, triples consisting of Testosterone and 
each of the 24 pairs, and triples consisting of Testosterone, Oxytocin, and one drug from each pair 
for a total of 74 drug/hormone combinations (plus SSRI by itself, for a total of 75 experiments).  
The results of this analysis can be viewed in Figure 17 below. The majority of the antidepressant 
combinations in Figure 17 show a reduction of NE levels (heatmap colors closer to the “blue” 
range) with chronic administration. It is unclear if the adapted configurations to these combinations 
all reduce NE, however. The histogram in Figure 14D illustrates that neuroadaptation to chronic 
antidepressant combinations (specifically SSRI/Quetiapine/Oxytocin in 14D) can lead to a bi-
modal distribution of NE, wherein about half of the neuroadapted configurations result in reduced 
NE levels, and the remaining half of the neuroadapted configurations result in elevated NE levels. 
The combined results of Figure 14D and Figure 17 suggest that different depressed male patients 
may respond to chronic administration of antidepressant with different patterns of NE release.       
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Figure 17: Heatmap of MSS-model adapted monoamine levels with SSRI, other selected drugs or 
hormones paired with SSRI, SSRI/other-drug/hormone triples, and drug/hormone/hormone 
triples. Adapted monoamine levels associated with neuroadaptation to SSRI, SSRI paired with other 
selected drugs or hormones, SSRI/other-drug/hormone triples, and drug (SSRI or 
other)/hormone/hormone triples were averaged over the three networks and expressed as a vector [5HTavg 
NEavg DAavg]. Vectors associated with drug or hormone pairs and triples, along with the baseline 
reference vector ([0.50 0.50 0.50]), were ordered by vector distance from the therapeutic reference vector 
([0.70 0.70 0.70]). The exceptions were drug or hormone combinations that resulted in one or more 
excess monoamine levels (> 0.80), which were ordered by vector distance from the excess monoamine 
reference vector ([0.80 0.80 0.80]). These combinations produced monoamine levels high enough that 
toxicity could be of concern.  
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3.2.4 FULL-RANGE INDIVIDUAL-WEIGHT ADJUSTMENT (FRIWA) TO EVALUATE THE 
THERAPEUTICITY OF EACH ADJUSTABLE WEIGHT 
Though we identified and examined adjustments in 10 (MS-model) or 13 (MSS-model) 
adjustable TSCs, it is possible that single TSCs can alone determine the therapeutic state in the 
MS- or MSS-model, regardless of the values of the weights representing the other adaptable TSCs. 
We define “therapeuticity” generally as the ability of a biological factor to alter the properties of 
a biological system in a therapeutic direction. Specifically here, therapeuticity is the ability of a 
TSC to alter 3 of the properties of interest in the MS- and MSS-models: the level of adaptation, 
the level of 5HT, and the level of CORT. Identification of the TSCs that could alone determine 
therapeutic state could enhance antidepressant drug design by identifying specific receptors or 
transporters that could be targeted in single-drug therapies. 
  In order to identify single adjustable TSCs that may be mediating therapeutic effects by 
themselves, a form of sensitivity analysis was conducted that evaluated the contribution of each 
individual adjustable TSC to therapeutic adaptation with chronic SSRI administration. Here we 
define “therapeutic configurations” as those adjusted TSC-strength configurations that endow their 
associated, adjusted network with 3 properties: adaptation (adaptation error lower than initial error 
(MS-model) or reduced by at least 25% of initial error (MSS-model); 5HT elevation (5HT >=0.70); 
and CORT reduction (CORT <=0.70)). The weights for each TSC were compiled for all resistant 
and all sensitive post-FRIWA configurations and averaged for each of the 3 representative 
networks separately in each model (see 2.2.2.2.3).  
The average values of the TSC weights over either the resistant or sensitive configurations 
are plotted for each representative network in blue, red, or green for the MS- and MSS-models in 
Figure 18 and Figure 19, respectively. These figures illustrate that the average resistant and 
sensitive TSC strengths (corresponding to TSC network connection weights) differ between the 3 
representative networks, but that the average resistant and sensitive TSC strengths are about the 
same in each network. Although the 3 networks are indeed different in their specific weight values, 
the FRIWA analysis shows that they are similar in that no single TSC in any of the 3 is 
determinative of the therapeutic state by itself. This finding is true of both the MS- and MSS-
models. 
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Figure 18: Comparison of MS-model average adjustable TSC strengths between resistant and 
sensitive configurations in all representative networks. Every configuration adapted to chronic SSRI 
that was also therapeutic (high 5HT and low CORT) at degree 6 was assessed for resistance to 
adjustments of each of the 10 adjustable TSCs. All TSC strength adjustments that resulted in 
configurations that were no longer adapted were excluded. Configurations that remained adapted and 
therapeutic following weight adjustments were determined to be “resistant” and adapted configurations 
that were no longer therapeutic following TSC adjustments were determined to be “sensitive.” The 
average strength of each of the 10 adjustable TSCs in all of the configurations, excluding those in which 
that TSC itself was adjusted, was computed for both the resistant and sensitive configurations and plotted 
as asterisks or diamonds, respectively. The results for all 3 networks are represented on this single plot 
using 3 different colors (red, blue, or green) to distinguish between the mean adjustable TSC strengths 
of each network. Note that the average resistant and sensitive strengths for each adjustable TSC are very 
close in all 3 networks, illustrating that each individual TSC can provide a contribution to therapeutic 
resistance, but no single TSC by itself determines the therapeutic state.  
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3.2.5 PAIRWISE CORRELATIONS BETWEEN ADAPTABLE TSC STRENGTHS 
The FRIWA analysis considered 1 adjustable TSC at a time. It does not rule out the 
possibility that therapeuticity may be a property of correlations between pairs of TSCs rather than 
of single TSCs by themselves. To evaluate this possibility in both the MS- and MSS-models, 
pairwise correlations between all TSC weights over either all resistant or all sensitive 
configurations were computed for each representative network (separately in each model), but 
again, the TSC weights that were adjusted using FRIWA were removed because their values were 
manipulated. Even at the permissive significance level of p = 0.05, the analysis found no 
significant pairwise correlations between adjustable TSCs that were consistent over all 3 
representative networks in either the resistant or the sensitive configurations. This finding was the 
same for both the MS- and MSS-models.   
Figure 19: Average MSS-model adjustable TSC-strength comparison between resistant and 
sensitive configurations. Every therapeutic (high 5HT and low CORT) configuration adapted to chronic 
SSRI was assessed for resistance to full-range adjustments of the weights representing each of the 13 
adjustable TSCs taken individually. The average strength of each of the 13 adjustable TSCs in all of the 
configurations, excluding those in which that TSC itself was adjusted using FRIWA analysis, was 
computed for both the resistant and sensitive configurations and plotted as asterisks or diamonds, 
respectively. The results for all 3 representative networks are shown on this single plot with 3 different 
colors (red, blue, or green) to distinguish between the mean adjustable-TSC strengths of each network. 
Note that the average resistant and sensitive strengths for each adjustable TSC are very close in all 3 
networks, illustrating that no individual TSC mediates the therapeutic state by itself.  
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3.2.6 TEMPORAL-LOGIC MODEL-CHECKING 
As described in 3.2.4, the FRIWA and correlation analyses examined a large space of 
configurations adapted to an SSRI and determined that no single TSC, nor pairs of TSCs, mediates 
therapeutic resistance by themselves in either the MS- or MSS-models. Neuroadaptation to chronic 
antidepressant, where each TSC change is incremental, can also be examined as a process to 
determine if specific states or degrees of neuroadaptation must be reached prior to arriving at 
therapeutic configurations. Linear temporal-logic (LTL) analysis can be used to elaborate all 
pathways of sequential TSC-strength adjustments in order to evaluate possible temporal 
relationships in neuroadaptation (see 2.3.2). This mode of analysis can be used to determine 
whether certain numbers of TSC-strength adjustments, once attained, will always lead to an 
adapted and therapeutic state. 
The antecedent of the LTL propositions we analyzed specified that a specific TSC had been 
adjusted 3 times, either up or down (see 2.3.2 for details). The antecedent of 3 adjustments was 
chosen because it was halfway between 0 and 6, the total number of adjustments to which we were 
limited for technical reasons. The consequent queried whether all subsequent sequences of up to 3 
adjustments in any subset of the 10 (MS-model) or 13 (MSS-model) TSCs would all lead to an 
adapted and therapeutic state (5HT >= 0.70 and CORT <= 0.70). Each LTL model-check was 
carried out using each of the 3 networks for 6 total adjustments in all TSCs, and only those model-
checking results that were consistent over all 3 networks are reported for each model. All 
propositions returned false for both the MS- and MSS-models.  
We next examined the more easily satisfiable propositions that once a specific TSC had 
been adjusted 3 times, either up or down, then all subsequent sequences of up to 3 adjustments in 
any subset of the adjustable TSCs would all lead to an adapted and therapeutic state, or the TSC 
no longer maintains its degree of adjustment. This proposition allowed for the possibility that 
failure to maintain an adapted and therapeutic state occurred because the specific TSC had not 
maintained the specified level of adjustment. All of these more satisfiable propositions, however, 
again returned false, as shown in Table 6 for the MS-model and Table 7 for the MSS-model.  
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Experiment 
Condition (at 3 adjustments         
and beyond) 
Leads to 5HT high and CORT 
low? 
1 DR 5HT1AR desensitization False 
2 LC AR2 desensitization False 
3 VTA D2R desensitization False 
4 5HT 5HTT desensitization False 
5 NE NET desensitization False 
6 DA DAT desensitization False 
7 PVN GCR desensitization False 
8 Pituitary GCR desensitization False 
9 Adrenal GCR desensitization False 
10 Pituitary CRF1R desensitization False 
11 DR 5HT1AR sensitization False 
12 LC AR2 sensitization False 
13 VTA D2R sensitization False 
14 5HT 5HTT sensitization False 
15 NE NET sensitization False 
16 DA DAT sensitization False 
17 PVN GCR sensitization False 
18 Pituitary GCR sensitization False 
19 Adrenal GCR sensitization False 
20 Pituitary CRF1R sensitization False 
 
 
 
 
 
 
 
 
 
Table 6: Linear temporal-logic (LTL) analysis on the relationship between TSC-adjustments and 
a therapeutic state in the MS-model. Each LTL analysis was used to evaluate whether 3 steps of 
sensitization (adjustment up) or desensitization (adjustment down) of a specific TSC during 
neuroadaptation to chronic SSRI leads, over an ensuing 3 additional adjustments over any subset of the 
10 TSCs, either to adapted and therapeutic configurations, or to failure to maintain sensitization or 
desensitization of the specific TSC. Only the results of LTL model-checks that were in agreement in all 
3 networks are reported here. All propositions returned false, meaning that desensitization or 
sensitization of single adjustable-TSCs for 3 adjustment steps is not determinative of subsequent adapted 
and therapeutic states.   
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Experiment Condition (at 3 adjustments and 
beyond)  
Leads to 5HT high 
and CORT low? 
1 DR 5HT1AR desensitization False 
2 LC AR2 desensitization False 
3 VTA D2R desensitization False 
4 5HT 5HTT desensitization False 
5 NE NET desensitization False 
6 DA DAT desensitization False 
7 PVN GCR desensitization False 
8 Corticotroph GCR desensitization False 
9 Adrenal gland GCR desensitization False 
10 POA AR desensitization False 
11 Gonadotroph AR desensitization False 
12 Testes FSHR desensitization False 
13 Testes LHR desensitization False 
14 DR 5HT1AR sensitization False 
15 LC AR2 sensitization False 
16 VTA D2R sensitization False 
17 5HT 5HTT sensitization False 
18 NE NET sensitization False 
19 DA DAT sensitization False 
20 PVN GCR sensitization False 
21 Corticotroph GCR sensitization False 
22 Adrenal gland GCR sensitization  False 
23 POA AR sensitization False 
24 Gonadotroph AR sensitization False 
25 Testes FSHR sensitization False 
26 Testes LHR sensitization False 
The LTL analysis shows that 3 adjustments of any single adjustable TSC weight up or 
down will not guarantee that a therapeutic state will be reached. All propositions returned false to 
degree 6, and it is unlikely that they would be true if the LTL analysis extended to greater degrees 
of adjustment because that would entail additional opportunities for TSC de-adjustment and 
Table 7: Linear temporal logic (LTL) analysis on the association between TSC-strength 
adjustments and the therapeutic state in the MSS-model. Each LTL analysis evaluated 
whether 3 steps of sensitization (adjustment up) or desensitization (adjustment down) of a 
specific adjustable TSC during neuroadaptation to chronic SSRI leads to adapted and therapeutic 
configurations when another 3 adjustments over all the TSCs are made. Only the results of LTL 
model-checking experiments that were in agreement in all 3 representative networks are 
reported. All propositions returned false, meaning that desensitization or sensitization of single 
TSCs for 3 adjustment steps does not lead to subsequent states that are all adapted and 
therapeutic.   
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overall de-adaptation. We did not attempt an exhaustive LTL analysis because the number of 
potentially relevant propositions that could be tested is simply too many. The result we generated, 
that 3 adjustments either up (sensitization) or down (desensitization) in no single TSC by itself can 
lead to states that are all therapeutic within 3 additional adjustments over the other TSCs or itself, 
supports the FRIWA analysis finding that adjustment of no single weight individually can 
determine the therapeutic state when the other TSCs can also adjust. These findings were in 
agreement between the MS- and MSS-models and impose potential challenges to effective 
antidepressant drug design (see 4.4). 
We were next interested in whether there are connected regions (clusters) of therapeutic 
states in the space of TSC-strength configurations. The Henceforth LTL analysis represents a 
technological advancement exclusive to the MSS-model. This MSS-model analysis determined 
that there are few TSC-strength configurations (0.06% of therapeutic states over all three 
networks) where all configurations that both precede and leave that configuration (before and after 
an adjustment in a specific TSC) are therapeutic. However, there are clusters where most TSC-
strength adjustments lead to therapeutic states; 37.8% of therapeutic states have the property that 
a majority of states within four adjustment steps are also therapeutic. This analysis shows that 
therapeutic states tend to be spatially localized in few pockets within the space of possible TSC-
strength configurations. Overall these results suggest that the space of TSC-strength configurations 
has some structure, but also shows that there are no single, pairs, or subsets of TSCs that can 
guarantee therapeuticity by themselves.  
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CHAPTER 4: DISCUSSION 
 
4.1 OVERVIEW 
We have developed three computational models of the antidepressant response. The 
Monoamine-model (M-model) represents the monoaminergic and related transmitter systems, the 
Monoamine-Stress-model (MS-model) extends that to include the stress hormone system, and the 
Monoamine-Stress-Sex-model (MSS-model) extends the MS-model to also incorporate the 
interactions of the male sex steroids. All three models were trained to reproduce experimental data 
on acute inputs and used to examine neuroadaptation through transmitter system component (TSC) 
strength adjustments with chronic drug, hormone, or combinations. Analysis of all three models 
utilized both imperative and declarative programming methods and leveraged their complementary 
capabilities. 
Our models differ in neurobiological detail (limited in M-model and expanded in MS- and 
MSS-models), structure (Region vs System), and training method (GA vs GD), but all three 
contribute to our understanding of adaptation to chronic antidepressant and suggest drug and 
drug/hormone combinations that are potentially more therapeutic than single antidepressants. 
Temporal-logic model-checking extended our use of declarative programming tools with analysis 
in the MS- and MSS-models of temporal relationships between different receptor-strength 
configurations in terms of neurotransmitter and hormone levels and receptor desensitization with 
adaptation to chronic SSRI. The three models differ substantially in extent, structure, and in 
method of parameter optimization, but all three are valid in that they accurately reproduce 
experimental observations over their domains and can therefore justifiably be used to make 
predictions in their respective domains. All three were used, specifically, to predict responses to 
chronic drug (or drug and hormone) combinations. Critically, all three models illustrate that 
heterogeneity in response to chronic antidepressant should be expected—due to the multiplicity in 
TSC types that are known to change their strength (expression and sensitivity) in that context.  
 
4.2 COMPARISON WITH OTHER MODELS OF THE MONOAMINERGIC NERVOUS 
SYSTEM  
Our models are the first of their kind in that they offer a more complete representation than 
all other available models of the monoaminergic neurotransmitter system and related interactions. 
They introduce declarative programming, exhaustive search methods, and temporal-logic model-
checking to the neuropharmacology field.  
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A mathematical model of serotonin synthesis, release, and reuptake in axon terminals was 
developed by one group to better understand the effects of autoreceptor activation on DA and 5HT 
neuron firing patterns (Best, Nijhout et al. 2010, Best, Reed et al. 2010, Best, Nijhout et al. 2011). 
The same group used mathematical models of DR neurons with normal and low vesicular 5HT to 
study the adaptation of DR neurons to chronic SSRI. Through the use of differential equations that 
represent the concentrations and activity levels of different proteins involved in 5HT metabolism 
and release, the authors demonstrated that acute doses of SSRIs do not bring the burst firing of DR 
neurons back to normal, but chronic use of SSRIs do return the burst response to normative levels. 
Although many models of DA-producing neurons exist, one group notably produced a neuro-
computational model of VTA afferents to better understand putative, neurobiological temporal-
difference learning rules, designing an architecture that is similar to ours in that it includes multiple 
units representing non-monoaminergic neurons that interact with a unit representing a 
monoaminergic (specifically a VTA) neuron (Vitay and Hamker 2014).  
Our models have features in common with these models, namely that they represent neuron 
activity levels and concentrations of transmitters. Our models can be distinguished from the others, 
however, in that they are the first of their kind to represent interactions between all three 
monoaminergic brain regions and regions producing non-monoaminergic transmitters. Among the 
potentially important factors left out of the M-model are presynaptic receptors, but they are 
included in the MS- and MSS-models. In the M-model, the non-monoaminergic transmitter units 
(tCRF, Tgal, and Tglu) are not included in the activation error calculation because they group 
together neurons from various brain regions that most likely do not all undergo drug-dependent 
changes of the same magnitude and direction. The non-monoaminergic units are differentiated into 
units representing discrete brain regions in the MS- and MSS- models.  
We took the monoamine hypothesis as a starting point due to the finding that drugs that 
elevate the monoamines are more effective than placebo in treating depression without making the 
assumption that monoamines are deficient in depressed patients (Anderson 2000, Khan, Brodhead 
et al. 2005, Li, Li et al. 2014). We expanded this view by also considering the relationship between 
the monoamines and the HPA axis in the MS-model, and the relationship between the 
monoamines, HPA axis, and the male HPG axis in the MSS-model.  
By modeling the monoaminergic neurotransmitter system, we do not exclude or refute 
other leading hypotheses on the neurobiology of depression. 5HT may or may not be deficient in 
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depressed patients, however, relief from depressive symptomology has been associated with 
elevated 5HT levels (Haddjeri, Blier et al. 1998, Evans, Golshan et al. 2002, Albert, Vahid-Ansari 
et al. 2014). Our approach does not assume that monoamine levels are deficient prior to 
antidepressant treatment, but it does assume that monoamine elevation, directly or indirectly, is 
involved in mediating antidepressant effects as consistent with the monoamine hypothesis 
(Schildkraut 1965, O'Reardon, Chopra et al. 2004).  
One leading alternative to the monoamine hypothesis is that the decrease in the level of 
hippocampal brain-derived neurotrophic factor (BDNF) (involved in hippocampal neurogenesis) 
may lead to depression (Duman and Monteggia 2006). However, drugs that elevate monoamine 
levels also elevate hippocampal BDNF (Coppell, Pei et al. 2003, De Foubert, Carney et al. 2004, 
Sillaber, Panhuysen et al. 2008, Berger, Mehra et al. 2010). Other groups hypothesize that 
neuropeptide transmitter systems or the relative activations of interacting brain regions may be 
implicated in depressive symptomology (Mayberg, Liotti et al. 1999, Mayberg, Brannan et al. 
2000, Kennedy, Evans et al. 2001, Holmes, Heilig et al. 2003, Flores-Burgess 2016). Depression 
relief associated with changes in the levels of neuropeptides or in the relative activity of brain 
regions, however, are also believed to be closely associated with elevations in monoamine levels 
(Mayberg, Liotti et al. 1999, Mayberg, Brannan et al. 2000, Lu, Barr et al. 2005, Rovin, Boss-
Williams et al. 2012). Moreover, changes in TSC strength with chronic antidepressant 
administration will most likely cause changes in transmitter levels, and we assume that 
therapeutically elevated monoamines alleviate depressive symptomology through associations 
with mechanisms that have been suggested previously. 
 
4.3 NEUROADAPTATION AS AN EXPLANATION FOR ANTIDEPRESSANT RESPONSE 
HETEROGENEITY 
A key contribution of our study is a possible explanation for the clinical finding that 
antidepressants are effective in less than half of depressed patients (Rush, Trivedi et al. 2006, 
Young, Kornstein et al. 2009, Li, Li et al. 2014). All three models show that states neuroadapted 
to chronic SSRI can have a distribution of many different adapted 5HT levels, and the MS- and 
MSS-models extend this finding by also showing that states neuroadapted to chronic SSRI can 
also have a distribution of many different adapted CORT levels. These findings agree with the 
high variability in response and low efficacy rate for SSRIs that has been observed clinically (Rush, 
Trivedi et al. 2006, Young, Kornstein et al. 2009, Li, Li et al. 2014). All three models also show 
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that states neuroadapted to other chronic antidepressants also have distributions of many different 
monoamine levels. This is also consistent with the results of clinical trials using various chronic 
antidepressants (Rush, Trivedi et al. 2006). 
Previous studies have found significant differences in baseline performance and behavioral 
response to antidepressant administration between rodent strains, with substantial variability even 
within inbred rodent strains (Liu and Gershenfeld 2001, Lucki, Dalvi et al. 2001, Ripoll, David et 
al. 2003, Petit-Demouliere, Chenu et al. 2005, Crowley, Brodkin et al. 2006). Differences in the 
phenotypic expression of the serotonin transporter have also been found within inbred rodent 
strains (Carneiro, Airey et al. 2009). Together, these findings support the prediction that different 
members of the same species can adapt differently to the same antidepressant.   
Our models make the general prediction that the monoaminergic and neuroendocrine 
systems of individuals of the same species, especially if they differ genetically or in previous 
experience or in environmental conditions or in other relevant ways, should differ in the activity 
levels of neuroadapted brain regions and patterns of release of the three monoaminergic 
neurotransmitters (5HT, NE, and DA) and CORT under chronic administration of the same 
antidepressant drug or drug combination. Although genetic and environmental associations 
between monoamine levels, depression susceptibility, and antidepressant response have been 
explored (Rogers, Martin et al. 2004, Walf and Frye 2010), experiments designed directly to test 
this general prediction have not been undertaken but would be needed to validate our modeling 
approach. The null hypothesis is that the nervous systems of individuals of the same species will 
all attain the same patterns of neural region activity level and neurotransmitter and neurohormone 
release under chronic administration of the same antidepressant drug or drug combination, 
regardless of differences in strain or prior experience or environmental conditions or in other 
relevant factors. Verification of this null hypothesis would be of immense value in itself. 
 
4.4 THERAPEUTIC NEUROADAPTATION TO CHRONIC ANTIDEPRESSANT AS 
OVERDETERMINED 
The finding that only a subset of the many possible TSC-strength configurations is both 
adaptive and therapeutic raises the possibility that one, or only a few, of the adjustable TSCs are 
determinative of the therapeutic state. This possibility was evaluated with the MS- and MSS-
models. First, we used FRIWA analysis (our customized variant of sensitivity analysis) to explore 
this possibility for individual TSCs in all 3 representative networks of each model. We found that 
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some configurations were “resistant” in that they remained adapted and therapeutic despite 
individual-weight adjustment (IWA) applied to a TSC. Other configurations were “sensitive” in 
that they did not remain adapted and therapeutic despite IWA applied to a TSC. The average values 
of individual TSC strengths, however, were essentially the same in resistant versus sensitive 
configurations (Figure 8) in all 3 networks of both (MS- and MSS-) models, indicating that no 
TSC by itself is determinative of the therapeutic state.  
We then used correlation analysis to explore the possibility that pairs of TSCs were 
determinative of the therapeutic state, and considered all pairs that were significantly correlated at 
the relatively permissive significance level of p = 0.05. We found that no pair of TSCs was 
significantly correlated in either the resistant or sensitive configurations over all 3 representative 
networks (Figures 18 and 19), showing that no pairs of TSCs are together determinative of the 
therapeutic state in either the MS- or MSS- model. 
We then used LTL analysis to explore the possibility that a specific TSC, once it reached 
a certain level of sensitization or desensitization, could guarantee a therapeutic outcome. For 
technical reasons (see B.20), the number of steps of adjustment we allowed in the strength of each 
TSC was limited to 6, and our LTL analysis took this constraint into account. For each TSC, we 
tested the truth or falsehood of two LTL propositions essentially asserting that if a given TSC has 
reached a certain level of sensitization or desensitization by three adjustment steps, then the 
network is guaranteed to arrive at an adapted and therapeutic configuration no matter what the 
other TSCs do in the remaining three adjustment steps. All of these propositions returned false in 
our LTL analysis (Tables 6 and 7). The MSS-model took this analysis a step further to include a 
novel LTL analysis designed to search for specific clusters of therapeutic states that are near each 
other in the space of TSC-strength configurations. It considered all degree-1 neighborhoods, 
defined as all the TSC-strength configurations within 1 adjustment step from a specified TSC-
strength configuration. This LTL analysis found that there were no therapeutic TSC-strength 
configurations whose degree-1 neighbors were all also therapeutic. Clearly then, there would be 
no completely therapeutic neighborhoods of degree higher than 1. 
What all of these analyses show is that no single TSC, nor pair of TSCs, nor TSCs that 
have attained a certain degree of adjustment, can determine the therapeutic state. They 
demonstrate, more generally, that the properties of interest in the model (the level of adaptation, 
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the levels of the 3 monoaminergic transmitters, and the level of CORT) are overdetermined by the 
10 (MS-model) or 13 (MSS-model) TSCs. 
In their overdeterminedness (or degeneracy), the MS- and MSS-models make contact with 
other models depicting phenomena at both network and neuronal levels of neurobiological 
organization. In the vertebrate brain, sensory signals, motor commands, and information in general 
is represented not by single neurons but by networks of neurons. These representations are 
overdetermined because the pieces of information are few relative to the number of neurons in the 
network that represents them. In consequence, the same information can be distributed in many 
different ways over a network, and neurons in the same network can vary greatly in their response 
properties in what has been termed a non-uniform distributed representation (Anastasio 1991, 
Anastasio 2010).  
Overdetermination of physiological properties by the values of multiple, relevant 
parameters has also been demonstrated for single neurons and computational models of thereof 
(Edelman and Gally 2001, Golowasch, Goldman et al. 2002, Bucher, Prinz et al. 2005); reviewed 
in (Marder and Taylor 2011). The most well-known case in point was established by Eve Marder 
and colleagues in their model of the lateral pyloric neuron (LPN) in the lobster somatogastric 
ganglion (Taylor, Goaillard et al. 2009). In the invertebrate brain, information is sometimes 
represented not by neural networks but by single, very large (i.e. “giant”) neurons that are 
identifiable from one animal to another. Experiments revealed that many different ion channels 
determine the electrophysiological properties of LPNs, and that the parameters that determine the 
function of ion channels of specific types can vary between LPNs from different decapods 
(Golowasch and Marder 1992, Golowasch, Goldman et al. 2002, Schulz, Goaillard et al. 2007). 
The Marder group developed a biophysically detailed model of the LPN and identified 17 
parameters (i.e. the conductances and some related properties of 10 ion channel types) that 
plausibly could vary between individual LPNs. They generated ~6 x 105 different configurations 
of these 17 parameters and found, after evaluating them all computationally, that 1304 of those 
configurations endowed the LPN model with the same, realistic set of electrophysiological 
properties (number of spikes, spike frequency, spike duration, burst duration, etc.). Rather than 
grouping into specific sets of values, however, the Marder team found that LPN models having 
equally realistic electrophysiological properties could vary greatly in the values of their 17 
defining, ion-channel parameters (Taylor, Goaillard et al. 2009). By examining parameter value 
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distributions and correlations, they found further that no single parameter nor pair of parameters 
was determinative of LPN model properties.   
Analogously, we find that many different configurations of TSC-strengths can endow the 
MS-model with the property of adaptation to simulated, chronic SSRI, but we take this a step 
further and show that the adapted configurations can also differ in other properties, namely in their 
levels of the monoamines. Overall, these computational studies suggest that there is a large amount 
of degeneracy in neurobiological systems in general. Our models specifically implicate 
overdeterminedness as a consequence of the complexity inherent in the antidepressant response 
that poses a challenge to the identification of an antidepressant drug or hormone combination that 
is effective in all patients (Edelman and Gally 2001). An approach that recognizes different 
subtypes of depression, and matches those with monoamine profiles predicted from computational 
models of the adapted antidepressant response, could provide an effective means of identifying 
promising drug combinations.  
 
4.5 CLINICAL RELEVANCE OF THE MODELING RESULTS ON ANTIDEPRESSANT AND 
HORMONE COMBINATIONS  
A consensus is forming around the general idea that multifactorial diseases should be 
treated with multidrug therapies (Stewart, McGrath et al. 2014, Perry, Sperling et al. 2015, 
Anastasio 2017). It has become common practice to treat psychiatric disorders with combinations 
of drugs, but the approach has been ad hoc and based mainly on clinical trial-and-error (Barowsky 
and Schwartz 2006). SSRI non-responders are often treated with combinations of two drugs 
(Trivedi, Fava et al. 2006), but systematic evaluation of the relative benefits of different 
combinations of two or more drugs in depression treatment has not occurred. Clinicians designing 
antidepressant augmentation strategies are challenged by the overwhelming complexity of 
depression neurobiology, and the potentially even more overwhelming number of possible drug 
combinations to choose from to treat depression. 
The identification of novel, multidrug treatments for depression could proceed either 
through rational design or brute-force screening of drug combinations. The main challenge 
associated with rational design is the overwhelming complexity of the neurobiology of depression, 
which makes it extremely difficult to know a priori how any specific drug combination will work. 
The main challenge associated with brute-force screening is the sheer number of possible drug 
combinations, which grows geometrically with the number of drugs.   
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Our computational modeling approach addresses both challenges. It addresses rational 
design by computationally representing many aspects of the structure and function of the 
monoaminergic transmitter and stress hormone systems, whose interactions are central in 
depression neurobiology. It addresses combinatorial explosion by providing the means 
computationally to screen a large set of drug combinations, and to identify the most promising 
combinations for clinical evaluation. Addressing these dual challenges is crucial, because 
treatment with SSRI alone, which is currently the first-line treatment for depression, is less than 
40% effective, and efficacy is not greatly increased when SSRI is combined with another drug 
(Rush, Trivedi et al. 2006).  
The M-model predicted that the combination of an SSRI with SCH could potentially be 
therapeutic for a higher proportion of patients than SSRIs by themselves (see 3.1.6). It was also 
used to screen for the effects of combinations of antidepressants on the proportions of adapted 
states with high monoamines (see D.1: Potential Clinical Relevance of M-model Results). The 
MS-model was then used to identify drug and hormone combinations that could potentially be 
more therapeutic than single drugs for patients suffering from specific subtypes of depression (see 
Figure 16). Because the therapeutic effects of chronic antidepressant use have been associated with 
elevations in monoamine levels and reductions in CORT levels, we were specifically interested in 
configurations that reproduced these experimentally and clinically observed changes (Ruhe, 
Khoenkhoen et al. 2015) (Ceglia, Acconcia et al. 2004).  
The MS-model identifies Asenapine, Olanzapine, Bupropion, and Oxytocin as adjuncts to 
SSRI therapy that hold particular promise. Precedent for the use of these adjuncts has been 
established clinically. Physicians in practice frequently resort to the augmentation of SSRIs with 
antipsychotics such as Asenapine and Olanzapine in SSRI-monotherapy non-responders 
(Mathews, Garcia et al. 2006) (Bjorkholm, Franberg et al. 2015). The atypical antidepressant 
Bupropion has also been found to relieve depressive symptoms in SSRI non-responders and is 
widely used clinically, either by itself or in conjunction with SSRI (Maron, Eller et al. 2009) 
(Zisook, Rush et al. 2006). Intranasal administration of the hormone Oxytocin combined with 
chronic SSRI also can be more effective in treating depressed patients than SSRI by itself (Parker, 
Buckmaster et al. 2005). 
Our computational drug/hormone combination screen can potentially fine-tune combined 
pharmacotherapy for depression, as different subtypes of depression have previously been shown 
74 
 
to respond best to elevations in the levels of the different monoamines (Malhi, Parker et al. 2002, 
Malhi, Parker et al. 2005). Specifically, patients with non-melancholic, melancholic, or psychotic 
depression have been observed to respond best to antidepressants that elevate 5HT, NE, or DA, 
respectively (Malhi, Parker et al. 2005) (Parker, Roy et al. 1992) (Malhi, Parker et al. 2002). Drug 
combinations that included Trazodone (an SNRI), Olanzapine (an antipsychotic), and GBR-12935 
(a DAT antagonist) tended to raise 5HT, NE, and DA levels, respectively, in the MS-model.  
The MSS-model is specific to the male neuroendocrine system. The histograms in Figure 
15 and the heatmap in Figure 17 show that certain combinations of antidepressants and the 
hormone testosterone could be more effective than SSRI by itself as a treatment for depression in 
men. Preliminary clinical studies suggest that Testosterone supplementation can enhance the 
antidepressant response (Orengo, Fullerton et al. 2005, Miller, Perlis et al. 2009). The 
combinations that included an SSRI, another drug that targeted the monoamines, and Testosterone 
were in the upper range of the Figure 17 heatmap, close to the therapeutic reference vector. Of 
note, SSRI/Desipramine/Testosterone, SSRI/Clozapine/Testosterone, and 
SSRI/Venlafaxine/Testosterone were found by the MSS-model to elevate levels of all 3 
monoamines, and may increase the proportion of male patients who experience depression relief.  
Our overall modeling strategy is both rational and brute force. It is rational in that the 
models incorporate, both in their structure and function, many aspects of the known interactions 
between the monoamines and related transmitter and neuroendocrine systems. It is brute force in 
that it can be used to screen large numbers of drug combinations computationally, and to predict 
the distributions of monoamine levels that could be expected in a diverse patient population in 
which each individual can adapt to the chronic drug regimen in their own unique way. Our models 
can be used to explore neuroadaptive configurations and to propose drug/hormone combinations 
that could be therapeutic for a higher proportion of patients than single-drugs by themselves. They 
could also be used to direct antidepressant drug-design toward specific depressive subtypes, by 
predicting the average levels of each of the three monoamines that would be expected in a patient 
population following adaptation to chronic administration of various drug combinations.  
 
4.6 CALL FOR MORE DEPRESSION RESEARCH IN FEMALE MODELS 
Unfortunately, data on the female neuroendocrine system sufficient to develop a female 
version of the MSS-model analogous to the male version was unavailable. Although the depression 
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literature has a reasonable volume of experimental data on the female sex-steroid system and 
depression, scientific reports of findings on the interactions between the monoaminergic-
neurotransmitter, stress-hormone, and sex-hormone systems of females are rare. This lack of data 
from female animal models of depression is especially problematic because women are twice as 
likely as men to suffer from depression (Weissman, Bland et al. 1996) (Strine, Mokdad et al. 2008). 
Current clinical approaches to antidepressant pharmacotherapy are largely similar for both sexes 
(MacQueen, Santaguida et al. 2017), yet it has been observed that women and men respond better 
to different antidepressant drugs and combinations (Young, Kornstein et al. 2009).  
Sex-specific computational models would provide the capability to individualize 
antidepressant treatment regimens by computationally screening for drug and drug and hormone 
combinations in models that incorporate sex differences in their structure and behavior. It is 
therefore crucial for experimental neurobiologists to collect data on female monoaminergic-
hormonal interactions, in order to permit modelization of the female neuroendocrine system and 
computational identification of novel drug/hormone combinations that potentially could treat 
depressed women more effectively.  
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APPENDIX A: INTRODUCTION APPENDICES 
 
A.1 OVERVIEW OF STRESS, HPA AXIS, AND CORTISOL 
Stress is a condition that perturbs the physiological and psychological balance of an 
individual. The brain responds to stress through activation of the hypothalamic-pituitary-adrenal 
axis (HPA axis) (Pariante and Lightman 2008). Hypothalamic neurons located in the 
paraventricular nucleus (PVN) of the hypothalamus respond by releasing corticotropin-releasing 
factor (CRF), which in turn stimulates the release of adrenocorticotropin (ACTH) from the anterior 
pituitary gland, signaling the release of cortisol from the adrenal gland (Nemeroff and Vale 2005). 
In addition to its role in the stress response, CRF has been found to be involved in the regulation 
of several autonomic nervous system functions, including learning, memory, feeding, and 
reproduction (Valentino and Foote 1988, Chatterton 1990, Valentino, Foote et al. 1993, Petraglia, 
Florio et al. 1994). CRF is widely expression throughout the central nervous system and has even 
been found to be expression in some peripheral tissues (Waters, Rivalan et al. 2015).  
CRF binding to CRF receptors in the anterior pituitary leads to the release of ACTH into 
the systemic circulation. ACTH binds to melanocortin type 2 (MCR-2) receptors of the adrenal 
gland, leading to secretion of cortisol and other steroid hormones, including androgenic steroids 
(Mountjoy, Robbins et al. 1992). Cortisol secretion has profound effects on metabolism and 
behavior through interactions with glucocorticoid receptors (GRs). GRs are widely distributed 
throughout the brain and peripheral tissues (Patel, Lopez et al. 2000). They are involved in 
mediating metabolic, cardiovascular, immune, and behavioral responses to stress (Evans, Murray 
et al. 2000, Furay, Bruestle et al. 2008, Matthews, Berry et al. 2015). Some of cortisol’s known 
effects on the brain include regulation of neuronal survival, neurogenesis, hippocampus size, and 
the acquisition of new memories (Herbert, Goodyer et al. 2006, Pariante and Lightman 2008). 
Importantly, they are also involved in feedback inhibition of the HPA axis (Nestler, Barrot et al. 
2002). Although they have been thought traditionally to mediate their negative feedback through 
a delayed feedback system involving intracellular GRs and genomic changes, there is recent 
evidence that GRs can also mediate a fast, nongenomic feedback effect as well through plasma-
membrane receptors (Losel and Wehling 2003). This “fast feedback” effect mediated by GRs is 
not yet fully understood. GRs have been found to mediate negative feedback at all levels of the 
HPA axis (PVN, pituitary gland, and adrenal gland), and have also been found to mediate feedback 
inhibition on the HPA axis at the level of the hippocampus (Pariante and Lightman 2008).  
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Due to its involvement in mediating the physiological response to stress, dysregulation of 
the HPA axis has been studied extensively in the context of psychiatric disorders. Abnormalities 
in HPA axis regulation have been consistently found in association with depression (Gold and 
Chrousos 2002, Gillespie and Nemeroff 2005, Becker, Zeau et al. 2008). Evidence supporting the 
claim that HPA activity is dysregulated in depressed patients is supported by the outcome of the 
Dexamethasone test in humans. Dexamethasone is a synthetic glucocorticoid that induces a potent 
inhibitory effect on the HPA axis in healthy patients by stimulating the GRs that mediate HPA 
axis negative feedback. However, depressed patients do not respond to Dexamethasone, as 
evidenced by elevated cortisol levels in response to the test when compared to controls. 
Interestingly, antidepressant drugs that target the monoamines have been found to reverse this 
impairment in HPA axis negative feedback. 
Evidence suggests that stressful life events are involved in the precipitation of depression 
(Shea, Walsh et al. 2005, Bravo, Dinan et al. 2014, Weder, Zhang et al. 2014). Activation of the 
stress response by acute stressors can be adaptive in the short-term (Korte, Koolhaas et al. 2005). 
However, chronic or repeated stress can prevent a return to a healthy state in susceptible 
individuals, and lead to the HPA axis hyperactivation observed in depressed patients (Heim, 
Newport et al. 2001, de Kloet, Joels et al. 2005). This hyperactivation is characterized by increased 
levels of cortisol in the saliva, plasma and urine, and increased size (as well as activity) of the 
pituitary and adrenal glands (Shea, Walsh et al. 2005). 
Current antidepressant drugs target the monoaminergic neurotransmitter systems (Berton 
and Nestler 2006, Hamon and Blier 2013). In addition to (or potentially as an indirect result of) 
their influence on the monoamines, antidepressant drugs can reverse the hyperactivation of the 
HPA axis observed in depressed patients (Aihara, Ida et al. 2007). The relationships between the 
monoaminergic neurotransmitter-producing regions and the HPA axis regions are unclear. Both 
5HT and NE have been shown to increase the secretion of CRF from the PVN, and CRF has been 
found to bind to CRF receptors in the DR, LC, and VTA to increase the activity level of these 
regions (Merchenthaler 1984, Valentino, Foote et al. 1993, Itoi, Suda et al. 1994, Stout, Owens et 
al. 2002, Reyes, Valentino et al. 2005, Heisler, Pronchuk et al. 2007, Reyes, Valentino et al. 2008, 
Wanat, Hopf et al. 2008, Sparta, Hopf et al. 2013). Interestingly, cortisol has been found to 
influence monoamine neurotransmission through transcriptional effects on proteins that regulate 
monoamine levels. Although cortisol binding to GRs in the DR has been found to increase the 
78 
 
activity of tyrosine hydroxylase hydroxylase (TH, an enzyme involved in the synthesis of NE and 
DA), desensitize 5HT1A receptors, and decrease the expression of 5HT transporters, it has also 
been found to increase expression of monoamine oxidase A, an enzyme involved in the breakdown 
of the monoamines (Caspi, Sugden et al. 2003, Clark, Pai et al. 2005, Lindley, She et al. 2005, 
Manoli, Le et al. 2005, Heydendael and Jacobson 2009, Miller, Wankerl et al. 2013, Bravo, Dinan 
et al. 2014). These effects seem to be opposing one another and are not completely understood.  
These findings suggest that the relationship between the HPA axis and the monoamines 
involves many complicated interactions that are not clear-cut or simple to interpret. It is unclear 
whether monoamine elevation as a result of chronic antidepressant administration is responsible 
for normalizing cortisol levels, or vice versa. Our computational modeling experiments explore 
the relationship between drugs that target the monoaminergic neurotransmitter systems, the HPA 
axis, and cortisol.  
 
A.2 OVERVIEW OF THE HPG AXIS AND DEPRESSION 
Hypothalamus-Pituitary-Gonad (HPG) axis activity begins with hypothalamic secretion of 
gonadotropin-releasing hormone (GnRH), which leads to release of the gonadotropins, luteinizing 
hormone (LH) and follicle-stimulating hormone (FSH), from the pituitary gland (Moore and Price 
1932, Harris 1964). LH and FSH then stimulate the gonads (ovaries and testes in females and 
males, respectively) to produce the gonadal hormones, estrogen (E), progesterone (P), and 
testosterone (T) (de Kretser, Hedger et al. 2002). The levels of each of these hormones are 
regulated by complex feedback. The cyclical nature of the HPG axis in females is dependent on 
folliculogenesis (Knight and Glister 2001). Serum concentrations of E and P rise and fall during 
pregnancy and puberty depending on the phase of each (Shang, Zhao et al. 2003). HPG hormone 
levels are dependent upon the reproductive state of the organism throughout life.  
Depressive symptomology associated with menopause and andropause is believed to be 
related to a decline in the levels of the gonadal hormones (Buchanan, Eccles et al. 1992). 
Menopause and andropause are characterized by a loss of gonadal function resulting in 
dysregulation of the HPG axis (Rosario, Chang et al. 2004). Depressive symptomology has been 
observed to be associated with decreases in serum estrogen concentrations, and elevated levels of 
estrogen have been found to be associated with a more positive mood (Buchanan, Eccles et al. 
1992). In adult women, reduced estrogen levels have even been considered to be a risk factor for 
depression (Steiner, Dunn et al. 2003). Hypofunction of the HPG axis in males, leading to 
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decreased testosterone levels, has also been shown to lead to depressive symptomology. The 
decline in sex steroid production by the gonads following menopause and andropause leads to a 
loss of hypothalamic feedback inhibition which actually stimulates GnRH and gonadotropin 
production (Schwall, Szonyi et al. 1988).  
The sex steroids have been shown to interact with important proteins involved in the 
synthesis, actions, and breakdown of the monoamines. Ovariectomy has been found to decrease 
the expression of 5HT1A and 5HT2A receptors in the brain, which can be reversed through 
estrogen replacement (Joffe and Cohen 1998). When estrogen was administered to female rodents, 
an increase in the level of tryptophan hydroxylase-2 (TPH2, an enzyme involved in 5HT synthesis) 
was observed in DR neurons (Solomon and Herman 2009). Interestingly, monoamine oxidase 
levels have been found to decrease with estrogen but increase with progesterone in rodent studies 
(Frackiewicz, Sramek et al. 2000). TPH2 levels in the DR and 5HT2A receptor levels in the cortex 
have both been shown to increase with estrogen (Summer and Fink 1995, Donner and Handa 
2009). 
The effects of the sex steroids on mood are complex and involve interactions between many 
systems. It is likely that sex differences and cyclical changes in their levels play an important role 
on how these hormones affect mood. Computational modeling of the complicated interactions 
between the HPG axis, the HPA axis, and the monoaminergic neurotransmitters could help with 
our understanding of the relationship between the sex hormones and depression.  
 
A.3 DIFFERENCE BETWEEN IMPERATIVE AND DECLARATIVE PROGRAMMING 
Imperative and declarative programming languages are fundamentally different and 
provide complementary functionality. Specifically, imperative languages are designed for writing 
programs that compute efficiently along a single processing stream while declarative languages 
are designed for writing programs that can be used to evaluate the consequences of processing 
along many different streams. Imperative and declarative programs differ mainly in the nature of 
their statements.  
A statement in an imperative language is a command (e.g., add two and two to get four) 
that is meant to be executed at a pre-specified point relative to the execution of other commands. 
This means that the order of the statements in the program determines the order of the execution 
of the statements. A statement in a declarative language is a declaration of a fact (e.g., two and two 
can be combined to get four) that may be executed as a command at various points relative to the 
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execution of other declarations. A declarative program can be written so that certain declarations 
execute in all possible orders, thereby elaborating the entire space of possible consequences of 
executions of those declarations. In the exhaustive Maude searches used in analysis of the M-
model, the declarations that specified TSC-strength adjustments were allowed to execute in all 
possible orders. In this way, Maude evaluated the consequences for unit activations and 
monoaminergic transmitter levels of every possible combination of TSC strengths (TSC-strength 
configurations) that were reachable given the allowed number of adjustments. Temporal-logic 
model-checking analysis of the MS-model was carried out on samples of the state-space in order 
to reach states at deeper depths.   
In this stochastic case, receptor-strength adjustment declarations did not execute in all 
possible orders, but only is some randomly chosen orders. The goal here was to characterize the 
properties of the receptor-adjustment process through analysis of a sufficiently large, random 
sample of the possible orders of declaration executions. 
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APPENDIX B: METHODS APPENDICES 
 
B.1 DETAILS ON M-MODEL STRUCTURE AND FUNCTION 
The monoaminergic units of the M-model have receptors for each transmitter type they 
receive from themselves and from other units. The specific receptors represented in the model are 
those that mediate the predominant effect of each transmitter as described in the literature. The 
monoaminergic regions, DR, LC, and VTA, have been found to project directly to one another 
(Beckstead, Domesick et al. 1979, Ornstein, Milon et al. 1987, Kalen, Skagerberg et al. 1988, 
Guiard, El Mansari et al. 2008). DR inhibits LC and VTA through 5HT2A and 5HT2C receptors 
(5HT2AR, 5HT2CR), respectively (Pessia, Jiang et al. 1994, Prisco, Pagannone et al. 1994, 
Stanford and Lacey 1996, Gobert, Rivet et al. 2000). DR also excites VTA through postsynaptic 
5HT2ARs (Nocjar, Roth et al. 2002). LC and VTA excite DR through the noradrenergic receptor 
1 (AR1) and D2 receptor (D2R), respectively (Svensson, Bunney et al. 1975, Baraban and 
Aghajanian 1980, Clement, Gemsa et al. 1992, Ferre and Artigas 1993, Martin-Ruiz, Ugedo et al. 
2001). Evidence exists supporting the claim that LC and VTA inhibit one another (Aghajanian and 
Bunney 1977, Elam, Clark et al. 1986, Grenhoff, North et al. 1995), while some groups have found 
that these regions can excite each other (Deutch, Goldstein et al. 1986, Grenhoff, Nisell et al. 
1993). Our model contains both excitatory and inhibitory receptors mediating the interactions 
between these regions. Their respective initial strengths are assigned during the parameter 
optimization process. DR and LC also secrete galanin onto one another (Melander, Hokfelt et al. 
1986, Melander, Hokfelt et al. 1986, Xu, Zhang et al. 1998, Lu, Barr et al. 2005), which binds 
predominantly to inhibitory galanin receptors (galR1s) in these regions (Hawes and Picciotto 
2004). There is some binding to excitatory galR2 receptors in the DR as well (Hawes and Picciotto 
2004). The DR has inhibitory CRF1 and excitatory CRF2 receptors (CRF1R, CRF2R) mediating 
its responses to CRF innervations from the hypothalamus and the amygdala (Kirby, Freeman-
Daniels et al. 2008, Spannuth, Hale et al. 2011, Wood, Zhang et al. 2013). The LC and VTA both 
have excitatory CRF1Rs mediating their responses to CRF released from the hypothalamus and 
the amygdala (Van Pett, Viau et al. 2000, Reyes, Valentino et al. 2008, Wanat, Hopf et al. 2008).  
Each non-monoaminergic unit of the M-model represents all sources of its corresponding 
non-monoaminergic transmitter that impinge on the monoaminergic regions from other brain 
areas. Sources of CRF include amygdala and paraventricular nucleus CRF-producing neurons 
(Curtis, Bello et al. 2002, Hauger, Risbrough et al. 2006, Rodaros, Caruana et al. 2007). Widely 
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distributed in the central nervous system (CNS), sources of galanin include the LC, DR, and the 
hypothalamus, among others (Melander, Hokfelt et al. 1986). Sources of glutamate are also widely 
distributed, and include the cortex and the DR (Johnson 1994, Bagley and Moghaddam 1997, 
Tassone, Madeo et al. 2011, Shikanai, Yoshida et al. 2012, Liu, Zhou et al. 2014).  
Together, the monoaminergic units in the M-model possess 23 total receptors (of 11 
distinct receptor types) to represent their actions on themselves (via autoreceptors), their 
interactions with each other, and their responses to the non-monoaminergic transmitter units 
impinging on them. In addition to receptors (monoaminergic units) or generic weights (non-
monoaminergic units), each unit also has a bias parameter representing intrinsic influence on its 
activity. The net input to any unit is then the sum of its inputs from other units, its input from itself, 
and its own intrinsic bias. For a monoaminergic unit of the M-model, which has a cognate receptor 
for each specific transmitter it receives, the amount of released transmitter is multiplied by the 
strength of the cognate receptor for that transmitter. The net input is the sum of all the receptor-
times-transmitter products. For a non-monoaminergic unit of the M-model, which only has a 
generic weight for each connection it receives, the activation level of the sending unit is multiplied 
by the strength of the weight of its connection to the receiving unit. The net input is the sum of the 
weight-times-activation products (as in a conventional neural network). For any unit, 
monoaminergic or non-monoaminergic, its intrinsic bias is added to its net input from other units. 
The activation level of any unit is then computed according to the sigmoidal squashing function 
as y = 1/(1+exp(-x)), where y is the activation level and x is the net input. As such, the activation 
levels of all units are bounded from 0 to 1.  
On each time step, each unit updates its activation level by computing its net input and its 
resulting output according to the sigmoidal squashing function. Because the amount of released 
transmitter is equal to the activation level of the releasing unit, the squashing function ensures that 
no transmitter level falls below zero in the model. The monoaminergic transmitters are the 
exception, because their levels are reduced by their corresponding transporters by subtracting the 
numerical value representing the level of the transporter from the amount of released transmitter. 
Because this could cause the levels to fall below zero, the levels of the monoaminergic transmitters 
are actively bounded from below at zero (hard limit of zero). Any changes in TSC strength due to 
drugs are made prior to the unit updates, and any modifications in transmitter levels due to 
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transporters or drugs are made after the updates. The activation levels of all units are set to zero at 
time step zero, and the units then influence each other’s activation for 150 time steps. 
 
B.2 MS- AND MSS-MODEL CANONICAL WEIGHTS 
B2.1 CANONICAL MS-MODEL WEIGHTS 
The MS-model has 23 weights that were treated as “canonical weights.” The canonical 
weights are the weights that mediate the known interactions of the monoaminergic nervous system 
and the stress-steroid system. The training procedure set the lower bound of the canonical weights 
to absolute value 1. Subsequent analysis revealed that the canonical weights developed the 
strongest weights and that each network was most sensitive to the canonical weights. They also 
revealed that the pruning procedure increased the sensitivity of the networks to the canonical 
weights.  
 
Number Weight Polarity References 
1 DR to 5HT + 
(Hensler, Ferry et al. 
1994, Monti 2010) 
2 5HT to 5HT1AR + 
(Davidson and 
Stamford 1995, Blier, 
Pineyro et al. 1998) 
3 5HT1AR to DR − 
(Davidson and 
Stamford 1995, 
Azmitia, Gannon et al. 
1996) 
4 5HTT to 5HT − 
(Lesch, Aulakh et al. 
1993, Hensler, Ferry et 
al. 1994) 
5 LC to NE + 
(Grenhoff, Nisell et al. 
1993, Samuels and 
Szabadi 2008) 
6 NE to AR2 + 
(Cedarbaum and 
Aghajanian 1977, 
Washburn and Moises 
1989) 
7 AR2 to LC − 
(Cedarbaum and 
Aghajanian 1977, 
Washburn and Moises 
1989) 
8 NET to NE − 
(Iversen 2000, Bonisch 
and Bruss 2006) 
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9 VTA to DA + 
(Ornstein, Milon et al. 
1987, Guiard, El 
Mansari et al. 2008) 
10 DA to D2R + 
(Benoit-Marand, 
Borrelli et al. 2001, 
Perra, Clements et al. 
2011) 
11 D2R to VTA − 
(Hall, Sedvall et al. 
1994, Perra, Clements 
et al. 2011, Koyama, 
Mori et al. 2014) 
12 DAT to DA − 
(Ciliax, Heilman et al. 
1995, Iversen 2000) 
13 PVN to CRF + 
(Makara, Stark et al. 
1981, Bruhn, Plotsky 
et al. 1984) 
14 CRF to CRF1R + 
(Van Pett, Viau et al. 
2000, Hauger, 
Risbrough et al. 2006, 
Holsboer and Ising 
2008) 
15 CRF1R to Pituitary Gland + 
(Van Pett, Viau et al. 
2000, Nikodemova, 
Diehl et al. 2002) 
16 Pituitary Gland to ACTH + 
(Makara, Stark et al. 
1981, Bruhn, Plotsky 
et al. 1984) 
17 ACTH to ACTHR + 
(Xia and Wikberg 
1996, Papadimitriou 
and Priftis 2009) 
18 ACTHR to Adrenal Gland + 
(Yang, Koistinaho et 
al. 1990, Xia and 
Wikberg 1996, 
Papadimitriou and 
Priftis 2009) 
19 Adrenal Gland to CORT + 
(Grant, Forrest et al. 
1957, Papadimitriou 
and Priftis 2009) 
20 CORT to GCR + 
(Pariante and Miller 
2001, Papadimitriou 
and Priftis 2009) 
21 GCR to Adrenal Gland − 
(Loose, Do et al. 1980, 
Kalinyak, Dorin et al. 
1987) 
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22 GCR to Pituitary Gland − 
(Morimoto, Morita et 
al. 1996, Ozawa, Ito et 
al. 1999) 
23 GCR to PVN − 
(Morimoto, Morita et 
al. 1996, Ozawa, Ito et 
al. 1999) 
 
 
B.2.2 CANONICAL MSS-MODEL WEIGHTS 
The MSS-model has 36 weights classified as “canonical weights,” because these weights 
mediate the known interactions of the monoaminergic nervous system, the stress-steroid system, 
and the sex-steroid system. The lower bound of the canonical weights was set to |1| during training. 
Upon further analysis it was determined that the canonical weights developed the strongest weights 
in the networks, and each network was most sensitive to changes in the canonical weights. The 
pruning procedure was also found to increase network sensitivity to the canonical weights.  
Number Weight Polarity References 
1 DR to 5HT + (Hensler, Ferry et al. 1994, Monti 2010) 
2 5HT to 5HT1AR + 
(Davidson and Stamford 1995, Blier, Pineyro et 
al. 1998) 
3 5HT1AR to DR − 
(Davidson and Stamford 1995, Azmitia, Gannon 
et al. 1996) 
4 5HTT to 5HT − 
(Lesch, Aulakh et al. 1993, Hensler, Ferry et al. 
1994) 
5 LC to NE + 
(Grenhoff, Nisell et al. 1993, Samuels and Szabadi 
2008) 
6 NE to AR2 + 
(Cedarbaum and Aghajanian 1977, Washburn and 
Moises 1989) 
7 AR2 to LC − 
(Cedarbaum and Aghajanian 1977, Washburn and 
Moises 1989) 
8 NET to NE − (Iversen 2000, Bonisch and Bruss 2006) 
9 VTA to DA + 
(Ornstein, Milon et al. 1987, Guiard, El Mansari et 
al. 2008) 
10 DA to D2R + 
(Benoit-Marand, Borrelli et al. 2001, Perra, 
Clements et al. 2011) 
11 D2R to VTA − 
(Hall, Sedvall et al. 1994, Perra, Clements et al. 
2011, Koyama, Mori et al. 2014) 
12 DAT to DA − (Ciliax, Heilman et al. 1995, Iversen 2000) 
13 PVN to CRF + 
(Makara, Stark et al. 1981, Bruhn, Plotsky et al. 
1984) 
14 CRF to CRF1R + 
(Van Pett, Viau et al. 2000, Hauger, Risbrough et 
al. 2006, Holsboer and Ising 2008) 
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15 
CRF1R to 
Corticotroph 
+ 
(Van Pett, Viau et al. 2000, Nikodemova, Diehl et 
al. 2002) 
16 
Corticotroph to 
ACTH 
+ 
(Makara, Stark et al. 1981, Bruhn, Plotsky et al. 
1984) 
17 ACTH to ACTHR + 
(Xia and Wikberg 1996, Papadimitriou and Priftis 
2009) 
18 
ACTHR to Adrenal 
Gland 
+ 
(Yang, Koistinaho et al. 1990, Xia and Wikberg 
1996, Papadimitriou and Priftis 2009) 
19 
Adrenal Gland to 
CORT 
+ 
(Grant, Forrest et al. 1957, Papadimitriou and 
Priftis 2009) 
20 CORT to GCR + 
(Pariante and Miller 2001, Papadimitriou and 
Priftis 2009) 
21 
GCR to Adrenal 
Gland 
− 
(Loose, Do et al. 1980, Kalinyak, Dorin et al. 
1987) 
22 
GCR to 
Corticotroph 
− 
(Morimoto, Morita et al. 1996, Ozawa, Ito et al. 
1999) 
23 GCR to PVN − 
(Morimoto, Morita et al. 1996, Ozawa, Ito et al. 
1999) 
24 POA to GnRH + (Pfaus, Jakob et al. 1994) 
25 GnRH to GnRHR + (Kakar, Musgrove et al. 1992) 
26 
GnRHR to 
Gonadotroph 
+ (Shacham, Harris et al. 2001) 
27 
Gonadotroph to 
FSH 
+ (Shacham, Harris et al. 2001) 
28 Gonadotroph to LH + (Shacham, Harris et al. 2001) 
29 FSH to FSHR + (Dierich, Sairam et al. 1998) 
30 LH to LHR + (Jia, Oikawa et al. 1991) 
31 FSHR to Testes + 
(Catt, Baukal et al. 1979, Heckert and Griswold 
1991) 
32 LHR to Testes + 
(Belanger, Auclair et al. 1979, Catt, Baukal et al. 
1979) 
33 
Testes to 
Testosterone 
+ (Royland, Weber et al. 1994) 
34 Testosterone to AR + (Grino, Griffin et al. 1990) 
35 AR to POA − (Handa, Kerr et al. 1996) 
36 AR to Gonadotroph − (Herbison, Skinner et al. 1996) 
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B.3 DETAILS ON MS-MODEL STRUCTURE AND FUNCTION 
The structure matrix includes the subset of interactions between units in the model that are 
known from experimental observation. Inhibitory connections were given a −1, excitatory 
connections were given a +1, and connections of unknown polarity were given a 2 in the structure 
matrix. If the polarity was unknown by the literature, it was set by training algorithm.  
SSRIs inhibit the 5HT transporter protein, so there is an inhibitory connection from SSRI 
to the 5HT transporter (Sanchez, Bergqvist et al. 2003, Nemeroff and Owens 2004). Nomifensine 
blocks the NE and DA transporters, and weakly blocks the 5HT transporter, so there are inhibitory 
connections from Nomifensine to NET, DAT, and 5HTT (Schacht and Heptner 1974, Brogden, 
Heel et al. 1979, Tatsumi, Groshan et al. 1997). Reboxetine potently blocks the NE transporter, so 
there is an inhibitory connection from Reboxetine to NET (Hajos, Fleishaker et al. 2004). 
Trazodone inhibits the 5HT transporter, is an agonist at the 5HT1A receptor, an antagonist of 
5HT2A, 5HT2C, A1, and A2 receptors (Waldmeier 1982, Cusack, Nelson et al. 1994, Krege, 
Goepel et al. 2000 Asenapine is an agonist at 5HT1A receptors and an antagonist at 5HT2A, 
5HT2C, A1, A2, D1, D2, D3, and D4 receptors {Ghanbari, 2009 #331, Balsara, Jadhav et al. 2005, 
Odagaki, Toyoshima et al. 2005, Corporation 2009, Shahid, Walker et al. 2009, Stahl 2009, Stahl 
2009). Aripiprazole is an agonist at 5HT1A, 5HT2C, D2, D3, and D4 receptors, an antagonist at 
5HT2A receptors, and interacts with A1, A2, B1, and B2 receptors with unknown polarity (Keck 
and McElroy 2003, Kroeze, Hufeisen et al. 2003, Shapiro, Renock et al. 2003). Bupropion inhibits 
the NE and DA transporters, so it has inhibitory projections to NET and DAT (Waldmeier 1982, 
Cooper, Wang et al. 1994, Stahl, Pradko et al. 2004). Humans metabolize Quetiapine to N-
Desalkyl quetiapine (Nquet) so we simulated the effects of Quetiapine in the model by giving 
Quetiapine all the targets of both Quetiapine and Nquet (DeVane and Nemeroff 2001, Jensen, 
Rodriguiz et al. 2008). Quetiapine inhibits the NE transporter and 5HT2A, 5HT2C, A1, A2, D1, 
D2 and D3 receptors and is an agonist of 5HT1A receptors (DeVane and Nemeroff 2001, Jensen, 
Rodriguiz et al. 2008). Pramipexole (PPX) is an agonist at D2, D3 and D4 receptors (Mierau, 
Schneider et al. 1995). GBR is a DA transporter antagonist (TOCRIS , Andersen 1989). Clozapine 
is an agonist at 5HT1A receptors, is an antagonist at 5HT2A, 5HT2C, A1, D2, and D4 receptors, 
and has unknown polarity at A2, D1, and D3 receptors (Roth , Meltzer 1994, Newman-Tancredi, 
Chaput et al. 1996). Ketamine is an antagonist at NMDA receptors (Vollenweider and Kometer 
2010). Reserpine depletes monoamines by inhibiting the activity of the vesicular monoamine 
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transporter 2 (VMAT2), which transports monoamines to the cell membrane for release into the 
extracellular space (Scherman and Henry 1984, Rudnick, Steiner-Mordoch et al. 1990). Because 
VMAT2 is not an element in our model, Reserpine sends inhibitory projections directly to 5HT, 
NE and DA.  Venlafaxine is a selective serotonin-norepinephrine reuptake inhibitor (SNRI) with 
some antagonistic effects at the DA transporter (Roseboom and Kalin 2000, Wellington and Perry 
2001). Desipramine is a tricyclic antidepressant that strongly inhibits the NE transporter and 
inhibits the 5HT and DA transporters with weaker affinity (Berti and Shore 1967). It is also an 
antagonist of the 5HT2A (Wander, Nelson et al. 1986). CP96345 (CP) is a neurokinin-1 receptor 
antagonist (Fong, Yu et al. 1992). Gepirone is an agonist of 5HT1A receptors (Blier and Ward 
2003). RU28362 (RU) is a glucocorticoid receptor agonist (Sernia and Thomas 1994).  Org34850 
(Org) is a glucocorticoid receptor antagonist (Reynolds, Saunders et al. 2015).  Oxytocin is a 
hormone input that projects to oxytocin receptors in the model (Gimpl and Fahrenholz 2001). 
Dexamethasone is a corticosteroid that acts as an agonist at glucocorticoid receptors but not 
mineralocorticoid receptors (Bamberger, Bamberger et al. 1995, Reul, Gesing et al. 2000, Pariante 
and Miller 2001). WAY100635 (WAY) is a selective 5HT1A receptor antagonist (Fletcher, Forster 
et al. 1996). Monoamine Oxidase Inhibitors (MAOI) block the activity of monoamine oxidase, 
which is an enzyme that mediates the breakdown of the monoamines (Stein 1960, Remick and 
Froese 1990). M617 is a galanin receptor 1 (galR1) agonist (Blackshear, Yamamoto et al. 2007). 
The CRF1R antagonist input has an inhibitory projection to the CRF1 receptor. Haloperidol is a 
dopamine D2 receptor antagonist (Schotte, Janssen et al. 1993). Olanzapine is dopamine D2 
receptor antagonist and 5HT2A receptor antagonist (Pilowsky, Busatto et al. 1996). Clonidine is 
an alpha-2 receptor agonist (Unnerstall, Kopajtic et al. 1984). Yohimbine is an alpha-2 receptor 
antagonist (Perry and U'Prichard 1981). DR lesion, LC lesion, VTA lesion, PVN lesion, Amygdala 
lesion, Hippocampus lesion, PFC lesion and Adrenalecotmy are inhibitory to DR, LC, VTA, PVN, 
Amygdala, Hippocampus, PFC, the adrenal gland, respectively. The stress response begins with 
activation of the HPA axis, so the stress input sends an excitatory projection to the PVN (Sapolsky 
2000, Gold and Chrousos 2002, de Kloet, Joels et al. 2005). Exogenous ACTH is excitatory to 
ACTH receptors (Kitay, Holub et al. 1959). Exogenous CRF is excitatory to CRF1 and CRF2 
receptors (Merchenthaler 1984).  
Each unit has a bias of unknown polarity. 
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Each region has an excitatory (+1) connection to the units it secretes. The DR secretes 5HT, 
glutamate, galanin, and NK1 (Melander, Hokfelt et al. 1986, Johnson 1994, Santarelli, Gobbi et 
al. 2001, Guiard, Guilloux et al. 2007, Soiza-Reilly and Commons 2011, Gagnon and Parent 2014, 
Liu, Zhou et al. 2014). The LC secretes NE, galanin, and NK1 (Holets, Hokfelt et al. 1988, Jordan, 
Kermadi et al. 1995, Pieribone, Xu et al. 1995, Maubach, Martin et al. 2002, Kawa, Barde et al. 
2016). The VTA secretes DA and glutamate (Stuber, Hnasko et al. 2010, Root, Mejias-Aponte et 
al. 2014). The amygdala secretes glutamate, CRF, AVP, and NK1 (Buijs and Swaab 1979, 
Merchenthaler 1984, Curtis, Bello et al. 2002, Roberto, Schweitzer et al. 2004, Singewald, Chicchi 
et al. 2008). The PFC secretes glutamate (Bagley and Moghaddam 1997, Geisler, Derst et al. 2007, 
Albert, Vahid-Ansari et al. 2014). The PVN secretes CRF, AVP, oxytocin, and NK1 (Antoni, Fink 
et al. 1990, Yamashita, Kasai et al. 1991, Makara 1992, Emiliano, Cruz et al. 2007, Rodaros, 
Caruana et al. 2007, Bulbul, Babygirija et al. 2011, Feetham and Barrett-Jolley 2014). The 
hippocampus secretes glutamate (Bagley and Moghaddam 1997). The pituitary gland secretes 
ACTH and the adrenal gland produces cortisol (Kitay, Holub et al. 1959, Butler, Clarke et al. 1969, 
Seiden and Brodish 1971, Loose, Do et al. 1980). 
Each enzyme or substrate has either an excitatory (+1) or inhibitory (−1) connection with 
its corresponding enzyme or substrate. The 5HT transporter is inhibitory on 5HT, the NE 
transporter is inhibitory on NE and DA, and the DA transporter is inhibitory on DA (Iversen 1971, 
Carboni, Tanda et al. 1990, Giros, Wang et al. 1994). In order to represent the 5HT synthesis 
pathway, there is an excitatory connection from tryptophan to tryptophan hydroxylase (TPH), an 
excitatory connection from TPH to 5-hydroxytryptamine (5HTP), 5HTP to 5HT-decarboxylase 
(5HTDC), from 5HTDC to 5HT, from 5HT to N-acetylserotonin O-methyltransferase (ASMT), 
and from ASMT to melatonin (Schott, Nicolai et al. 2010). Synthesis of NE and DA were 
represented with an excitatory connection from tyrosine to tyrosine hydroxylase (TH), an 
excitatory connection from TH to levadopa (L-DOPA), an excitatory connection from L-DOPA to 
aromatic L-amino acid decarboxylase (L-AADC), an excitatory connection from L-AADC to DA, 
an excitatory connection from DA to dopamine beta-hydroxylase (DBH), and an excitatory 
connection from DBH to NE (Cosentino, Marino et al. 2015). There is an inhibitory connection 
from monoamine oxidase (MAO) to 5HT, NE and DA to represent how MAO is responsible for 
the breakdown of the monoamines (Edmondson, Mattevi et al. 2004).  
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The neurotransmitters and hormones all have excitatory connections (+1) to their 
corresponding receptors to the model. 5HT projects to 5HT1A, 5HT1B, 5HT2A, and 5HT2C 
receptors. NE projects to A1, A2, B1, and B2 receptors. DA projects to D1, D2, D3, and D4 
receptors. Glutamate projects to alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid 
(AMPA) and N-methyl-D-aspartate (NMDA) receptors. Galanin projects to galR1 and galR2. 
AVP projects to vasopressin receptor 1a (V1AR). CRF projects to CRF1 and CRF2 receptors. 
Cortisol projects to glucocorticoid (GC) and mineralocorticoid (MC) receptors. Oxytocin projects 
to oxytocin receptors. NK1 projects to NK1 receptors. ACTH projects to melanocortin 2 (MC2) 
receptors. GABA projects to GABA receptors. 
Receptors have either excitatory (+1), inhibitory (−1), or unknown polarities on the brain 
regions and neurotransmitters. To account for the effect of presynaptic receptors, known 
presynaptic receptors had projections to neurotransmitters whose levels are regulated by the 
presynaptic receptor.  
5HT1A receptors are inhibitory on DR, LC, PFC, and hippocampus neurons (Azmitia, 
Gannon et al. 1996, Blier, Pineyro et al. 1998, Celada, Puig et al. 2004, Santana, Bortolozzi et al. 
2004, Puig, Artigas et al. 2005, Lanzenberger, Baldinger et al. 2013). 5HT1A receptors are also 
present on PVN neurons, but their overall polarity on PVN neurons has not been determined 
conclusively due to their presence on GABAergic interneurons impinging on PVN neurons (Pan 
and Gilbert 1992, Dinan 1996). Presynaptic 5HT1A receptors have been found to inhibit GABA 
release (Koyama, Matsumoto et al. 2002). 5HT2A receptors have been found to be inhibitory on 
LC but excitatory on the amygdala, PFC, and hippocampus (Haddjeri, de Montigny et al. 1997, 
Xu and Pandey 2000, Szabo and Blier 2002, Santana, Bortolozzi et al. 2004, Bombardi 2011). A1 
receptors are excitatory on DR, amygdala, and PVN neurons (Baraban and Aghajanian 1980, 
Clement, Gemsa et al. 1992, Itoi, Suda et al. 1994, Cecchi, Khoshbouei et al. 2002). A2 receptors 
are inhibitory autoreceptors on LC neurons, and also reside with unknown polarities on VTA, 
amygdala, PFC, hippocampus, and PVN neurons (Cedarbaum and Aghajanian 1977, Talley, Rosin 
et al. 1996). AR2 receptors have also been found presynaptically to decrease NE, galanin, and 
NK1 levels (Cedarbaum and Aghajanian 1977, Kuraishi, Hirota et al. 1985, Tsuda, Yokoo et al. 
1989, Bertolino, Vicini et al. 1997). B1 and B2 receptors are excitatory on LC, PFC and 
hippocampus neurons (Rainbow, Parsons et al. 1984). D1 receptors exist in the PFC with unknown 
polarity (Pirot, Godbout et al. 1992, Hall, Sedvall et al. 1994, Chen and Yang 2002). D2 receptors 
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are inhibitory autoreceptors on VTA neurons, are excitatory on amygdala, DR, and PFC neurons, 
and exist in the PVN with unknown polarity (Ferre and Artigas 1993, Hall, Sedvall et al. 1994, 
Haj-Dahmane 2001, Rosenkranz and Grace 2002, Brady and O'Donnell 2004, Succu, Sanna et al. 
2007). D3 receptors are present in the PFC and PVN with unknown polarity (Levesque, Diaz et al. 
1992, Succu, Sanna et al. 2007). D4 receptors are present in the PFC with unknown polarity 
(Primus, Thurkauf et al. 1997). AMPA and NMDA receptors have been found in the DR, LC, 
VTA, amygdala, PFC, and PVN, and vary in polarity depending on whether they are present on 
GABAergic interneurons or not, so their polarities were not fixed (Petralia and Wenthold 1992, 
Martin, Blackstone et al. 1993, Huntley, Vickers et al. 1994, de Kock, Cornelisse et al. 2006). 
galR1s are inhibitory galanin receptors, and they have been found to inhibit DR, LC, VTA, 
amygdala, and PVN neurons (Perez, Basile et al. 2002, Hawes and Picciotto 2004, Hawes, 
Brunzell et al. 2005). galR2s are excitatory on DR and hippocampus neurons (Hawes and Picciotto 
2004, Elliott-Hunt, Pope et al. 2007). V1ARs have been found on amygdala and hippocampus 
neurons, and are excitatory on DR neurons and the pituitary gland (Ostrowski, Lolait et al. 1992, 
Rood and Beck 2014). CRF1 receptors are inhibitory on DR neurons, but are excitatory on LC, 
VTA, amygdala, PVN, and the pituitary gland (Van Pett, Viau et al. 2000, Kirby, Freeman-Daniels 
et al. 2008, Reyes, Valentino et al. 2008, Wanat, Hopf et al. 2008, Ji, Fu et al. 2013, Sparta, Hopf 
et al. 2013, Baiamonte, Valenza et al. 2014, Reyes, Bangasser et al. 2014). CRF2 receptors are 
excitatory on DR and VTA neurons (Wang, You et al. 2007, Spannuth, Hale et al. 2011, Wood, 
Zhang et al. 2013). GC receptors have been found on DR, LC, VTA, and hippocampus neurons 
with unknown polarity (Makara and Haller 2001, Makino, Smith et al. 2002, Lanfumey, Mongeau 
et al. 2008, Vincent and Jacobson 2014). They are inhibitory to PVN neurons, the pituitary gland, 
adrenal gland, and they decrease expression of the 5HT transporter (Fumagalli, Jones et al. 1996, 
Pariante and Lightman 2008, Heydendael and Jacobson 2010). They have been found to increase 
activity and/or expression of TPH, MAO, and TH (Clark, Pai et al. 2005, Lindley, She et al. 2005, 
Ou, Chen et al. 2006, Heydendael and Jacobson 2009). Mineralocorticoid receptors have been 
found in the hippocampus with unknown polarity (Herman, Watson et al. 1993, Patel, Lopez et al. 
2000, Yau, Noble et al. 2001). They also mediate negative feedback on the HPA axis through 
inhibitory effects on the PVN, pituitary gland, and adrenal gland (Ratka, Sutanto et al. 1989, Patel, 
Lopez et al. 2000, Ladd, Huot et al. 2004). Oxytocin receptors have been found in the DR, LC, 
VTA, hippocampus, and pituitary gland with unknown polarity (Elands, Beetsma et al. 1988, 
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Breton, Pechoux et al. 1995, Gimpl and Fahrenholz 2001, Yoshida, Takayanagi et al. 2009). They 
are inhibitory in the amygdala (Buijs and Swaab 1979, Huber, Veinante et al. 2005). NK1 receptors 
are inhibitory on DR neurons, and have been found on LC, VTA, amygdala, PFC, and PVN 
neurons with unknown polarity (Tooney, Au et al. 2000, Conley, Cumberbatch et al. 2002, Rigby, 
O'Donnell et al. 2005, Renoldi and Invernizzi 2006, Gobbi, Cassano et al. 2007, Guiard, Guilloux 
et al. 2007, Haddjeri and Blier 2008, Feetham and Barrett-Jolley 2014). MC2 receptors are 
excitatory on the adrenal gland (Papadimitriou and Priftis 2009). GABA receptors have been found 
to be inhibitory on DR neurons, and have also been found on LC, VTA, amygdala, PFC, 
hippocampus, and PVN neurons, as well as the pituitary gland with unassigned polarities due to 
the presence of interneurons modulating their effects on the corresponding neurons (Baraban and 
Aghajanian 1980, Chang, Tran et al. 1980, Biggio, Corda et al. 1981, Roland and Sawchenko 1993, 
Van Bockstaele and Pickel 1995, Hatfield, Spanis et al. 1999, Cai, Flores-Hernandez et al. 2002, 
Katsurabayashi, Kubota et al. 2003, Puig, Santana et al. 2004, Tan, Zhong et al. 2004, Cornelisse, 
Van der Harst et al. 2007, Kreft and Zorec 2008, Bulbul, Babygirija et al. 2011, Jin, Bhandage et 
al. 2014, Kudo, Konno et al. 2014). 
 
B.4 DETAILS ON MSS-MODEL STRUCTURE AND FUNCTION 
The structure of the monoamine-stress-sex model (MSS-model) is based on known 
interactions within and between the monoaminergic neurotransmitter systems and the stress- and 
sex-hormone systems. The MSS-model is an extension of our previous monoamine-stress model 
(MS-model). Details on monoamine-stress interactions can be found in the Supplemental Material 
for our MS-model article (Camacho, Vijitbenjaronk et al. 2018). Details concerning monoamine-
stress interactions with the sex-hormone system, which were used to augment the MS-model in 
creating the MSS-model, are described in this section.  
All excitatory, inhibitory, or unknown polarities between structure connections are 
represented as a +1, −1, or +2 in the structure matrix. The polarities of connections where the 
polarity is unknown from the literature was assigned a polarity by the training procedure.    
VTA DA neurons can co-release glutamate, GABA, and corticotropin-releasing factor 
(CRF), so there are excitatory projections from VTA to glutamate, GABA, and CRF.  
The PVN secretes GnRH, so there is an excitatory connection from the PVN to GnRH 
(Moore and Price 1932). GnRH binds and activates the GnRH receptor (GnRHR), so there is an 
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excitatory connection from GnRH to GnRHR (Millar 2005). GnRHRs are excitatory on the 
pituitary gland, so there is an excitatory projection from GnRHR to the pituitary gland (Eidne, 
Sellar et al. 1992). The pituitary gland secretes the gonadotropins, luteinizing hormone (LH) and 
follicle-stimulating hormone (FSH) (Moore and Price 1932, Harris 1964). LH and FSH then bind 
to LH and FSH receptors on the gonads, so there are excitatory connections from LH to LH 
receptors (LHR) and FSH to FSH receptors (FSHR) (Simoni, Gromoll et al. 1997, Dufau 1998). 
LHR and FSHR activate the gonads, so there are excitatory projections from LHR and FSHR to 
the ovaries and testes (Whitelaw, Smyth et al. 1992, Simoni, Gromoll et al. 1997, Gunnarsson, 
Nordberg et al. 2003). The ovaries produce estrogen (E) and progesterone (P), and the testes 
produce testosterone (T) (de Kretser, Hedger et al. 2002). There are excitatory projections from 
the ovary to estrogen and progesterone and from the testes to testosterone.  
ER-beta receptors increase TPH2 mRNA expression in rodents, so there is an excitatory 
projection from ER-beta to TPH (Donner and Handa 2009). Progesterone has also been found to 
increase TPH2 expression, so there is an excitatory connection from progesterone receptors to 
TPH (Bethea, Mirkes et al. 2000). Both estrogen and progesterone have been found to decrease 
MAO activity in female OVX Rhesus monkeys, so there are inhibitory projections from estrogen 
and progesterone receptors to MAO (Gundlah, Lu et al. 2002). Both estrogen and progesterone 
have also been found to decrease 5HT1A gene expression in female OVX Rhesus monkeys, so 
there are inhibitory projections from estrogen and progesterone receptors (ER and PR, 
respectively) to the 5HT1A receptor (Pecins-Thompson and Bethea 1999). Estrogen receptors 
exist in alpha and beta forms, described here as ER-alpha and ER-beta, respectively. A study using 
OVX female rats found that estrogen decreases 5HT1B receptor mRNA, so there is an inhibitory 
projection from estrogen receptors to 5HT1B receptors (Hiroi and Neumaier 2009). Estrogen 
administration to male rats has been found to increase 5HT2A receptor mRNA, so there is an 
excitatory projection from estrogen receptors to 5HT2A receptors (Summer and Fink 1995, 
Sumner and Fink 1998). 
Estrogen has been found in OVX female rats to increase levels of tyrosine hydroxylase 
(TH) and dopamine beta-hydroxylase (DBH) mRNA through an unspecified estrogen receptor, so 
there are excitatory projections from both estrogen receptors to TH and DBH (Serova, Rivkin et 
al. 2002). 
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Testosterone administration to male rats has been found to increase 5HT2A receptor mRNA, so 
there is an excitatory projection from testosterone to 5HT2A receptors (Sumner and Fink 1998). 
Estrogen, progesterone, and testosterone receptors have been found in DR neurons and influence 
DR neuron firing with unknown polarity, so there are projections of unknown polarity from ER-
alpha, ER-beta, PR, and AR to the DR (Alves, Weiland et al. 1998, Robichaud and Debonnel 
2005).  
Both ER-alpha and ER-beta receptors have been found to mediate the inhibitory effect of 
estrogen on hypothalamic neurons, so there are inhibitory projections from ER-alpha and ER-beta 
to the hypothalamus (Lagrange, Ronnekleiv et al. 1995, Roy, Angelini et al. 1999, Skynner, Sim 
et al. 1999, Herbison and Pape 2001). The inhibitory effect of progesterone on hypothalamic 
neurons are mediated by progesterone receptors, so there is an inhibitory projection from PR to 
the hypothalamus (Bashour and Wray 2012). ER-alpha mediates negative feedback on the HPG 
axis at the level of the hypothalamus, which is the receptor that is included as an inhibitory weight 
in the POA (Glidewell-Kenney, Hurley et al. 2007).  The inhibitory effect of testosterone on 
hypothalamic neurons is mediated by androgen receptors, so there is an inhibitory projection from 
AR to the hypothalamus (Belsham, Evangelou et al. 1998).  
Negative feedback on the HPG axis also occurs at the level of the Pituitary gland in both 
males and females, mediated by androgen receptors and ER-alpha receptors, respectively (Scully, 
Gleiberman et al. 1997, Thorner, Vance et al. 1998, Cheong, Porteous et al. 2014). 
Androgen receptors, progesterone receptors, ER-alpha and ER-beta have all been found on 
both the ovary and testis (Due, Dieckmann et al. 1989, Vornberger, Prins et al. 1994, 
Brandenberger, Tee et al. 1998, Saunders, Fisher et al. 1998, Weil, Vendola et al. 1998, Makinen, 
Makela et al. 2001, Juengel, Heath et al. 2006). Testosterone provides negative feedback directly 
on the testis through activation of androgen receptors, so there is an inhibitory connection from 
the testosterone receptor to the testis (Darney and Ewing 1981). The polarity of the interaction 
between the estrogen and progesterone receptors on the gonads, as well as the androgen receptor 
on the ovary, have not been determined so there are connections of unknown polarity between 
these receptors and the gonads. 
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B.5: DETAILS ON GA OPTIMIZATION OF M-MODEL 
The parameters of the M-model were optimized using the genetic algorithm (GA) as 
implemented in the MATLAB Global Optimization Toolbox. A robust optimization procedure 
such as the GA is appropriate because the M-model is both nonlinear (sigmoidal squashing 
function for unit activations) and discontinuous (hard limit of zero for monoaminergic transmitter 
levels). The 76 real-valued parameters were 23 receptor strengths (on monoaminergic units), 18 
connection weights (onto and between non-monoaminergic units), 3 monoaminergic transporters, 
29 drug effects (most of the drugs have multiple targets), and 6 biases (one for each monoaminergic 
and non-monoaminergic unit). The 76 parameters form a parameter set that was organized as a 
vector of 76 elements, where each element is a different parameter. Each run of the GA maintained 
a population of 100 parameter sets (parameter vectors) and was allowed to “evolve” through 
simulated mutation and recombination over many generations until the change in fitness between 
generations was less than a tolerance set to 10-12.  
We minimized an inverse fitness function (error function) that was based mainly on the 
difference between the behavior of the monoaminergic units in the M-model and that of real 
monoaminergic neurons in their responses to acute administration of various drugs targeting the 
monoaminergic neurotransmitter systems in rats (Dong and Blier 2001, Szabo and Blier 2001, 
Chernoloz, El Mansari et al. 2009, Katz, Guiard et al. 2010, Ghanbari, El Mansari et al. 2012, El 
Mansari, Manta et al. 2015, Oosterhof, El Mansari et al. 2015). The rats in these studies were 
normal, and were not subjected to stressors or other manipulations designed to evoke a depressive 
phenotype (ibid). The drugs and drug combinations included in the error function constitute the 
set of drugs that target the monoaminergic neurotransmitter systems studied by Pierre Blier and 
his lab, with the exceptions of GBR12909 (GBR) and Pramipexole (PPX).  
GBR is a high-affinity DA reuptake inhibitor, with 500-fold higher affinity for the 
dopamine transporter (DAT) than for the other monoaminergic transporters (Andersen 1989). It 
does not have significant affinity for any other receptors (TOCRIS , Andersen 1989, Rothman, 
Mele et al. 1991). The Blier group found a 26% decrease in VTA DA neuron firing in response to 
acute GBR, with no change in the firing parameters of LC NE neurons or DR 5HT neurons (Katz, 
Guiard et al. 2010). This is inconsistent with the behavior of the other reuptake blockers, 
Escitalopram, Nomifensine, and Reboxetine, which all produce changes in neuronal firing rate in 
more than one monoaminergic region (Katz, Guiard et al. 2010, Chernoloz, El Mansari et al. 2012). 
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During GA searches, the strength of GBR was repeatedly pushed to zero by the algorithm. Due to 
inconsistency of GBR data with the behavior of the other reuptake inhibitors, as well as consistent 
GA assignment of zero strength for GBR in the M-model, data obtained from GBR experiments 
was removed from the error function and was not considered further in M-model analysis.  
PPX primarily targets D3 receptors (D3R) (Mierau, Schneider et al. 1995). PPX has been 
found to be 8 times more potent as a D3 receptor agonist than as a D2 receptor agonist through 
functional measurements of receptor activation (Mierau, Schneider et al. 1995). The dissociation 
constant (Ki) of PPX is 0.5 nM at D3R and 3.9 nM at D2R, demonstrating that the binding affinity 
of PPX at D3R is almost 8 times higher than that of PPX at D2R (Newman-Tancredi, Cussac et 
al. 2002). D3Rs are mainly expressed in the nucleus accumbens, hypothalamus, and prefrontal 
cortex, but are not present in significant levels in the monoaminergic regions (Levesque, Diaz et 
al. 1992). In the M-model, receptors are represented explicitly only on monoaminergic units, so 
D3Rs are not represented. PPX data was not included in the error function nor was it considered 
in M-model analysis because its primary target, D3R, is not represented in the M-model. 
Interpretations of data by different groups ascribe to Bupropion a mechanism of action that 
elevates NE and DA through either a releasing (Dong and Blier 2001) or reuptake blocking (NDRI) 
mechanism (Cooper, Wang et al. 1994). The Blier lab adheres to the releasing mechanism 
interpretation, which is the mechanism that is implemented in the M-model. To study the effects 
of Quetiapine, the Blier lab used a compound combination they called “human Quetiapine.” 
Because humans metabolize Quetiapine to N-Desalkyl quetiapine (Nquet) but rodents do not, 
rodents were given a mixture of Nquet and Quetiapine in the ratio present in humans during the 
metabolism of quetiapine to produce human Quetiapine (Chernoloz, El Mansari et al. 2012). We 
simulated the effects of human Quetiapine in the M-model by giving Quetiapine all the targets of 
both Quetiapine and Nquet. 
The error function that was minimized by the GA computed a modified root mean square 
(RMS) error. The heart of the error function is the differences between the observed percentage 
changes and the percentage changes in the average activation levels of the monoaminergic units 
in the M-model due to acute drug administration, as described above. Acute drug data were 
obtained from the experimental findings of the Blier group. Through reduction of error, the GA 
had to optimize several criteria in addition to the agreement in the percentage changes in 
monoaminergic activation levels due to acute drugs. The baseline (no-drug) activity levels of the 
97 
 
6 units were required to be near 0.50, which is the midpoint of the unit activity range as governed 
by the squashing function. This gave the units maximal freedom to increase or decrease their 
activations with drug administrations or TSC strength adjustments. Monoaminergic baseline (no-
drug) neurotransmitter levels had to be 0.10 or greater. This ensured that pre-drug transmitter 
levels were high enough for all drugs to have a substantial effect. The rise in 5HT following acute 
Escitalopram had to be 0.20 or greater, and the rise in NE following acute Reboxetine had to be 
0.20 or greater. This ensured that levels of 5HT and NE due to acute blockade of their respective 
transporters agreed with experimental findings (Kreiss and Lucki 1995, Malagie, Trillat et al. 1995, 
Bymaster, Zhang et al. 2002, Page, Brown et al. 2003, Romero, Celada et al. 2003).  
In the error function, differences in the no-drug monoaminergic unit activations from 0.5, 
and differences between the observed and simulated monoaminergic activation percentage 
changes due to acute drug, were expressed as actual RMS differences (i.e., RMS errors). However, 
each no-drug monoaminergic transmitter level below 0.1, and each 5HT or NE level below 0.2 
with acute Escitalopram or Reboxetine, respectively, conditionally contributed a value of 100 to 
the error term for the offending parameter set. Because discrepancies between desired and 
simulated transmitter levels were expressed as conditionals, our error function computed a 
modified RMS error measure.  
For programming convenience, parameters whose values could be positive or negative (i.e., 
strengths of receptors, transporters, and drugs) were set as absolute values and their signs were 
fixed in program code. Other parameters (i.e., generic weights and unit biases) were signed by the 
optimization procedure. Lower and upper bounds for the parameter values in the GA were set by 
hand. Lower and upper bounds for the generic weights of the connections onto non-
monoaminergic transmitter units, and for all unit biases, were set at −10 and +10. Lower and upper 
autoreceptor bounds were set at 3 and 10, respectively. The GA-determined levels for all 
autoreceptors (DR 5HT1A, LC AR2, and VTA D2R) were near 3 in almost all 200 
parameterizations and in all of the “ten-best” parameterizations. All other receptor bounds were 
set at 1 and 10. Transporter bounds were set at 0.3 and 0.9. Bounds for the strengths of the drugs 
were set at 0 and 1. The bounds on the strengths of drugs provided consistency in effects for drugs 
of different classes in the M-model. 
All receptors contributed a component to net input equal to the product of their strength 
and the level of their cognate transmitter, regardless of whether or not a drug that affects them was 
98 
 
present. Agonist drugs add a contribution from a receptor equal to the product of the receptor 
strength and the drug strength. Antagonist drugs subtract a component equal to the product of the 
receptor strength, the drug strength, and the level of the cognate transmitter. Because transmitters 
and drugs are bounded between 0 and 1, this scheme ensures that an agonist drug can increase the 
receptor contribution at most by one full receptor strength, while an antagonist can decrease the 
receptor contribution at most to zero. Transporter blocking drugs worked similarly, reducing the 
level of a transporter by an amount equal to the product of the transporter strength and the drug 
strength. Therefore, a blocker could reduce the strength of a transporter at most to zero. Transmitter 
releasing drugs add a contribution of neurotransmitter to the unit activation level equal to the 
product of the amount of released transmitter (which is equal to the unit activation) and the drug 
strength. Because the releasing drug strengths (like all drug strengths) are bounded between 0 and 
1, this ensures that a releasing drug can at most double the amount of released transmitter.  
The 10 lowest-error parameter sets of the 200 GA searches were separated out for further 
consideration. For all of these “ten best” parameterizations, the transmitter levels achieved their 
required levels. Therefore, the conditional contributions to the error functions were zero, leaving 
only the actual RMS differences in desired and actual monoaminergic unit activities. Note that the 
purpose of the GA optimization was to set baseline parameter values according to the data on the 
acute effects of drugs. Data on chronic drug effects, which involve adjustments in baseline receptor 
values, were therefore not represented in the fitness function. 
 
B.6: SUMMARY OF DRUGS AND DRUG COMBINATIONS CONSIDERED IN THE M-
MODEL 
Each row contains the name of a drug, its class, current uses, its effects as represented in 
the M-model, and supporting references. These drugs and drug combinations were used in the 
experiments by the Blier lab that determined the percent changes from baseline in the firing rates 
of neurons in the monoaminergic nuclei after acute (2-day) and chronic (14-day) drug 
administration. The drug types include transporter blockers, receptor agonists, receptor 
antagonists, and neurotransmitter releasers. The strengths of each of these drugs at their targets 
were determined using the GA implemented in MATLAB.   
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Drug name Drug class Drug uses 
Drug 
effects at 
targets 
References 
Escitalopram 
2nd generation 
antidepressant 
Depression 
5HT 
transporter 
blocker 
(Sanchez, Bergqvist et al. 
2003, Chen, Larsen et al. 
2005) 
Nomifensine 
2nd generation 
antidepressant 
Depression 
DA, NE 
and 5HT 
transporter 
blocker 
(Brogden, Heel et al. 
1979, Tatsumi, Groshan 
et al. 1997) 
Reboxetine 
2nd generation 
antidepressant 
Depression, 
panic disorder, 
attention 
deficit 
hyperactivity 
disorder 
(ADHD) 
NE 
transporter 
blocker 
(Page, Brown et al. 2003, 
Hajos, Fleishaker et al. 
2004) 
Trazodone 
Tetracyclic 
antidepressant 
Depression, 
post-traumatic 
stress disorder 
(PTSD), 
insomnia 
5HT 
transporter 
blocker, 
agonist at 
5HT1AR, 
antagonist 
at 
5HT2AR, 
5HT2CR, 
AR1, AR2, 
and D2R 
(Cusack, Nelson et al. 
1994, Nierenberg, Adler 
et al. 1994, Krege, 
Goepel et al. 2000, 
Balsara, Jadhav et al. 
2005, Odagaki, 
Toyoshima et al. 2005, 
Stahl 2009, Stahl 2009) 
Asenapine 
Atypical 
antipsychotic 
Bipolar 
disorder, 
schizophrenia 
Agonist at 
5HT1AR, 
antagonist 
at 
5HT2AR, 
AR2, and 
D2R 
(Ghanbari, El Mansari et 
al. 2009, Bjorkholm, 
Franberg et al. 2015) 
Aripiprazole 
Atypical 
antipsychotic 
Bipolar 
disorder, 
schizophrenia 
Agonist at 
5HT1AR 
and D2R, 
antagonist 
at 5HT2AR 
and 
5HT2CR 
(Shapiro, Renock et al. 
2003, Li, Ichikawa et al. 
2004, Han, Wang et al. 
2013) 
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Bupropion 
Atypical 
antidepressant 
Depression, 
seasonal 
affective 
disorder 
Releaser of 
NE and DA 
(Cooper, Wang et al. 
1994, Cusack, Nelson et 
al. 1994, Dong and Blier 
2001, El Mansari, 
Ghanbari et al. 2008) 
Quetiapine 
Atypical 
antipsychotic 
Bipolar 
disorder, 
schizophrenia, 
depression 
NE 
transporter 
blocker, 
agonist at 
5HT1AR, 
antagonist 
at 
5HT2AR, 
AR1, AR2, 
D1R, and 
D2R 
(DeVane and Nemeroff 
2001, Jensen, Rodriguiz 
et al. 2008, Han, Wang et 
al. 2013) 
 
 
B.7: MS-MODEL TRUTH-TABLE JUSTIFICATION 
The MS-model was trained on baseline values and to reproduce data on the effects of 
neuron activations, transmitter, enzyme, and hormone levels of acute receptor blockade, lesions, 
and other experimental manipulations. All of the manipulations (drug or hormone administration, 
chemical lesioning, etc.) will be referred to as “inputs.” For the purposes of training the model the 
training data were assembled into an input-output table or “truth table” in which the inputs are 
acute drug administrations, and the outputs are changes from baseline firing-rate of the 
monoaminergic neurons expressed as a percentage. Data on the effects of inputs on model unit 
activations were obtained through an extensive literature search that compiled findings from 
multiple groups using a broad range of experimental methods. Training data were for 40 single 
inputs and 25 combination inputs. Each row of the truth table represents the results of one or more 
actual experiments where output levels were measured in response to one or more inputs. Inputs 
are either present or absent (0 or 1) and outputs are assigned integer values between 0.30 (lowest) 
to 0.70 (highest). Output findings from the literature and their corresponding integer values are 
shown in the table below. All outputs bound between 0 and 1 by the sigmoidal squashing function.   
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0.30 0.40 0.50 0.60 0.70 
Decrease 
maximally 
Decrease 
moderately 
No change 
Increase 
moderately 
Increase 
maximally 
 
Determinations of “moderate” versus “maximal” changes were made based on both the qualitative 
and quantitative data that was available. When more than one finding was available on a particular 
input-output relationship, a consensus was reached using the available data. If neurotransmitter 
level changes differed in different brain regions, the change in the level of the neurotransmitter in 
the prefrontal cortex (PFC) was used in the truth table. If whole brain neurotransmitter level change 
was available, then the effect of the input on whole brain neurotransmitter level was used in the 
truth table. If neurotransmitter level change data for the whole brain or PFC was not available, 
then the change in the neurotransmitter level of the brain regions that were available was used to 
determine the truth-table value with that input. This subjective approach was necessary to account 
for differences between research labs in experimental methods, drug dosages and routes of 
administration, and levels of quantification. The majority of the findings were derived from rodent 
studies but some were obtained from horse, monkey, cat, cow, fish, squirrel and human studies.  
The first single-input is an SSRI, which consolidates the findings associated with acute 
administration of several different SSRIs. Although different SSRIs have different low-affinity 
off-target effects, all of them have strong affinity for the 5HT transporter, which is the only 
structure connection from the SSRI input included in the model (Tatsumi, Groshan et al. 1997, 
Sanchez, Bergqvist et al. 2003). Binding of the SSRI to the 5HT transporter leads to a doubling of 
extracellular 5HT, so the output for 5HT with acute SSRI was set to 0.60 (Invernizzi, Belli et al. 
1992, Koch, Perry et al. 2002, Calcagno, Guzzetti et al. 2009). Because acute administration of 
SSRIs other than fluoxetine does not significantly change NE and DA levels, the truth table values 
for these neurotransmitters were set to 0.50 (Bymaster, Zhang et al. 2002, Koch, Perry et al. 2002). 
The increase in extracellular 5HT associated with acute SSRI administration has been 
associated with increased binding to the 5HT1A autoreceptor on DR neurons, decreasing the firing 
activity of these neurons (Calcagno, Guzzetti et al. 2009). The Blier group and others have found 
that the DR neuron firing rate decreases by about 65% with acute SSRI, so the truth table value 
for this output was set to 0.40 (de Montigny, Chaput et al. 1990, Czachura and Rasmussen 2000, 
Chernoloz, El Mansari et al. 2012). The Blier group found that acute SSRI administration 
decreases the firing rate of LC neurons by 45% and decreases the firing rate of VTA neurons by 
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41%, so the truth table values for the LC and VTA firing rates with acute SSRI were also set to 
0.40 (Chernoloz, El Mansari et al. 2009, Dremencov, El Mansari et al. 2009, Chernoloz, El 
Mansari et al. 2012). fMRI studies indicate that amygdala activity decreases moderately, while 
cortical activity does not change with acute SSRI administration (Mayberg, Brannan et al. 2000, 
Kennedy, Evans et al. 2001, Takahashi, Yahata et al. 2005, Murphy, Norbury et al. 2009). The 
Murphy lab found that amygdala activity decreases moderately in response to neutral faces with 
acute SSRI, and the Mayberg lab found that PFC activity increases after 6-weeks of SSRI treatment 
but not after acute (1-week) SSRI treatment. The truth table values for the amygdala and PFC with 
acute SSRI are set to 0.40 and 0.50, respectively.  
Acute SSRI administration has been found to stimulate the rodent HPA axis by increasing 
CRF, ACTH, and cortisol levels while also increasing PVN activity (Jensen, Jessop et al. 1999, 
Wieczorek, Schulz et al. 2001, Hesketh, Jessop et al. 2005). Specifically, 30 minutes of 
subcutaneous cannula citalopram administration maximally increases cortisol and ACTH levels 
(Jensen, Jessop et al. 1999). This lab also found that PVN activity increases moderately as 
measured by the percentage of c-Fos immunoreactive cells in the PVN. The same lab did not find 
a significant difference in CRF mRNA with acute citalopram treatment; however, another lab 
found that acute citalopram moderately increases CRF levels (Moncek, Duncko et al. 2003). The 
Moncek lab also found that acute citalopram produces very large increases in cortisol and ACTH 
levels.  The truth table values for ACTH and cortisol with acute SSRI was both set to 0.70. The 
truth table value for CRF with acute SSRI was set to 0.60 to reflect the moderate increase in CRF 
found by the Moncek lab and the finding that cortisol and ACTH levels increase maximally. 
Oxytocin levels have been found to moderately increase with acute SSRI, while arginine-
vasopressin (AVP) levels have been found to stay the same (Hesketh, Jessop et al. 2005). We set 
the oxytocin target to 0.60 and the AVP target to 0.50 with acute SSRI. Acute fluoxetine injection 
moderately increases galanin mRNA levels, so the truth-table value for galanin with acute SSRI 
was set to 0.60 (Kuteeva, Wardi et al. 2008).   
The second single-input is Nomifensine, a reuptake blocker of the NE and DA transporter 
proteins, with slight affinity for the 5HT transporter (Samanin, Bernasconi et al. 1975, Brogden, 
Heel et al. 1979, Tatsumi, Groshan et al. 1997). The Blier group found that acute administration 
of Nomifensine increases DR neuron activity by 50%, decreases VTA neuron activity by 39%, 
and decreases LC neuron activity by 71% (Katz, Guiard et al. 2010). The truth-table values for the 
103 
 
acute effect of Nomifensine on DR, LC and VTA neurons were therefore set to 0.60, 0.40, and 
0.40, respectively. The Masana lab found that acute Nomifensine maximally increases DA levels, 
but the Samanin lab found that acute Nomifensine did not significantly change DA levels 
(Samanin, Bernasconi et al. 1975). The Carboni lab found that acute Nomifensine increases DA 
levels by a very large amount (Carboni, Imperato et al. 1989). The Butcher lab found a moderate 
increase in DA levels with acute Nomifensine (Butcher, Fairbrother et al. 1988). Because some 
labs report a maximal increase in DA with acute Nomifensine while others do not detect any 
change in DA levels, the truth-table value for DA with acute Nomifensine was set to 0.60 to reflect 
a moderate increase in DA. 
Reboxetine is a selective NE transporter blocker (Hajos, Fleishaker et al. 2004). The Blier 
group found that acute Reboxetine administration decreases LC firing rate by 68% without 
affecting DR firing rate (Szabo and Blier 2001). They also found that acute Reboxetine 
administration decreases VTA neuron firing rate by 31% (Katz, Guiard et al. 2010). The truth-
table values for acute Reboxetine for DR, LC, and VTA were therefore set to 0.50, 0.40, and 0.40, 
respectively. Acute Reboxetine administration doubles NE levels and produces a moderate 
increase in DA levels while producing no change in 5HT levels, corresponding to values of 0.60, 
0.60, and 0.50 in the truth table for these neurotransmitters, respectively (Page and Lucki 2002). 
One fMRI study in humans shows that acute Reboxetine administration moderately decreases 
amygdala response to neutral stimuli, so the truth-table value for the amygdala with acute 
Reboxetine was set to 0.40 (Onur, Walter et al. 2009). Acute Reboxetine administration in humans 
has been found to moderately increase ACTH levels in two studies using male volunteers, so the 
truth-table value for ACTH with acute Reboxetine was set to 0.60. Acute Reboxetine 
administration has also been shown to moderately increase cortisol levels in two different studies 
using male human volunteers, so the truth-table value for cortisol with acute Reboxetine was set 
to 0.60 (Hennig, Lange et al. 2000, Schule, Baghai et al. 2004).  
Trazodone is a multifunctional drug that blocks the 5HT transporter and interacts with 
multiple monoaminergic receptors (Stahl 2009, Stahl 2009). The Blier lab found that acute 
Trazodone administration decreases DR neuron firing by 65%, increases LC neuron firing by 25%, 
and does not alter VTA neuron firing (Ghanbari, El Mansari et al. 2010, Ghanbari, El Mansari et 
al. 2012). We set the target output values for DR, LC, and VTA with acute Trazodone to 0.40, 
0.60, and 0.50, respectively. Acute Trazodone administration has been found to double 5HT levels 
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without changing NE levels, so the truth-table values for these were set to 0.60 and 0.50, 
respectively (Rowbotham, Jones et al. 1984, Pazzagli, Giovannini et al. 1999).  
Asenapine is an antipsychotic drug that interacts with multiple monoaminergic receptors 
(Franberg, Wiker et al. 2008, Ghanbari, El Mansari et al. 2009). The Blier group found that acute 
Asenapine administration decreases DR neuron firing by about 30% without affecting the firing 
rates of the LC or VTA (Oosterhof, El Mansari et al. 2015). We set the truth table values for DR, 
LC, and VTA to 0.40, 0.50, and 0.50. Acute Asenapine administration in rats has been found to 
moderately increase 5HT, NE, and DA levels (Franberg, Marcus et al. 2009). The truth table 
outputs for 5HT, NE, and DA with acute Asenapine were all set to 0.60.  
Aripiprazole is an antipsychotic drug with strong affinity for DA and 5HT receptors 
(Shapiro, Renock et al. 2003). The Blier group found that acute Aripiprazole administration 
increases DR neuron firing rate by 48%, without affecting the firing rates of LC or VTA neurons 
(Chernoloz, El Mansari et al. 2009). The truth-table values for the DR, LC and VTA were set to 
0.60, 0.50 and 0.50, respectively. Acute Aripiprazole administration has been found to moderately 
increase DA levels in experiments done by Zocchi et al and Li et al without affecting 5HT, NE, or 
cortisol levels (Li, Ichikawa et al. 2004, Zocchi, Fabbri et al. 2005, Assie, Carilla-Durand et al. 
2008). The truth-table values for 5HT, NE, DA, and cortisol were set to 0.50, 0.50, 0.60, and 0.50 
with acute Aripiprazole, respectively.  
Bupropion is an antidepressant drug that blocks the NE and DA transporter proteins 
(Cooper, Wang et al. 1994, Stahl, Pradko et al. 2004). The Blier group found that acute Bupropion 
administration doubles DR neuron firing rate, decreases LC neuron firing rate by half, and does 
not change VTA neuron firing rate (El Mansari, Ghanbari et al. 2008). Another group found that 
acute Bupropion moderately decreases LC and VTA neuron firing rate (Cooper, Wang et al. 1994). 
The truth-table values for the DR, LC and VTA were set to 0.60, 0.40 and 0.40, respectively, with 
acute Bupropion administration. Acute Bupropion administration has been found to moderately 
increase DA and NE levels without affecting 5HT levels (Piacentini, Clinckers et al. 2003). The 
truth-table values for 5HT, NE, DA were set to 0.50, 0.60, and 0.60 with acute Bupropion.  
Quetiapine is an antipsychotic drug with multiple receptor and transporter targets, 
including the dopamine D2 receptor, the 5HT2A receptor, and the alpha-1 adrenergic receptor 
(AR1) (DeVane and Nemeroff 2001, Jensen, Rodriguiz et al. 2008). The Blier group found that 
acute Quetiapine administration decreases the DR neuron firing rate by 43% and increases the LC 
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neuron firing rate by 40% (Chernoloz, El Mansari et al. 2012). The truth-table values for the DR 
and LC with acute Quetiapine were set to 0.40 and 0.60, respectively. Another group found that 
acute Quetiapine moderately increases VTA firing rate, so the truth-table value for the VTA with 
acute Quetiapine was set to 0.60 (Werkman, Olijslagers et al. 2004). Denys et al found that acute 
Quetiapine moderately increases 5HT and DA levels in the PFC, while Silverstone et al found that 
acute Quetiapine has no effect on 5HT levels, but moderately increases NE and DA levels (Denys, 
Klompmakers et al. 2004, Silverstone, Lalies et al. 2012). The truth table values for 5HT, NE, and 
DA with acute Quetiapine were all set to 0.60.  
Pramipexole (PPX) is a D2, D3, and D4 receptor agonist (Mierau, Schneider et al. 1995). 
The Blier group found that acute PPX administration does not change DR neuron firing rate, 
decreases LC neuron firing rate by 33%, and decreases VTA neuron firing rate by 40% (Chernoloz, 
El Mansari et al. 2009). The truth-table values for the DR, LC and VTA were therefore 0.50, 0.40 
and 0.40 with acute PPX administration. 
GBR12909 (GBR) is a DA transporter blocker (TOCRIS , Andersen 1989, Singh 2000). 
The Blier group found that acute GBR administration does not change DR or LC neuron firing rate 
but decreases VTA neuron firing rate by 26% (Katz, Guiard et al. 2010). Another group found a 
similar decrease of about 25% in VTA neuron firing rate with acute GBR (Choong and Shen 2004). 
The truth-table values for the DR, LC and VTA were set to 0.50, 0.50 and 0.40, respectively, with 
acute GBR administration. Three groups have found moderate increases in DA levels with acute 
GBR, so the truth-table value of DA with acute GBR was set to 0.60 (Rothman, Mele et al. 1991, 
Choong and Shen 2004, Masana, Bortolozzi et al. 2011).  
Clozapine is an antipsychotic drug that targets many serotonergic, noradrenergic, and 
dopaminergic receptors (Meltzer 1994). Acute administration of Clozapine has been found to 
moderately decrease the firing activity of DR neurons, moderately increase the firing rate of LC 
neurons, moderately increase the firing rate of VTA neurons, and moderately increase the firing 
activity of PFC neurons (Souto, Monti et al. 1979, Sprouse, Reynolds et al. 1999, Chen and Yang 
2002, Gao 2007). Another group found that acute Clozapine completely inhibits DR firing activity, 
however, the dose that was used was much higher than the standard rodent dose (Gallager and 
Aghajanian 1976). The truth-table values for DR, LC, VTA, and PFC were set to 0.40, 0.60, 0.60, 
and 0.60, respectively. Acute Clozapine administration has been found by Zocche et al to 
maximally increase NE levels and moderately increase DA levels. Masana et al also found that 
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Clozapine moderately increases DA levels. Lee et al 2001 found that Clozapine moderately 
increases cortisol levels in awake humans, so the truth table value for NE was set to 0.70 and the 
truth table values for DA and cortisol were set to 0.60 (Zocchi, Fabbri et al. 2005, Masana, 
Bortolozzi et al. 2011). One group has found that Clozapine decreases 5HT release in the nucleus 
accumbens, while another found that Clozapine increases 5HT in the nucleus accumbens and the 
PFC (Ferre and Artigas 1995, Ichikawa, Kuroki et al. 1998). Because these two groups found 
opposing effects of Clozapine on 5HT, and a third group found that 5HT does not change in the 
PFC with acute Clozapine, we used a truth-table value of 0.50 for 5HT with acute Clozapine 
(Zocchi, Fabbri et al. 2005). 
Ketamine is an antagonist at N-methyl-D-asparatate (NMDA) receptors (Hall and Murdoch 
1990). The Blier group found that acute Ketamine administration does not change DR or VTA 
neuron firing rate but increases LC neuron firing rate by 23% (El Iskandrani, Oosterhof et al. 
2015). The truth-table values for the DR, LC and VTA were set to 0.50, 0.60, and 0.50, 
respectively, with acute Ketamine administration. Razoux et al found that Ketamine moderately 
increases PFC neuron activity and moderately increases extracellular glutamate. Stone et al also 
found that Ketamine moderately increases anterior cingulate glutamate, so the truth-table value for 
the PFC and glutamate were set to 0.60 (Razoux, Garcia et al. 2007, Stone, Dietrich et al. 2012, 
Pehrson and Sanchez 2014, Bjorkholm, Franberg et al. 2015). Nishitani et al found that Ketamine 
moderately increases PFC 5HT levels, so the truth table value for 5HT was set to 0.60 with acute 
Ketamine. Stone et al and Lindeforsa et al both found that Ketamine has no effect on GABA levels, 
so the truth table value for GABA was set to 0.50 with acute Ketamine. Glisson et al found that 
acute Ketamine had no effect on rabbit whole brain NE or NE levels in any of the brain areas 
examined, so the truth table value for NE with acute Ketamine was set to 0.50. Glisson et al also 
found that DA levels did not change in rabbit whole brain with Ketamine, but did find a moderate 
increase in thalamus and hypothalamus DA. Lindeforsa et al found that acute Ketamine moderately 
increases DA levels in rat PFC. Because whole brain neurotransmitter level change is the standard 
criterion for the truth table, the truth-table value for DA with Ketamine was set to 0.50. 
Reserpine depletes monoamines by inhibiting the activity of the vesicular monoamine 
transporter 2 (VMAT2), which transports monoamines to the cell membrane for release into the 
extracellular space (Scherman and Henry 1984, Rudnick, Steiner-Mordoch et al. 1990). Because 
VMAT2 is not an element in our model, Reserpine sends inhibitory projections directly to 5HT, 
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NE and DA.  Reserpine maximally decreases 5HT, NE, and DA levels, so the truth-table values 
for 5HT, NE, and DA were all set to 3 (Cooper, Wang et al. 1994). Cooper et al found that 
Reserpine did not affect LC neuron firing rate, so the truth table value for LC with acute Reserpine 
was set to 0.50. Baraban et al found that Reserpine moderately increases DR activity, then 
suppresses DR activity after about 30 minutes (Baraban, Wang et al. 1978, Baraban and 
Aghajanian 1980). Because we are interested in the immediate, acute effect of Reserpine, we set 
the truth-table value for DR with acute Reserpine to 0.60. An injection of Reserpine in cows 
produces no change in cortisol levels, so the truth-table value for cortisol was set to 0.50 for 
Reserpine (Bauman, Collier et al. 1977). The combination of Reserpine and Buproprion produces 
no change in the firing rate of LC neurons, so the truth-table value for LC with 
Reserpine/Bupropion was set to 0.50 (Cooper, Wang et al. 1994).   
Venlafaxine is a selective serotonin-norepinephrine reuptake inhibitor (SNRI) (Roseboom 
and Kalin 2000). The Blier group found that Venlafaxine decreases DR firing rate by 47% and 
decreases LC firing rate by 21%, so the truth-table values for DR and LC were both set to 0.40 
(Gartside, Umbers et al. 1997). Because acute Venlafaxine administration moderately increases 
the firing activity of the PFC in a c-fos study, we set the truth-table value for PFC with Venlafaxine 
to 0.60 (Higashino, Ago et al. 2014). Higashino et al found that acute Venlafaxine administration 
moderately increases 5HT in the PFC, moderately increases NE in the PFC, and maximally 
increases DA in the PFC and Beyer et al found that acute Venlafaxine has no effect on 5HT levels 
but maximally increases NE levels in the PFC (Beyer, Boikess et al. 2002, Higashino, Ago et al. 
2014). The truth-table value for 5HT was set to 0.60 to reflect a moderate increase due to 
Venlafaxine’s 5HT transporter inhibition. The truth-table values for NE and DA were both set to 
0.70 to reflect the large increases in the levels of these neurotransmitters with acute Venlafaxine 
observed by the Higashino and Beyer groups.     
Desipramine is a tricyclic antidepressant with strong affinity for the NE transporter and 
weaker affinity for the 5HT and DA transporters as well as affinity for various monoaminergic 
receptors (Berti and Shore 1967). DR firing was found to moderately decrease with acute 
Desipramine, so the truth-table value for DR was set to 0.40 with acute Desipramine (Gartside, 
Umbers et al. 1997). Acute Desipramine also moderately decreases LC neuron activity, so the 
truth-table value for LC was set to 0.40 (Scuvee-Moreau and Dresse 1979). Acute administration 
of Desipramine was found by Beyer et al to maximally increase NE levels without changing 5HT 
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levels, and Kreiss et al also found that Desipramine has no effect on 5HT levels (Kreiss and Lucki 
1995, Beyer, Boikess et al. 2002). Higashino et al found no change in 5HT levels with acute 
Desipramine, but found a maximal increase in NE levels and a moderate increase in DA levels 
(Kreiss and Lucki 1995, Higashino, Ago et al. 2014). The truth-table value for 5HT was set to 
0.50, for NE was set to 0.70, and for DA was set to 0.60. Acute Desipramine was found to have 
no effect on PFC activity, so this truth-table value was set to 0.50 (Higashino, Ago et al. 2014). 
Desipramine injection in humans moderately increases blood cortisol levels after 30 minutes, so 
the truth-table value for cortisol with Desipramine was set to 0.60 (Asnis, Halbreich et al. 1985).  
CP-96345 (CP) is a neurokinin-1 receptor antagonist (Fong, Yu et al. 1992). The Blier 
group found that acute administration of CP increases the firing rate of DR neurons by 46% but 
does not affect the firing rate of LC neurons, so the truth-table values for DR and LC were set to 
0.60 and 0.50 for the DR and LC with acute CP, respectively (Conley, Cumberbatch et al. 2002, 
Haddjeri and Blier 2008). Lejeune et al found that NK1 receptor antagonists moderately enhance 
VTA firing rate, so the truth-table value for VTA with acute CP was set to 0.60. Lejeune et al also 
found that NK1 receptor antagonists have no effect on 5HT levels, so the 5HT value with acute 
CP was set to 0.50. Renoldi et al found that acute CP has no effect on NE levels, but moderately 
increases DA levels in the PFC of gerbils. Lejeune et al also found a moderate increase in DA 
levels with acute NK1 receptor antagonists. The truth table value for NE was set to 0.50 and for 
DA was set to 0.60 with acute CP (Lejeune, Gobert et al. 2002, Renoldi and Invernizzi 2006, 
Guiard, Guilloux et al. 2007). Renoldi et al also found that the combination of NK1 antagonists 
and stress leads to no change in NE or DA levels (Renoldi and Invernizzi 2006). The truth-table 
values for NE and DA with CP/Stress were set to 0.50.     
Gepirone is an agonist of 5HT1A receptors (Blier and Ward 2003). The Blier group and 
others have found that acute administration of 5HT1A agonists maximally decrease DR neuron 
firing rate, so the truth-table value of DR with Gepirone was set to 0.30 (VanderMaelen, Matheson 
et al. 1986, Blier and de Montigny 1987, Blier and de Montigny 1990). 5HT1A receptor agonists 
have been found to maximally decrease 5HT levels by multiple groups, so the truth table value for 
5HT with acute Gepirone was set to 0.30 (Rutter, Gundlah et al. 1994, Dawson, Nguyen et al. 
2002). 5HT1A receptor agonists have also been found to moderately increase CRF, ACTH, and 
cortisol release in rodents, so the truth-table values for CRF, ACTH, and cortisol with acute 
Gepirone were set to 0.60 (Pan and Gilbert 1992, Matheson, Knowles et al. 1997). The 
109 
 
combination of Gepirone and stress also moderately increases cortisol levels, so the cortisol level 
in the truth-table with acute Gepirone/stress was set to 0.60 (Matheson, Knowles et al. 1997). The 
combination of Gepirone/Dexamethasone moderately decreases cortisol levels, so the cortisol 
level in the truth-table with acute Gepirone/Dexamethasone was set to 0.40 (Matheson, Knowles 
et al. 1997).  
RU-28362 (RU) is a glucocorticoid receptor agonist (Sernia and Thomas 1994).  
Administration of RU alone does not change ACTH levels, so the truth-table value for ACTH with 
acute RU was set to 0.50 (Hinz and Hirschelmann 2000).  
Org-34850 (Org) is a glucocorticoid receptor antagonist (Reynolds, Saunders et al. 2015). 
Glucocorticoid receptors mediating negative feedback on the HPA axis are present in the 
hypothalamus, pituitary gland, and adrenal gland (among others) (Loose, Do et al. 1980, 
Morimoto, Morita et al. 1996, Ozawa, Ito et al. 1999). Acute Org administration by itself has been 
found by Spiga et al 2007 and Spiga et al 2008 to have no effect on cortisol levels, so the truth-
table value for cortisol with acute Org was set to 0.50. Acute Org/Stress was also found by this 
group to have no effect on cortisol levels, so the truth-table value for cortisol with acute Org/Stress 
was set to 0.50.   
Oxytocin is an input that projects to oxytocin receptors in the model (Gimpl and Fahrenholz 
2001). Oxytocin administration to rats has been shown to double DA levels, so the truth-table 
value for DA was set to 0.60 (Melis, Melis et al. 2007). Oxytocin by itself as well as 
Oxytocin/Stress had no effect on PVN CRF mRNA, so the CRF value with Oxytocin and with 
Oxytocin/Stress was set to 0.50 (Bulbul, Babygirija et al. 2011). Oxytocin has been found to 
moderately decrease amygdala response to fearful stimuli (faces and scenery), so the truth-table 
value for amygdala with Oxytocin/Stress was set to 0.40 (Kirsch, Esslinger et al. 2005). One study 
in rats from 1984 found that Oxytocin does not have a significant effect on ACTH levels, however, 
because several other groups since 1984 have found that Oxytocin moderately decreases ACTH in 
both humans and monkeys, the truth-table value for ACTH with Oxytocin was set to 0.40 (Gibbs, 
Vale et al. 1984, Chiodera and Coiro 1987, Parker, Buckmaster et al. 2005). It has also been found 
that Oxytocin moderately decreases cortisol levels, so the truth-table value for cortisol with 
Oxytocin was set to 0.40 (Legros, Chiodera et al. 1984). 
Dexamethasone is a corticosteroid with significant affinity for glucocorticoid receptors but 
not mineralocorticoid receptors in vivo (Bamberger, Bamberger et al. 1995, Reul, Gesing et al. 
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2000, Pariante and Miller 2001). Rush et al found that Dexamethasone maximally suppresses 
cortisol levels, so the truth-table value for cortisol with Dexamethasone was set to 0.30 (Rush, 
Giles et al. 1996).  Kovacs et al found that Dexamethasone maximally suppresses PVN CRF 
mRNA, so the truth-table value for CRF with Dexamethasone was set to 0.30 (Kovacs and Mezey 
1987). Hohnloser et al found that acute Dexamethasone administration moderately decreases 
ACTH levels, so the truth-table value for ACTH with Dexamethasone was set to 0.40 (Hohnloser, 
Von Werder et al. 1989).  Kovacs et al found that acute Dexamethasone moderately decreases 
AVP mRNA in the PVN, so the truth-table value for AVP with Dexamethasone was set to 0.40 
(Kovacs and Makara 1988). C-Fos mRNA responses in the PVN and pituitary gland were found 
to be moderately decreased with acute Dexamethasone, so the truth-table values for the PVN and 
pituitary gland were set to 0.40 (Karssen, Meijer et al. 2005). Dexamethasone has been shown to 
interact with the monoamines. Specifically, Dexamethasone administration has been shown to 
moderately increase the levels of 5HT precursors and 5HT, so the truth-table values for Trp, 5HTP, 
and 5HT were set to 0.60 with Dexamethasone (Maes, Meltzer et al. 1995, Tsubota, Adachi et al. 
1999, Clark, Flick et al. 2008). Dexamethasone has also been found to moderately increase the 
levels of extracellular DA but moderately decrease extracellular NE, so the truth-table values for 
DA and NE were set to 0.60 and 0.40, respectively (Stene, Panagiotis et al. 1980, Tsubota, Adachi 
et al. 1999). Oxytocin levels were unaffected by Dexamethasone, so the truth table value for 
oxytocin with Dexamethasone was set to 0.50 (Fink, Robinson et al. 1988). 
WAY-100635 (WAY) is a selective 5HT1A receptor antagonist (Fletcher, Forster et al. 
1996). Administration of WAY has been shown to reverse the inhibitory effects of 5HT1A receptor 
agonists on DR firing rate, so the truth-table value for DR with WAY/Gepirone was set to 0.50 
(Fletcher, Forster et al. 1996). WAY/Gepirone together has also been shown to prevent the rise in 
ACTH observed with Gepirone, so the truth-table value for ACTH with WAY/Gepirone was set 
to 0.50 (Fletcher, Forster et al. 1996). 5HT1AR antagonists by themselves moderately increase 
extracellular 5HT, so the truth-table value for 5HT with WAY was set to 0.60 (Arborelius, 
Nomikos et al. 1996). 
Monoamine Oxidase Inhibitors (MAOI) block the activity of monoamine oxidase, which 
is an enzyme that mediates the breakdown of the monoamines (Stein 1960, Remick and Froese 
1990). The Blier group found that acute MAOI administration moderately decreases DR and LC 
neuron firing without affecting VTA neuron firing, so the truth-table values for DR and LC were 
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set to 0.40 and the truth table value for VTA was set to 0.50 with MAOI (Blier and de Montigny 
1985, Chenu, El Mansari et al. 2009). Acute MAOI administration has been shown to produce 
maximal increases in all 3 of the monoamines, so the truth-table values for 5HT, NE and DA were 
set to 0.70 (Butcher, Fairbrother et al. 1990, Celada and Artigas 1993, Kitaichi, Inoue et al. 2006).  
Galanin is a 29 amino acid neuropeptide that is widely distributed in the central nervous 
system and co-secreted by DR and LC neurons (Tatemoto, Rokaeus et al. 1983). Agonists to the 
galR1 receptor (M-617) have been shown to have a pro-depressive effect, which is believed to be 
related to the inhibitory effect of galR1 receptors on DR and LC neurons (Sevcik, Finta et al. 1993, 
Larm, Shen et al. 2003, Wang, Li et al. 2016). Acute M-617 administration has been found to 
moderately decrease DR and LC firing rate and moderately decrease 5HT and NE levels (Jacobs, 
Wise et al. 1974, Azmitia and Segal 1978, Seutin, Verbanck et al. 1989, Sevcik, Finta et al. 1993, 
Yoshitake, Reenila et al. 2003, Hawes, Brunzell et al. 2005, Mazarati, Baldwin et al. 2005). We 
therefore set the truth-table values for DR, LC, 5HT, and NE to 0.40. It has also been found that 
M-617 administration produces moderate increases in the activities of the amygdala and PVN as 
measured by increases in c-fos expression in these regions, so the truth-table values for these 
regions were set to 0.60 (Blackshear, Yamamoto et al. 2007).  
CRF1 receptor antagonists (CRF1R antagonist) block the CRF1 receptor to decrease HPA 
axis activity (Holsboer and Ising 2008). Specifically, it has been found by multiple labs that 
CRF1R antagonists moderately decrease ACTH and cortisol release, so the truth-table values for 
ACTH and cortisol with Antalarmin were set to 0.40 (Broadbear, Winger et al. 2004, Jutkiewicz, 
Wood et al. 2005, Ising and Holsboer 2007). It has also been found that acute administration of 
CRF1R antagonist/Stress moderately increases ACTH and cortisol, so the truth-table values for 
ACTH and cortisol for Antalarmin/stress was set to 0.60 (compared to +100% with stress alone) 
(Deak, Nguyen et al. 1999, Jutkiewicz, Wood et al. 2005). 
Haloperidol is a dopamine D2 receptor antagonist (Schotte, Janssen et al. 1993). 
Subcutaneous haloperidol administration in rats produced no change in PFC NE or DA levels, so 
the truth table values for NE and DA with acute Haloperidol were set to 0.50 (Li, Perry et al. 1998). 
The combination of Haloperidol and Bupropion produced no change in the firing rate of VTA 
neurons, so the truth-table value for VTA with Haloperidol/Bupropion was set to 0.50 (Cooper, 
Wang et al. 1994).  
Olanzapine is dopamine D2 receptor antagonist and 5HT2A receptor antagonist (Pilowsky, 
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Busatto et al. 1996). Subcutaneous Olanzapine administration in rats moderately increases PFC 
NE and DA levels, so the truth table values for NE and DA with acute Olanzapine were set to 0.60 
(Li, Perry et al. 1998). 
Clonidine is an α-2 receptor agonist (Unnerstall, Kopajtic et al. 1984). Administration of 
Clonidine has been found to moderately decrease LC neuron firing in rodents, and moderately 
decrease NE levels in humans (Veith, Best et al. 1984, Jacobs 1986). The truth-table values for LC 
and NE with acute Clonidine were set to 0.40.  
Yohimbine is an alpha-2 receptor antagonist (Perry and U'Prichard 1981). Yohimbine 
administration in rats moderately elevates NE levels in the amygdala, so the truth-table value for 
NE with acute Yohimbine was set to 0.60 (Khoshbouei, Cecchi et al. 2002). The combination of 
Yohimbine and Stress maximally increase NE levels in the amygdala, so the truth-table value for 
NE with acute Yohimbine/Stress was set to 0.70 (Khoshbouei, Cecchi et al. 2002).  The 
combination of Yohimbine/Stress was also found to moderately elevate galanin levels, so the truth-
table value for galanin with Yohimbine/Stress was set to 0.60 (Khoshbouei, Cecchi et al. 2002).  
The Blier group did a series of experiments where they lesioned one of the monoaminergic 
nuclei, then observed the change in the firing activity of the other two monoaminergic regions in 
order to determine how they influence one another. The results of these experiments are included 
in the truth table. Lesioning DR neurons maximally decreases 5HT levels, lesioning LC neurons 
maximally decreases NE levels, and lesioning VTA neurons maximally decreases DA levels 
(Guiard, El Mansari et al. 2008). The truth-table values of each were set to 0.30, respective to each 
lesion and neurotransmitter. DR lesion moderately increases LC and VTA firing rates (Haddjeri, 
de Montigny et al. 1997, Guiard, El Mansari et al. 2008, Ito, Shimogawa et al. 2014). The truth-
table values for both LC and VTA with DR lesion were set to 0.60. LC lesion moderately increases 
VTA firing without changing DR firing rate (Gobbi, Cassano et al. 2007, Guiard, El Mansari et al. 
2008). The truth-table values for VTA and DR with LC lesion were set to 0.60 and 0.50, 
respectively. VTA lesion moderately decreases DR firing rate and moderately increases LC firing 
rate (Guiard, El Mansari et al. 2008, Guiard, El Mansari et al. 2008). The truth table values for DR 
and LC with VTA lesion were set to 0.40 and 0.60, respectively. 
The stress response begins with activation of the HPA axis, so the stress input sends an 
excitatory projection to the PVN (Sapolsky 2000, Gold and Chrousos 2002, de Kloet, Joels et al. 
2005). Stress leads to maximal elevation of PVN activity as measured by induction of c-fos mRNA 
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expression (Cullinan, Herman et al. 1995). Stress also leads to maximal increases in the activity 
of the anterior pituitary gland and adrenal gland as measured by maximal blood flow increases 
after acute stress and c-fos induction (Goldman 1963, Yang, Koistinaho et al. 1989). The truth-
table values for PVN, anterior pituitary, and adrenal gland with acute stress were set to 0.70. Stress 
maximally increases plasma CRF, ACTH, and cortisol, so the truth-table value for CRF, ACTH 
and cortisol with stress were set to 0.70 (Goldman 1963, Zimmermann and Critchlow 1967, 
Harbuz and Lightman 1989).  NE levels have been found to moderately increase in response to 
stressful stimuli (Galvez, Mesches et al. 1996, Hatfield, Spanis et al. 1999). LC neuron activity 
has been found to moderately increase in response to stress (Abercrombie and Jacobs 1987, 
Buffalari and Grace 2007). Stress has also been shown to moderately increase tryptophan, 5HTP, 
5HT and DA levels in many different brain regions (Thierry, Fekete et al. 1968, Abercrombie, 
Keefe et al. 1989, Kawahara, Yoshida et al. 1993, Summers, Kampshoff et al. 2003). We set the 
truth-table values for tryptophan, 5HTP, 5HT, NE and DA to 0.60.  Acute stress moderately 
increases DR neuron firing rate in rodents, and VTA firing rate in cats, so the truth-table values 
for DR and VTA were set to 0.60 (Trulson and Preussler 1984, Bambico, Nguyen et al. 2009). 
Acute stress moderately increases glutamate levels, so the truth-table value for glutamate was set 
to 0.60 (Reznikov, Grillo et al. 2007). Acute stress moderately increases AVP and oxytocin levels, 
so the truth-table values for AVP and oxytocin were set to 0.60 (Hesketh, Jessop et al. 2005). The 
amygdala and hippocampus are moderately activated in response to stress while the PFC is 
moderately inhibited, so the truth-table values for the amygdala, hippocampus, and PFC were set 
to 0.60, 0.60 and 0.40, respectively (Sakanaka, Shibasaki et al. 1986, Van de Kar, Piechowski et 
al. 1991, Chen, Fenoglio et al. 2006, Alexander, Hillier et al. 2007, Qin, Hermans et al. 2009). 
Acute stress moderately elevates melatonin levels, so the truth-table value for melatonin was set 
to 0.60 (Lynch, Eng et al. 1973, Vollrath and Welker 1988). Foot-shock stress causes a moderate 
decrease in GABA in rats, so this truth-table value was set to 0.40 (Biggio, Corda et al. 1981). 
Acute immobilization-stress produces no change in galanin levels in the amygdala, so the truth-
table value for galanin with stress was set to 0.50 (Khoshbouei, Cecchi et al. 2002).   
With the adrenalectomy (ADX) input, the adrenal gland truth-table value was set to 0.30 
(Iacobone, Albiger et al. 2008). ADX has been found to maximally decrease plasma cortisol levels, 
so the truth-table value for cortisol with ADX was set to 0.30 (Butler, Clarke et al. 1969). This 
results in a maximal rise in CRF and ACTH as well as a moderate rise in AVP, so the truth table 
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values for CRF and ACTH were set to 0.70 for AVP was set to 0.60 with adrenalectomy (Vernikos-
Danellis 1965, Fink, Robinson et al. 1988, Unno, Wu et al. 1998, Iacobone, Albiger et al. 2008). 
Because subsequent PVN and pituitary-gland firing rates moderately increase with ADX, we set 
the truth-table values for PVN and pituitary gland to 0.60 (Kitay, Holub et al. 1959, Wynn, 
Harwood et al. 1985, Kasai and Yamashita 1988). Oxytocin levels were unaffected by 
adrenalectomy, so the truth table value for oxytocin with adrenalectomy was set to 0.50 (Fink, 
Robinson et al. 1988). The combination of ADX/Stress has been found to maximally increase 
ACTH levels in female rats, so the truth-table value for ACTH with ADX/Stress was set to 0.70 
(Vernikos-Danellis 1965). The combination of ADX/Dex has been found to moderately decrease 
ACTH and AVP levels, so the truth-table values of ACTH and AVP with ADX/Dex were set to 
0.40 (Fink, Robinson et al. 1988).    
Exogenous ACTH projects to ACTH receptors (Kitay, Holub et al. 1959). Intramuscular 
injections of ACTH in horses leads to a moderate increase in cortisol levels after 2-4 hours, so the 
truth-table value for cortisol with exogenous ACTH was set to 0.60 (Thorn, Forsham et al. 1950, 
Larsson, Edqvist et al. 1979). ACTH has been shown to increase adrenal gland activity, so the 
truth-table value for adrenal gland with exogenous ACTH was set to 0.60 (Yang, Koistinaho et al. 
1990). 
Exogenous CRF projects to CRF1 and CRF2 receptors in the structure matrix 
(Merchenthaler 1984). Exogenous CRF administration in humans has been found to moderately 
increase plasma ACTH and cortisol levels (Hermus, Pieters et al. 1984). The truth-table values for 
ACTH and cortisol with exogenous CRF were both set to 0.60.    
Lesions to the PVN, amygdala, hippocampus and PFC all result in maximal decreases in 
PVN, amygdala, hippocampus, and PFC, respectively (Chang, Tran et al. 1980). The truth-table 
values for PVN, amygdala, hippocampus, and PFC, with PVN lesion, amygdala lesion, 
hippocampus lesion, and PFC lesion, respectively, were all set to 0.30. PVN lesion maximally 
reduces CRF levels and moderately reduces oxytocin levels, so the truth-table values for CRF and 
oxytocin with PVN lesion were set to 0.30 and 0.40, respectively (Bruhn, Plotsky et al. 1984, 
Antoni, Fink et al. 1990). Basal ACTH levels have also been found to moderately decrease with a 
PVN lesion, so the truth-table value for ACTH was set to 0.40. PVN lesion has been found to 
maximally decrease melatonin levels, so the truth-table value for melatonin with PVN lesion was 
set to 0.30 (Klein, Smoot et al. 1983). Adrenal gland activity has been found to moderately 
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decrease with PVN lesion, so the truth-table value for adrenal gland was set to 0.40 (Makara, Stark 
et al. 1981).   
The combination of PVN lesion and stress results in a moderate increase in CRF, ACTH, 
and cortisol (Makara, Stark et al. 1981, Bruhn, Plotsky et al. 1984, Makara 1992). The truth table 
values for these were therefore set to 0.60. Amygdala lesion and stress has been shown to lead to 
a moderate increase in CRF, ACTH, and cortisol, so the truth table values for these were also set 
to 0.60 (Sakanaka, Shibasaki et al. 1986, Van de Kar, Piechowski et al. 1991, Feldman, Conforti 
et al. 1994). However, lesions of the PFC and hippocampus combined with stress lead to maximal 
elevations of ACTH and cortisol (Jacobs, Wise et al. 1974, Herman, Schafer et al. 1989, Jacobson 
and Sapolsky 1991, Diorio, Viau et al. 1993, Herman, Cullinan et al. 1995). We set the truth-table 
values for ACTH and cortisol with PFC lesion/Stress and Hippocampus lesion/stress to 0.70.  
The combination of PVN lesion and a 5HT1A receptor agonist prevented the rise in ACTH 
observed with the agonist by itself, so the truth-table value for ACTH with PVN lesion/Gepirone 
was set to 0.50 (Bluet Pajot, Mounier et al. 1995).   
The Dexamethasone/CRF test is widely used in depression research to detect HPA axis 
dysfunction (Rush, Giles et al. 1996, Kunugi, Ida et al. 2006, Heim, Mletzko et al. 2008). CRF is 
injected after pretreatment with Dexamethasone (Kunugi, Ida et al. 2006). In normal control 
subjects, ACTH and cortisol secretion does not increase, but in stressed subjects, this test shows 
moderate increases in ACTH and cortisol secretion (Hohnloser, Von Werder et al. 1989, Kunugi, 
Ida et al. 2006, Heim, Mletzko et al. 2008). We therefore set the truth-table values for ACTH and 
cortisol with Dexamethasone/CRF to 0.50, and the truth-table values for ACTH and cortisol with 
Dexamethasone/CRF/stress to 0.60. 
Acute restraint stress with acute SSRI has been found to moderately increase AVP levels, 
so the truth-table value for AVP with SSRI/stress was set to 0.60 (Hesketh, Jessop et al. 2005). 
Oxytocin and CRF levels moderately increase with SSRI/stress, so the truth-table values for 
oxytocin and CRF with SSRI/Stress were set to 0.60 (Hesketh, Jessop et al. 2005). The 
combination of SSRI/Stress has been found to produce a maximal increase in ACTH and cortisol, 
so the truth-table values for ACTH and cortisol were set to 0.70 with SSRI/Stress (Hesketh, Jessop 
et al. 2005). SSRI/Stress has been found to maximally increase NE levels, so the truth-table value 
for NE with SSRI/stress was set to 0.70 (Page and Abercrombie 1997).  
The combination of an SSRI and a 5HT1AR antagonist (SSRI/WAY) has been found to 
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maximally increase 5HT levels, so the truth-table value for SSRI/WAY was set to 0.70 
(Arborelius, Nomikos et al. 1996). The combination of an SSRI and WAY has been found to 
produce no change in DR firing rate from baseline, so the truth-table value for DR with SSRI/WAY 
was set to 0.50 (Arborelius, Nomikos et al. 1995, Hajos, Gartside et al. 1995).  
Co-administration of an SSRI and Bupropion (SSRI/Bupropion) has been found by the 
Blier group to double DR firing rate and decrease LC firing rate by 60% (Ghanbari, El Mansari et 
al. 2010). The truth-table values for DR and LC with SSRI/Bupropion were set to 0.60 and 0.40, 
respectively. SSRI/Bupropion have been found to moderately increase 5HT, NE and DA levels, 
so the truth-table values for 5HT, NE and DA with acute SSRI/Bupropion were set to 0.60 (Li, 
Perry et al. 2002).  
The Blier group found that the combination of an SSRI and Aripiprazole 
(SSRI/Aripiprazole) produces no significant change in the firing of DR or VTA neurons, but 
decreases LC neuron firing by 26%. (Chernoloz, El Mansari et al. 2009). The truth table values for 
DR, LC, and VTA with SSRI/Aripiprazole were set to 0.50, 0.40, and 0.50, respectively. 
The Blier group found that the combination of an SSRI and Quetiapine (SSRI/Quetiapine) 
produces a 65% decrease in DR neuron firing and a 27% increase in LC neuron firing (Chernoloz, 
El Mansari et al. 2012). The truth table values for DR and LC with SSRI/Quetiapine were therefore 
set to 0.40 and 0.60, respectively.  
The combination of Reboxetine and fearful stimuli (fearful faces) has been found to 
moderately increase amygdala activity in fMRI experiments (Onur, Walter et al. 2009). The truth-
table value for amygdala with Reboxetine/Stress was set to 0.60. The combination of Reboxetine 
and stress in rodents has been found to produce no change in 5HT levels, maximally increases NE 
levels, and moderately increase DA levels (Page and Lucki 2002). The truth-table values for 5HT, 
NE and DA with Reboxetine/Stress were set to 0.50, 0.70, and 0.60, respectively. 
 
B.8 MSS-MODEL TRUTH-TABLE JUSTIFICATION 
The MSS-model includes the truth-table input/desired-output relationships derived from 
male organisms in the MS-model. All additional input/desired-output relationships are described 
here. The scale used to describe truth-table desired-outputs (where 0.30, 0.40, 0.50, 0.60, and 0.70 
represent maximal decrease, moderate decrease, baseline, moderate increase, and maximal 
increase) is the same in both studies (Camacho, Vijitbenjaronk et al. 2018). The only exception in 
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the MSS-model is that he baseline for testosterone, estrogen, and progesterone was set to 0.60, 
0.40, and 0.40, respectively, to reflect the difference in the levels of these hormones in males.  
Binding of the SSRI to 5HTT leads to a doubling of extracellular 5HT in male rodents, so 
the target-output value for 5HT with acute SSRI was set to 0.60 (Invernizzi, Belli et al. 1992, 
Koch, Perry et al. 2002, Calcagno, Guzzetti et al. 2009). Because acute administration of SSRIs 
other than fluoxetine does not significantly change NE and DA levels in male rodents, the truth 
table values for these neurotransmitters were set to 0.50 (Bymaster, Zhang et al. 2002, Koch, Perry 
et al. 2002). 
The increase in extracellular 5HT associated with acute SSRI administration has been 
associated with increased binding to the 5HT1A autoreceptor on DR neurons, decreasing the firing 
activity of these neurons in male rodents (Calcagno, Guzzetti et al. 2009). The Blier group and 
others have found that the DR neuron firing rate decreases by about 65% in male rodents with 
acute SSRI, so the truth-table value for this output was set to 0.40 (de Montigny, Chaput et al. 
1990, Czachura and Rasmussen 2000, Chernoloz, El Mansari et al. 2012). The Blier group found 
that acute SSRI administration decreases the firing rate of LC neurons by 45% and decreases the 
firing rate of VTA neurons by 41% in male rodents, so the truth table values for the LC and VTA 
firing rates with acute SSRI were also set to 0.40 (Chernoloz, El Mansari et al. 2009, Dremencov, 
El Mansari et al. 2009, Chernoloz, El Mansari et al. 2012). fMRI studies indicate that amygdala 
activity decreases moderately in both males and females, while cortical activity does not change 
with acute SSRI administration in males (Mayberg, Brannan et al. 2000, Kennedy, Evans et al. 
2001, Takahashi, Yahata et al. 2005, Murphy, Norbury et al. 2009). The Murphy lab found that 
amygdala activity decreases moderately in response to neutral faces with acute SSRI in both male 
and female subjects, and the Mayberg lab found that PFC activity moderately increases after 6-
weeks of SSRI treatment but not after acute (1-week) SSRI treatment in male subjects. The truth 
table value for the amygdala with acute SSRI were set to 0.40 and the truth table value for PFC 
was set to 0.50.  
Acute SSRI administration has been found to stimulate the rodent HPA axis by increasing 
CRF, ACTH, and cortisol levels while also increasing PVN activity in male rodents (Jensen, Jessop 
et al. 1999, Wieczorek, Schulz et al. 2001, Hesketh, Jessop et al. 2005). Specifically, 30 minutes 
of subcutaneous cannula citalopram administration moderately increases ACTH levels (Jensen, 
Jessop et al. 1999). This lab also found that PVN activity increases moderately as measured by the 
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increase in c-fos immunoreactive cells in the PVN with acute SSRI. The same lab did not find a 
significant difference in CRF mRNA with acute citalopram treatment; however, another lab found 
that acute citalopram moderately increases CRF levels in male rodents (Moncek, Duncko et al. 
2003). The truth table value for ACTH with acute SSRI was set to 0.60 in the MSS-model. The 
truth table value for CRF with acute SSRI was set to 0.60. Systemic injection citalopram increases 
corticosterone response maximally in males so the cortisol level with SSRI was set to 0.70 (Goel 
and Bale 2010, Goel, Plyler et al. 2011, Goel, Workman et al. 2014). Oxytocin levels have been 
found to moderately increase with acute SSRI, while arginine-vasopressin (AVP) levels have been 
found to stay the same in male rodents (Hesketh, Jessop et al. 2005). We set the oxytocin target to 
0.60 and the AVP target to 0.50 with acute SSRI for males. Acute fluoxetine injection moderately 
increases galanin mRNA levels in male rodents, so the truth-table value for galanin with acute 
SSRI was set to 0.60 for males (Kuteeva, Wardi et al. 2008).  Acute SSRI administration in male 
humans had no effect on testosterone levels, so the truth-table value for testosterone with acute 
SSRI for males was set to 0.60 (Schlosser, Wetzel et al. 2000).  
The Blier group found that acute administration of Nomifensine increases DR neuron 
activity by 50%, decreases VTA neuron activity by 39%, and decreases LC neuron activity by 
71% in male rodents (Katz, Guiard et al. 2010). The truth-table values for the acute effect of 
Nomifensine on DR, LC and VTA neurons were set to 0.60, 0.40, and 0.40, respectively. The 
Masana study also found that acute Nomifensine maximally increases DA levels in males. The 
Carboni lab found that acute Nomifensine maximally increases DA levels in male rodents 
(Carboni, Imperato et al. 1989). The Butcher lab found a moderate increase in DA levels with 
acute Nomifensine in male rats (Butcher, Fairbrother et al. 1988). The truth-table value for DA 
with acute Nomifensine was set to 0.60. 
Reboxetine is a selective NET blocker (Hajos, Fleishaker et al. 2004). The Blier group 
found that acute Reboxetine administration decreases LC firing rate by 68% without affecting DR 
firing rate in male rodents (Szabo and Blier 2001). They also found that acute Reboxetine 
administration decreases VTA neuron firing rate by 31% in male rodents (Katz, Guiard et al. 2010). 
The truth-table values for acute Reboxetine for DR, LC, and VTA were therefore set to 0.50, 0.40, 
and 0.40, respectively. Acute Reboxetine administration moderately increases NE and DA levels 
while producing no change in 5HT levels in male rodents, corresponding to values of 0.60, 0.60, 
and 0.50 in the truth table for these neurotransmitters, respectively (Page and Lucki 2002). One 
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fMRI study in both male and female humans shows that acute Reboxetine administration 
moderately decreases amygdala response to neutral stimuli, so the truth-table value for the 
amygdala with acute Reboxetine was set to 0.40 (Onur, Walter et al. 2009). Acute Reboxetine 
administration in male humans has been found to moderately increase ACTH levels in two studies 
using male volunteers, so the truth-table value for ACTH with acute Reboxetine was set to 0.60. 
Acute Reboxetine administration has also been shown to moderately increase cortisol levels in two 
different studies using male human volunteers, so the truth-table value for cortisol with acute 
Reboxetine was set to 0.60 (Hennig, Lange et al. 2000, Schule, Baghai et al. 2004).  
Trazodone blocks 5HTT and interacts with multiple receptors of the monoaminergic 
system (Stahl 2009, Stahl 2009). The Blier lab found that acute Trazodone administration 
decreases DR neuron firing by 65%, increases LC neuron firing by 25%, and does not alter VTA 
neuron firing in male rodents (Ghanbari, El Mansari et al. 2010, Ghanbari, El Mansari et al. 2012). 
We set the target output values for DR, LC, and VTA with acute Trazodone to 0.40, 0.60, and 
0.50, respectively. Acute Trazodone administration has been found to moderately increase 5HT 
levels without changing NE levels in male rodents, so the truth-table values for these were set to 
0.60 and 0.50, respectively (Rowbotham, Jones et al. 1984, Pazzagli, Giovannini et al. 1999).  
Asenapine is an antipsychotic drug that interacts with multiple receptors of the 
monoaminergic neurotransmitter system (Franberg, Wiker et al. 2008, Ghanbari, El Mansari et al. 
2009). The Blier group found that acute Asenapine administration decreases DR neuron firing by 
about 30% without affecting the firing rates of the LC or VTA in male rodents (Oosterhof, El 
Mansari et al. 2015). We set the truth table values for DR, LC, and VTA to 0.40, 0.50, and 0.50, 
respectively. Acute Asenapine administration in male rats has been found to moderately increase 
5HT, NE, and DA levels (Franberg, Marcus et al. 2009). The truth table outputs for 5HT, NE, and 
DA with acute Asenapine were all set to 0.60.  
Aripiprazole is an antipsychotic drug that interacts strongly with DA and 5HT receptors 
(Shapiro, Renock et al. 2003). The Blier group found that acute Aripiprazole administration 
increases DR neuron firing rate by 48%, without affecting the firing rates of LC or VTA neurons 
in male rodents (Chernoloz, El Mansari et al. 2009). The truth-table values for the DR, LC and 
VTA were set to 0.60, 0.50 and 0.50, respectively. Acute Aripiprazole administration has been 
found to moderately increase DA levels without affecting 5HT, NE, or cortisol levels in male 
rodents (Li, Ichikawa et al. 2004, Zocchi, Fabbri et al. 2005, Assie, Carilla-Durand et al. 2008). 
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The truth-table values for 5HT, NE, DA, and cortisol were set to 0.50, 0.50, 0.60, and 0.50 with 
acute Aripiprazole, respectively.  
Bupropion is an atypical antidepressant that blocks NET and DAT (Cooper, Wang et al. 
1994, Stahl, Pradko et al. 2004). The Blier group found that acute Bupropion administration 
moderately increases DR neuron firing rate, moderately decreases LC neuron firing rate, and does 
not change VTA neuron firing rate in male rodents (El Mansari, Ghanbari et al. 2008). The truth-
table values for the DR, LC and VTA were set to 0.60, 0.40 and 0.50, respectively, for males with 
acute Bupropion administration. Acute Bupropion administration has been found to moderately 
increase DA and NE levels without affecting 5HT levels in male rodents (Piacentini, Clinckers et 
al. 2003). The truth-table values for 5HT, NE, DA were set to 0.50, 0.60, and 0.60 with acute 
Bupropion in the MSS-model.  
Quetiapine is an antipsychotic drug with multiple receptor and transporter affinities, 
including the dopamine D2 receptor, the 5HT2A receptor, and the α-1 receptor (DeVane and 
Nemeroff 2001, Jensen, Rodriguiz et al. 2008). The Blier group found that acute Quetiapine 
administration decreases the DR neuron firing rate by 43% and increases the LC neuron firing rate 
by 40% in male rodents (Chernoloz, El Mansari et al. 2012). The truth-table values for the DR and 
LC with acute Quetiapine were set to 0.40 and 0.60, respectively. Another group found that acute 
Quetiapine moderately increases VTA firing rate in males, so the truth-table value for the VTA 
with acute Quetiapine was set to 0.60 for males (Werkman, Olijslagers et al. 2004). Denys et al 
found that acute Quetiapine moderately increases 5HT and DA levels in the PFC, while Silverstone 
et al found that acute Quetiapine has no effect on 5HT levels in the PFC, but moderately increases 
NE and DA levels (Denys, Klompmakers et al. 2004, Silverstone, Lalies et al. 2012). Both of these 
studies were in male rodents. Because the Denys et al study examined multiple brain regions and 
also found a moderate increase in 5HT levels in the dorsal striatum with acute Quetiapine, the truth 
table value for DA was set to 0.60. The truth table values for 5HT and NE with acute Quetiapine 
were also set to 0.60.  
Pramipexole (PPX) is a D2, D3, and D4 receptor agonist (Mierau, Schneider et al. 1995). 
The Blier group found that acute PPX administration does not change DR neuron firing rate, 
decreases LC neuron firing rate by 33%, and decreases VTA neuron firing rate by 40% in male 
rodents (Chernoloz, El Mansari et al. 2009). The truth-table values for the DR, LC and VTA were 
set to 0.50, 0.40 and 0.40, respectively, with acute PPX administration, for males. 
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GBR-12909 (GBR) is a DA transporter blocker (TOCRIS , Andersen 1989, Singh 2000). 
The Blier group found that acute GBR administration does not change DR or LC neuron firing rate 
but decreases VTA neuron firing rate by 26% in male rodents (Katz, Guiard et al. 2010). Another 
group also found a moderate decrease in VTA neuron firing rate with acute GBR in male rodents 
(Choong and Shen 2004). The truth-table values for the DR, LC and VTA were set to 0.50, 0.50 
and 0.40, respectively, with acute GBR administration. Three labs have found moderate increases 
in DA levels with acute GBR in male rodents, so the truth-table value of DA with acute GBR was 
set to 0.60 (Rothman, Mele et al. 1991, Choong and Shen 2004, Masana, Bortolozzi et al. 2011).  
Clozapine is an antipsychotic drug that targets many monoaminergic receptors (Meltzer 
1994). Acute administration of Clozapine has been found to moderately decrease the firing rate of 
DR neurons, moderately increase the firing rate of LC neurons, moderately increase the firing rate 
of VTA neurons, and moderately increase the firing rate of PFC neurons in male subjects (Souto, 
Monti et al. 1979, Sprouse, Reynolds et al. 1999, Chen and Yang 2002, Gao 2007). Another group 
found that acute Clozapine completely inhibits DR firing activity in male rodents; however, the 
dose that was used was much higher than the standard rodent dose (Gallager and Aghajanian 1976). 
The truth-table values for DR, LC, VTA, and PFC were set to 0.40, 0.60, 0.60, and 0.60, 
respectively. Acute Clozapine administration has been found to maximally increase NE levels and 
moderately increase DA levels in male rodents (Zocchi, Fabbri et al. 2005). Another group also 
found that Clozapine moderately increases DA levels in male rodents (Masana, Bortolozzi et al. 
2011). One study found that Clozapine moderately increases cortisol levels in male humans, so the 
truth table value for NE was set to 0.70 and the truth table values for DA and cortisol were set to 
0.60 (Lee, Woo et al. 2001). One group has found that Clozapine decreases 5HT in the nucleus 
accumbens, while another found that Clozapine increases 5HT in the nucleus accumbens and the 
PFC in male rodents (Ferre and Artigas 1995, Ichikawa, Kuroki et al. 1998). Because these two 
groups found opposing effects of Clozapine on 5HT, and a third group found that 5HT does not 
change in the PFC with acute Clozapine, we used a truth-table value of 0.50 for 5HT with acute 
Clozapine (Zocchi, Fabbri et al. 2005). 
Ketamine is an NMDA receptor antagonist (Hall and Murdoch 1990). The Blier group 
found that acute Ketamine administration does not change DR or VTA neuron firing rate but 
increases LC neuron firing rate by 23% in male rodents (El Iskandrani, Oosterhof et al. 2015). The 
truth-table values for the DR, LC and VTA were set to 0.50, 0.60, and 0.50, respectively, with 
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acute Ketamine administration. One group found that Ketamine moderately increases PFC neuron 
activity and moderately increases extracellular glutamate while another group found that Ketamine 
moderately increases anterior cingulate glutamate, so the truth-table value for the PFC and 
glutamate were set to 0.60 (Razoux, Garcia et al. 2007, Stone, Dietrich et al. 2012, Pehrson and 
Sanchez 2014, Bjorkholm, Franberg et al. 2015). These studies were done in male rodents and 
humans. One study found that Ketamine moderately increases PFC 5HT levels in male rodents, so 
the truth table value for 5HT was set to 0.60 with acute Ketamine for males (Nishitani, Nagayasu 
et al. 2014). Two groups found that Ketamine has no effect on GABA levels in male rodents, so 
the truth table value for GABA was set to 0.50 with acute Ketamine for males (Lindefors, Barati 
et al. 1997, Stone, Dietrich et al. 2012). One lab found that acute Ketamine had no effect on male 
rabbit whole brain NE or NE levels in any of the brain areas examined, so the truth table value for 
NE with acute Ketamine was set to 0.50. The same lab also found that DA levels did not change 
in male rabbit whole brain with Ketamine, but did find a moderate increase in thalamus and 
hypothalamus DA (Glisson, el-Etr et al. 1976). Another group found that acute Ketamine 
moderately increases DA levels in rat PFC (Lindefors, Barati et al. 1997). Because whole brain 
neurotransmitter level change is the standard criterion for the truth table, the truth-table value for 
DA with Ketamine was set to 0.50. 
Reserpine depletes monoamines by inhibiting the activity of the vesicular monoamine 
transporter 2 (VMAT2), which traffics monoamines to the cell membrane for extracellular release 
(Scherman and Henry 1984, Rudnick, Steiner-Mordoch et al. 1990). Because VMAT2 is not an 
element in our model, Reserpine sends inhibitory projections directly to 5HT, NE and DA directly.  
One group found that Reserpine moderately increases DR activity, then suppresses DR activity 
after about 30 minutes in male rodents (Baraban, Wang et al. 1978, Baraban and Aghajanian 1980). 
Because we are interested in the immediate, acute effect of Reserpine, we set the truth-table value 
for DR with acute Reserpine to 0.60.  
Venlafaxine is a selective serotonin-norepinephrine reuptake inhibitor (SNRI) (Roseboom 
and Kalin 2000). The Blier group found that Venlafaxine decreases DR firing rate by 47% and 
decreases LC firing rate by 21% in male rodents, so the truth-table values for DR and LC were 
both set to 0.40 (Gartside, Umbers et al. 1997). Because acute Venlafaxine administration 
moderately increases the firing activity of the PFC in a c-fos study with male rodents, we set the 
truth-table value for PFC with Venlafaxine to 0.60 (Higashino, Ago et al. 2014). Higashino et al 
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found that acute Venlafaxine administration moderately increases 5HT in the PFC, moderately 
increases NE in the PFC, and maximally increases DA in the PFC and Beyer et al found that acute 
Venlafaxine has no effect on forebrain 5HT levels but maximally increases forebrain NE levels 
(Beyer, Boikess et al. 2002, Higashino, Ago et al. 2014). Both of these studies were in male 
rodents. The truth-table value for 5HT was set to 0.60 in males to reflect a moderate increase in 
5HT due to the observation by Higashino et al that 5HT increases in the PFC with Venlafaxine, 
and the fact that Venlafaxine is a 5HTT blocker, which are known to elevate 5HT (El Mansari, 
Sanchez et al. 2005). The truth-table values for NE and DA were both set to 0.70 in males to reflect 
the maximal increases in the levels of these neurotransmitters with acute Venlafaxine observed by 
the Higashino and Beyer groups.     
Desipramine is a tricyclic antidepressant with strong affinity for NET and weaker affinity 
for the 5HTT and DAT as well as various monoaminergic receptor targets (Berti and Shore 1967). 
DR firing was found to moderately decrease with acute Desipramine in male rodents, so the truth-
table value for DR was set to 0.40 with acute Desipramine (Gartside, Umbers et al. 1997). Acute 
Desipramine also moderately decreases LC neuron activity in male rodents, so the truth-table value 
for LC was set to 0.40 (Scuvee-Moreau and Dresse 1979). Acute administration of Desipramine 
was found by Beyer et al to maximally increase NE levels without changing 5HT levels, and Kreiss 
et al also found that Desipramine has no effect on 5HT levels (Kreiss and Lucki 1995, Beyer, 
Boikess et al. 2002). Both of these studies were in male rodents. Another group found no change 
in 5HT levels with acute Desipramine in male rodents, but found a maximal increase in NE levels 
and a moderate increase in DA levels (Higashino, Ago et al. 2014). The truth-table value for 5HT 
was set to 0.50, for NE was set to 0.70, and for DA was set to 0.60. Acute Desipramine was found 
to have no effect on PFC activity in male rodents, so this truth-table value was set to 0.50 
(Higashino, Ago et al. 2014). Desipramine injection in both male and female humans moderately 
increases blood cortisol levels after 30 minutes, so the truth-table value for cortisol with 
Desipramine was set to 0.60 (Asnis, Halbreich et al. 1985). Desipramine moderately increases 
ACTH levels in males so the truth-table value for ACTH was set to 0.60 with acute Desipramine 
(Kuhn and Francis 1997). 
CP-96345 (CP) is a neurokinin-1 receptor antagonist (Fong, Yu et al. 1992). The Blier 
group found that acute administration of CP in male rodents increases the firing rate of DR neurons 
by 46% but does not affect the firing rate of LC neurons, so the truth-table values for DR and LC 
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were set to 0.60 and 0.50 for the DR and LC with acute CP, respectively (Conley, Cumberbatch et 
al. 2002, Haddjeri and Blier 2008). One group found that NK1 receptor antagonists moderately 
increase VTA firing rate in male rodents, so the truth-table value for VTA with acute CP was set 
to 0.60. The same group also found that NK1 receptor antagonists have no effect on 5HT levels in 
male rodents, so the 5HT value with acute CP was set to 0.50 (Lejeune, Gobert et al. 2002). 
Another group found that acute CP has no effect on NE levels, but moderately increases DA levels 
in the PFC of male gerbils (Renoldi and Invernizzi 2006). DA levels moderately increase in male 
rodents with acute NK1 receptor antagonists (Lejeune, Gobert et al. 2002). The truth table value 
for NE was set to 0.50 and for DA was set to 0.60 with acute CP. The combination of NK1 
antagonists and stress leads to no change in NE or DA levels in male rodents (Renoldi and 
Invernizzi 2006). The truth-table values for NE and DA with CP/Stress were set to 0.50.    
Gepirone is a 5HT1A receptor agonist (Blier and Ward 2003). The Blier group and others 
have found that acute administration of 5HT1A agonists maximally decrease DR neuron firing 
rate in male rodents, so the truth-table value of DR with Gepirone was set to 0.30 (VanderMaelen, 
Matheson et al. 1986, Blier and de Montigny 1987, Blier and de Montigny 1990). 5HT1A receptor 
agonists have been found to maximally decrease 5HT levels in male rodents by multiple groups, 
so the truth table value for 5HT with acute Gepirone was set to 0.30 (Rutter, Gundlah et al. 1994, 
Dawson, Nguyen et al. 2002). 5HT1A receptor agonists have also been found to moderately 
increase CRF, ACTH, and cortisol release in male rodents, so the truth-table values for CRF, 
ACTH, and cortisol with acute Gepirone were set to 0.60 (Pan and Gilbert 1992, Matheson, 
Knowles et al. 1997). When males are castrated, their cortisol response to 5HT1A receptor agonists 
reach maximal levels, so the cortisol level for castrated males with gepirone was set to 0.70 
(Matsuda, Nakano et al. 1991). The combination of Gepirone and stress moderately increases 
cortisol levels in male rodents, so the cortisol level in the truth-table with acute Gepirone/stress 
was set to 0.60 (Matheson, Knowles et al. 1997). The combination of Gepirone/Dexamethasone 
moderately decreases cortisol levels in male rodents, so the cortisol level in the truth-table with 
acute Gepirone/Dexamethasone was set to 0.40 (Matheson, Knowles et al. 1997).   
Org34850 (Org) is a glucocorticoid receptor antagonist (Reynolds, Saunders et al. 2015). 
Acute Org administration by itself has been found to have no effect on cortisol, 5HT, or DA levels 
in male rodents, so the truth-table values for cortisol, 5HT, and DA with acute Org were set to 0.50 
(Spiga, Harrison et al. 2007, Spiga, Harrison et al. 2008). Acute Org/Stress was also found by this 
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group to have no effect on cortisol levels in male rodents, so the truth-table value for cortisol with 
acute Org/Stress was set to 0.50.   
Oxytocin is an input that projects to model oxytocin receptors (Gimpl and Fahrenholz 
2001). Oxytocin administration to male rats has been shown to double DA levels, so the truth-table 
value for DA was set to 0.60 (Melis, Melis et al. 2007). Oxytocin by itself as well as 
Oxytocin/Stress has no effect on PVN CRF mRNA in male rats, so the CRF value with Oxytocin 
and with Oxytocin/Stress was set to 0.50 (Bulbul, Babygirija et al. 2011). Oxytocin has been found 
to moderately decrease amygdala response to fearful stimuli (faces and scenery) in human males, 
so the truth-table value for amygdala with Oxytocin/Stress was set to 0.40 (Kirsch, Esslinger et al. 
2005). One study in rats from 1984 found that Oxytocin does not have a significant effect on 
ACTH levels, however, because several other groups since 1984 have found that Oxytocin 
moderately decreases ACTH in both male and female subjects, the truth-table values for ACTH 
with Oxytocin were set to 0.40 (Gibbs, Vale et al. 1984, Chiodera and Coiro 1987, Parker, 
Buckmaster et al. 2005). It has also been found that Oxytocin moderately decreases cortisol levels 
in male humans, so the truth-table value for cortisol with Oxytocin was set to 0.40 (Legros, 
Chiodera et al. 1984).  
Dexamethasone is a corticosteroid with significant in vivo affinity for glucocorticoid 
receptors but not mineralocorticoid receptors (Bamberger, Bamberger et al. 1995, Reul, Gesing et 
al. 2000, Pariante and Miller 2001). One group found that Dexamethasone maximally decreases 
cortisol levels in males, so the truth-table value for cortisol with Dexamethasone was set to 0.30 
(Heuser, Gotthardt et al. 1994, Rush, Giles et al. 1996).  Dexamethasone maximally suppresses 
PVN CRF mRNA in male rodents, so the truth-table value for CRF with Dexamethasone was set 
to 0.30 (Kovacs and Mezey 1987). Acute Dexamethasone administration moderately decreases 
ACTH levels in male humans, so the truth-table value for ACTH with Dexamethasone was set to 
0.40 (Hohnloser, Von Werder et al. 1989).  Acute Dexamethasone moderately decreases AVP 
mRNA in the PVN of male rodents, so the truth-table value for AVP with Dexamethasone was set 
to 0.40 (Kovacs and Makara 1988). C-fos mRNA responses in the PVN and pituitary gland were 
found to be moderately decreased with acute Dexamethasone in male rodents, so the truth-table 
values for the PVN and pituitary gland were set to 0.40 (Karssen, Meijer et al. 2005). 
Dexamethasone administration has been shown to moderately increase the levels of 5HT 
precursors and 5HT in male rodents, so the truth-table values for Trp, 5HTP, and 5HT were set to 
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0.60 with Dexamethasone (Tsubota, Adachi et al. 1999, Clark, Flick et al. 2008). Dexamethasone 
has also been found to moderately increase the levels of extracellular DA in male rodents but 
moderately decrease extracellular NE in both male and female humans, so the truth-table values 
for DA and NE were set to 0.60 and 0.40, respectively (Stene, Panagiotis et al. 1980, Tsubota, 
Adachi et al. 1999). Dexamethasone administration in male rodents has been found to decrease 
testosterone levels, so the truth-table value for testosterone with Dexamethasone was set to 0.50 
(Saez, Morera et al. 1977). 
WAY-100635 (WAY) is a 5HT1A receptor antagonist (Fletcher, Forster et al. 1996). 
Administration of WAY has been shown to reverse the inhibitory effects of 5HT1A receptor 
agonists on DR firing rate in both male and female rodents, so the truth-table value for DR with 
WAY/Gepirone was set to 0.50 (Evrard, Laporte et al. 1999). WAY/Gepirone together has also 
been shown to prevent the rise in ACTH observed with Gepirone in male rodents, so the truth-
table value for ACTH with WAY/Gepirone was set to 0.50 (Fletcher, Forster et al. 1996). 5HT1AR 
antagonists by themselves moderately increase extracellular 5HT in male rodents, so the truth-
table value for 5HT with WAY was set to 0.60 (Arborelius, Nomikos et al. 1996). 
Monoamine Oxidase Inhibitors (MAOI) block the activity of monoamine oxidase, which 
is an enzyme that breaks down monoamines (Stein 1960, Remick and Froese 1990). The Blier 
group found that acute MAOI administration moderately decreases DR and LC neuron firing 
without affecting VTA neuron firing in male rodents, so the truth-table values for DR and LC were 
set to 0.40 and the truth table value for VTA was set to 0.50 with MAOI for males (Blier and de 
Montigny 1985, Chenu, El Mansari et al. 2009). Acute MAOI administration has been shown to 
produce maximal increases in all three of the monoamines in male rodents, so the truth-table values 
for 5HT, NE and DA were set to 0.70 (Butcher, Fairbrother et al. 1990, Celada and Artigas 1993, 
Kitaichi, Inoue et al. 2006).  
M-617 inhibits galR1 receptors (Sevcik, Finta et al. 1993, Larm, Shen et al. 2003, Wang, 
Li et al. 2016). Acute M617 administration moderately decreases DR and LC firing rate and 
moderately decreases 5HT and NE levels in male rodents (Jacobs, Wise et al. 1974, Azmitia and 
Segal 1978, Seutin, Verbanck et al. 1989, Sevcik, Finta et al. 1993, Yoshitake, Reenila et al. 2003, 
Hawes, Brunzell et al. 2005, Mazarati, Baldwin et al. 2005). We therefore set the truth-table values 
for DR, LC, 5HT, and NE to 0.40. It has also been found that M617 administration produces 
moderate increases in the activity of the amygdala and PVN as measured by increases in c-fos 
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expression in these regions of male rodents, so the truth-table values for these regions were set to 
0.60 (Blackshear, Yamamoto et al. 2007).  
CRF1 receptor antagonists block the CRF1 receptor (Holsboer and Ising 2008). 
Specifically, multiple labs have found that CRF1R antagonists moderately decrease ACTH and 
cortisol release in both male and female subjects, so the truth-table values for ACTH and cortisol 
with CRF1R antagonist were set to 0.40 (Broadbear, Winger et al. 2004, Jutkiewicz, Wood et al. 
2005, Ising and Holsboer 2007). Acute administration of CRF1R antagonist/Stress moderately 
increases ACTH and cortisol in male rodents, so the truth-table values for ACTH and cortisol for 
CRF1R antagonist/stress was set to 0.60 for males (Deak, Nguyen et al. 1999, Jutkiewicz, Wood 
et al. 2005). 
Haloperidol is a dopamine D2 receptor antagonist (Schotte, Janssen et al. 1993). 
Subcutaneous haloperidol administration in rats produces no change in PFC NE or DA levels in 
male rodents, so the truth table values for NE and DA with acute Haloperidol were set to 0.50 (Li, 
Perry et al. 1998). The combination of Haloperidol and Bupropion produces no change in the firing 
rate of VTA neurons in male rodents, so the truth-table value for VTA with Haloperidol/Bupropion 
was set to 0.50 (Cooper, Wang et al. 1994).  
Olanzapine is dopamine D2 receptor antagonist and 5HT2A receptor antagonist (Pilowsky, 
Busatto et al. 1996). Subcutaneous Olanzapine administration in male rats moderately increases 
PFC NE and DA levels, so the truth table values for NE and DA with acute Olanzapine were set 
to 0.60 (Li, Perry et al. 1998). 
Clonidine is an α-2 receptor agonist (Unnerstall, Kopajtic et al. 1984). Administration of 
Clonidine has been found to moderately decrease LC neuron firing in male rodents, and moderately 
decrease NE levels in both male and female humans (Svensson, Bunney et al. 1975, Veith, Best et 
al. 1984, Jacobs 1986). The truth-table value for LC with acute Clonidine was set to 0.40. The 
truth-table value for NE with acute Clonidine was set to 0.40.  
Yohimbine is an α-2 receptor antagonist (Perry and U'Prichard 1981). Yohimbine 
administration in male rats moderately elevates NE levels in the amygdala, so the truth-table value 
for NE with acute Yohimbine was set to 0.60 (Khoshbouei, Cecchi et al. 2002). The combination 
of Yohimbine and Stress maximally increases NE levels in the amygdala of male rats, so the truth-
table value for NE with acute Yohimbine/Stress was set to 0.70 (Khoshbouei, Cecchi et al. 2002).  
The combination of Yohimbine/Stress was also found to moderately elevate galanin levels in male 
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rats, so the truth-table value for galanin with Yohimbine/Stress was set to 0.60 (Khoshbouei, 
Cecchi et al. 2002). The combination of an alpha-2 receptor antagonist and CRF produces 
moderate increases in ACTH and cortisol in both males and females, so the truth-table values for 
ACTH and cortisol with Yoh/CRF were set to 0.60 (Kizildere, Gluck et al. 2003).  
Administration of an alpha-1 agonist in male subjects moderately increases AVP levels, so 
the truth-table value for AVP with alpha-1 agonist was set to 0.60 (Armstrong, Gallagher et al. 
1986). 
The Blier group did a series of experiments in male rodents where they lesioned one of the 
monoaminergic nuclei, then observed the change in the firing activity of the other two 
monoaminergic nuclei to determine how they influence one another. The results of these 
experiments are included in the truth table and described in detail in the supplement to the MS-
model study (Camacho, Vijitbenjaronk et al. 2018). 
  The stress input sends an excitatory projection to the PVN (Sapolsky 2000, Gold and 
Chrousos 2002, de Kloet, Joels et al. 2005). Stress leads to maximal elevation of PVN activity as 
measured by induction of c-fos mRNA expression in male rats (Cullinan, Herman et al. 1995). 
Stress also leads to maximal increases in the activity of the adrenal gland in male rodents as 
measured by maximal blood flow increases after acute stress and c-fos induction (Goldman 1963, 
Yang, Koistinaho et al. 1989). The truth-table values for PVN and adrenal gland were set to 0.70 
with stress. Stress moderately increases plasma CRF, ACTH, and cortisol in male subjects, so the 
truth-table values for CRF, ACTH and cortisol with stress were set to 0.60 (Kitay 1961, Viau, 
Bingham et al. 2005, Iwasaki-Sekino, Mano-Otagiri et al. 2009) (Goldman 1963, Zimmermann 
and Critchlow 1967, Harbuz and Lightman 1989, Rivier 1993).  Castrated males have maximal 
increases in CRF, ACTH, cortisol, and AVP in response to stress, so the truth-table values for 
CRF, ACTH, cortisol, and AVP were all set to 0.70 for castrated males (Seale, Wood et al. 2004). 
When testosterone is administered to castrated males, their stress-induced increases in ACTH and 
cortisol return to moderate levels, so the truth-table values for ACTH and cortisol for stressed, 
castrated and testosterone-infused males were set to 0.60 (Handa, Nunley et al. 1994, Viau and 
Meaney 1996). NE levels have been found to moderately increase in response to stressful stimuli 
in both male and female subjects, so the truth-table value for NE with stress was set to 0.60 
(Galvez, Mesches et al. 1996, Hatfield, Spanis et al. 1999). LC neuron activity in both male and 
female subjects has been found to moderately increase in response to stress (Abercrombie and 
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Jacobs 1987, Buffalari and Grace 2007). Stress has also been shown to moderately increase 
tryptophan, 5HTP, 5HT and DA levels in many different brain regions of male subjects (Thierry, 
Fekete et al. 1968, Abercrombie, Keefe et al. 1989, Kawahara, Yoshida et al. 1993, Summers, 
Kampshoff et al. 2003). We set the truth-table values for tryptophan, 5HTP, 5HT, NE, LC and DA 
to 0.60.  Acute stress moderately increases DR neuron firing rate in male rodents, and VTA firing 
rate in both male and female cats, so the truth-table values for DR and VTA were set to 0.60 
(Trulson and Preussler 1984, Bambico, Nguyen et al. 2009). Acute stress also moderately increase 
5HT and DA levels in castrated males, so the truth-table values for 5HT and DA with acute stress 
were set to 0.60 for castrated males (Doge 1993). Acute stress moderately increases glutamate 
levels in male rodents, so the truth-table value for glutamate was set to 0.60 (Reznikov, Grillo et 
al. 2007). Acute stress moderately increases AVP and oxytocin levels in male rodents, so the truth-
table values for AVP and oxytocin were set to 0.60 (Hesketh, Jessop et al. 2005). The amygdala 
and hippocampus are moderately activated in response to stress in males while the PFC is 
moderately inhibited in both males and females, so the truth-table values for the amygdala, 
hippocampus, and PFC were set to 0.60, 0.60 and 0.40, respectively (Sakanaka, Shibasaki et al. 
1986, Van de Kar, Piechowski et al. 1991, Chen, Fenoglio et al. 2006, Alexander, Hillier et al. 
2007, Qin, Hermans et al. 2009). Acute stress moderately elevates melatonin levels in male 
rodents, so the truth-table value for melatonin was set to 0.60 (Lynch, Eng et al. 1973, Vollrath 
and Welker 1988). Foot-shock stress causes a moderate decrease in GABA in both male and female 
rats, so this truth-table value was set to 0.40 (Biggio, Corda et al. 1981). Acute immobilization-
stress produces no change in galanin levels in the amygdala of male rodents, so the truth-table 
value for galanin with stress was set to 0.50 (Khoshbouei, Cecchi et al. 2002).  Surgical stress was 
found to moderately decrease testosterone levels in human males, so testosterone was set to 0.50 
with stress (Aono, Kurachi et al. 1976).  Stress moderately increases 5HT levels in males, so the 
truth-table value for 5HT was set to 0.60 (Mitsushima, Yamada et al. 2006, Lanfumey, Mongeau 
et al. 2008, Jacobson-Pick, Audet et al. 2013). Adding progesterone to stress in males moderately 
increases plasma progesterone levels and prevents the rise in cortisol associated with stress 
(Childs, Van Dam et al. 2010). The truth-table value for progesterone and cortisol for 
Progesterone/Stress were set to 0.50.  
With the adrenalectomy (ADX) input, the adrenal gland truth-table value was set to 0.30 
(Iacobone, Albiger et al. 2008). ADX moderately increases testis activity in male rodents, so the 
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truth-table value for testis with ADX was set to 0.60 (Desjardins and Ewing 1971). However, 
testosterone levels have been found to stay the same with ADX in intact male rats (Saez, Morera 
et al. 1977). ADX results in a maximal rise in CRF and ACTH as well as a moderate rise in AVP 
in both male and female subjects, so the truth table values for CRF and ACTH were set to 0.70 for 
AVP was set to 0.60 with adrenalectomy (Vernikos-Danellis 1965, Fink, Robinson et al. 1988, 
Unno, Wu et al. 1998, Iacobone, Albiger et al. 2008). Because PVN and pituitary gland firing-
rates moderately increase with ADX in male subjects, we set the truth-table values for PVN and 
pituitary gland to 0.60 (Kitay, Holub et al. 1959, Wynn, Harwood et al. 1985, Kasai and Yamashita 
1988). ADX/Dex has been found to produce no change in testosterone levels in male rats, so the 
truth-table value for testosterone with ADX/Dex was set to 0.60 (Saez, Morera et al. 1977). ADX 
produces no change in serum LH levels in intact male rats, so the truth-table value for LH with 
ADX was set to 0.50 (Mann, Free et al. 1987). ADX in castrated male rats does not change LH 
and FSH levels, so the truth-table values for LH and FSH with ADX were set to 0.50 for castrated 
males (Schwartz and Justo 1977). The combination of ADX/Corticosterone was found to have no 
change on testis activity, but a decrease in testosterone level (Desjardins and Ewing 1971). The 
truth-table values for testis and testosterone were both set to 0.50 with corticosterone/ADX. The 
combinations of ADX/hCG, ADX/hCG/Dex, and ADX/ACTH/hCG all resulted in a moderate 
increase in testosterone levels in intact male rats, so testosterone was set to 0.70 for all of these 
combinations (Saez, Morera et al. 1977).   
Exogenous ACTH projects to ACTH receptors, and raises ACTH levels, so the truth-table 
value for ACTH was set to 0.60 (Kitay, Holub et al. 1959). Intramuscular injections of ACTH in 
male horses leads to a moderate increase in cortisol levels after 2-4 hours, so the truth-table value 
for cortisol with exogenous ACTH was set to 0.60 (Thorn, Forsham et al. 1950, Larsson, Edqvist 
et al. 1979). ACTH has been shown to increase adrenal gland activity in male rats, so the truth-
table value for adrenal gland with exogenous ACTH was set to 0.60 (Yang, Koistinaho et al. 1990). 
Exogenous ACTH for three days produces no change in LH levels but moderately decreases 
testosterone levels in intact male rats, so the truth-table values for LH and testosterone with 
exogenous ACTH were both set to 0.50 (Saez, Morera et al. 1977, Mann, Free et al. 1987). 
Exogenous ACTH in intact male rats has been found to decrease testis size, so the truth-table value 
for testis was set to 0.40 with Exogenous ACTH (Baker, Schairer et al. 1950). Exogenous ACTH 
has also been found to increase progesterone levels in intact male rats, so the truth-table value for 
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progesterone with exogenous ACTH was set to 0.50 (Mann, Free et al. 1987). Exogenous ACTH 
moderately decreases FSH levels in intact male rats, so the truth-table value for FSH with 
exogenous ACTH was set to 0.40 (Mann, Free et al. 1987). Exogenous ACTH administration in 
castrated male rats produces no change in LH levels, so the truth-table value for LH with ACTH 
was set to 0.50 for castrated males (Mann, Free et al. 1987). Exogenous ACTH results in a maximal 
decrease in testosterone levels in castrated male rats, so the truth-table value for testosterone with 
ACTH was set to 0.40 for castrated males (Mann, Free et al. 1987). Exogenous ACTH results in 
moderately elevates cortisol and progesterone levels in castrated male rats, so the truth-table values 
for cortisol and progesterone were set to 0.60 and 0.50, respectively, for castrated males (Mann, 
Free et al. 1987). Exogenous ACTH moderately decreases FSH levels in castrated males, so the 
truth-table value for FSH with exogenous ACTH was set to 0.40 for castrated males (Mann, Free 
et al. 1987).  
Exogenous CRF projects to CRF1 and CRF2 receptors and elevates CRF levels in both 
males and females (Merchenthaler 1984). Exogenous CRF administration in both male and female 
humans has been found to moderately increase plasma ACTH and cortisol levels (Hermus, Pieters 
et al. 1984). The truth-table values for ACTH and cortisol with exogenous CRF were both set to 
0.60.  
Lesions to the PVN, amygdala, hippocampus and PFC all result in maximal decreases in 
PVN, amygdala, hippocampus, and PFC, respectively (Chang, Tran et al. 1980). The truth-table 
values for PVN, amygdala, hippocampus, and PFC, with PVN lesion, amygdala lesion, 
hippocampus lesion, and PFC lesion, respectively, were all set to 0.30. PVN lesion maximally 
reduces CRF levels and moderately reduces oxytocin levels in both male and female rodents, so 
the truth-table values for CRF and oxytocin with PVN lesion were set to 0.30 and 0.40, respectively 
(Bruhn, Plotsky et al. 1984, Antoni, Fink et al. 1990). Basal ACTH levels have also been found to 
moderately decrease with a PVN lesion in both male and female rodents, so the truth-table value 
for ACTH was set to 0.40 (Makara, Stark et al. 1981). PVN lesion has been found to maximally 
decrease melatonin levels in male rodents, so the truth-table value for melatonin with PVN lesion 
was set to 0.30 (Klein, Smoot et al. 1983). Adrenal gland activity has been found to moderately 
decrease with PVN lesion in both male and female rodents, so the truth-table value for adrenal 
gland was set to 0.40 (Makara, Stark et al. 1981).   
The combination of PVN lesion and stress results in a moderate increase in CRF, ACTH, 
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and cortisol in both males and females (Makara, Stark et al. 1981, Bruhn, Plotsky et al. 1984, 
Makara 1992). The truth-table values for these were set to 0.60. Amygdala lesion and stress has 
been shown to lead to a moderate increase in CRF, ACTH, and cortisol in male subjects, so the 
truth table values for these were also set to 0.60 (Sakanaka, Shibasaki et al. 1986, Van de Kar, 
Piechowski et al. 1991, Feldman, Conforti et al. 1994). However, lesions of the PFC and 
hippocampus combined with stress lead to maximal elevations of ACTH and cortisol in male 
subjects (Jacobs, Wise et al. 1974, Herman, Schafer et al. 1989, Jacobson and Sapolsky 1991, 
Diorio, Viau et al. 1993, Herman, Cullinan et al. 1995). We set the truth-table values for ACTH 
and cortisol with PFC lesion/Stress and Hippocampus lesion/stress to 0.70.  
The combination of PVN lesion and a 5HT1A receptor agonist prevented the rise in ACTH 
observed with the agonist by itself in male rats, so the truth-table value for ACTH with PVN 
lesion/Gepirone was set to 0.50 (Bluet Pajot, Mounier et al. 1995).   
The Dexamethasone/CRF test is widely used in depression research to detect HPA axis 
dysfunction (Rush, Giles et al. 1996, Kunugi, Ida et al. 2006, Heim, Mletzko et al. 2008). CRF is 
injected after pretreatment with Dexamethasone (Kunugi, Ida et al. 2006). In normal control 
subjects, ACTH and cortisol secretion does not increase, but in stressed subjects, this test shows 
moderate increases in ACTH and cortisol secretion (Hohnloser, Von Werder et al. 1989, Kunugi, 
Ida et al. 2006, Heim, Mletzko et al. 2008). This was found for both males and females. We 
therefore set the truth-table values for ACTH and cortisol with Dexamethasone/CRF to 0.50, and 
the truth-table values for ACTH and cortisol with Dexamethasone/CRF/stress to 0.60. 
Acute restraint stress with acute SSRI has been found to moderately increase AVP levels 
in male rodents, so the truth-table value for AVP with SSRI/stress was set to 0.60 (Hesketh, Jessop 
et al. 2005). Oxytocin and CRF levels moderately increase with SSRI/stress in male rodents, so 
the truth-table values for oxytocin and CRF with SSRI/Stress were set to 0.60 (Hesketh, Jessop et 
al. 2005). The combination of SSRI/Stress maximally increases ACTH and cortisol in male 
rodents, so the truth-table values for ACTH and cortisol were set to 0.70 with SSRI/Stress 
(Hesketh, Jessop et al. 2005). SSRI/Stress has been found to maximally increase NE levels in male 
rodents, so the truth-table value for NE with SSRI/stress was set to 0.70 (Page and Abercrombie 
1997).  
  The combination of an SSRI and a 5HT1AR antagonist (SSRI/WAY) maximally increases 
5HT levels in male rodents, so the truth-table value for SSRI/WAY was set to 0.70 (Arborelius, 
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Nomikos et al. 1996). The combination of an SSRI and WAY produces no change in DR firing 
rate from baseline in male and female rodents, so the truth-table value for DR with SSRI/WAY 
was set to 0.50 (Arborelius, Nomikos et al. 1995, Hajos, Gartside et al. 1995) (Evrard, Laporte et 
al. 1999)  
Co-administration of an SSRI and Bupropion (SSRI/Bupropion) has been found by the 
Blier group to double DR firing rate and decrease LC firing rate by 60% in male rodents (Ghanbari, 
El Mansari et al. 2010). The truth-table values for DR and LC with SSRI/Bupropion were set to 
0.60 and 0.40, respectively. SSRI/Bupropion have been found to moderately increase 5HT, NE 
and DA levels in male rodents, so the truth-table values for 5HT, NE and DA with acute 
SSRI/Bupropion were set to 0.60 (Li, Perry et al. 2002).  
The Blier group found that the combination of an SSRI and Aripiprazole 
(SSRI/Aripiprazole) produces no significant change in the firing rates of DR or VTA neurons, but 
decreases LC neuron firing by 26% in male rodents (Chernoloz, El Mansari et al. 2009). The truth 
table values for DR, LC, and VTA with SSRI/Aripiprazole were set to 0.50, 0.40, and 0.50, 
respectively. 
The Blier group found that the combination of an SSRI and Quetiapine (SSRI/Quetiapine) 
produces a 65% decrease in DR neuron firing and a 27% increase in LC neuron firing in male 
rodents (Chernoloz, El Mansari et al. 2012). The truth table values for DR and LC with 
SSRI/Quetiapine were therefore set to 0.40 and 0.60, respectively.  
The combination of Reboxetine and fearful stimuli (fearful faces) has been found to 
moderately increase amygdala activity in males and females in fMRI experiments (Onur, Walter 
et al. 2009). The truth-table value for amygdala with Reboxetine/Stress was set to 0.60. The 
combination of Reboxetine and stress in male rodents has been found to produce no change in 5HT 
levels, maximally increases NE levels, and moderately increase DA levels (Page and Lucki 2002). 
The truth-table values for 5HT, NE and DA with Reboxetine/Stress were set to 0.50, 0.70, and 
0.60, respectively.   
Estrogen is a hormone input that projects to alpha and beta estrogen receptors in the model 
(Shughrue, Lane et al. 1997). Estrogen administration in both male and female intact rats has been 
shown to moderately increase DR neuron activity, so the truth-table value for DR was set to 0.60 
for exogenous estrogen (Robichaud and Debonnel 2005). Estrogen produces no change CRF or 
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AVP levels in castrated male rats, so the truth-table values for CRF and AVP with estrogen were 
set to 0.50 for castrated males (Patchev, Hayashi et al. 1995).  
Testosterone projects to the testosterone receptor in the model. Acute (3-day) 
administration of testosterone moderately increases DR neuron firing in both male and freely 
cycling female rats, so the truth-table value for DR with testosterone was set to 0.60 (Robichaud 
and Debonnel 2005). Testosterone administration to male rats was found to moderately increase 
5HT and DA levels, so the truth-table values for 5HT and DA were set to 0.60 (de Souza Silva, 
Mattern et al. 2009).   
Administration of hCG to intact male rats has been shown to moderately increase 
testosterone levels, so the truth-table value for testosterone was set to 0.70 (Saez, Morera et al. 
1977). The combination of hCG and Dexamethasone as well as the combination of hCG and 
Corticosteroid to male testicular cell culture were both found to moderately decrease testosterone 
levels, so the truth-table values for testosterone with hCG/Dex and hCG/Corticosteroid were set 
to 0.50 (Bambino and Hsueh 1981). 
ER-beta agonist projects to the Beta estrogen receptor. Administration of the ER-beta 
agonist to intact male rodents produces no change in testosterone levels, so the truth-table value 
for testosterone with ER-beta agonist was set to 0.60 (Patisaul, Burke et al. 2009). ER-beta agonist 
moderately increases 5HT and DA levels after 3-hours of administration in male rodents, so the 
truth-table values for 5HT and DA were set to 0.60 with acute ER-beta agonist (Hughes, Liu et al. 
2008). 
ER-alpha agonist projects to the Alpha estrogen receptor. Administration of the ER-alpha 
agonist to intact male rodents produces no change in testosterone levels, so the truth-table value 
for testosterone with ER-alpha agonist was set to 0.60 (Patisaul, Burke et al. 2009). 
Exogenous AVP binds to V1A receptors in the model. Exogenous AVP has been found to 
moderately increase ACTH and cortisol levels in male humans, so the truth-table values for ACTH 
and cortisol with Exogenous AVP were set to 0.60 (Hensen, Hader et al. 1988).  
Exogenous GnRH is a hormone input that binds to the GnRH receptor. Exogenous GnRH 
administration for three days to intact male rats moderately increases LH, FSH, and testosterone 
levels, so the truth-table values for LH, FSH and testosterone with exogenous GnRH were set to 
0.60, 0.60, and 0.70 (Bruni, Huang et al. 1977, Mann, Free et al. 1987).  
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The combination of Exogenous ACTH and GnRH resulted in no change in serum 
testosterone levels in intact male rats, so the truth-table value for testosterone with Exogenous 
ACTH/GnRH were set to 0.60 (Mann, Free et al. 1987). The combination of exogenous ACTH 
and GnRH resulted in a moderate increase in LH levels in intact male rats, so the truth-table value 
for LH with exogenous ACTH/GnRH was set to 0.60 (Mann, Free et al. 1987). 
The combination of ADX, exogenous ACTH and exogenous GnRH produces a moderate 
increase in LH levels in intact male rats, so the truth table value for LH with ADX/ACTH/GnRH 
was set to 0.60 (Mann, Free et al. 1987). 
The combination of ADX and exogenous ACTH produces no change in testosterone levels 
of intact male rats, so the truth-table value of testosterone with ADX/ACTH was set to 0.60 (Saez, 
Morera et al. 1977, Mann, Free et al. 1987). 
The combination of ADX/GnRH produces no change in testosterone levels in intact male 
rats, so the truth-table value for testosterone with ADX/GnRH was set to 0.60 (Mann, Free et al. 
1987). 
Corticosterone is a hormone input that projects to MC and GC receptors in the model. 
Corticosterone treatment moderately decreases adrenal gland weight in male rats, so the truth-table 
value for adrenal gland was set to 0.40 with corticosterone (Mann, Free et al. 1987). Serum LH 
levels were found to be unaffected by corticosterone in male rats, so the truth-table value for LH 
was set to 0.50 with corticosterone (Mann, Free et al. 1987). Testosterone levels were found to 
moderately decrease with acute corticosterone in male rats, so the truth-table value for testosterone 
with corticosterone was set to 0.50 (Mann, Free et al. 1987).  
Cortisol infusion in castrated male Rhesus monkeys resulted in a maximal rise in cortisol 
levels, so the truth-table value for cortisol was set to 0.70 for cortisol infusion in castrated males. 
Cortisol infusion in castrated male Rhesus monkeys moderately decreases FSH and LH levels, but 
the addition of GnRH to the Cortisol infusion in castrated males results in in normal FSH and LH 
levels. The truth-table values for FSH and LH for cortisol infusion in castrated males were set to 
0.40 and the truth-table values for FSH and LH for cortisol infusion in castrated males and GnRH 
were set to 0.50 (Dubey and Plant 1985). 
The combination of corticosterone/GnRH moderately increases LH levels, does not change 
testosterone levels or testes size, and decreases adrenal gland size in male rats (Mann, Free et al. 
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1987). The truth-table values for LH, testosterone, testes, and adrenal gland were set to 0.60, 0.50, 
0.50, and 0.40, respectively, with corticosterone/GnRH. 
Castration has an inhibitory projection to the testes in the model. Castration has been found 
to maximally decrease testosterone levels and produce no change in DR neuron firing rate, so the 
truth-table value for testosterone was set to 0.40 and for DR was set to 0.50 (Robichaud and 
Debonnel 2005). Castration in intact male rats has also been found to moderately increase LH, 
FSH and progesterone levels, so the truth-table values for LH, FSH and progesterone with 
castration were set to 0.60, 0.60, and 0.50, respectively (Schwartz and Justo 1977, Mann, Free et 
al. 1987). 
Exogenous 5HT injections in intact male rats increases 5HT levels and decreases testis 
weight, Gepso the truth-table value for 5HT was set to 0.60 and for testis was set to 0.40 with acute 
5HT exogenous. Exogenous 5HT also increases LH and FSH levels, but decreases testosterone 
levels. The truth-table values for LH and FSH were set to 0.60, and for testosterone was set to 0.50 
for exogenous 5HT (Hedger, Khatab et al. 1995).    
 
B.9 COMPLETE MS-MODEL TRUTH-TABLE 
The MS-model truth table spreadsheet is below. All truth-table values were divided by 10 in the 
program code. 
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B.11 DETAILS ON TRAINING THE MS- AND MSS-MODELS USING GD 
The MS-model takes the form of a recurrent network of units that all have the same 
sigmoidal (S-shaped, nonlinear but differentiable) activation function. This powerful 
computational formalism is a Turing-equivalent universal approximator that can be efficiently 
trained, via machine learning, to perform a broad range of desired, dynamic input-output 
transformations (Siegelmann and Sontag 1991). When used to model neural systems, the units in 
a recurrent network usually represent single neurons, or the average activity of the neurons in the 
same brain region (Anastasio 2010). In modeling and analysis of the transmitter and hormonal 
systems that mediate mood, however, multiple levels of organization must be taken into account 
that include not only brain regions and neurons but also proteins and small molecules. 
In the MS-model, individual units represent the brain regions, transmitters, receptors, 
transporters, enzymes, precursors, metabolites, and hormones that are involved in the pathologies 
of anxiety and depression. Some individual units represented whole brain regions that are central 
to these pathologies. The monoaminergic neurotransmitter-producing regions (DR, LC and VTA) 
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were represented as single units because the majority of antidepressant drugs target these regions 
directly (Koenig and Thase 2009). The HPA axis regions (PVN, pituitary gland, and adrenal gland) 
were represented as single units in order to incorporate the effects of the stress response in our 
analysis. The amygdala, prefrontal cortex (PFC), and hippocampus were represented because these 
regions are implicated in regulation of the HPA axis, and because they are also implicated in the 
antidepressant response itself through their involvement in cognitive control (Dinan 1996, 
Malagie, Trillat et al. 1996, Godlewska, Norbury et al. 2012, Albert, Vahid-Ansari et al. 2014). 
Single units also represented key neurotransmitters (e.g. 5HT, NE, and DA) and hormones 
(e.g. cortisol (CORT) and oxytocin (Oxt)), and many of the key transmitter receptors, transporters, 
and enzymes that are transmitter-system components (TSCs).  
Representing neurobiological entities (brain regions, transmitters, receptors, etc.) as single 
units enabled the model to represent the level (of activity, expression, concentration, etc.) of that 
entity in the whole brain, or in specific brain regions as appropriate. The 5HT unit, for example, 
represented the brain serotonin level, which is the major neurobiological endpoint for 
antidepressant action. The weights of the connections between the units also had specific identities 
in the model. For example, the effectiveness of the 5HT autoreceptor in inhibiting DR neurons was 
represented in the model by the absolute value of the inhibitory weight of the 5HT1A receptor 
(5HT1AR) unit onto the DR unit.  
Relative to the overall number of network weights, a very small number of weights were 
of great significance because they represented TSCs whose efficacies, or strengths (expression 
levels, sensitivities, concentrations, synaptic locations, etc.), are known to adapt under chronic 
stress or chronic antidepressant administration. All of the weights in a trained network represent 
the normative strengths of influences of specific neurobiological entities on each other. The 
weights of the adaptable TSCs specifically were further adjusted to analyze the possible modes of 
adaptation to chronic stress, drugs, or hormones in the model.  
In describing neural networks it is necessary to distinguish inputs/outputs to/from the 
network overall, and inputs/outputs to/from individual units in the network.  Units are categorized 
as input, output, or “hidden units.” There were 40 input units that provided input to the overall 
network.  They take on assigned values and project to other units but do not receive connections 
from other units. Hidden and output units receive connections from input units and from each 
other. There were 23 output units that provided the output of the overall network. Output units are 
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distinguished from hidden units in having targets (desired outputs). Hidden units have neither 
assigned nor desired values. The network consisted of 102 total units (input, hidden, and output).   
Individually, the activity of each unit is a function of its inputs from the other units (this is 
not true for input units that do not receive inputs from other units). Each sending unit provides 
inputs to receiving units that are equal to the product of the sending unit’s activity level and the 
value of the weight (positive or negative) of the connection from the sending unit to the receiving 
unit. The net input to a receiving unit is the sum of the weighted inputs from all its sending units. 
The activity level of a unit is the value of its net input (i.e. weighted input sum) after it has passed 
through the sigmoidal activation function, which “squashes” the net input sigmoidally in the range 
between 0 and 1.  The value of the sigmoidal squashing function for net input 0 is 0.50 (the 
midpoint of the 0−1 range).   
The connection weights from the input, hidden, and output units to the hidden and output 
units are organized into the network weight matrix. The weight matrix consisted of 61 rows and 
102 columns for a total of 6222 weights.  Any input, hidden, or output unit could project to any 
hidden or output unit, but various distinctions between specific classes of connection weights were 
made in order to satisfy modeling goals. 
The subject of the MS-model is the behavior of the monoaminergic transmitter systems 
and the stress hormone system (i.e. the monoamine-stress system) as they relate to the 
pathophysiology of depression. This behavior involves heavy interaction between the 3 
monoaminergic transmitter systems and the stress hormone system, but also involves interactions 
between those systems and many other systems throughout the nervous system. The MS-model is 
therefore focused on the interactions between the monoaminergic transmitter and stress hormone 
systems, but also represents many other interactions that are included to ensure that model behavior 
is in line with a large set of empirical observations on the monoamine-stress system, as described 
in the literature.  
In order to foreground monoamine-stress system interactions in the model, 3 classes of 
connection weights are distinguished: canonical, structure, and non-structure. Canonical weights 
are the weights of the known connections between units representing key components of the 
monoamine-stress system, such as the weight from the DR to 5HT, representing the effectiveness 
of the DR in producing 5HT. There were 23 canonical weights. Structure weights are the weights 
of the connections between units representing neurobiological entities that are also known to 
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interact empirically but are not canonical weights, such as the weight from DR to galanin, 
representing the effectiveness of the DR in co-releasing galanin. There were 305 total structure 
weights.  Non-structure weights denote all other connection weights; they may or may not 
represent as yet unidentified interactions that actually do occur neurobiology. There were 5894 
non-structure weights in total. The three classes of weights are treated differently during model 
training. 
Two data structures were needed in order to construct and train the MS-model: a structure 
matrix and a truth table. Both the structure matrix and the truth table were compiled via a 
comprehensive literature search. The structure matrix is a two-dimensional matrix, coextensive 
with the network weight matrix, which specifies which neurobiological entities in the model are 
known to interact with which others, and their valance (positive or negative) if also known. The 
structure matrix designates all structure and canonical weights in the model using non-zero 
integers. Non-structure weights take value 0 in the structure matrix.  
The truth table is an array of input/desired-output training patterns that specifies how 
specific experimental manipulations, which are represented as patterns of network inputs, are 
known to affect specific neurobiological endpoints, which are represented as patterns of desired 
network outputs. Each row of the truth table represents the statistically significant results of one 
or more actual experiments. Inputs are either present or absent (1 or 0) and outputs are assigned 
discrete levels between 0.30 and 0.70. Outputs could either decrease maximally, decrease 
moderately, have no change, increase moderately, or increase maximally, corresponding to 
desired-output values of 0.30, 0.40, 0.50, 0.60, and 0.70, respectively. The complete truth table 
has 66 input/desired output patterns. 
The MSS-model has a “foreground” and a “background.” The foreground is a 
representation of the main components of the 3 monoaminergic-transmitters systems and of the 
stress- and sex-hormone systems. The background is a representation of most of the related neural, 
transmitter, and hormonal systems that are known to interact with the monoaminergic-transmitter, 
stress, and sex hormone systems but on which fewer data are available. Single elements of the 
MSS-model represented key brain regions including all of the foreground brain regions (e.g. DR, 
LC, PVN, and POA) and key molecular components of the interacting biological systems including 
receptors, transporters, enzymes, precursors, metabolites, and the transmitters and hormones 
themselves.  
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The MSS-model was constructed, parameterized, run, adapted, and analyzed in the same 
way as the MS-model. Methodological details can be found in (Camacho, Vijitbenjaronk et al. 
2018). Computational and analytical procedures will be briefly summarized here and any 
differences with the MS-model will be noted. 
The MSS-model takes the form of a recurrent network of nonlinear elements or “units.” 
All of the units have the same sigmoidal (S-shaped) nonlinearity that bounds their activity between 
0 and 1 and produces an output of 0.50 for 0 input. Units in the network are classified as input, 
output, or “hidden.” Input units send connections to hidden and output units, while hidden and 
output units send connections to each other but not to input units. Input values are preassigned to 
input units, and desired (or target) values are preassigned to output units during training. Hidden 
units have no preassigned values. All connections in the network are weighted. On each network 
update, each hidden or output unit computes the sum of its weighted inputs from other units and 
applies the sigmoid to its weighted input sum. Typically, networks are updated for 100 time steps.  
The units in the model corresponded to regional or brain-wide biological variables. Some 
single units represented the average activity of all of the neurons in specific brain regions including 
the foreground regions: DR, LC, VTA, PVN, and POA. Other single units represented brain levels 
of key transmitters (e.g. 5HT, NE, or DA) and hormones (e.g. cortisol (CORT) or testosterone 
(TEST)). Still others represented the overall brain “activity” (expression, sensitivity, 
concentration, etc., or combinations thereof) of key receptors, transporters, enzymes, and small 
molecules that constitute transmitter-system components (TSCs). While the units represented 
regional or brain-wide variables, the weights of the connections between units represented cellular-
level variables. The effectiveness of the 5HT transporter (5HTT) in inhibiting 5HT levels, for 
example, was represented in the model by the absolute value of the inhibitory weight of the 5HTT 
unit onto the 5HT unit.   
A small subset (precisely 13) of the connection weights represent cell-specific entities that 
known to adapt or adjust their strengths (through changes in expression, sensitivity, concentration, 
etc.) under chronic stress, or with chronic administration of drugs or hormones. These will be 
referred to as “adjustable TSCs.” The adjustable-TSC weights were used to analyze adaptation 
(specifically, neuroadaptation) to chronic administration of drugs, hormones, and combinations in 
the MSS-model. 
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There were 132 total network units (54 input, 32 output, and 46 hidden units). The 77x130 
network weight matrix organizes the connection weights from the input, hidden, and output units 
to the hidden and output units for a total of 10,010 connection weights. There are 3 major classes 
of connection weights in the MSS-model: canonical, structure, and non-structure. 
The 36 canonical weights represent empirically known interactions between key elements 
of the foreground systems: monoaminergic system, HPA axis, and HPG axis. One canonical 
weight, for example, is the weight of the connection from the testes unit to the TEST unit. This 
canonical weight represents the efficacy of the testes in releasing testosterone. The 426 structure 
weights represent other empirically known interactions between elements of the background 
systems, such as the connection weight between the LC and galanin units, representing the efficacy 
of galanin co-released by the LC. The 9548 non-structure weights are all the other connection 
weights which represent interactions that have not been identified as yet and may or may not 
represent interactions that occur neurobiologically.   
The MSS-model was constructed and parameterized on the basis of two data structures: a 
structure matrix and a truth table, both of which were populated through extensive literature 
review. The structure matrix is a 77x130 matrix that is coextensive with the network weight matrix, 
which specifies the canonical and structure connections between model units as well as their 
valence (positive or negative) if known. 
The truth table is an array of input/desired-output training patterns that specifies how 
specific inputs (experimental manipulations such as drugs, stress, hormones, lesions, etc.) are 
known to affect specific output units (such as 5HT, CORT, or TEST level). Each row of the truth-
table represents the results of at least one experiment. Inputs can be either present (1) or absent 
(0). Desired outputs specify maximal decrease, moderate decrease, no change, moderate increase, 
or maximal increase, corresponding to values of 0.30, 0.40, 0.50, 0.60, and 0.70, respectively. 
 
 
B.12 PRUNING METHODS 
We were interested in pruning the networks in order to eliminate unneeded non-structure 
connections, and to minimize overfitting in order to increase the generalizability of model results. 
Two previously studied methods are pruning on the basis of the magnitude of the weight, or on the 
basis of sensitivity of the error to each individual weight. In the former, weights below a certain 
absolute value cutoff are removed. This is based on the idea that weights trained to a low value 
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should make a smaller contribution to model behavior (Rumelhart 1988). In the latter method, 
contribution to network behavior is measured explicitly as the sensitivity of the error to each 
individual weight. Weights below a certain sensitivity cutoff are removed (Mozer 1989). These 
methods are believed to produce comparable results and are commonly used to prune neural 
networks (Segee 1991). 
To evaluate the difference specifically for the MS-model between pruning on the basis of 
absolute value or sensitivity, we trained all connections in a network and plotted the sensitivity of 
each weight (y-axis) against the absolute value of each weight (x-axis). Figure A shows the 
relationship on a linear-linear plot while Figure B shows it on a log-log plot for a representative 
case. We found a very interesting power function relationship in all of 10 cases where the 
exponents ranged from 1.77 to 2.72 and the scale factors ranged from 0.012 to 0.026. The 
correlation coefficients ranged between 0.32 and 0.71. 
 
The lack of perfect correlation between weight absolute values and sensitivity proves that pruning 
on the basis of absolute value and pruning on the basis of sensitivity would prune different weights 
from the networks.  
A 
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To determine which pruning strategy is better, non-structure connections of each of the ten 
original networks were pruned at various cutoffs according to the specified pruning criterion 
(absolute value or sensitivity), and the pruned network was then re-trained. During re-training, the 
structure connections were trained at the same fast learning rate (3) while the non-structure 
connections were trained at a learning rate that was an order of magnitude lower than that of the 
fast connections (0.30). The purpose of this was to favor strengthening connections that were 
known from the experimental literature. Non-structure connections were still trained because they 
were necessary to produce reasonable agreement with the training set. 
A visual comparison of the effect of pruning on the basis of sensitivity or pruning on the 
basis of absolute value on RMS error is shown in Figure C. This plot has number of pruned 
connections on the x-axis and the average RMS error of the ten networks after pruning on the y-
axis. It suggests that pruning on the basis of absolute value will eliminate the most connections 
while still maintaining a low RMS error over the entire truth table. Even though having a low RMS 
error is important for fitting truth-table information, the overall goal is for the model to predict 
novel drug combinations to improve antidepressant therapeutic efficacy. We evaluated if pruning 
on the basis of absolute value was still the ideal pruning method for this purpose. 
 
B
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The best way to determine if a machine-learning procedure has indeed learned input-output 
relationships over its domain is to evaluate how well it generalizes to data that it was not trained 
on (Sietsma and Dow 1991). We then trained the model on only the single inputs by removing all 
of the combination inputs from the truth table (two inputs or more). We obtained ten fits trained 
only on single input data with an average RMS error of 9.53x10-18. These ten fits were then pruned 
at 20 different cutoffs on the basis of absolute value and on the basis of sensitivity and re-trained 
as described in the previous subsection. The pruned and re-trained weight matrices were then given 
the drug combinations that were removed from the training set and their outputs were obtained and 
compared with experimental findings to produce an average RMS error. We found that the 
original, unpruned weight matrices had an average RMS error of 0.1637 over the untrained drug 
combination data. 
Interestingly, we found that pruning could significantly decrease this average RMS error. 
We plotted the untrained drug-combination RMS errors versus the number of pruned connections 
to determine which pruning method can decrease this RMS value the most. Figure D shows that 
pruning on the basis of sensitivity will achieve better generalizability than pruning on the basis of 
absolute value. Specifically, we found the best method was pruning on the basis of sensitivity at a 
cutoff of 1x10−3.35 pruned 4081 connections on average and produced an average RMS error over 
the untrained data of 0.139. The Mann-Whitney U test showed that this was significantly better 
C
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than the best result pruning on the basis of absolute value (p-value of 0.002). All further training 
sets were trained using the full truth table and pruned at a sensitivity cutoff of 1x10−3.35 and 
retrained using the retraining method described above. This optimized our MS-model to generalize 
on acute drug combinations that it was not trained on. 
 
 
B.13 MS-MODEL ADJUSTABLE TSCS 
Neuroadaptation was simulated by allowing the networks to adjust the strengths of the 
weights that are known to adjust under the conditions of the experiments from which the truth 
table was derived. The adjustable TSCs were a subset of the canonical weights. Configurations of 
adjusted TSCs that resulted in a reduction in network imbalance by bringing the most heavily 
trained brain regions (DR, LC, VTA, PVN) back toward their baseline values were considered 
adapted.  
Number Adjustable TSC Polarity References 
1 5HT1AR to DR − 
(Blier and de 
Montigny 1987, 
Szabo and Blier 
2001, El 
Mansari, 
Ghanbari et al. 
2008, Ghanbari, 
El Mansari et al. 
D
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2010, Rozeske, 
Evans et al. 
2011) 
2 AR2 to LC − 
(Szabo and Blier 
2002, El 
Mansari, 
Ghanbari et al. 
2008) 
3 D2R to VTA − 
(Chernoloz, El 
Mansari et al. 
2009, Katz, 
Guiard et al. 
2010, 
Madhavan, 
Argilli et al. 
2013) 
4 5HTT to 5HT − 
(Lesch, Aulakh 
et al. 1993, 
Benmansour, 
Cecchi et al. 
1999, Lau, 
Horschitz et al. 
2008) 
5 NET to NE − 
(Hebert, 
Habimana et al. 
2001, Miner, 
Jedema et al. 
2006, Pietrzak, 
Gallezot et al. 
2013) 
6 DAT to DA − 
(Neumeister, 
Willeit et al. 
2001, 
Brunswick, 
Amsterdam et al. 
2003, Kugaya, 
Seneca et al. 
2003, Yang, Yeh 
et al. 2008) 
7 GCR to PVN − 
(Pariante and 
Miller 2001, 
Barden 2004, 
Ladd, Huot et al. 
2004) 
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8 GCR to Pituitary Gland − 
(Barden 2004, 
Ladd, Huot et al. 
2004) 
9 GCR to Adrenal Gland − 
(Barden 2004, 
Ladd, Huot et al. 
2004) 
10 
CRF1R to Pituitary 
Gland 
+ 
(Nikodemova, 
Diehl et al. 
2002, 
Kageyama, 
Hanada et al. 
2006) 
 
 
B.14 MSS-MODEL ADJUSTABLE TSCS 
A subset of the model transmitter-system components (TSCs) are known to be adaptable 
under the conditions of the experiments from which the truth table was derived. These 13 TSCs 
are referred to as “adjustable TSCs” and are comprised of canonical weights from each of the 3 
systems (monoaminergic, stress-steroid, sex-steroid) in the model. Adjusted TSC configurations 
that reduced adaptation error by bringing responses of the most heavily trained brain regions (DR, 
LC, and VTA) back toward their baseline values were considered adapted.    
 
Number Weight Polarity References 
1 5HT1AR to DR − 
(Blier and de 
Montigny 1987, 
Szabo and Blier 
2001, El Mansari, 
Ghanbari et al. 
2008, Ghanbari, 
El Mansari et al. 
2010, Rozeske, 
Evans et al. 
2011) 
2 AR2 to LC − 
(Szabo and Blier 
2002, El Mansari, 
Ghanbari et al. 
2008) 
3 D2R to VTA − 
(Chernoloz, El 
Mansari et al. 
2009, Katz, 
Guiard et al. 
2010, Madhavan, 
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Argilli et al. 
2013) 
4 5HTT to 5HT − 
(Lesch, Aulakh et 
al. 1993, 
Benmansour, 
Cecchi et al. 
1999, Lau, 
Horschitz et al. 
2008) 
5 NET to NE − 
(Hebert, 
Habimana et al. 
2001, Miner, 
Jedema et al. 
2006, Pietrzak, 
Gallezot et al. 
2013) 
6 DAT to DA − 
(Neumeister, 
Willeit et al. 
2001, Brunswick, 
Amsterdam et al. 
2003, Kugaya, 
Seneca et al. 
2003, Yang, Yeh 
et al. 2008) 
7 GCR to PVN − 
(Pariante and 
Miller 2001, 
Barden 2004, 
Ladd, Huot et al. 
2004) 
8 GCR to Corticotroph − 
(Barden 2004, 
Ladd, Huot et al. 
2004) 
9 GCR to Adrenal Gland − 
(Barden 2004, 
Ladd, Huot et al. 
2004) 
10 AR to POA − 
(Handa, Kerr et 
al. 1996) 
11 AR to Gonadotroph − 
(Bremner, Millar 
et al. 1994) 
12 FSHR to Testes + 
(Catt, Baukal et 
al. 1979, Heckert 
and Griswold 
1991) 
13 LHR to Testes + 
(Belanger, 
Auclair et al. 
1979, Catt, 
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Baukal et al. 
1979) 
 
B.15 M-MODEL STRICTLY ERROR-REDUCING ADJUSTMENTS  
The MATLAB version of the M-model was used for making TSC strength adjustments 
along single sequences in which adjustment of a randomly chosen TSC was retained only if it 
resulted in a homeostatic reduction in activation error. Here 1,000,000 randomly-ordered 
sequences of strictly error-reducing adjustments were allowed to continue until the M-model 
achieved terminal adaptation, in which further adjustments no longer reduced activation error with 
chronic Escitalopram. The histogram plots the number of sequences achieving terminal adaptation 
as a function of the number of adjustments. The mean number of adjustments is 7.90, the mode is 
7, the median is 8, and the range is from 2 to 26.  
 
 
 
The MATLAB version of the M-model was then used to make 1000 randomly-ordered, 
strictly error-reducing sequences of adjustments until further adjustments no longer reduced the 
activation error with chronic Escitalopram. This approach produced 1000 terminally adapted TSC-
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strength configurations, which we plotted using a heat map. Each of 1000 rows is a vector of final 
receptor values for all 11 adjustable TSCs. The 1000 terminally adapted configurations were 
ordered by Euclidian distance from a reference vector of all 0s, which is shown in row 0. The 11 
adjustable TSCs can adjust by 1 to any level between 0 and 10 for a total of 1111 or more than 285 
billion possible TSC-strength configurations. This very small sample of 1000 terminally adapted 
configurations reveals considerable heterogeneity, and clearly shows that there are very many 
distinct configurations that are terminally adapted in the sense that further TSC strength adjustment 
will not further decrease activation error. 
 
 
B.16 SETTING THERAPEUTIC CRITERIA 
B.16.1 M-MODEL 
Among the adapted TSC-strength configurations, we also searched for configurations that 
achieved certain levels of the monoaminergic transmitters. “Therapeutic” monoamine levels have 
not yet been determined unequivocally. For the M-model, we set our search criteria conservatively 
on the basis of the percentage changes in monoaminergic transmitter levels associated with 
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reduction in depression symptomology that we were able to find in the literature. We were unable 
to find reports of studies directly showing efficacy of SSRIs that also measure 5HT levels in the 
brain. However, both preclinical and clinical evidence has accumulated to support the hypothesis 
that the 5HT system is involved in the therapeutic action of SSRIs and several other antidepressant 
drugs by elevating 5HT (reviewed in (Blier and de Montigny 1994)). Specifically, one study found 
that chronic Escitalopram increases 5HT levels in the prefrontal cortex to 422% of baseline 
(Ceglia, Acconcia et al. 2004). Also, it has repeatedly been found that chronic SSRI use elevates 
5HT levels to around 400% (Romero, Celada et al. 2003, Beyer and Cremers 2008). We considered 
adapted TSC strength configurations for which 5HT was elevated by more than 400% of normal 
baseline to be therapeutic. 
Rodents undergoing the forced swim test (which produces “behavioral despair”) that were 
given Reboxetine [a norepinephrine reuptake inhibitor, (NERI)] and demonstrated decreased 
immobility (i.e., antidepressant effect) were found using microdialysis to increase NE levels to 
212% of baseline (Page, Brown et al. 2003, Can, Dao et al. 2012). Rats that demonstrated 
alleviation of depressive symptomatology (measured through increased locomotor activity) due to 
administration of St. John’s Wort were found to increase DA levels to 140% of baseline in the 
prefrontal cortex (Yoshitake, Iizuka et al. 2004). We considered adapted TSC configurations for 
which NE or DA were elevated by more than 200% of normal baseline to be therapeutic. These 
therapeutic cutoffs were used in Maude analysis of the M-model to identify TSC strength 
configurations with therapeutic elevations in the monoamines.  
 
B.16.2 MS- AND MSS-MODELS  
Therapeutic criteria were set using the same criteria as described in the MS-model 
(Camacho, Vijitbenjaronk et al. 2018). Briefly, chronic SSRI administration has been shown to 
double 5HT levels associated with acute SSRI administration (Ceglia, Acconcia et al. 2004). The 
desired baseline 5HT level was set to 0.50, and the desired 5HT output for acute SSRI was set to 
0.60. The therapeutic 5HT floor was therefore set to 0.70 in order to double the increase of 0.10 
observed with acute SSRI. For consistency, 0.70 was also used as the therapeutic floor for NE and 
DA although therapeutic NE and DA levels resulting from chronic antidepressant administration 
have not been determined. Because the high CORT levels associated with acute SSRI have been 
found to decrease with chronic SSRI (Ruhe, Khoenkhoen et al. 2015), the therapeutic ceiling for 
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CORT was set to 0.70, which is the level assigned to the desired, high CORT level due to acute 
SSRI in the model.  
 
B.17 DETAILS ON TEMPORAL-LOGIC MODEL-CHECKING PROCEDURE 
Temporal logic is a system of symbols and rules for representing and reasoning about 
propositions examined in terms of time. Temporal logic can be used to express a unary occurrence 
through time, such as “I am always strong” or “I will eventually be strong,” and it can also be used 
to express binary relationships between two different statements, such as “I will be strong until I 
stop going to the gym.” Maude is an excellent tool for assessing the validity of temporal-logic 
propositions, by telling us whether or not a particular proposition is true (e.g., to address questions 
such as: Is it true that “I am always strong?”).  
Temporal relationships in models of neurobiological processes can be examined in Maude 
to determine if a particular statement is true, or if a particular relationship between two (or more) 
statements is true. In a system as complicated as the MS- and MSS-models, where there are 
hundreds of thousands of TSC-strength adjustment pathways being elaborated to depth 6, 
temporal-logic model-checking in Maude is an extremely useful tool for determining if properties 
of neurobiological interest have certain relationships with one another as neuroadaptive pathways 
are elaborated. We implemented temporal-logic model-checking procedures into Python in order 
to maximize computational efficiency. Extensive cross-checking ensured that Maude and Python 
temporal-logic analyses were in agreement.  
In all three models, each state has a unique TSC-strength configuration associated with a 
unique pattern of neural-region activities and neurotransmitters and hormone levels. Temporal-
logic analysis can be used to ascertain the validity of temporal relationships between these states 
in terms of their properties (e.g., neurotransmitter levels, hormone levels, receptor strengths). 
Python can be used to evaluate these relationships by elaborating the tree of TSC strength 
configurations and searching for a counterexample to the temporal-logic model-check specified. 
If the analysis does not find a counterexample, the result is a Boolean “true.” If a counterexample 
is found, then the counterexample state is listed and followed by the statement “false.”  
All temporal-logic model-checks were carried out to a depth of 6 over all 3 networks for 
each model and only the results that were consistent across all 3 networks are reported in this 
document. The neurobiological relationships that were examined, as well as their symbolic 
representations, are all reported in the Results chapter of the main text.  
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B.18 HARDWARE CONSIDERATIONS 
B.18.1 M-MODEL 
The most computationally intensive procedures undertaken for this analysis were GA 
optimizations (in MATLAB) and state-space searches (in Maude). Both of these procedures are 
immanently parallelizable. MATLAB has built-in options for parallelizing GA optimizations. 
Unfortunately, options for parallelizing Maude searches were not available. Multiple computers 
were used for computational analysis. All computers had dual-core, Intel-based processors but 
varied in number of processors, memory capacity, and operating system. 
All MATLAB GA optimizations were carried out on 16-processor Intel Zeon machines 
with 2, 2.60 GHz cores per processor (32 cores total) and 128GB of RAM under the Windows 7 
operating system. The machines were made available by the Beckman Institute Visualization Lab. 
A single GA optimization that evolved a population of 100, 76-element parameter sets until the 
change in the fitness between generations was less than a tolerance of 10-12 took about 3 h on those 
32-core VizLab machines.  
Although parallelized Maude search was not an option, we did run multiple, serial Maude 
searches simultaneously on cores distributed over several machines. Maude searches were run on 
an Intel-inside CORE i7 processor with 2, 2.69 GHz cores and 8.00 GB of RAM under the 
Windows 8 operating system, and on an Intel Core 2 Duo CPU processor with 2, 2.33 GHz cores 
and 4.00 GB of RAM under the Windows 7 operating system. Maude elaboration and search of a 
state-transition tree having up to 11,155 states (i.e., TSC-strength configurations) took between 4 
and 22 h on each core of those dual-core machines. Given the large number of optimizations and 
searches necessary both to establish the paradigm and then generate the actual results, these 
hardware constraints largely determined the complexity of the model that we could optimize (76 
parameters per optimization) and the depth of the state-transition tree we could exhaustively search 
(to level 3 or up to 11,155 states per search). 
 
B.18.2 MS-MODEL 
All MATLAB computational procedures were performed on an Intel Core 2 Duo CPU 
processor with 2, 2.33 GHz cores and 4.00 GB of RAM under the Windows 7 operating system, 
an Intel-inside CORE i7 processor with 2, 2.69 GHz cores and 8.00 GB of RAM under the 
Windows 8 operating system, and an Intel Core i7 processor with 4, 4.00 GHz cores and 32.00 GB 
of RAM under the Windows 10 operating system. MATLAB was used for training, pruning, 
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enumerating, and analyzing all adjustable-TSC configurations with up to 6 adjustments in TSC 
strength, generation of all histograms and heatmaps, and FRIWA analysis. Training a network 
(100 time steps, 1x106 iterations, 66 training patterns) took between 20 and 25 minutes. 
Exhaustively computing full sets of adjustable TSC configurations to degree 6 took 1 minute. 
Computational overhead (memory limitations) prevented computing the full set to degree 7. 
Checking the set of TSC-strength configurations for neuroadaptation to chronic drug or hormone 
combinations in each of the 3 representative networks took 8 minutes per network using 
MATLAB.  
Python was used for enumeration of TSC-strength configurations and LTL analysis. 
Python search and LTL analysis of TSC-strength configurations having 382,747 states took 34 
seconds on one quad-core Intel Core i5 processor. For subsequent model checks where steady-
state values had been cached, model checks took an average of 3.10 seconds. Python enumeration 
of TSC-strength configurations was limited to degree 6 for consistency with the MATLAB 
analysis and because the results were unlikely to be different for degree 7 than for degree 6.  
 
B.18.3 MSS-MODEL 
All training, pruning, enumeration of adjustable-TSC configurations with up to 6 possible 
adjustments, compiling of data into histograms and heatmaps, and FRIWA analysis was conducted 
in MATLAB with an Intel Core 2 Duo CPU processors with 2, 2.33 GHz cores and 4.00 GB of 
RAM under the Windows 7 operating system, an Intel-inside CORE i7 processor with 2, 2.69 GHz 
cores and 8.00 GB of RMA under the Windows 8 operating system, and an Intel Core i7 processor 
with 4, 4.00 GHz cores and 32.00 GB of RAM under the Windows 10 operating system Training 
a network (100 time steps, 1x106 iterations, 99 training patterns) took between 30 and 35 minutes. 
Exhaustive enumeration of full sets of adjustable-TSC configurations to degree 6 took 1 minute. 
Computational overhead (limitations in computer memory) prevented computing the full set to 
level 7. Evaluating the degree of neuroadapation, neurotransmitter, and hormone levels of the full 
set of TSC-strength configurations to chronic drug or hormone combinations in each of the 3 
representative networks took 17 minutes per network with MATLAB. Python was used for 
enumeration and storage of TSC-strength configurations for temporal-logic analysis. Python 
search and LTL analysis of TSC-strength configurations having 579,125 states took 4 minutes on 
one quad-core Intel Core i5 processor. After steady-state values had been cached, all subsequent 
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model checks took an average of 12 seconds. Python analysis was limited to 6 adjustments for 
consistency with the MATLAB analysis and because the LTL results were unlikely to be different 
for degree 7 than for degree 6. 
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APPENDIX C: RESULTS APPENDICES 
 
C.1 ANALYSIS OF M-MODEL OPTIMIZED PARAMTER VECTORS 
Before the M-model could be used for analysis of adapted TSC strength configurations, its 
parameters must be set so that model behavior agrees with experimental observations on the acute 
effects of antidepressants that occur before TSCs have adapted. The GA was used to obtain 200 
sets of parameters that achieve this agreement with acute data by minimizing the RMS value of an 
error function. Panel A of the figure below is a heat map showing the parameter sets as parameter 
vectors, arranged with increasing Euclidian distance from a reference vector of all zeros. The RMS 
errors ranged between 5.66 and 18.45 and did not change systematically with distance from the 
reference vector. The heat map reveals no obvious sign of clustering, suggesting that the error 
function does not have multiple, widely separated minima. 
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Panel B of the figure is a heat map showing the 10 best (lowest error) parameter vectors 
arranged with increasing Euclidian distance from the reference vector. The RMS errors ranged 
between 5.66 and 9.94. Again there is no obvious clustering. Of the 10 best fits, one was eliminated 
due to its aberrant adaptive behavior (see Results). The remaining nine parameterizations produced 
model instances that all had similar adaptive behavior that was also consistent with experimental 
observations. All elevated 5HT after acute Escitalopram administration (de Montigny, Chaput et 
al. 1990, El Mansari, Sanchez et al. 2005), all responded to acute Escitalopram with decreased DR 
unit activity (de Montigny, Chaput et al. 1990), and all elevated 5HT to an even higher level after 
adaptation to Escitalopram (de Montigny, Chaput et al. 1990, Invernizzi, Belli et al. 1992, El 
Mansari, Sanchez et al. 2005). When only the DR 5HT1A autoreceptor was allowed to adapt, all 
desensitized this receptor to reduce activation error (de Montigny, Chaput et al. 1990) (Naudon, 
El Yacoubi et al. 2002). The fit with the RMS error of 9.93 was selected for further analysis. It 
was considered representative because it had an error near the top of the error range but still 
displayed the required adaptive capability. The model with the representative parameter set was 
used in the generation of all M-model results. 
 
C.2 VERIFYING AGREEMENT BETWEEN BETWEEN THE MATLAB AND MAUDE 
VERSIONS OF THE M-MODEL 
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To verify agreement between the MATLAB and Maude versions of the M-Model, the 
values of multiple variables were compared after the same number of time steps (150) in both 
programs. We found that the activity levels of all 6 units (DR, LC, VTA, tCRF, Tgal, Tglu) and 
levels of all of the neurotransmitters were in agreement between the 2 programs after 150 iterations 
to 4 significant places in the no-drug condition. We also verified that the 2 versions agreed on the 
effects of all drugs and combinations (Escitalopram, Nomifensine, Reboxetine, Trazodone, 
Asenapine, Aripiprazole, Bupropion, Quetiapine, Escitalopram/Aripiprazole, and 
Escitalopram/Quetiapine). We found agreement on the activity levels of all 6 units, levels of all of 
the neurotransmitters, and activation errors after 150 iterations to 4 significant places with acute 
administration (no-adaptation) of all of the drugs and combinations.  
 
C.3 SINGLE-PATHWAY ADAPTATION RUNS IN MATLAB 
Because the GA-determined values of the autoreceptor strengths of the M-model were all 
near 3 (3.10 for DR 5HT1A, 3.20 for LC AR2, and 3.20 for VTA D2R in the representative 
parameter set), DR 5HT1A autoreceptors could desensitize almost completely in 3 adjustment 
steps (3 adjustments down by 1) as part of simulated neuroadaptation. This is consistent with 
experimental observation on DR 5HT1A autoreceptor desensitization under chronic SSRI (Blier, 
Pineyro et al. 1998, Rainer, Nguyen et al. 2012). An example, short MATLAB adaptation run, out 
to five adjustments steps, is shown in the figure below.  
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Neuroadaptation to chronic Escitalopram decreases activation error in the M-model, 
thereby bringing the activations of the monoaminergic units back towards their normative levels. 
In this single-sequence adaptation run, only the 5HT1A autoreceptor on the DR unit (the 5HT1A 
autoreceptor) was allowed to adapt. It could adjust its strength up or down by 1 on each of 5 
adjustments, but the adjustment is retained only if it results in a decrease in activation error. The 
receptor decrements to 0 over adjustment steps 2, 3, and 4. No change occurs on adjustment step 
1 because the randomly chosen adjustment was an increment, but that adjustment was rejected 
because it did not decrease activation error. Similarly, no change occurs on the last step because 
no further error-reducing adjustment can be made. 
 
C.4 CLOSE AGREEMENT BETWEEN DESIRED (I.E. TARGET) AND ACTUAL OUTPUT 
RESPONSES AFTER TRAINING BUT BEFORE PRUNING (A-C) AND AFTER PRUNING 
AND RE-TRAINING (D-F) WITH MS- AND MSS-MODELS 
C.4.1 MS-MODEL 
The colormap scales for the desired and actual output plots (A, B, D, and E) are the same, 
ranging from 0.00 to 0.70. Each row represents the same input pattern and each column represents 
an output value. The first row represents the no-drug baseline values. The colormap for the 
absolute differences or errors between the desired and actual outputs (C and F) are between the 
minimum and maximum absolute difference values for each plot, which is 0.00 to 3.77x10−4 for 
(C) and 0.00 to 1.10x10−3 for (F). Pruning was done to minimize non-structure connections. The 
RMS error over all training patterns was 2.39x10−5 for the unpruned network and 5.10x10−5 for 
the pruned and re-trained network. 
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C.4.2 MSS-MODEL 
The colormap scales for the desired and actual output plots (A,B,C,D, and E) range from 
0.00 to 0.70. Each row represents a single input pattern and each column represents an output 
value. The first row represents baseline output values when no inputs are present. The colormap 
for the absolute differences between the desired and actual output values (C and F) are between 
0.00 and 4.50x10-3 for (C) and 0.00 and 3.50x10-3 for (F). The networks were pruned to minimize 
non-structure connections. The RMS error over all training patterns was 2.02x10-4 for the unpruned 
network in (A-C) and 1.84x10-4 for the pruned network in D-F.   
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APPENDIX D: DISCUSSION APPENDICES 
 
D.1 POTENTIAL CLINICAL RELEVANCE OF M-MODEL RESULTS 
The potential clinical relevance of the M-model results is evaluated on the basis of the idea 
that depression subtypes exist and can be categorized as psychotic or melancholic depression, or 
as heterogeneous, non-melancholic depressive disorder (Parker 2000). Patients with psychotic 
depression have consistently been found to respond to antidepressant drug combinations that 
chronically elevate DA levels, while patients with melancholic depression have shown 
considerable improvement with interventions that elevate NE levels (Spiker, Weiss et al. 1985, 
Parker, Roy et al. 1992, Guelfi, White et al. 1995, Kelly and Cooper 1997). Due to the finding that 
enhancing 5HT neurotransmission has been found to alleviate depressive symptomatology in 
patients with heterogeneous pathology not classically associated with either psychotic or 
melancholic depression, it has been proposed that serotonergic dysfunction may explain 
heterogeneous, non-melancholic depression (Malhi, Parker et al. 2002, Malhi, Parker et al. 2005). 
Although we focus on SSRIs (e.g., Escitalopram), the M-model also provides potential 
insights into the clinical efficacies of some antidepressant drugs other than Escitalopram, and 
combinations of other drugs with Escitalopram. The selective NE and DA releaser Bupropion, for 
example, has been shown to be at least as effective as SSRIs in clinical studies (Thase, Haight et 
al. 2005, Papakostas, Montgomery et al. 2007). In the M-model, Bupropion does not 
therapeutically elevate 5HT in as high a percentage of adapted configurations as Escitalopram 
(24% for Bupropion alone, 29% for Escitalopram alone), but Bupropion therapeutically elevates 
both NE and DA in 96% of adapted TSC strength configurations. Thus, the M-model suggests that 
Escitalopram would be more effective in cases where 5HT alone is deficient (non-melancholic 
depression), but that Bupropion would be most effective in cases where NE or DA is deficient 
(melancholic and psychotic depressions, respectively). The M-model suggests that Escitalopram 
or Bupropion alone achieve their main therapeutic effects through elevation in 5HT, or NE and 
DA, respectively. This is consistent with observations that 5HT depletion, but not NE depletion, 
cause relapse following chronic Escitalopram and that NE depletion, but not 5HT depletion, cause 
relapse following chronic Bupropion (Cooper, Wang et al. 1994, Evans, Golshan et al. 2002). 
The therapeutic efficacy of the combination of Escitalopram and Bupropion has not been 
rigorously studied with placebo controls, but some depressed patients that did not respond to SSRIs 
showed significant improvement with this combination (Leuchter, Lesser et al. 2008). In the M-
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model, almost all TSC strength configurations adapted to chronic Escitalopram/Bupropion are 
associated with elevated levels of one or more of the monoamines, with all three monoamines 
elevated in 72% of these configurations. This finding offers the prediction that the combination of 
Escitalopram and Bupropion would exhibit high efficacy in patient populations comprising more 
than one depressive subtype. 
Nomifensine was found to be an effective antidepressant before its use was discontinued 
due to the development of hemolytic anemia in patients (Brogden, Heel et al. 1979, Mueller-
Eckhardt, Giers et al. 1988). Because 62% of adapted TSC strength configurations in the M-model 
therapeutically elevate all three monoamines with chronic Nomifensine, this drug could be 
efficacious in depressed patients deficient in any of the three monoamines. When Nomifensine 
and Escitalopram are combined, the monoamine profile we obtained from the M-model is very 
similar to Nomifensine by itself. This was expected because Nomifensine also targets the 5HT 
transporter (Brogden, Heel et al. 1979, Tatsumi, Groshan et al. 1997). The M-model therefore 
suggests that Nomifensine by itself would be an effective antidepressant, but the use of this drug 
clinically has been discontinued (Mueller-Eckhardt, Giers et al. 1988). Development of a drug with 
a mechanism of action similar to Nomifensine but with fewer side effects could be useful for a 
broader range of depressed patients. 
Reboxetine has previously been shown to alleviate depressive symptomatology by 
elevating NE levels with chronic use, but these findings have been contested by a meta-analysis 
that includes unpublished clinical trials (Page and Lucki 2002, Page, Brown et al. 2003, Hajos, 
Fleishaker et al. 2004, Eyding, Lelgemann et al. 2010). When the M-model was allowed to adapt 
to Reboxetine, NE was the only monoamine that was significantly elevated, and reached 
therapeutic levels in 100% of adaptive configurations. This is in agreement with previous findings 
that chronic Reboxetine is associated with elevated NE levels (Hajos, Fleishaker et al. 2004). 
However, antidepressants acting selectively on one monoamine, such as Reboxetine, alleviate 
symptoms of depression in a limited percentage of patients (Kornstein, Li et al. 2009, Eyding, 
Lelgemann et al. 2010), suggesting that elevating NE alone may not be sufficient to alleviate 
depressive symptomatology in most depressed patients. The combination of Escitalopram and 
Reboxetine has been studied in clinical trials with limited placebo controls, and it was found that 
the combination reduced depressive symptomatology in some SSRI non-responders (Rubio, San 
et al. 2004). We hypothesize that this clinical outcome could result because combining 
166 
 
Escitalopram and Reboxetine increases the number of adapted states in which NE as well as 5HT 
levels are therapeutically elevated, providing relief to patients whose depression involves deficient 
NE and/or 5HT. 
When the M-model adapted to chronic Trazodone, 10% of adapted configurations had 
elevated DA and 18% had elevated NE, suggesting that this drug should ameliorate depression in 
some cases. Trazodone has previously been shown to significantly improve depressive 
symptomatology over placebo in depressed patients (Cunningham, Borison et al. 1994, Weisler, 
Johnston et al. 1994). Some authors posit this occurs by improving sleep quality (Weisler, Johnston 
et al. 1994), suggesting that its antidepressant effect may be secondary to its anti-insomnia effect 
and may not directly involve monoamine elevation. The anti-insomnia effect is thought to be 
mediated by the effects of Trazodone on histamine receptors (Stahl 2009). Histamine was excluded 
from the M-model because it is not co-released by any monoaminergic neurons and because we 
found no evidence that histamine receptors adjust their levels with chronic antidepressant 
administration. Trazodone itself was included in our drug corpus because, as a multi-target drug, 
it affects the 5HT1A, AR1, and AR2 receptors as well as the serotonin reuptake transporter (SERT) 
(Krege, Goepel et al. 2000, Stahl 2009), which are represented in the initial model. Data on 
trazodone was included mainly to expand the dataset that was used to parameterize the M-model. 
Asenapine and Aripiprazole are antipsychotic drugs that have not been studied by 
themselves in clinical studies of unipolar depression. Chronic administration of these drugs 
produce very few adapted configurations that are associated with therapeutically elevated levels 
of any of the monoamines in the M-model, suggesting that Asenapine or Aripiprazole, 
administered by themselves, would not be clinically effective for depressed patients. In the M-
model, 56% of TSC strength configurations adapted to chronic, combined Escitalopram and 
Asenapine were associated with therapeutically elevated NE levels. The clinical efficacy of the 
combination of Escitalopram and Asenapine in depression has not yet been studied, and the M-
model suggests that this combination may have significant therapeutic efficacy in patients whose 
depression involves deficiencies in NE. The combination of Escitalopram and Aripiprazole 
therapeutically elevated 5HT levels in 36% of adapted TSC strength configurations in the M-
model, which is somewhat higher than the 29% found with Escitalopram by itself. The M-model 
also found that 17% of configurations adapted to the combination of Escitalopram and 
Aripiprazole elevate both 5HT and DA, whereas no configurations adapted to Escitalopram alone 
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elevate DA. This modeling result suggests that the combination of Escitalopram and Aripiprazole 
may help alleviate depressive symptomatology in patients whose depression involves deficiencies 
in either 5HT or DA, and agrees with findings that this combination is effective in some depressed 
patients who do not respond to SSRIs (Marcus, McQuade et al. 2008, Matthews, Siefert et al. 2009, 
Boulton, Balch et al. 2010, Han, Wang et al. 2013). 
Quetiapine (an antipsychotic) by itself has recently been shown to ameliorate depressive 
symptomatology in some patients in its extended release form (Cutler, Montgomery et al. 2009). 
In the M-model, Quetiapine does not therapeutically elevate 5HT in any configuration, but it does 
therapeutically elevate NE in all adapted configurations. Importantly, one of the observed effects 
of Quetiapine is to elevate DA levels (Werkman, Olijslagers et al. 2004). Only 9% of the receptor 
configurations adapted to Quetiapine by itself elevated DA to therapeutic levels in the M-model, 
suggesting that Quetiapine by itself can ameliorate depressive symptomatology in cases where NE 
is deficient and in some cases where DA is deficient. Although studies to date have not had 
adequate controls, the combination of an SSRI and Quetiapine appears to afford some 
improvement in patients that did not respond to SSRIs (Adson, Kushner et al. 2004, Baune, 
Caliskan et al. 2007). When the M-model adapted to chronic Escitalopram/Quetiapine, 100% of 
adapted configurations elevate NE to therapeutic levels, 34% elevate DA to therapeutic levels, and 
11% elevate 5HT to therapeutic levels. The M-model found that 34% of adapted TSC strength 
configurations had therapeutic elevations in both DA and NE. This combination could be effective 
in depressive subtypes that involve a deficiency of DA and NE, and in some cases where 5HT is 
deficient. 
 
 
 
 
 
 
 
 
 
 
 
168 
 
REFERENCES 
 
Abercrombie, E. D. and B. L. Jacobs (1987). "Single-unit response of noradrenergic neurons in 
the locus coeruleus of freely moving cats. II. Adaptation to chronically presented stressful 
stimuli." J Neurosci 7(9): 2844-2848. 
Abercrombie, E. D., K. A. Keefe, D. S. DiFrischia and M. J. Zigmond (1989). "Differential 
effect of stress on in vivo dopamine release in striatum, nucleus accumbens, and medial frontal 
cortex." J Neurochem 52(5): 1655-1658. 
Adson, D. E., M. G. Kushner, K. M. Eiben and S. C. Schulz (2004). "Preliminary experience 
with adjunctive quetiapine in patients receiving selective serotonin reuptake inhibitors." Depress 
Anxiety 19(2): 121-126. 
Aghajanian, G. K. and B. S. Bunney (1977). "Dopamine"autoreceptors": pharmacological 
characterization by microiontophoretic single cell recording studies." Naunyn Schmiedebergs 
Arch Pharmacol 297(1): 1-7. 
Aihara, M., I. Ida, N. Yuuki, A. Oshima, H. Kumano, K. Takahashi, M. Fukuda, N. Oriuchi, K. 
Endo, H. Matsuda and M. Mikuni (2007). "HPA axis dysfunction in unmedicated major 
depressive disorder and its normalization by pharmacotherapy correlates with alteration of neural 
activity in prefrontal cortex and limbic/paralimbic regions." Psychiatry Res 155(3): 245-256. 
Albert, P. R., F. Vahid-Ansari and C. Luckhart (2014). "Serotonin-prefrontal cortical circuitry in 
anxiety and depression phenotypes: pivotal role of pre- and post-synaptic 5-HT1A receptor 
expression." Front Behav Neurosci 8: 199. 
Alexander, J. K., A. Hillier, R. M. Smith, M. E. Tivarus and D. Q. Beversdorf (2007). "Beta-
adrenergic modulation of cognitive flexibility during stress." J Cogn Neurosci 19(3): 468-478. 
Alves, S. E., N. G. Weiland, S. Hayashi and B. S. McEwen (1998). "Immunocytochemical 
localization of nuclear estrogen receptors and progestin receptors within the rat dorsal raphe 
nucleus." J Comp Neurol 391(3): 322-334. 
Anastasio, T. J. (1991). "Distributed processing in vestibulo-ocular and other oculomotor 
subsystems in monkeys and cats." Arbib MA, Ewert J-P 95-109. 
Anastasio, T. J. (2010). Tutorial on Neural Systems Modeling, Sinauer Associates. 
Anastasio, T. J. (2011). "Data-driven modeling of Alzheimer disease pathogenesis." J Theor Biol 
290: 60-72. 
Anastasio, T. J. (2013). "Computational search for hypotheses concerning the endocannabinoid 
contribution to the extinction of fear conditioning." Front Comput Neurosci 7: 74. 
Anastasio, T. J. (2015). "Computer Modeling in Neuroscience: From Imperative to Declarative 
Programming Maude Modeling in Neuroscience." Logic, Rewriting, and Concurrency 9200: 97-
113. 
Anastasio, T. J. (2017). "Editorial: Computational and Experimental Approaches in Multi-target 
Pharmacology." Front Pharmacol 8: 443. 
Andersen, P. H. (1989). "The dopamine inhibitor GBR 12909: selectivity and molecular 
mechanism of action." Eur J Pharmacol 166(3): 493-504. 
Anderson, I. M. (2000). "Selective serotonin reuptake inhibitors versus tricyclic antidepressants: 
a meta-analysis of efficacy and tolerability." J Affect Disord 58(1): 19-36. 
Antoni, F. A., G. Fink and W. J. Sheward (1990). "Corticotrophin-releasing peptides in rat 
hypophysial portal blood after paraventricular lesions: a marked reduction in the concentration of 
corticotrophin-releasing factor-41, but no change in vasopressin." J Endocrinol 125(2): 175-183. 
169 
 
Aono, T., K. Kurachi, M. Miyata, A. Nakasima and K. Koshiyama (1976). "Influence of surgical 
stress under general anesthesia on serum gonadotropin levels in male and female patients." J Clin 
Endocrinol Metab 42(1): 144-148. 
Arborelius, L., G. G. Nomikos, P. Grillner, P. Hertel, B. B. Hook, U. Hacksell and T. H. 
Svensson (1995). "5-HT1A receptor antagonists increase the activity of serotonergic cells in the 
dorsal raphe nucleus in rats treated acutely or chronically with citalopram." Naunyn 
Schmiedebergs Arch Pharmacol 352(2): 157-165. 
Arborelius, L., G. G. Nomikos, P. Hertel, P. Salmi, P. Grillner, B. B. Hook, U. Hacksell and T. 
H. Svensson (1996). "The 5-HT1A receptor antagonist (S)-UH-301 augments the increase in 
extracellular concentrations of 5-HT in the frontal cortex produced by both acute and chronic 
treatment with citalopram." Naunyn Schmiedebergs Arch Pharmacol 353(6): 630-640. 
Armstrong, W. E., M. J. Gallagher and C. D. Sladek (1986). "Noradrenergic stimulation of 
supraoptic neuronal activity and vasopressin release in vitro: mediation by an alpha 1-receptor." 
Brain Res 365(1): 192-197. 
Asnis, G. M., U. Halbreich, H. Rabinovich, N. D. Ryan, E. J. Sachar, B. Nelson, J. Puig-Antich 
and H. Novacenko (1985). "The cortisol response to desipramine in endogenous depressives and 
normal controls: preliminary findings." Psychiatry Res 14(3): 225-233. 
Assie, M. B., E. Carilla-Durand, L. Bardin, M. Maraval, M. Aliaga, N. Malfetes, M. Barbara and 
A. Newman-Tancredi (2008). "The antipsychotics clozapine and olanzapine increase plasma 
glucose and corticosterone levels in rats: comparison with aripiprazole, ziprasidone, bifeprunox 
and F15063." Eur J Pharmacol 592(1-3): 160-166. 
Azmitia, E. C., P. J. Gannon, N. M. Kheck and P. M. Whitaker-Azmitia (1996). "Cellular 
localization of the 5-HT1A receptor in primate brain neurons and glial cells." 
Neuropsychopharmacology 14(1): 35-46. 
Azmitia, E. C. and M. Segal (1978). "An autoradiographic analysis of the differential ascending 
projections of the dorsal and median raphe nuclei in the rat." J Comp Neurol 179(3): 641-667. 
Bagley, J. and B. Moghaddam (1997). "Temporal dynamics of glutamate efflux in the prefrontal 
cortex and in the hippocampus following repeated stress: effects of pretreatment with saline or 
diazepam." Neuroscience 77(1): 65-73. 
Baiamonte, B. A., M. Valenza, E. A. Roltsch, A. M. Whitaker, B. B. Baynes, V. Sabino and N. 
W. Gilpin (2014). "Nicotine dependence produces hyperalgesia: role of corticotropin-releasing 
factor-1 receptors (CRF1Rs) in the central amygdala (CeA)." Neuropharmacology 77: 217-223. 
Baker, B. L., M. A. Schairer, D. J. Ingle and C. H. Li (1950). "The induction of involution in the 
male reproductive system by treatment with adrenocorticotropin." Anat Rec 106(3): 345-358. 
Balsara, J. J., S. A. Jadhav, R. K. Gaonkar, R. V. Gaikwad and J. H. Jadhav (2005). "Effects of 
the antidepressant trazodone, a 5-HT 2A/2C receptor antagonist, on dopamine-dependent 
behaviors in rats." Psychopharmacology (Berl) 179(3): 597-605. 
Bamberger, C. M., A. M. Bamberger, M. de Castro and G. P. Chrousos (1995). "Glucocorticoid 
receptor beta, a potential endogenous inhibitor of glucocorticoid action in humans." J Clin Invest 
95(6): 2435-2441. 
Bambico, F. R., N. T. Nguyen and G. Gobbi (2009). "Decline in serotonergic firing activity and 
desensitization of 5-HT1A autoreceptors after chronic unpredictable stress." Eur 
Neuropsychopharmacol 19(3): 215-228. 
Bambino, T. H. and A. J. Hsueh (1981). "Direct inhibitory effect of glucocorticoids upon 
testicular luteinizing hormone receptor and steroidogenesis in vivo and in vitro." Endocrinology 
108(6): 2142-2148. 
170 
 
Baraban, J. M. and G. K. Aghajanian (1980). "Suppression of firing activity of 5-HT neurons in 
the dorsal raphe by alpha-adrenoceptor antagonists." Neuropharmacology 19(4): 355-363. 
Baraban, J. M. and G. K. Aghajanian (1980). "Suppression of serotonergic neuronal firing by 
alpha-adrenoceptor antagonists: evidence against GABA mediation." Eur J Pharmacol 66(4): 
287-294. 
Baraban, J. M., R. Y. Wang and G. Aghajanian (1978). "Reserpine suppression of dorsal raphe 
neuronal firing: mediation by adrenergic system." Eur J Pharmacol 52(1): 27-36. 
Barden, N. (2004). "Implication of the hypothalamic-pituitary-adrenal axis in the 
physiopathology of depression." J Psychiatry Neurosci 29(3): 185-193. 
Barowsky, J. and T. L. Schwartz (2006). "An Evidence-Based Approach to Augmentation and 
Combination Strategies for: Treatment-Resistant Depression." Psychiatry (Edgmont) 3(7): 42-61. 
Bauman, D. E., R. J. Collier and H. A. Tucker (1977). "Effect of reserpine on serum prolactin, 
growth hormone, and glucocorticoids in dairy cows." Proc Soc Exp Biol Med 155(2): 189-192. 
Baune, B. T., S. Caliskan and D. Todder (2007). "Effects of adjunctive antidepressant therapy 
with quetiapine on clinical outcome, quality of sleep and daytime motor activity in patients with 
treatment-resistant depression." Hum Psychopharmacol 22(1): 1-9. 
Becker, C., B. Zeau, C. Rivat, A. Blugeot, M. Hamon and J. J. Benoliel (2008). "Repeated social 
defeat-induced depression-like behavioral and biological alterations in rats: involvement of 
cholecystokinin." Mol Psychiatry 13(12): 1079-1092. 
Beckstead, R. M., V. B. Domesick and W. J. Nauta (1979). "Efferent connections of the 
substantia nigra and ventral tegmental area in the rat." Brain Res 175(2): 191-217. 
Belanger, A., C. Auclair, C. Seguin, P. A. Kelly and F. Labrie (1979). "Down-regulation of 
testicular androgen biosynthesis and LH receptor levels by an LHRH agonist: role of prolactin." 
Mol Cell Endocrinol 13(1): 47-53. 
Benmansour, S., M. Cecchi, D. A. Morilak, G. A. Gerhardt, M. A. Javors, G. G. Gould and A. 
Frazer (1999). "Effects of chronic antidepressant treatments on serotonin transporter function, 
density, and mRNA level." J Neurosci 19(23): 10494-10501. 
Benoit-Marand, M., E. Borrelli and F. Gonon (2001). "Inhibition of dopamine release via 
presynaptic D2 receptors: time course and functional characteristics in vivo." J Neurosci 21(23): 
9134-9141. 
Berger, W., A. Mehra, M. Lenoci, T. J. Metzler, C. Otte, G. Tarasovsky, S. H. Mellon, O. M. 
Wolkowitz, C. R. Marmar and T. C. Neylan (2010). "Serum brain-derived neurotrophic factor 
predicts responses to escitalopram in chronic posttraumatic stress disorder." Prog 
Neuropsychopharmacol Biol Psychiatry 34(7): 1279-1284. 
Berti, F. and P. A. Shore (1967). "A kinetic analysis of drugs that inhibit the adrenergic neuronal 
membrane amine pump." Biochem Pharmacol 16(11): 2091-2094. 
Bertolino, M., S. Vicini, R. Gillis and A. Travagli (1997). "Presynaptic alpha2-adrenoceptors 
inhibit excitatory synaptic transmission in rat brain stem." Am J Physiol 272(3 Pt 1): G654-661. 
Berton, O. and E. J. Nestler (2006). "New approaches to antidepressant drug discovery: beyond 
monoamines." Nat Rev Neurosci 7(2): 137-151. 
Best, J., H. F. Nijhout and M. Reed (2010). "Serotonin synthesis, release and reuptake in 
terminals: a mathematical model." Theor Biol Med Model 7: 34. 
Best, J., H. F. Nijhout and M. Reed (2011). "Bursts and the efficacy of selective serotonin 
reuptake inhibitors." Pharmacopsychiatry 44 Suppl 1: S76-83. 
Best, J., M. Reed and H. F. Nijhout (2010). "Models of dopaminergic and serotonergic 
signaling." Pharmacopsychiatry 43 Suppl 1: S61-66. 
171 
 
Beyer, C. E., S. Boikess, B. Luo and L. A. Dawson (2002). "Comparison of the effects of 
antidepressants on norepinephrine and serotonin concentrations in the rat frontal cortex: an in-
vivo microdialysis study." J Psychopharmacol 16(4): 297-304. 
Beyer, C. E. and T. I. Cremers (2008). "Do selective serotonin reuptake inhibitors acutely 
increase frontal cortex levels of serotonin?" Eur J Pharmacol 580(3): 350-354. 
Biggio, G., M. G. Corda, A. Concas, G. Demontis, Z. Rossetti and G. L. Gessa (1981). "Rapid 
changes in GABA binding induced by stress in different areas of the rat brain." Brain Res 
229(2): 363-369. 
Bjorkholm, C., O. Franberg, A. Malmerfelt, M. M. Marcus, A. Konradsson-Geuken, B. 
Schilstrom, K. Jardemark and T. H. Svensson (2015). "Adjunctive treatment with asenapine 
augments the escitalopram-induced effects on monoaminergic outflow and glutamatergic 
neurotransmission in the medial prefrontal cortex of the rat." Int J Neuropsychopharmacol 18(3). 
Blackshear, A., M. Yamamoto, B. J. Anderson, P. V. Holmes, L. Lundstrom, U. Langel and J. K. 
Robinson (2007). "Intracerebroventricular administration of galanin or galanin receptor subtype 
1 agonist M617 induces c-Fos activation in central amygdala and dorsomedial hypothalamus." 
Peptides 28(5): 1120-1124. 
Blier, P. and C. de Montigny (1985). "Serotoninergic but not noradrenergic neurons in rat central 
nervous system adapt to long-term treatment with monoamine oxidase inhibitors." Neuroscience 
16(4): 949-955. 
Blier, P. and C. de Montigny (1987). "Modification of 5-HT neuron properties by sustained 
administration of the 5-HT1A agonist gepirone: electrophysiological studies in the rat brain." 
Synapse 1(5): 470-480. 
Blier, P. and C. de Montigny (1990). "Electrophysiological investigation of the adaptive 
response of the 5-HT system to the administration of 5-HT1A receptor agonists." J Cardiovasc 
Pharmacol 15 Suppl 7: S42-48. 
Blier, P. and C. de Montigny (1994). "Current advances and trends in the treatment of 
depression." Trends Pharmacol Sci 15(7): 220-226. 
Blier, P., C. de Montigny and Y. Chaput (1990). "A role for the serotonin system in the 
mechanism of action of antidepressant treatments: preclinical evidence." J Clin Psychiatry 51 
Suppl: 14-20; discussion 21. 
Blier, P. and M. El Mansari (2013). "Serotonin and beyond: therapeutics for major depression." 
Philos Trans R Soc Lond B Biol Sci 368(1615): 20120536. 
Blier, P., G. Pineyro, M. el Mansari, R. Bergeron and C. de Montigny (1998). "Role of 
somatodendritic 5-HT autoreceptors in modulating 5-HT neurotransmission." Ann N Y Acad Sci 
861: 204-216. 
Blier, P. and N. M. Ward (2003). "Is there a role for 5-HT1A agonists in the treatment of 
depression?" Biol Psychiatry 53(3): 193-203. 
Bluet Pajot, M. T., F. Mounier, A. di Sciullo, B. Schmidt and C. Kordon (1995). "Differential 
sites of action of 8OHDPAT, a 5HT1A agonist, on ACTH and PRL secretion in the rat." 
Neuroendocrinology 61(2): 159-166. 
Bombardi, C. (2011). "Distribution of 5-HT2A receptor immunoreactivity in the rat amygdaloid 
complex and colocalization with gamma-aminobutyric acid." Brain Res 1370: 112-128. 
Bonisch, H. and M. Bruss (2006). "The norepinephrine transporter in physiology and disease." 
Handb Exp Pharmacol(175): 485-524. 
Borroto-Escuela, D. O., M. Narvaez, D. Marcellino, C. Parrado, J. A. Narvaez, A. O. Tarakanov, 
L. F. Agnati, Z. Diaz-Cabiale and K. Fuxe (2010). "Galanin receptor-1 modulates 5-
172 
 
hydroxtryptamine-1A signaling via heterodimerization." Biochem Biophys Res Commun 393(4): 
767-772. 
Bottcher, B., K. Radenbach, L. Wildt and B. Hinney (2012). "Hormonal contraception and 
depression: a survey of the present state of knowledge." Arch Gynecol Obstet 286(1): 231-236. 
Boulton, D. W., A. H. Balch, K. Royzman, C. G. Patel, R. M. Berman, S. Mallikaarjun and R. A. 
Reeves (2010). "The pharmacokinetics of standard antidepressants with aripiprazole as 
adjunctive therapy: studies in healthy subjects and in patients with major depressive disorder." J 
Psychopharmacol 24(4): 537-546. 
Boyer, E. W. and M. Shannon (2005). "The serotonin syndrome." N Engl J Med 352(11): 1112-
1120. 
Brady, A. M. and P. O'Donnell (2004). "Dopaminergic modulation of prefrontal cortical input to 
nucleus accumbens neurons in vivo." J Neurosci 24(5): 1040-1049. 
Bravo, J. A., T. G. Dinan and J. F. Cryan (2014). "Early-life stress induces persistent alterations 
in 5-HT1A receptor and serotonin transporter mRNA expression in the adult rat brain." Front 
Mol Neurosci 7: 24. 
Bremner, W. J., M. R. Millar, R. M. Sharpe and P. T. Saunders (1994). "Immunohistochemical 
localization of androgen receptors in the rat testis: evidence for stage-dependent expression and 
regulation by androgens." Endocrinology 135(3): 1227-1234. 
Breton, C., C. Pechoux, G. Morel and H. H. Zingg (1995). "Oxytocin receptor messenger 
ribonucleic acid: characterization, regulation, and cellular localization in the rat pituitary gland." 
Endocrinology 136(7): 2928-2936. 
Broadbear, J. H., G. Winger, J. E. Rivier, K. C. Rice and J. H. Woods (2004). "Corticotropin-
releasing hormone antagonists, astressin B and antalarmin: differing profiles of activity in rhesus 
monkeys." Neuropsychopharmacology 29(6): 1112-1121. 
Brogden, R. N., R. C. Heel, T. M. Speight and G. S. Avery (1979). "Nomifensine: A review of 
its pharmacological properties and therapeutic efficacy in depressive illness." Drugs 18(1): 1-24. 
Bruhn, T. O., P. M. Plotsky and W. W. Vale (1984). "Effect of paraventricular lesions on 
corticotropin-releasing factor (CRF)-like immunoreactivity in the stalk-median eminence: studies 
on the adrenocorticotropin response to ether stress and exogenous CRF." Endocrinology 114(1): 
57-62. 
Bruni, J. F., H. H. Huang, S. Marshall and J. Meites (1977). "Effects of single and multiple 
injections of synthetic GnRH on serum LH, FSH and testosterone in young and old male rats." 
Biol Reprod 17(3): 309-312. 
Brunswick, D. J., J. D. Amsterdam, P. D. Mozley and A. Newberg (2003). "Greater availability 
of brain dopamine transporters in major depression shown by [99m Tc]TRODAT-1 SPECT 
imaging." Am J Psychiatry 160(10): 1836-1841. 
Buchanan, C. M., J. S. Eccles and J. B. Becker (1992). "Are adolescents the victims of raging 
hormones: evidence for activational effects of hormones on moods and behavior at adolescence." 
Psychol Bull 111(1): 62-107. 
Bucher, D., A. A. Prinz and E. Marder (2005). "Animal-to-animal variability in motor pattern 
production in adults and during growth." J Neurosci 25(7): 1611-1619. 
Buffalari, D. M. and A. A. Grace (2007). "Noradrenergic modulation of basolateral amygdala 
neuronal activity: opposing influences of alpha-2 and beta receptor activation." J Neurosci 
27(45): 12358-12366. 
173 
 
Buijs, R. M. and D. F. Swaab (1979). "Immuno-electron microscopical demonstration of 
vasopressin and oxytocin synapses in the limbic system of the rat." Cell Tissue Res 204(3): 355-
365. 
Bulbul, M., R. Babygirija, D. Cerjak, S. Yoshimoto, K. Ludwig and T. Takahashi (2011). 
"Hypothalamic oxytocin attenuates CRF expression via GABA(A) receptors in rats." Brain Res 
1387: 39-45. 
Butcher, S. P., I. S. Fairbrother, J. S. Kelly and G. W. Arbuthnott (1988). "Amphetamine-
induced dopamine release in the rat striatum: an in vivo microdialysis study." J Neurochem 
50(2): 346-355. 
Butcher, S. P., I. S. Fairbrother, J. S. Kelly and G. W. Arbuthnott (1990). "Effects of selective 
monoamine oxidase inhibitors on the in vivo release and metabolism of dopamine in the rat 
striatum." J Neurochem 55(3): 981-988. 
Butler, D. G., W. C. Clarke, E. M. Donaldson and R. W. Langford (1969). "Surgical 
adrenalectomy of a teleost fish (Anguilla rostrata lesueur): effect on plasma cortisol and tissue 
electrolyte and carbohydrate concentrations." Gen Comp Endocrinol 12(3): 503-514. 
Bymaster, F. P., W. Zhang, P. A. Carter, J. Shaw, E. Chernet, L. Phebus, D. T. Wong and K. W. 
Perry (2002). "Fluoxetine, but not other selective serotonin uptake inhibitors, increases 
norepinephrine and dopamine extracellular levels in prefrontal cortex." Psychopharmacology 
(Berl) 160(4): 353-361. 
Cai, X., J. Flores-Hernandez, J. Feng and Z. Yan (2002). "Activity-dependent bidirectional 
regulation of GABA(A) receptor channels by the 5-HT4 receptor-mediated signalling in rat 
prefrontal cortical pyramidal neurons." Journal of Physiology-London 540(3): 743-759. 
Calcagno, E., S. Guzzetti, A. Canetta, C. Fracasso, S. Caccia, L. Cervo and R. W. Invernizzi 
(2009). "Enhancement of cortical extracellular 5-HT by 5-HT1A and 5-HT2C receptor blockade 
restores the antidepressant-like effect of citalopram in non-responder mice." Int J 
Neuropsychopharmacol 12(6): 793-803. 
Camacho, M. B. and T. J. Anastasio (2017). "Computational Model of Antidepressant Response 
Heterogeneity as Multi-pathway Neuroadaptation." Frontiers in Pharmacology 8. 
Camacho, M. B., W. D. Vijitbenjaronk and T. J. Anastasio (2018). "Computational Analysis of 
Therapeutic Neuroadaptation to Chronic Antidepressant in a Model of the Monoaminergic 
Neurotransmitter and Stress Hormone Systems." Progress in Neuropsychopharmacology and 
Biological Psychiatry [Under review]. 
Camacho, M. B., W. D. Vijitbenjaronk and T. J. Anastasio (2018). "Computational Analysis of 
Therapeutic Neuroadaptation to Chronic Antidepressant in a Model of the Monoaminergic 
Neurotransmitter, Stress Hormone, and Male Sex Hormone Systems." European 
Neuropsychopharmacology [Under review]. 
Can, A., D. T. Dao, M. Arad, C. E. Terrillion, S. C. Piantadosi and T. D. Gould (2012). "The 
mouse forced swim test." J Vis Exp(59): e3638. 
Carboni, E., A. Imperato, L. Perezzani and G. Di Chiara (1989). "Amphetamine, cocaine, 
phencyclidine and nomifensine increase extracellular dopamine concentrations preferentially in 
the nucleus accumbens of freely moving rats." Neuroscience 28(3): 653-661. 
Carboni, E., G. L. Tanda, R. Frau and G. Di Chiara (1990). "Blockade of the noradrenaline 
carrier increases extracellular dopamine concentrations in the prefrontal cortex: evidence that 
dopamine is taken up in vivo by noradrenergic terminals." J Neurochem 55(3): 1067-1070. 
Carneiro, A. M., D. C. Airey, B. Thompson, C. B. Zhu, L. Lu, E. J. Chesler, K. M. Erikson and 
R. D. Blakely (2009). "Functional coding variation in recombinant inbred mouse lines reveals 
174 
 
multiple serotonin transporter-associated phenotypes." Proc Natl Acad Sci U S A 106(6): 2047-
2052. 
Caspi, A., K. Sugden, T. E. Moffitt, A. Taylor, I. W. Craig, H. Harrington, J. McClay, J. Mill, J. 
Martin, A. Braithwaite and R. Poulton (2003). "Influence of life stress on depression: moderation 
by a polymorphism in the 5-HTT gene." Science 301(5631): 386-389. 
Catt, K. J., A. J. Baukal, T. F. Davies and M. L. Dufau (1979). "Luteinizing hormone-releasing 
hormone-induced regulation of gonadotropin and prolactin receptors in the rat testis." 
Endocrinology 104(1): 17-25. 
Cecchi, M., H. Khoshbouei and D. A. Morilak (2002). "Modulatory effects of norepinephrine, 
acting on alpha 1 receptors in the central nucleus of the amygdala, on behavioral and 
neuroendocrine responses to acute immobilization stress." Neuropharmacology 43(7): 1139-
1147. 
Cedarbaum, J. M. and G. K. Aghajanian (1977). "Catecholamine receptors on locus coeruleus 
neurons: pharmacological characterization." Eur J Pharmacol 44(4): 375-385. 
Ceglia, I., S. Acconcia, C. Fracasso, M. Colovic, S. Caccia and R. W. Invernizzi (2004). "Effects 
of chronic treatment with escitalopram or citalopram on extracellular 5-HT in the prefrontal 
cortex of rats: role of 5-HT1A receptors." Br J Pharmacol 142(3): 469-478. 
Celada, P. and F. Artigas (1993). "Monoamine oxidase inhibitors increase preferentially 
extracellular 5-hydroxytryptamine in the midbrain raphe nuclei. A brain microdialysis study in 
the awake rat." Naunyn Schmiedebergs Arch Pharmacol 347(6): 583-590. 
Celada, P., M. Puig, M. Amargos-Bosch, A. Adell and F. Artigas (2004). "The therapeutic role 
of 5-HT1A and 5-HT2A receptors in depression." J Psychiatry Neurosci 29(4): 252-265. 
Celada, P., M. V. Puig and F. Artigas (2013). "Serotonin modulation of cortical neurons and 
networks." Front Integr Neurosci 7: 25. 
Chang, R. S., V. T. Tran and S. H. Snyder (1980). "Neurotransmitter receptor localizations: brain 
lesion induced alterations in benzodiazepine, GABA, beta-adrenergic and histamine H1-receptor 
binding." Brain Res 190(1): 95-110. 
Chatterton, R. T. (1990). "The role of stress in female reproduction: animal and human 
considerations." Int J Fertil 35(1): 8-13. 
Chen, F., M. B. Larsen, C. Sanchez and O. Wiborg (2005). "The S-enantiomer of R,S-
citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric 
mechanism. Comparison with other serotonin transporter inhibitors." Eur 
Neuropsychopharmacol 15(2): 193-198. 
Chen, L. and C. R. Yang (2002). "Interaction of dopamine D1 and NMDA receptors mediates 
acute clozapine potentiation of glutamate EPSPs in rat prefrontal cortex." J Neurophysiol 87(5): 
2324-2336. 
Chen, Y., K. A. Fenoglio, C. M. Dube, D. E. Grigoriadis and T. Z. Baram (2006). "Cellular and 
molecular mechanisms of hippocampal activation by acute stress are age-dependent." Mol 
Psychiatry 11(11): 992-1002. 
Chenu, F., M. El Mansari and P. Blier (2009). "Long-term administration of monoamine oxidase 
inhibitors alters the firing rate and pattern of dopamine neurons in the ventral tegmental area." 
Int J Neuropsychopharmacol 12(4): 475-485. 
Chergui, K., M. F. Suaud-Chagny and F. Gonon (1994). "Nonlinear relationship between 
impulse flow, dopamine release and dopamine elimination in the rat brain in vivo." Neuroscience 
62(3): 641-645. 
175 
 
Chernoloz, O., M. El Mansari and P. Blier (2009). "Electrophysiological studies in the rat brain 
on the basis for aripiprazole augmentation of antidepressants in major depressive disorder." 
Psychopharmacology (Berl) 206(2): 335-344. 
Chernoloz, O., M. El Mansari and P. Blier (2009). "Sustained administration of pramipexole 
modifies the spontaneous firing of dopamine, norepinephrine, and serotonin neurons in the rat 
brain." Neuropsychopharmacology 34(3): 651-661. 
Chernoloz, O., M. El Mansari and P. Blier (2012). "Effects of sustained administration of 
quetiapine alone and in combination with a serotonin reuptake inhibitor on norepinephrine and 
serotonin transmission." Neuropsychopharmacology 37(7): 1717-1728. 
Childs, E., N. T. Van Dam and H. de Wit (2010). "Effects of acute progesterone administration 
upon responses to acute psychosocial stress in men." Exp Clin Psychopharmacol 18(1): 78-86. 
Chiodera, P. and V. Coiro (1987). "Oxytocin reduces metyrapone-induced ACTH secretion in 
human subjects." Brain Res 420(1): 178-181. 
Choong, K. C. and R. Y. Shen (2004). "Methylphenidate restores ventral tegmental area 
dopamine neuron activity in prenatal ethanol-exposed rats by augmenting dopamine 
neurotransmission." J Pharmacol Exp Ther 309(2): 444-451. 
Ciliax, B. J., C. Heilman, L. L. Demchyshyn, Z. B. Pristupa, E. Ince, S. M. Hersch, H. B. Niznik 
and A. I. Levey (1995). "The dopamine transporter: immunochemical characterization and 
localization in brain." J Neurosci 15(3 Pt 1): 1714-1723. 
Clark, J. A., R. B. Flick, L. Y. Pai, I. Szalayova, S. Key, R. K. Conley, A. Y. Deutch, P. H. 
Hutson and E. Mezey (2008). "Glucocorticoid modulation of tryptophan hydroxylase-2 protein 
in raphe nuclei and 5-hydroxytryptophan concentrations in frontal cortex of C57/Bl6 mice." Mol 
Psychiatry 13(5): 498-506. 
Clark, J. A., L. Y. Pai, R. B. Flick and S. P. Rohrer (2005). "Differential hormonal regulation of 
tryptophan hydroxylase-2 mRNA in the murine dorsal raphe nucleus." Biol Psychiatry 57(8): 
943-946. 
Clement, H. W., D. Gemsa and W. Wesemann (1992). "The effect of adrenergic drugs on 
serotonin metabolism in the nucleus raphe dorsalis of the rat, studied by in vivo voltammetry." 
Eur J Pharmacol 217(1): 43-48. 
Cole, M. G. and N. Dendukuri (2003). "Risk factors for depression among elderly community 
subjects: a systematic review and meta-analysis." Am J Psychiatry 160(6): 1147-1156. 
Conley, R. K., M. J. Cumberbatch, G. S. Mason, D. J. Williamson, T. Harrison, K. Locker, C. 
Swain, K. Maubach, R. O'Donnell, M. Rigby, L. Hewson, D. Smith and N. M. Rupniak (2002). 
"Substance P (neurokinin 1) receptor antagonists enhance dorsal raphe neuronal activity." J 
Neurosci 22(17): 7730-7736. 
Cooper, B. R., C. M. Wang, R. F. Cox, R. Norton, V. Shea and R. M. Ferris (1994). "Evidence 
that the acute behavioral and electrophysiological effects of bupropion (Wellbutrin) are mediated 
by a noradrenergic mechanism." Neuropsychopharmacology 11(2): 133-141. 
Coppell, A. L., Q. Pei and T. S. Zetterstrom (2003). "Bi-phasic change in BDNF gene expression 
following antidepressant drug treatment." Neuropharmacology 44(7): 903-910. 
Coppen, A. (1967). "The biochemistry of affective disorders." Br J Psychiatry 113(504): 1237-
1264. 
Cornelisse, L. N., J. E. Van der Harst, J. C. Lodder, P. J. Baarendse, A. J. Timmerman, H. D. 
Mansvelder, B. M. Spruijt and A. B. Brussaard (2007). "Reduced 5-HT1A- and GABAB 
receptor function in dorsal raphe neurons upon chronic fluoxetine treatment of socially stressed 
rats." J Neurophysiol 98(1): 196-204. 
176 
 
Corporation, S. (2009). "SAPHRIS (asenapine) sublingual tablets." 
Corrigan, M. H., A. Q. Denahan, C. E. Wright, R. J. Ragual and D. L. Evans (2000). 
"Comparison of pramipexole, fluoxetine, and placebo in patients with major depression." 
Depress Anxiety 11(2): 58-65. 
Corya, S. A., S. W. Andersen, H. C. Detke, L. S. Kelly, L. E. Van Campen, T. M. Sanger, D. J. 
Williamson and S. Dube (2003). "Long-term antidepressant efficacy and safety of 
olanzapine/fluoxetine combination: a 76-week open-label study." J Clin Psychiatry 64(11): 1349-
1356. 
Cosentino, M., F. Marino and G. J. Maestroni (2015). "Sympathoadrenergic modulation of 
hematopoiesis: a review of available evidence and of therapeutic perspectives." Front Cell 
Neurosci 9: 302. 
Crowley, J. J., E. S. Brodkin, J. A. Blendy, W. H. Berrettini and I. Lucki (2006). 
"Pharmacogenomic evaluation of the antidepressant citalopram in the mouse tail suspension 
test." Neuropsychopharmacology 31(11): 2433-2442. 
Cullinan, W. E., J. P. Herman, D. F. Battaglia, H. Akil and S. J. Watson (1995). "Pattern and 
time course of immediate early gene expression in rat brain following acute stress." 
Neuroscience 64(2): 477-505. 
Cunningham, L. A., R. L. Borison, J. S. Carman, G. Chouinard, J. E. Crowder, B. I. Diamond, D. 
E. Fischer and E. Hearst (1994). "A comparison of venlafaxine, trazodone, and placebo in major 
depression." J Clin Psychopharmacol 14(2): 99-106. 
Curtis, A. L., N. T. Bello, K. R. Connolly and R. J. Valentino (2002). "Corticotropin-releasing 
factor neurones of the central nucleus of the amygdala mediate locus coeruleus activation by 
cardiovascular stress." J Neuroendocrinol 14(8): 667-682. 
Cusack, B., A. Nelson and E. Richelson (1994). "Binding of antidepressants to human brain 
receptors: focus on newer generation compounds." Psychopharmacology (Berl) 114(4): 559-565. 
Cutler, A. J., S. A. Montgomery, D. Feifel, A. Lazarus, M. Astrom and M. Brecher (2009). 
"Extended release quetiapine fumarate monotherapy in major depressive disorder: a placebo- and 
duloxetine-controlled study." J Clin Psychiatry 70(4): 526-539. 
Czachura, J. F. and K. Rasmussen (2000). "Effects of acute and chronic administration of 
fluoxetine on the activity of serotonergic neurons in the dorsal raphe nucleus of the rat." Naunyn 
Schmiedebergs Arch Pharmacol 362(3): 266-275. 
Davidson, C. and J. A. Stamford (1995). "Evidence that 5-hydroxytryptamine release in rat 
dorsal raphe nucleus is controlled by 5-HT1A, 5-HT1B and 5-HT1D autoreceptors." Br J 
Pharmacol 114(6): 1107-1109. 
Dawson, L. A., H. Q. Nguyen, D. L. Smith and L. E. Schechter (2002). "Effect of chronic 
fluoxetine and WAY-100635 treatment on serotonergic neurotransmission in the frontal cortex." 
J Psychopharmacol 16(2): 145-152. 
De Foubert, G., S. L. Carney, C. S. Robinson, E. J. Destexhe, R. Tomlinson, C. A. Hicks, T. K. 
Murray, J. P. Gaillard, C. Deville, V. Xhenseval, C. E. Thomas, M. J. O'Neill and T. S. 
Zetterstrom (2004). "Fluoxetine-induced change in rat brain expression of brain-derived 
neurotrophic factor varies depending on length of treatment." Neuroscience 128(3): 597-604. 
de Jong, H. (2002). "Modeling and simulation of genetic regulatory systems: a literature review." 
J Comput Biol 9(1): 67-103. 
de Kloet, E. R., M. Joels and F. Holsboer (2005). "Stress and the brain: from adaptation to 
disease." Nat Rev Neurosci 6(6): 463-475. 
177 
 
de Kock, C. P., L. N. Cornelisse, N. Burnashev, J. C. Lodder, A. J. Timmerman, J. J. Couey, H. 
D. Mansvelder and A. B. Brussaard (2006). "NMDA receptors trigger neurosecretion of 5-HT 
within dorsal raphe nucleus of the rat in the absence of action potential firing." J Physiol 577(Pt 
3): 891-905. 
de Kretser, D. M., M. P. Hedger, K. L. Loveland and D. J. Phillips (2002). "Inhibins, activins 
and follistatin in reproduction." Hum Reprod Update 8(6): 529-541. 
de Montigny, C., Y. Chaput and P. Blier (1990). "Modification of serotonergic neuron properties 
by long-term treatment with serotonin reuptake blockers." J Clin Psychiatry 51 Suppl B: 4-8. 
de Souza Silva, M. A., C. Mattern, B. Topic, T. E. Buddenberg and J. P. Huston (2009). 
"Dopaminergic and serotonergic activity in neostriatum and nucleus accumbens enhanced by 
intranasal administration of testosterone." Eur Neuropsychopharmacol 19(1): 53-63. 
Deak, T., K. T. Nguyen, A. L. Ehrlich, L. R. Watkins, R. L. Spencer, S. F. Maier, J. Licinio, M. 
L. Wong, G. P. Chrousos, E. Webster and P. W. Gold (1999). "The impact of the nonpeptide 
corticotropin-releasing hormone antagonist antalarmin on behavioral and endocrine responses to 
stress." Endocrinology 140(1): 79-86. 
Denys, D., A. A. Klompmakers and H. G. Westenberg (2004). "Synergistic dopamine increase in 
the rat prefrontal cortex with the combination of quetiapine and fluvoxamine." 
Psychopharmacology (Berl) 176(2): 195-203. 
Desai, N. S., L. C. Rutherford and G. G. Turrigiano (1999). "Plasticity in the intrinsic excitability 
of cortical pyramidal neurons." Nat Neurosci 2(6): 515-520. 
Desjardins, C. and L. L. Ewing (1971). "Testicular Metabolism in Adrenalectomized and 
Corticosterone Treated Rats." Proceedings of the Society for Experimental Biology and 
Medicine 137(2): 578-+. 
Deutch, A. Y., M. Goldstein and R. H. Roth (1986). "Activation of the locus coeruleus induced 
by selective stimulation of the ventral tegmental area." Brain Res 363(2): 307-314. 
DeVane, C. L. and C. B. Nemeroff (2001). "Clinical pharmacokinetics of quetiapine: an atypical 
antipsychotic." Clin Pharmacokinet 40(7): 509-522. 
Dierich, A., M. R. Sairam, L. Monaco, G. M. Fimia, A. Gansmuller, M. LeMeur and P. Sassone-
Corsi (1998). "Impairing follicle-stimulating hormone (FSH) signaling in vivo: targeted 
disruption of the FSH receptor leads to aberrant gametogenesis and hormonal imbalance." Proc 
Natl Acad Sci U S A 95(23): 13612-13617. 
Dinan, T. G. (1996). "Serotonin and the regulation of hypothalamic-pituitary-adrenal axis 
function." Life Sci 58(20): 1683-1694. 
Diorio, D., V. Viau and M. J. Meaney (1993). "The role of the medial prefrontal cortex 
(cingulate gyrus) in the regulation of hypothalamic-pituitary-adrenal responses to stress." J 
Neurosci 13(9): 3839-3847. 
Doge, K. (1993). "[Sex difference of rat brain monoamine metabolism under restraint stress]." 
Nihon Hoigaku Zasshi 47(1): 46-56. 
Dong, J. and P. Blier (2001). "Modification of norepinephrine and serotonin, but not dopamine, 
neuron firing by sustained bupropion treatment." Psychopharmacology (Berl) 155(1): 52-57. 
Donner, N. and R. J. Handa (2009). "Estrogen receptor beta regulates the expression of 
tryptophan-hydroxylase 2 mRNA within serotonergic neurons of the rat dorsal raphe nuclei." 
Neuroscience 163(2): 705-718. 
Dremencov, E., M. El Mansari and P. Blier (2009). "Effects of sustained serotonin reuptake 
inhibition on the firing of dopamine neurons in the rat ventral tegmental area." J Psychiatry 
Neurosci 34(3): 223-229. 
178 
 
Dubey, A. K. and T. M. Plant (1985). "A suppression of gonadotropin secretion by cortisol in 
castrated male rhesus monkeys (Macaca mulatta) mediated by the interruption of hypothalamic 
gonadotropin-releasing hormone release." Biol Reprod 33(2): 423-431. 
Ducottet, C., G. Griebel and C. Belzung (2003). "Effects of the selective nonpeptide 
corticotropin-releasing factor receptor 1 antagonist antalarmin in the chronic mild stress model of 
depression in mice." Prog Neuropsychopharmacol Biol Psychiatry 27(4): 625-631. 
Duman, R. S. and L. M. Monteggia (2006). "A neurotrophic model for stress-related mood 
disorders." Biol Psychiatry 59(12): 1116-1127. 
Edelman, G. M. and J. A. Gally (2001). "Degeneracy and complexity in biological systems." 
Proc Natl Acad Sci U S A 98(24): 13763-13768. 
Edmondson, D. E., A. Mattevi, C. Binda, M. Li and F. Hubalek (2004). "Structure and 
mechanism of monoamine oxidase." Curr Med Chem 11(15): 1983-1993. 
El Iskandrani, K. S., C. A. Oosterhof, M. El Mansari and P. Blier (2015). "Impact of 
subanesthetic doses of ketamine on AMPA-mediated responses in rats: An in vivo 
electrophysiological study on monoaminergic and glutamatergic neurons." J Psychopharmacol. 
El Mansari, M., R. Ghanbari, S. Janssen and P. Blier (2008). "Sustained administration of 
bupropion alters the neuronal activity of serotonin, norepinephrine but not dopamine neurons in 
the rat brain." Neuropharmacology 55(7): 1191-1198. 
El Mansari, M., S. Manta, C. Oosterhof, K. S. El Iskandrani, F. Chenu, S. Shim and P. Blier 
(2015). "Restoration of serotonin neuronal firing following long-term administration of 
bupropion but not paroxetine in olfactory bulbectomized rats." Int J Neuropsychopharmacol 
18(4). 
El Mansari, M., C. Sanchez, G. Chouvet, B. Renaud and N. Haddjeri (2005). "Effects of acute 
and long-term administration of escitalopram and citalopram on serotonin neurotransmission: an 
in vivo electrophysiological study in rat brain." Neuropsychopharmacology 30(7): 1269-1277. 
Elam, M., D. Clark and T. H. Svensson (1986). "Electrophysiological effects of the enantiomers 
of 3-PPP on neurons in the locus coeruleus of the rat." Neuropharmacology 25(9): 1003-1008. 
Elands, J., A. Beetsma, C. Barberis and E. R. de Kloet (1988). "Topography of the oxytocin 
receptor system in rat brain: an autoradiographical study with a selective radioiodinated oxytocin 
antagonist." J Chem Neuroanat 1(6): 293-302. 
Elliott-Hunt, C. R., R. J. Pope, P. Vanderplank and D. Wynick (2007). "Activation of the galanin 
receptor 2 (GalR2) protects the hippocampus from neuronal damage." J Neurochem 100(3): 780-
789. 
Emiliano, A. B., T. Cruz, V. Pannoni and J. L. Fudge (2007). "The interface of oxytocin-labeled 
cells and serotonin transporter-containing fibers in the primate hypothalamus: a substrate for 
SSRIs therapeutic effects?" Neuropsychopharmacology 32(5): 977-988. 
Evans, L., S. Golshan, J. Kelsoe, M. Rapaport, K. Resovsky, L. Sutton and J. C. Gillin (2002). 
"Effects of rapid tryptophan depletion on sleep electroencephalogram and mood in subjects with 
partially remitted depression on bupropion." Neuropsychopharmacology 27(6): 1016-1026. 
Evans, S. J., T. F. Murray and F. L. Moore (2000). "Partial purification and biochemical 
characterization of a membrane glucocorticoid receptor from an amphibian brain." J Steroid 
Biochem Mol Biol 72(5): 209-221. 
Evrard, A., A. M. Laporte, M. Chastanet, R. Hen, M. Hamon and J. Adrien (1999). "5-HT1A and 
5-HT1B receptors control the firing of serotoninergic neurons in the dorsal raphe nucleus of the 
mouse: studies in 5-HT1B knock-out mice." Eur J Neurosci 11(11): 3823-3831. 
179 
 
Eyding, D., M. Lelgemann, U. Grouven, M. Harter, M. Kromp, T. Kaiser, M. F. Kerekes, M. 
Gerken and B. Wieseler (2010). "Reboxetine for acute treatment of major depression: systematic 
review and meta-analysis of published and unpublished placebo and selective serotonin reuptake 
inhibitor controlled trials." BMJ 341: c4737. 
Fairchild, G., M. M. Leitch and C. D. Ingram (2003). "Acute and chronic effects of 
corticosterone on 5-HT1A receptor-mediated autoinhibition in the rat dorsal raphe nucleus." 
Neuropharmacology 45(7): 925-934. 
Fava, M. and A. J. Rush (2006). "Current status of augmentation and combination treatments for 
major depressive disorder: a literature review and a proposal for a novel approach to improve 
practice." Psychother Psychosom 75(3): 139-153. 
Feetham, C. H. and R. Barrett-Jolley (2014). "NK1-receptor-expressing paraventricular nucleus 
neurones modulate daily variation in heart rate and stress-induced changes in heart rate 
variability." Physiol Rep 2(12). 
Feldman, S., N. Conforti, A. Itzik and J. Weidenfeld (1994). "Differential effect of amygdaloid 
lesions on CRF-41, ACTH and corticosterone responses following neural stimuli." Brain Res 
658(1-2): 21-26. 
Ferre, S. and F. Artigas (1993). "Dopamine D2 receptor-mediated regulation of serotonin 
extracellular concentration in the dorsal raphe nucleus of freely moving rats." J Neurochem 
61(2): 772-775. 
Ferre, S. and F. Artigas (1995). "Clozapine decreases serotonin extracellular levels in the nucleus 
accumbens by a dopamine receptor-independent mechanism." Neurosci Lett 187(1): 61-64. 
Fink, G., I. C. Robinson and L. A. Tannahill (1988). "Effects of adrenalectomy and 
glucocorticoids on the peptides CRF-41, AVP and oxytocin in rat hypophysial portal blood." J 
Physiol 401: 329-345. 
Fletcher, A., E. A. Forster, D. J. Bill, G. Brown, I. A. Cliffe, J. E. Hartley, D. E. Jones, A. 
McLenachan, K. J. Stanhope, D. J. Critchley, K. J. Childs, V. C. Middlefell, L. Lanfumey, R. 
Corradetti, A. M. Laporte, H. Gozlan, M. Hamon and C. T. Dourish (1996). 
"Electrophysiological, biochemical, neurohormonal and behavioural studies with WAY-100635, 
a potent, selective and silent 5-HT1A receptor antagonist." Behav Brain Res 73(1-2): 337-353. 
Flores-Burgess, A. (2016). "Galanin(1-15) Enhancement of the Behavioral Effects of Fluoxetine 
in the Forced Swim Test Gives a New Therapeutic Strategy Against Depression." 
Fong, T. M., H. Yu and C. D. Strader (1992). "Molecular basis for the species selectivity of the 
neurokinin-1 receptor antagonists CP-96,345 and RP67580." J Biol Chem 267(36): 25668-
25671. 
Fountoulakis, K. N., C. Hoschl, S. Kasper, J. Lopez-Ibor and H. J. Moller (2013). "The media 
and intellectuals' response to medical publications: the antidepressants' case." Ann Gen 
Psychiatry 12(1): 11. 
Fountoulakis, K. N. and H. J. Moller (2011). "Efficacy of antidepressants: a re-analysis and re-
interpretation of the Kirsch data." Int J Neuropsychopharmacol 14(3): 405-412. 
Frackiewicz, E. J., J. J. Sramek and N. R. Cutler (2000). "Gender differences in depression and 
antidepressant pharmacokinetics and adverse events." Ann Pharmacother 34(1): 80-88. 
Franberg, O., M. M. Marcus, V. Ivanov, B. Schilstrom, M. Shahid and T. H. Svensson (2009). 
"Asenapine elevates cortical dopamine, noradrenaline and serotonin release. Evidence for 
activation of cortical and subcortical dopamine systems by different mechanisms." 
Psychopharmacology (Berl) 204(2): 251-264. 
180 
 
Franberg, O., C. Wiker, M. M. Marcus, A. Konradsson, K. Jardemark, B. Schilstrom, M. Shahid, 
E. H. Wong and T. H. Svensson (2008). "Asenapine, a novel psychopharmacologic agent: 
preclinical evidence for clinical effects in schizophrenia." Psychopharmacology (Berl) 196(3): 
417-429. 
Fumagalli, F., S. R. Jones, M. G. Caron, F. J. Seidler and T. A. Slotkin (1996). "Expression of 
mRNA coding for the serotonin transporter in aged vs. young rat brain: differential effects of 
glucocorticoids." Brain Res 719(1-2): 225-228. 
Furay, A. R., A. E. Bruestle and J. P. Herman (2008). "The role of the forebrain glucocorticoid 
receptor in acute and chronic stress." Endocrinology 149(11): 5482-5490. 
Gagnon, D. and M. Parent (2014). "Distribution of VGLUT3 in highly collateralized axons from 
the rat dorsal raphe nucleus as revealed by single-neuron reconstructions." PLoS One 9(2): 
e87709. 
Gallager, D. W. and G. K. Aghajanian (1976). "Effect of antipsychotic drugs on the firing of 
dorsal raphe cells. I. Role of adrenergic system." Eur J Pharmacol 39(2): 341-355. 
Galvez, R., M. H. Mesches and J. L. McGaugh (1996). "Norepinephrine release in the amygdala 
in response to footshock stimulation." Neurobiol Learn Mem 66(3): 253-257. 
Gao, M., C. L. Liu, S. Yang, G. Z. Jin, B. S. Bunney and W. X. Shi (2007). "Functional coupling 
between the prefrontal cortex and dopamine neurons in the ventral tegmental area." J Neurosci 
27(20): 5414-5421. 
Gao, W. J. (2007). "Acute clozapine suppresses synchronized pyramidal synaptic network 
activity by increasing inhibition in the ferret prefrontal cortex." J Neurophysiol 97(2): 1196-
1208. 
Gartside, S. E., V. Umbers and T. Sharp (1997). "Inhibition of 5-HT cell firing in the DRN by 
non-selective 5-HT reuptake inhibitors: studies on the role of 5-HT1A autoreceptors and 
noradrenergic mechanisms." Psychopharmacology (Berl) 130(3): 261-268. 
Geisler, S., C. Derst, R. W. Veh and D. S. Zahm (2007). "Glutamatergic afferents of the ventral 
tegmental area in the rat." J Neurosci 27(21): 5730-5743. 
Ghanbari, R., M. El Mansari and P. Blier (2010). "Electrophysiological effects of the co-
administration of escitalopram and bupropion on rat serotonin and norepinephrine neurons." J 
Psychopharmacol 24(1): 39-50. 
Ghanbari, R., M. El Mansari and P. Blier (2010). "Sustained administration of trazodone 
enhances serotonergic neurotransmission: in vivo electrophysiological study in the rat brain." J 
Pharmacol Exp Ther 335(1): 197-206. 
Ghanbari, R., M. El Mansari and P. Blier (2012). "Electrophysiological impact of trazodone on 
the dopamine and norepinephrine systems in the rat brain." Eur Neuropsychopharmacol 22(7): 
518-526. 
Ghanbari, R., M. El Mansari, M. Shahid and P. Blier (2009). "Electrophysiological 
characterization of the effects of asenapine at 5-HT(1A), 5-HT(2A), alpha(2)-adrenergic and 
D(2) receptors in the rat brain." Eur Neuropsychopharmacol 19(3): 177-187. 
Gibbs, D. M., W. Vale, J. Rivier and S. S. Yen (1984). "Oxytocin potentiates the ACTH-
releasing activity of CRF(41) but not vasopressin." Life Sci 34(23): 2245-2249. 
Gillespie, C. F. and C. B. Nemeroff (2005). "Hypercortisolemia and depression." Psychosom 
Med 67 Suppl 1: S26-28. 
Gimpl, G. and F. Fahrenholz (2001). "The oxytocin receptor system: structure, function, and 
regulation." Physiol Rev 81(2): 629-683. 
181 
 
Giros, B., Y. M. Wang, S. Suter, S. B. McLeskey, C. Pifl and M. G. Caron (1994). "Delineation 
of discrete domains for substrate, cocaine, and tricyclic antidepressant interactions using 
chimeric dopamine-norepinephrine transporters." J Biol Chem 269(23): 15985-15988. 
Glisson, S. N., A. A. el-Etr and B. C. Bloor (1976). "The effect of ketamine upon norepinephrine 
and dopamine levels in rabbit brain parts." Naunyn Schmiedebergs Arch Pharmacol 295(2): 149-
152. 
Gobbi, G., T. Cassano, F. Radja, M. G. Morgese, V. Cuomo, L. Santarelli, R. Hen and P. Blier 
(2007). "Neurokinin 1 receptor antagonism requires norepinephrine to increase serotonin 
function." Eur Neuropsychopharmacol 17(5): 328-338. 
Gobert, A., J. M. Rivet, F. Lejeune, A. Newman-Tancredi, A. Adhumeau-Auclair, J. P. Nicolas, 
L. Cistarelli, C. Melon and M. J. Millan (2000). "Serotonin(2C) receptors tonically suppress the 
activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: a 
combined dialysis and electrophysiological analysis in the rat." Synapse 36(3): 205-221. 
Godlewska, B. R., R. Norbury, S. Selvaraj, P. J. Cowen and C. J. Harmer (2012). "Short-term 
SSRI treatment normalises amygdala hyperactivity in depressed patients." Psychol Med 42(12): 
2609-2617. 
Goel, N. and T. L. Bale (2010). "Sex differences in the serotonergic influence on the 
hypothalamic-pituitary-adrenal stress axis." Endocrinology 151(4): 1784-1794. 
Goel, N., K. S. Plyler, D. Daniels and T. L. Bale (2011). "Androgenic influence on serotonergic 
activation of the HPA stress axis." Endocrinology 152(5): 2001-2010. 
Goel, N., J. L. Workman, T. T. Lee, L. Innala and V. Viau (2014). "Sex differences in the HPA 
axis." Compr Physiol 4(3): 1121-1155. 
Gold, P. W. and G. P. Chrousos (2002). "Organization of the stress system and its dysregulation 
in melancholic and atypical depression: high vs low CRH/NE states." Mol Psychiatry 7(3): 254-
275. 
Goldman, H. (1963). "Effect of acute stress on the pituitary gland: endocrine gland blood flow." 
Endocrinology 72: 588-591. 
Golowasch, J., M. S. Goldman, L. F. Abbott and E. Marder (2002). "Failure of averaging in the 
construction of a conductance-based neuron model." J Neurophysiol 87(2): 1129-1131. 
Golowasch, J. and E. Marder (1992). "Ionic currents of the lateral pyloric neuron of the 
stomatogastric ganglion of the crab." J Neurophysiol 67(2): 318-331. 
Grant, J. K., A. P. Forrest and T. Symington (1957). "The secretion of cortisol and corticosterone 
by the human adrenal cortex." Acta Endocrinol (Copenh) 26(2): 195-203. 
Gray, N. A., M. S. Milak, C. DeLorenzo, R. T. Ogden, Y. Y. Huang, J. J. Mann and R. V. Parsey 
(2013). "Antidepressant treatment reduces serotonin-1A autoreceptor binding in major 
depressive disorder." Biol Psychiatry 74(1): 26-31. 
Greenberg, P. E., A. A. Fournier, T. Sisitsky, C. T. Pike and R. C. Kessler (2015). "The 
economic burden of adults with major depressive disorder in the United States (2005 and 2010)." 
J Clin Psychiatry 76(2): 155-162. 
Greenberg, P. E., L. E. Stiglin, S. N. Finkelstein and E. R. Berndt (1993). "The economic burden 
of depression in 1990." J Clin Psychiatry 54(11): 405-418. 
Grenhoff, J., M. Nisell, S. Ferre, G. Aston-Jones and T. H. Svensson (1993). "Noradrenergic 
modulation of midbrain dopamine cell firing elicited by stimulation of the locus coeruleus in the 
rat." J Neural Transm Gen Sect 93(1): 11-25. 
Grenhoff, J., R. A. North and S. W. Johnson (1995). "Alpha 1-adrenergic effects on dopamine 
neurons recorded intracellularly in the rat midbrain slice." Eur J Neurosci 7(8): 1707-1713. 
182 
 
Grino, P. B., J. E. Griffin and J. D. Wilson (1990). "Testosterone at high concentrations interacts 
with the human androgen receptor similarly to dihydrotestosterone." Endocrinology 126(2): 
1165-1172. 
Guelfi, J. D., C. White, D. Hackett, J. Y. Guichoux and G. Magni (1995). "Effectiveness of 
venlafaxine in patients hospitalized for major depression and melancholia." J Clin Psychiatry 
56(10): 450-458. 
Guiard, B. P., M. El Mansari and P. Blier (2008). "Cross-talk between dopaminergic and 
noradrenergic systems in the rat ventral tegmental area, locus ceruleus, and dorsal hippocampus." 
Mol Pharmacol 74(5): 1463-1475. 
Guiard, B. P., M. El Mansari, Z. Merali and P. Blier (2008). "Functional interactions between 
dopamine, serotonin and norepinephrine neurons: an in-vivo electrophysiological study in rats 
with monoaminergic lesions." Int J Neuropsychopharmacol 11(5): 625-639. 
Guiard, B. P., J. P. Guilloux, C. Reperant, S. P. Hunt, M. Toth and A. M. Gardier (2007). 
"Substance P neurokinin 1 receptor activation within the dorsal raphe nucleus controls serotonin 
release in the mouse frontal cortex." Mol Pharmacol 72(6): 1411-1418. 
Haddjeri, N. and P. Blier (2008). "Neurokinin-1 receptor antagonists modulate brain 
noradrenaline and serotonin interactions." Eur J Pharmacol 600(1-3): 64-70. 
Haddjeri, N., P. Blier and C. de Montigny (1998). "Long-term antidepressant treatments result in 
a tonic activation of forebrain 5-HT1A receptors." J Neurosci 18(23): 10150-10156. 
Haddjeri, N., C. de Montigny and P. Blier (1997). "Modulation of the firing activity of 
noradrenergic neurones in the rat locus coeruleus by the 5-hydroxtryptamine system." Br J 
Pharmacol 120(5): 865-875. 
Haj-Dahmane, S. (2001). "D2-like dopamine receptor activation excites rat dorsal raphe 5-HT 
neurons in vitro." Eur J Neurosci 14(1): 125-134. 
Hajos, M., J. C. Fleishaker, J. K. Filipiak-Reisner, M. T. Brown and E. H. F. Wong (2004). "The 
selective norepinephrine reuptake inhibitor antidepressant reboxetine: Pharmacological and 
clinical profile." Cns Drug Reviews 10(1): 23-44. 
Hajos, M., S. E. Gartside and T. Sharp (1995). "Inhibition of median and dorsal raphe neurones 
following administration of the selective serotonin reuptake inhibitor paroxetine." Naunyn 
Schmiedebergs Arch Pharmacol 351(6): 624-629. 
Hall, H., G. Sedvall, O. Magnusson, J. Kopp, C. Halldin and L. Farde (1994). "Distribution of 
D1- and D2-dopamine receptors, and dopamine and its metabolites in the human brain." 
Neuropsychopharmacology 11(4): 245-256. 
Hall, R. and J. Murdoch (1990). "Brain protection: physiological and pharmacological 
considerations. Part II: The pharmacology of brain protection." Can J Anaesth 37(7): 762-777. 
Hamon, M. and P. Blier (2013). "Monoamine neurocircuitry in depression and strategies for new 
treatments." Prog Neuropsychopharmacol Biol Psychiatry 45: 54-63. 
Han, C., S. M. Wang, M. Kato, S. J. Lee, A. A. Patkar, P. S. Masand and C. U. Pae (2013). 
"Second-generation antipsychotics in the treatment of major depressive disorder: current 
evidence." Expert Rev Neurother 13(7): 851-870. 
Handa, R. J., J. E. Kerr, L. L. DonCarlos, R. F. McGivern and G. Hejna (1996). "Hormonal 
regulation of androgen receptor messenger RNA in the medial preoptic area of the male rat." 
Brain Res Mol Brain Res 39(1-2): 57-67. 
Handa, R. J., K. M. Nunley, S. A. Lorens, J. P. Louie, R. F. McGivern and M. R. Bollnow 
(1994). "Androgen regulation of adrenocorticotropin and corticosterone secretion in the male rat 
following novelty and foot shock stressors." Physiol Behav 55(1): 117-124. 
183 
 
Harbuz, M. S. and S. L. Lightman (1989). "Responses of hypothalamic and pituitary mRNA to 
physical and psychological stress in the rat." J Endocrinol 122(3): 705-711. 
Harris, G. W. (1964). "Sex Hormones, Brain Development and Brain Function." Endocrinology 
75: 627-648. 
Hatfield, T., C. Spanis and J. L. McGaugh (1999). "Response of amygdalar norepinephrine to 
footshock and GABAergic drugs using in vivo microdialysis and HPLC." Brain Res 835(2): 340-
345. 
Hauger, R. L., V. Risbrough, O. Brauns and F. M. Dautzenberg (2006). "Corticotropin releasing 
factor (CRF) receptor signaling in the central nervous system: new molecular targets." CNS 
Neurol Disord Drug Targets 5(4): 453-479. 
Hawes, J. J., D. H. Brunzell, D. Wynick, V. Zachariou and M. R. Picciotto (2005). "GalR1, but 
not GalR2 or GalR3, levels are regulated by galanin signaling in the locus coeruleus through a 
cyclic AMP-dependent mechanism." J Neurochem 93(5): 1168-1176. 
Hawes, J. J. and M. R. Picciotto (2004). "Characterization of GalR1, GalR2, and GalR3 
immunoreactivity in catecholaminergic nuclei of the mouse brain." J Comp Neurol 479(4): 410-
423. 
Hebert, C., A. Habimana, R. Elie and T. A. Reader (2001). "Effects of chronic antidepressant 
treatments on 5-HT and NA transporters in rat brain: an autoradiographic study." Neurochem Int 
38(1): 63-74. 
Heckert, L. L. and M. D. Griswold (1991). "Expression of follicle-stimulating hormone receptor 
mRNA in rat testes and Sertoli cells." Mol Endocrinol 5(5): 670-677. 
Hedger, M. P., S. Khatab, G. Gonzales and D. M. de Kretser (1995). "Acute and short-term 
actions of serotonin administration on the pituitary-testicular axis in the adult rat." Reprod Fertil 
Dev 7(5): 1101-1109. 
Heim, C., T. Mletzko, D. Purselle, D. L. Musselman and C. B. Nemeroff (2008). "The 
dexamethasone/corticotropin-releasing factor test in men with major depression: role of 
childhood trauma." Biol Psychiatry 63(4): 398-405. 
Heim, C., D. J. Newport, R. Bonsall, A. H. Miller and C. B. Nemeroff (2001). "Altered pituitary-
adrenal axis responses to provocative challenge tests in adult survivors of childhood abuse." Am 
J Psychiatry 158(4): 575-581. 
Heisler, L. K., N. Pronchuk, K. Nonogaki, L. Zhou, J. Raber, L. Tung, G. S. Yeo, S. O'Rahilly, 
W. F. Colmers, J. K. Elmquist and L. H. Tecott (2007). "Serotonin activates the hypothalamic-
pituitary-adrenal axis via serotonin 2C receptor stimulation." J Neurosci 27(26): 6956-6964. 
Hennig, J., N. Lange, A. Haag, S. Rohrmann and P. Netter (2000). "Reboxetine in a 
neuroendocrine challenge paradigm: evidence for high cortisol responses in healthy volunteers 
scoring high on subclinical depression." Int J Neuropsychopharmacol 3(3): 193-201. 
Hensen, J., O. Hader, V. Bahr and W. Oelkers (1988). "Effects of incremental infusions of 
arginine vasopressin on adrenocorticotropin and cortisol secretion in man." J Clin Endocrinol 
Metab 66(4): 668-671. 
Hensler, J. G., R. C. Ferry, D. M. Labow, G. B. Kovachich and A. Frazer (1994). "Quantitative 
autoradiography of the serotonin transporter to assess the distribution of serotonergic projections 
from the dorsal raphe nucleus." Synapse 17(1): 1-15. 
Herbert, J., I. M. Goodyer, A. B. Grossman, M. H. Hastings, E. R. de Kloet, S. L. Lightman, S. J. 
Lupien, B. Roozendaal and J. R. Seckl (2006). "Do corticosteroids damage the brain?" J 
Neuroendocrinol 18(6): 393-411. 
184 
 
Herbison, A. E., D. C. Skinner, J. E. Robinson and I. S. King (1996). "Androgen receptor-
immunoreactive cells in ram hypothalamus: distribution and co-localization patterns with 
gonadotropin-releasing hormone, somatostatin and tyrosine hydroxylase." Neuroendocrinology 
63(2): 120-131. 
Herman, J. P., W. E. Cullinan, M. I. Morano, H. Akil and S. J. Watson (1995). "Contribution of 
the ventral subiculum to inhibitory regulation of the hypothalamo-pituitary-adrenocortical axis." 
J Neuroendocrinol 7(6): 475-482. 
Herman, J. P., M. K. Schafer, E. A. Young, R. Thompson, J. Douglass, H. Akil and S. J. Watson 
(1989). "Evidence for hippocampal regulation of neuroendocrine neurons of the hypothalamo-
pituitary-adrenocortical axis." J Neurosci 9(9): 3072-3082. 
Herman, J. P., S. J. Watson, H. M. Chao, H. Coirini and B. S. McEwen (1993). "Diurnal 
Regulation of Glucocorticoid Receptor and Mineralocorticoid Receptor mRNAs in Rat 
Hippocampus." Mol Cell Neurosci 4(2): 181-190. 
Hermus, A. R., G. F. Pieters, A. G. Smals, T. J. Benraad and P. W. Kloppenborg (1984). "Plasma 
adrenocorticotropin, cortisol, and aldosterone responses to corticotropin-releasing factor: 
modulatory effect of basal cortisol levels." J Clin Endocrinol Metab 58(1): 187-191. 
Hesketh, S., D. S. Jessop, S. Hogg and M. S. Harbuz (2005). "Differential actions of acute and 
chronic citalopram on the rodent hypothalamic-pituitary-adrenal axis response to acute restraint 
stress." J Endocrinol 185(3): 373-382. 
Heuser, I. J., U. Gotthardt, U. Schweiger, J. Schmider, C. H. Lammers, M. Dettling and F. 
Holsboer (1994). "Age-associated changes of pituitary-adrenocortical hormone regulation in 
humans: importance of gender." Neurobiol Aging 15(2): 227-231. 
Heydendael, W. and L. Jacobson (2009). "Glucocorticoid status affects antidepressant regulation 
of locus coeruleus tyrosine hydroxylase and dorsal raphe tryptophan hydroxylase gene 
expression." Brain Res 1288: 69-78. 
Heydendael, W. and L. Jacobson (2010). "Widespread hypothalamic-pituitary-adrenocortical 
axis-relevant and mood-relevant effects of chronic fluoxetine treatment on glucocorticoid 
receptor gene expression in mice." Eur J Neurosci 31(5): 892-902. 
Higashino, K., Y. Ago, M. Umehara, Y. Kita, K. Fujita, K. Takuma and T. Matsuda (2014). 
"Effects of acute and chronic administration of venlafaxine and desipramine on extracellular 
monoamine levels in the mouse prefrontal cortex and striatum." Eur J Pharmacol 729: 86-93. 
Hinz, B. and R. Hirschelmann (2000). "Rapid non-genomic feedback effects of glucocorticoids 
on CRF-induced ACTH secretion in rats." Pharm Res 17(10): 1273-1277. 
Hohnloser, J., K. Von Werder and O. A. Muller (1989). "Acute dexamethasone suppression of 
ACTH secretion stimulated by human corticotrophin releasing hormone, AVP and 
hypoglycaemia." Clin Endocrinol (Oxf) 31(2): 175-184. 
Holahan, C. J., S. A. Pahl, R. C. Cronkite, C. K. Holahan, R. J. North and R. H. Moos (2010). 
"Depression and vulnerability to incident physical illness across 10 years." J Affect Disord 
123(1-3): 222-229. 
Holets, V. R., T. Hokfelt, A. Rokaeus, L. Terenius and M. Goldstein (1988). "Locus coeruleus 
neurons in the rat containing neuropeptide Y, tyrosine hydroxylase or galanin and their efferent 
projections to the spinal cord, cerebral cortex and hypothalamus." Neuroscience 24(3): 893-906. 
Holmes, A., M. Heilig, N. M. Rupniak, T. Steckler and G. Griebel (2003). "Neuropeptide 
systems as novel therapeutic targets for depression and anxiety disorders." Trends Pharmacol Sci 
24(11): 580-588. 
185 
 
Holsboer, F. and M. Ising (2008). "Central CRH system in depression and anxiety--evidence 
from clinical studies with CRH1 receptor antagonists." Eur J Pharmacol 583(2-3): 350-357. 
Horder, J., P. Matthews and R. Waldmann (2011). "Placebo, prozac and PLoS: significant 
lessons for psychopharmacology." J Psychopharmacol 25(10): 1277-1288. 
Huber, D., P. Veinante and R. Stoop (2005). "Vasopressin and oxytocin excite distinct neuronal 
populations in the central amygdala." Science 308(5719): 245-248. 
Hughes, Z. A., F. Liu, B. J. Platt, J. M. Dwyer, C. M. Pulicicchio, G. Zhang, L. E. Schechter, S. 
Rosenzweig-Lipson and M. Day (2008). "WAY-200070, a selective agonist of estrogen receptor 
beta as a potential novel anxiolytic/antidepressant agent." Neuropharmacology 54(7): 1136-1142. 
Huntley, G. W., J. C. Vickers, W. Janssen, N. Brose, S. F. Heinemann and J. H. Morrison 
(1994). "Distribution and synaptic localization of immunocytochemically identified NMDA 
receptor subunit proteins in sensory-motor and visual cortices of monkey and human." J 
Neurosci 14(6): 3603-3619. 
Huth, M. and M. Ryan (2004). Logic in computer science : modelling and reasoning about 
systems. Cambridge U.K. ; New York, Cambridge University Press. 
Iacobone, M., N. Albiger, C. Scaroni, F. Mantero, A. Fassina, G. Viel, M. Frego and G. Favia 
(2008). "The role of unilateral adrenalectomy in ACTH-independent macronodular adrenal 
hyperplasia (AIMAH)." World J Surg 32(5): 882-889. 
Ichikawa, J., T. Kuroki, J. Dai and H. Y. Meltzer (1998). "Effect of antipsychotic drugs on 
extracellular serotonin levels in rat medial prefrontal cortex and nucleus accumbens." Eur J 
Pharmacol 351(2): 163-171. 
Invernizzi, R., S. Belli and R. Samanin (1992). "Citalopram's ability to increase the extracellular 
concentrations of serotonin in the dorsal raphe prevents the drug's effect in the frontal cortex." 
Brain Res 584(1-2): 322-324. 
Ising, M. and F. Holsboer (2007). "CRH-sub-1 receptor antagonists for the treatment of 
depression and anxiety." Exp Clin Psychopharmacol 15(6): 519-528. 
Ito, H., Y. Shimogawa, D. Kohagura, T. Moriizumi and K. Yamanouchi (2014). "Inhibitory role 
of the serotonergic system on estrogen receptor alpha expression in the female rat 
hypothalamus." Neurosci Lett 583C: 194-198. 
Itoi, K., T. Suda, F. Tozawa, I. Dobashi, N. Ohmori, Y. Sakai, K. Abe and H. Demura (1994). 
"Microinjection of norepinephrine into the paraventricular nucleus of the hypothalamus 
stimulates corticotropin-releasing factor gene expression in conscious rats." Endocrinology 
135(5): 2177-2182. 
Iversen, L. (2000). "Neurotransmitter transporters: fruitful targets for CNS drug discovery." Mol 
Psychiatry 5(4): 357-362. 
Iversen, L. L. (1971). "Role of transmitter uptake mechanisms in synaptic neurotransmission." 
Br J Pharmacol 41(4): 571-591. 
Iwasaki-Sekino, A., A. Mano-Otagiri, H. Ohata, N. Yamauchi and T. Shibasaki (2009). "Gender 
differences in corticotropin and corticosterone secretion and corticotropin-releasing factor 
mRNA expression in the paraventricular nucleus of the hypothalamus and the central nucleus of 
the amygdala in response to footshock stress or psychological stress in rats." 
Psychoneuroendocrinology 34(2): 226-237. 
Jacobs, B. L. (1986). "Single unit activity of locus coeruleus neurons in behaving animals." Prog 
Neurobiol 27(2): 183-194. 
Jacobs, B. L., W. D. Wise and K. M. Taylor (1974). "Differential behavioral and neurochemical 
effects following lesions of the dorsal or median raphe nuclei in rats." Brain Res 79(3): 353-361. 
186 
 
Jacobson-Pick, S., M. C. Audet, R. J. McQuaid, R. Kalvapalle and H. Anisman (2013). "Social 
agonistic distress in male and female mice: changes of behavior and brain monoamine 
functioning in relation to acute and chronic challenges." PLoS One 8(4): e60133. 
Jacobson, L. and R. Sapolsky (1991). "The role of the hippocampus in feedback regulation of the 
hypothalamic-pituitary-adrenocortical axis." Endocr Rev 12(2): 118-134. 
Jensen, J. B., D. S. Jessop, M. S. Harbuz, A. Mork, C. Sanchez and J. D. Mikkelsen (1999). 
"Acute and long-term treatments with the selective serotonin reuptake inhibitor citalopram 
modulate the HPA axis activity at different levels in male rats." J Neuroendocrinol 11(6): 465-
471. 
Jensen, N. H., R. M. Rodriguiz, M. G. Caron, W. C. Wetsel, R. B. Rothman and B. L. Roth 
(2008). "N-desalkylquetiapine, a potent norepinephrine reuptake inhibitor and partial 5-HT1A 
agonist, as a putative mediator of quetiapine's antidepressant activity." 
Neuropsychopharmacology 33(10): 2303-2312. 
Ji, G., Y. Fu, H. Adwanikar and V. Neugebauer (2013). "Non-pain-related CRF1 activation in 
the amygdala facilitates synaptic transmission and pain responses." Mol Pain 9: 2. 
Jia, X. C., M. Oikawa, M. Bo, T. Tanaka, T. Ny, I. Boime and A. J. Hsueh (1991). "Expression 
of human luteinizing hormone (LH) receptor: interaction with LH and chorionic gonadotropin 
from human but not equine, rat, and ovine species." Mol Endocrinol 5(6): 759-768. 
Jin, Z., A. K. Bhandage, I. Bazov, O. Kononenko, G. Bakalkin, E. R. Korpi and B. Birnir (2014). 
"Expression of specific ionotropic glutamate and GABA-A receptor subunits is decreased in 
central amygdala of alcoholics." Front Cell Neurosci 8: 288. 
Joffe, H. and L. S. Cohen (1998). "Estrogen, serotonin, and mood disturbance: where is the 
therapeutic bridge?" Biol Psychiatry 44(9): 798-811. 
Johnson, E. O., T. C. Kamilaris, G. P. Chrousos and P. W. Gold (1992). "Mechanisms of stress: a 
dynamic overview of hormonal and behavioral homeostasis." Neurosci Biobehav Rev 16(2): 
115-130. 
Johnson, M. D. (1994). "Synaptic glutamate release by postnatal rat serotonergic neurons in 
microculture." Neuron 12(2): 433-442. 
Jordan, D., I. Kermadi, C. Rambaud, R. Gilly, R. Bouvier and N. Kopp (1995). "Regional 
distribution of substance P binding sites in the brainstem of the human newborn." Brain Res 
695(2): 117-124. 
Jutkiewicz, E. M., S. K. Wood, H. Houshyar, L. W. Hsin, K. C. Rice and J. H. Woods (2005). 
"The effects of CRF antagonists, antalarmin, CP154,526, LWH234, and R121919, in the forced 
swim test and on swim-induced increases in adrenocorticotropin in rats." Psychopharmacology 
(Berl) 180(2): 215-223. 
Kageyama, K., K. Hanada, T. Moriyama, T. Nigawara, S. Sakihara and T. Suda (2006). "G 
protein-coupled receptor kinase 2 involvement in desensitization of corticotropin-releasing factor 
(CRF) receptor type 1 by CRF in murine corticotrophs." Endocrinology 147(1): 441-450. 
Kakar, S. S., L. C. Musgrove, D. C. Devor, J. C. Sellers and J. D. Neill (1992). "Cloning, 
sequencing, and expression of human gonadotropin releasing hormone (GnRH) receptor." 
Biochem Biophys Res Commun 189(1): 289-295. 
Kalen, P., G. Skagerberg and O. Lindvall (1988). "Projections from the ventral tegmental area 
and mesencephalic raphe to the dorsal raphe nucleus in the rat. Evidence for a minor 
dopaminergic component." Exp Brain Res 73(1): 69-77. 
Kalinyak, J. E., R. I. Dorin, A. R. Hoffman and A. J. Perlman (1987). "Tissue-specific regulation 
of glucocorticoid receptor mRNA by dexamethasone." J Biol Chem 262(22): 10441-10444. 
187 
 
Karssen, A. M., O. C. Meijer, A. Berry, R. Sanjuan Pinol and E. R. de Kloet (2005). "Low doses 
of dexamethasone can produce a hypocorticosteroid state in the brain." Endocrinology 146(12): 
5587-5595. 
Kasai, M. and H. Yamashita (1988). "Inhibition by cortisol of neurons in the paraventricular 
nucleus of the hypothalamus in adrenalectomized rats; an in vitro study." Neurosci Lett 91(1): 
59-64. 
Katsurabayashi, S., H. Kubota, N. Tokutomi and N. Akaike (2003). "A distinct distribution of 
functional presynaptic 5-HT receptor subtypes on GABAergic nerve terminals projecting to 
single hippocampal CA1 pyramidal neurons." Neuropharmacology 44(8): 1022-1030. 
Katz, N. S., B. P. Guiard, M. El Mansari and P. Blier (2010). "Effects of acute and sustained 
administration of the catecholamine reuptake inhibitor nomifensine on the firing activity of 
monoaminergic neurons." J Psychopharmacol 24(8): 1223-1235. 
Kawa, L., S. Barde, U. P. Arborelius, E. Theodorsson, D. Agoston, M. Risling and T. Hokfelt 
(2016). "Expression of galanin and its receptors are perturbed in a rodent model of mild, blast-
induced traumatic brain injury." Exp Neurol 279: 159-167. 
Kawahara, H., M. Yoshida, H. Yokoo, M. Nishi and M. Tanaka (1993). "Psychological stress 
increases serotonin release in the rat amygdala and prefrontal cortex assessed by in vivo 
microdialysis." Neurosci Lett 162(1-2): 81-84. 
Keck, P. E., Jr. and S. L. McElroy (2003). "Aripiprazole: a partial dopamine D2 receptor agonist 
antipsychotic." Expert Opin Investig Drugs 12(4): 655-662. 
Kelly, C. B. and S. J. Cooper (1997). "Plasma noradrenaline response to electroconvulsive 
therapy in depressive illness." Br J Psychiatry 171: 182-186. 
Kendler, K. S., L. M. Karkowski and C. A. Prescott (1999). "Causal relationship between 
stressful life events and the onset of major depression." Am J Psychiatry 156(6): 837-841. 
Kennedy, S. H., K. R. Evans, S. Kruger, H. S. Mayberg, J. H. Meyer, S. McCann, A. I. 
Arifuzzman, S. Houle and F. J. Vaccarino (2001). "Changes in regional brain glucose 
metabolism measured with positron emission tomography after paroxetine treatment of major 
depression." Am J Psychiatry 158(6): 899-905. 
Kessler, R. C., P. Berglund, O. Demler, R. Jin, D. Koretz, K. R. Merikangas, A. J. Rush, E. E. 
Walters, P. S. Wang and R. National Comorbidity Survey (2003). "The epidemiology of major 
depressive disorder: results from the National Comorbidity Survey Replication (NCS-R)." 
JAMA 289(23): 3095-3105. 
Khan, A., A. E. Brodhead, R. L. Kolts and W. A. Brown (2005). "Severity of depressive 
symptoms and response to antidepressants and placebo in antidepressant trials." J Psychiatr Res 
39(2): 145-150. 
Khoshbouei, H., M. Cecchi, S. Dove, M. Javors and D. A. Morilak (2002). "Behavioral reactivity 
to stress: amplification of stress-induced noradrenergic activation elicits a galanin-mediated 
anxiolytic effect in central amygdala." Pharmacol Biochem Behav 71(3): 407-417. 
Kirby, L. G., E. Freeman-Daniels, J. C. Lemos, J. D. Nunan, C. Lamy, A. Akanwa and S. G. 
Beck (2008). "Corticotropin-releasing factor increases GABA synaptic activity and induces 
inward current in 5-hydroxytryptamine dorsal raphe neurons." J Neurosci 28(48): 12927-12937. 
Kirsch, I. (2009). "Antidepressants and the placebo response." Epidemiol Psichiatr Soc 18(4): 
318-322. 
Kirsch, I. (2010). The Emperor's New Drugs: Exploding the Antidepressant Myth. New York, 
New York, Basic Books. 
188 
 
Kirsch, I. (2017). "Response Expectancy and the Response to Antidepressant Medication." 
EBioMedicine 25: 13. 
Kirsch, I., B. J. Deacon, T. B. Huedo-Medina, A. Scoboria, T. J. Moore and B. T. Johnson 
(2008). "Initial severity and antidepressant benefits: a meta-analysis of data submitted to the 
Food and Drug Administration." PLoS Med 5(2): e45. 
Kirsch, P., C. Esslinger, Q. Chen, D. Mier, S. Lis, S. Siddhanti, H. Gruppe, V. S. Mattay, B. 
Gallhofer and A. Meyer-Lindenberg (2005). "Oxytocin modulates neural circuitry for social 
cognition and fear in humans." J Neurosci 25(49): 11489-11493. 
Kitaichi, Y., T. Inoue, S. Nakagawa, T. Izumi and T. Koyama (2006). "Effect of co-
administration of subchronic lithium pretreatment and acute MAO inhibitors on extracellular 
monoamine levels and the expression of contextual conditioned fear in rats." Eur J Pharmacol 
532(3): 236-245. 
Kitay, J. I. (1961). "Sex differences in adrenal cortical secretion in the rat." Endocrinology 68: 
818-824. 
Kitay, J. I., D. A. Holub and J. W. Jailer (1959). "Inhibition of pituitary ACTH release; an extra-
adrenal action of exogenous ACTH." Endocrinology 64(4): 475-482. 
Kizildere, S., T. Gluck, B. Zietz, J. Scholmerich and R. H. Straub (2003). "During a 
corticotropin-releasing hormone test in healthy subjects, administration of a beta-adrenergic 
antagonist induced secretion of cortisol and dehydroepiandrosterone sulfate and inhibited 
secretion of ACTH." Eur J Endocrinol 148(1): 45-53. 
Klein, D. C., R. Smoot, J. L. Weller, S. Higa, S. P. Markey, G. J. Creed and D. M. Jacobowitz 
(1983). "Lesions of the paraventricular nucleus area of the hypothalamus disrupt the 
suprachiasmatic leads to spinal cord circuit in the melatonin rhythm generating system." Brain 
Res Bull 10(5): 647-652. 
Knight, P. G. and C. Glister (2001). "Potential local regulatory functions of inhibins, activins and 
follistatin in the ovary." Reproduction 121(4): 503-512. 
Koch, S., K. W. Perry, D. L. Nelson, R. G. Conway, P. G. Threlkeld and F. P. Bymaster (2002). 
"R-fluoxetine increases extracellular DA, NE, as well as 5-HT in rat prefrontal cortex and 
hypothalamus: an in vivo microdialysis and receptor binding study." Neuropsychopharmacology 
27(6): 949-959. 
Koenig, A. M. and M. E. Thase (2009). "First-line pharmacotherapies for depression - what is 
the best choice?" Pol Arch Med Wewn 119(7-8): 478-486. 
Kornstein, S. G., D. Li, Y. Mao, S. Larsson, H. F. Andersen and G. I. Papakostas (2009). 
"Escitalopram versus SNRI antidepressants in the acute treatment of major depressive disorder: 
integrative analysis of four double-blind, randomized clinical trials." CNS Spectr 14(6): 326-333. 
Korte, S. M., J. M. Koolhaas, J. C. Wingfield and B. S. McEwen (2005). "The Darwinian 
concept of stress: benefits of allostasis and costs of allostatic load and the trade-offs in health and 
disease." Neurosci Biobehav Rev 29(1): 3-38. 
Kovacs, K. J. and G. B. Makara (1988). "Corticosterone and dexamethasone act at different brain 
sites to inhibit adrenalectomy-induced adrenocorticotropin hypersecretion." Brain Res 474(2): 
205-210. 
Kovacs, K. J. and E. Mezey (1987). "Dexamethasone inhibits corticotropin-releasing factor gene 
expression in the rat paraventricular nucleus." Neuroendocrinology 46(4): 365-368. 
Koyama, S., N. Matsumoto, N. Murakami, C. Kubo, J. Nabekura and N. Akaike (2002). "Role of 
presynaptic 5-HT1A and 5-HT3 receptors in modulation of synaptic GABA transmission in 
dissociated rat basolateral amygdala neurons." Life Sci 72(4-5): 375-387. 
189 
 
Koyama, S., M. Mori, S. Kanamaru, T. Sazawa, A. Miyazaki, H. Terai and S. Hirose (2014). 
"Obesity attenuates D2 autoreceptor-mediated inhibition of putative ventral tegmental area 
dopaminergic neurons." Physiol Rep 2(5): e12004. 
Kreft, M. and R. Zorec (2008). "Anterior pituitary cells excited by GABA." J Physiol 586(13): 
3023-3024. 
Krege, S., M. Goepel, H. Sperling and M. C. Michel (2000). "Affinity of trazodone for human 
penile alpha1- andalpha2-adrenoceptors." BJU Int 85(7): 959-961. 
Kreiss, D. S. and I. Lucki (1995). "Effects of acute and repeated administration of antidepressant 
drugs on extracellular levels of 5-hydroxytryptamine measured in vivo." J Pharmacol Exp Ther 
274(2): 866-876. 
Kroeze, W. K., S. J. Hufeisen, B. A. Popadak, S. M. Renock, S. Steinberg, P. Ernsberger, K. 
Jayathilake, H. Y. Meltzer and B. L. Roth (2003). "H1-histamine receptor affinity predicts short-
term weight gain for typical and atypical antipsychotic drugs." Neuropsychopharmacology 28(3): 
519-526. 
Kudo, T., K. Konno, M. Uchigashima, Y. Yanagawa, I. Sora, M. Minami and M. Watanabe 
(2014). "GABAergic neurons in the ventral tegmental area receive dual GABA/enkephalin-
mediated inhibitory inputs from the bed nucleus of the stria terminalis." Eur J Neurosci 39(11): 
1796-1809. 
Kugaya, A., N. M. Seneca, P. J. Snyder, S. A. Williams, R. T. Malison, R. M. Baldwin, J. P. 
Seibyl and R. B. Innis (2003). "Changes in human in vivo serotonin and dopamine transporter 
availabilities during chronic antidepressant administration." Neuropsychopharmacology 28(2): 
413-420. 
Kuhn, C. and R. Francis (1997). "Gender difference in cocaine-induced HPA axis activation." 
Neuropsychopharmacology 16(6): 399-407. 
Kunugi, H., I. Ida, T. Owashi, M. Kimura, Y. Inoue, S. Nakagawa, T. Yabana, T. Urushibara, R. 
Kanai, M. Aihara, N. Yuuki, T. Otsubo, A. Oshima, K. Kudo, T. Inoue, Y. Kitaichi, O. 
Shirakawa, K. Isogawa, H. Nagayama, K. Kamijima, S. Nanko, S. Kanba, T. Higuchi and M. 
Mikuni (2006). "Assessment of the dexamethasone/CRH test as a state-dependent marker for 
hypothalamic-pituitary-adrenal (HPA) axis abnormalities in major depressive episode: a 
Multicenter Study." Neuropsychopharmacology 31(1): 212-220. 
Kuraishi, Y., N. Hirota, Y. Sato, S. Kaneko, M. Satoh and H. Takagi (1985). "Noradrenergic 
inhibition of the release of substance P from the primary afferents in the rabbit spinal dorsal 
horn." Brain Res 359(1-2): 177-182. 
Kuteeva, E., T. Wardi, L. Lundstrom, U. Sollenberg, U. Langel, T. Hokfelt and S. O. Ogren 
(2008). "Differential role of galanin receptors in the regulation of depression-like behavior and 
monoamine/stress-related genes at the cell body level." Neuropsychopharmacology 33(11): 
2573-2585. 
Ladd, C. O., R. L. Huot, K. V. Thrivikraman, C. B. Nemeroff and P. M. Plotsky (2004). "Long-
term adaptations in glucocorticoid receptor and mineralocorticoid receptor mRNA and negative 
feedback on the hypothalamo-pituitary-adrenal axis following neonatal maternal separation." 
Biol Psychiatry 55(4): 367-375. 
Lanfumey, L., R. Mongeau, C. Cohen-Salmon and M. Hamon (2008). "Corticosteroid-serotonin 
interactions in the neurobiological mechanisms of stress-related disorders." Neurosci Biobehav 
Rev 32(6): 1174-1184. 
Lanzenberger, R., P. Baldinger, A. Hahn, J. Ungersboeck, M. Mitterhauser, D. Winkler, Z. 
Micskei, P. Stein, G. Karanikas, W. Wadsak, S. Kasper and R. Frey (2013). "Global decrease of 
190 
 
serotonin-1A receptor binding after electroconvulsive therapy in major depression measured by 
PET." Mol Psychiatry 18(1): 93-100. 
Larm, J. A., P. J. Shen and A. L. Gundlach (2003). "Differential galanin receptor-1 and galanin 
expression by 5-HT neurons in dorsal raphe nucleus of rat and mouse: evidence for species-
dependent modulation of serotonin transmission." Eur J Neurosci 17(3): 481-493. 
Larsson, M., L. E. Edqvist, L. Ekman and S. Persson (1979). "Plasma cortisol in the horse, 
diurnal rhythm and effects of exogenous ACTH." Acta Vet Scand 20(1): 16-24. 
Lau, T., S. Horschitz, S. Berger, D. Bartsch and P. Schloss (2008). "Antidepressant-induced 
internalization of the serotonin transporter in serotonergic neurons." FASEB J 22(6): 1702-1714. 
Lee, J. H., J. I. Woo and H. Y. Meltzer (2001). "Effects of clozapine on sleep measures and 
sleep-associated changes in growth hormone and cortisol in patients with schizophrenia." 
Psychiatry Res 103(2-3): 157-166. 
Legros, J. J., P. Chiodera, V. Geenen, S. Smitz and R. von Frenckell (1984). "Dose-response 
relationship between plasma oxytocin and cortisol and adrenocorticotropin concentrations during 
oxytocin infusion in normal men." J Clin Endocrinol Metab 58(1): 105-109. 
Lejeune, F., A. Gobert and M. J. Millan (2002). "The selective neurokinin (NK)(1) antagonist, 
GR205,171, stereospecifically enhances mesocortical dopaminergic transmission in the rat: a 
combined dialysis and electrophysiological study." Brain Res 935(1-2): 134-139. 
Lesch, K. P., C. S. Aulakh, B. L. Wolozin, T. J. Tolliver, J. L. Hill and D. L. Murphy (1993). 
"Regional brain expression of serotonin transporter mRNA and its regulation by reuptake 
inhibiting antidepressants." Brain Res Mol Brain Res 17(1-2): 31-35. 
Leuchter, A. F., I. M. Lesser, M. H. Trivedi, A. J. Rush, D. W. Morris, D. Warden, M. Fava, S. 
R. Wisniewski, J. F. Luther, M. Perales, B. N. Gaynes and J. W. Stewart (2008). "An open pilot 
study of the combination of escitalopram and bupropion-SR for outpatients with major 
depressive disorder." J Psychiatr Pract 14(5): 271-280. 
Levesque, D., J. Diaz, C. Pilon, M. P. Martres, B. Giros, E. Souil, D. Schott, J. L. Morgat, J. C. 
Schwartz and P. Sokoloff (1992). "Identification, characterization, and localization of the 
dopamine D3 receptor in rat brain using 7-[3H]hydroxy-N,N-di-n-propyl-2-aminotetralin." Proc 
Natl Acad Sci U S A 89(17): 8155-8159. 
Li, H., T. Li, G. Li and J. Luo (2014). "Citalopram and escitalopram in the treatment of major 
depressive disorder: A pooled analysis of 3 clinical trials." Ann Clin Psychiatry 26(4): 281-287. 
Li, S. X., K. W. Perry and D. T. Wong (2002). "Influence of fluoxetine on the ability of 
bupropion to modulate extracellular dopamine and norepinephrine concentrations in three 
mesocorticolimbic areas of rats." Neuropharmacology 42(2): 181-190. 
Li, X. M., K. W. Perry, D. T. Wong and F. P. Bymaster (1998). "Olanzapine increases in vivo 
dopamine and norepinephrine release in rat prefrontal cortex, nucleus accumbens and striatum." 
Psychopharmacology (Berl) 136(2): 153-161. 
Li, Z., J. Ichikawa, J. Dai and H. Y. Meltzer (2004). "Aripiprazole, a novel antipsychotic drug, 
preferentially increases dopamine release in the prefrontal cortex and hippocampus in rat brain." 
Eur J Pharmacol 493(1-3): 75-83. 
Lindefors, N., S. Barati and W. T. O'Connor (1997). "Differential effects of single and repeated 
ketamine administration on dopamine, serotonin and GABA transmission in rat medial prefrontal 
cortex." Brain Res 759(2): 205-212. 
Lindley, S. E., X. She and A. F. Schatzberg (2005). "Monoamine oxidase and catechol-o-
methyltransferase enzyme activity and gene expression in response to sustained glucocorticoids." 
Psychoneuroendocrinology 30(8): 785-790. 
191 
 
Liu, X. and H. K. Gershenfeld (2001). "Genetic differences in the tail-suspension test and its 
relationship to imipramine response among 11 inbred strains of mice." Biol Psychiatry 49(7): 
575-581. 
Liu, Z., J. Zhou, Y. Li, F. Hu, Y. Lu, M. Ma, Q. Feng, J. E. Zhang, D. Wang, J. Zeng, J. Bao, J. 
Y. Kim, Z. F. Chen, S. El Mestikawy and M. Luo (2014). "Dorsal raphe neurons signal reward 
through 5-HT and glutamate." Neuron 81(6): 1360-1374. 
Loose, D. S., Y. S. Do, T. L. Chen and D. Feldman (1980). "Demonstration of glucocorticoid 
receptors in the adrenal cortex: evidence for a direct dexamethasone suppressive effect on the rat 
adrenal gland." Endocrinology 107(1): 137-146. 
Losel, R. and M. Wehling (2003). "Nongenomic actions of steroid hormones." Nat Rev Mol Cell 
Biol 4(1): 46-56. 
Lu, X., A. M. Barr, J. W. Kinney, P. Sanna, B. Conti, M. M. Behrens and T. Bartfai (2005). "A 
role for galanin in antidepressant actions with a focus on the dorsal raphe nucleus." Proc Natl 
Acad Sci U S A 102(3): 874-879. 
Lucki, I., A. Dalvi and A. J. Mayorga (2001). "Sensitivity to the effects of pharmacologically 
selective antidepressants in different strains of mice." Psychopharmacology (Berl) 155(3): 315-
322. 
Luenberger, D. (1979). Introduction to Dynamic Systems: Theory, Models, and Applications, 
John Wiley & Sons. 
Lynch, H. J., J. P. Eng and R. J. Wurtman (1973). "Control of pineal indole biosynthesis by 
changes in sympathetic tone caused by factors other than environmental lighting." Proc Natl 
Acad Sci U S A 70(6): 1704-1707. 
MacQueen, G., P. Santaguida, H. Keshavarz, N. Jaworska, M. Levine, J. Beyene and P. Raina 
(2017). "Systematic Review of Clinical Practice Guidelines for Failed Antidepressant Treatment 
Response in Major Depressive Disorder, Dysthymia, and Subthreshold Depression in Adults." 
Can J Psychiatry 62(1): 11-23. 
Madhavan, A., E. Argilli, A. Bonci and J. L. Whistler (2013). "Loss of D2 dopamine receptor 
function modulates cocaine-induced glutamatergic synaptic potentiation in the ventral tegmental 
area." J Neurosci 33(30): 12329-12336. 
Maes, M., H. Y. Meltzer, P. D'Hondt, P. Cosyns and P. Blockx (1995). "Effects of serotonin 
precursors on the negative feedback effects of glucocorticoids on hypothalamic-pituitary-adrenal 
axis function in depression." Psychoneuroendocrinology 20(2): 149-167. 
Makara, G. B. (1992). "The relative importance of hypothalamic neurons containing 
corticotropin-releasing factor or vasopressin in the regulation of adrenocorticotropic hormone 
secretion." Ciba Found Symp 168: 43-51; discussion 51-43. 
Makara, G. B. and J. Haller (2001). "Non-genomic effects of glucocorticoids in the neural 
system. Evidence, mechanisms and implications." Prog Neurobiol 65(4): 367-390. 
Makara, G. B., E. Stark, M. Karteszi, M. Palkovits and G. Rappay (1981). "Effects of 
paraventricular lesions on stimulated ACTH release and CRF in stalk-median eminence of the 
rat." Am J Physiol 240(4): E441-446. 
Makino, S., M. A. Smith and P. W. Gold (2002). "Regulatory role of glucocorticoids and 
glucocorticoid receptor mRNA levels on tyrosine hydroxylase gene expression in the locus 
coeruleus during repeated immobilization stress." Brain Res 943(2): 216-223. 
Malagie, I., A. C. Trillat, E. Douvier, M. C. Anmella, M. C. Dessalles, C. Jacquot and A. M. 
Gardier (1996). "Regional differences in the effect of the combined treatment of WAY 100635 
192 
 
and fluoxetine: an in vivo microdialysis study." Naunyn Schmiedebergs Arch Pharmacol 354(6): 
785-790. 
Malagie, I., A. C. Trillat, C. Jacquot and A. M. Gardier (1995). "Effects of acute fluoxetine on 
extracellular serotonin levels in the raphe: an in vivo microdialysis study." Eur J Pharmacol 
286(2): 213-217. 
Malhi, G. S., G. B. Parker, G. Gladstone, K. Wilhelm and P. B. Mitchell (2002). "Recognizing 
the anxious face of depression." J Nerv Ment Dis 190(6): 366-373. 
Malhi, G. S., G. B. Parker and J. Greenwood (2005). "Structural and functional models of 
depression: from sub-types to substrates." Acta Psychiatr Scand 111(2): 94-105. 
Mann, D. R., C. Free, C. Nelson, C. Scott and D. C. Collins (1987). "Mutually independent 
effects of adrenocorticotropin on luteinizing hormone and testosterone secretion." Endocrinology 
120(4): 1542-1550. 
Manoli, I., H. Le, S. Alesci, K. K. McFann, Y. A. Su, T. Kino, G. P. Chrousos and M. R. 
Blackman (2005). "Monoamine oxidase-A is a major target gene for glucocorticoids in human 
skeletal muscle cells." FASEB J 19(10): 1359-1361. 
Marcus, R. N., R. D. McQuade, W. H. Carson, D. Hennicken, M. Fava, J. S. Simon, M. H. 
Trivedi, M. E. Thase and R. M. Berman (2008). "The efficacy and safety of aripiprazole as 
adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, 
placebo-controlled study." J Clin Psychopharmacol 28(2): 156-165. 
Marder, E. and A. L. Taylor (2011). "Multiple models to capture the variability in biological 
neurons and networks." Nat Neurosci 14(2): 133-138. 
Maron, E., T. Eller, V. Vasar and D. J. Nutt (2009). "Effects of bupropion augmentation in 
escitalopram-resistant patients with major depressive disorder: an open-label, naturalistic study." 
J Clin Psychiatry 70(7): 1054-1056. 
Martin-Ruiz, R., L. Ugedo, M. A. Honrubia, G. Mengod and F. Artigas (2001). "Control of 
serotonergic neurons in rat brain by dopaminergic receptors outside the dorsal raphe nucleus." J 
Neurochem 77(3): 762-775. 
Martin, L. J., C. D. Blackstone, A. I. Levey, R. L. Huganir and D. L. Price (1993). "Cellular 
localizations of AMPA glutamate receptors within the basal forebrain magnocellular complex of 
rat and monkey." J Neurosci 13(5): 2249-2263. 
Masana, M., A. Bortolozzi and F. Artigas (2011). "Selective enhancement of mesocortical 
dopaminergic transmission by noradrenergic drugs: therapeutic opportunities in schizophrenia." 
Int J Neuropsychopharmacol 14(1): 53-68. 
Matheson, G. K., A. Knowles, D. Guthrie, D. Gage, D. Weinzapfel and J. Blackbourne (1997). 
"Actions of serotonergic agents on hypothalamic-pituitary-adrenal axis activity in the rat." Gen 
Pharmacol 29(5): 823-828. 
Mathews, J., K. S. Garcia, M. A. Mintun and Y. I. Sheline (2006). "Antidepressant efficacy of 
olanzapine as monotherapy in major depressive disorder, without psychosis: a pilot study." 
Psychiatry Res 146(2): 149-155. 
Matsuda, T., Y. Nakano, T. Kanda, H. Iwata and A. Baba (1991). "Gonadectomy changes the 
pituitary-adrenocortical response in mice to 5-HT1A receptor agonists." Eur J Pharmacol 200(2-
3): 299-304. 
Matthews, J. D., C. Siefert, C. Dording, J. W. Denninger, L. Park, A. O. van Nieuwenhuizen, K. 
Sklarsky, S. Hilliker, C. Homberger, K. Rooney and M. Fava (2009). "An open study of 
aripiprazole and escitalopram for psychotic major depressive disorder." J Clin Psychopharmacol 
29(1): 73-76. 
193 
 
Matthews, L. C., A. A. Berry, D. J. Morgan, T. M. Poolman, K. Bauer, F. Kramer, D. G. Spiller, 
R. V. Richardson, K. E. Chapman, S. N. Farrow, M. R. Norman, A. J. Williamson, A. D. 
Whetton, S. S. Taylor, J. P. Tuckermann, M. R. White and D. W. Ray (2015). "Glucocorticoid 
receptor regulates accurate chromosome segregation and is associated with malignancy." Proc 
Natl Acad Sci U S A 112(17): 5479-5484. 
Maubach, K. A., K. Martin, G. Chicchi, T. Harrison, A. Wheeldon, C. J. Swain, M. J. 
Cumberbatch, N. M. Rupniak and G. R. Seabrook (2002). "Chronic substance P (NK1) receptor 
antagonist and conventional antidepressant treatment increases burst firing of monoamine 
neurones in the locus coeruleus." Neuroscience 109(3): 609-617. 
Mayberg, H. S., S. K. Brannan, J. L. Tekell, J. A. Silva, R. K. Mahurin, S. McGinnis and P. A. 
Jerabek (2000). "Regional metabolic effects of fluoxetine in major depression: serial changes and 
relationship to clinical response." Biol Psychiatry 48(8): 830-843. 
Mayberg, H. S., M. Liotti, S. K. Brannan, S. McGinnis, R. K. Mahurin, P. A. Jerabek, J. A. 
Silva, J. L. Tekell, C. C. Martin, J. L. Lancaster and P. T. Fox (1999). "Reciprocal limbic-
cortical function and negative mood: converging PET findings in depression and normal 
sadness." Am J Psychiatry 156(5): 675-682. 
Mazarati, A. M., R. A. Baldwin, S. Shinmei and R. Sankar (2005). "In vivo interaction between 
serotonin and galanin receptors types 1 and 2 in the dorsal raphe: implication for limbic 
seizures." J Neurochem 95(5): 1495-1503. 
Melander, T., T. Hokfelt and A. Rokaeus (1986). "Distribution of Galanin-Like 
Immunoreactivity in the Rat Central-Nervous-System." Journal of Comparative Neurology 
248(4): 475-517. 
Melander, T., T. Hokfelt, A. Rokaeus, A. C. Cuello, W. H. Oertel, A. Verhofstad and M. 
Goldstein (1986). "Coexistence of galanin-like immunoreactivity with catecholamines, 5-
hydroxytryptamine, GABA and neuropeptides in the rat CNS." J Neurosci 6(12): 3640-3654. 
Melis, M. R., T. Melis, C. Cocco, S. Succu, F. Sanna, G. Pillolla, A. Boi, G. L. Ferri and A. 
Argiolas (2007). "Oxytocin injected into the ventral tegmental area induces penile erection and 
increases extracellular dopamine in the nucleus accumbens and paraventricular nucleus of the 
hypothalamus of male rats." Eur J Neurosci 26(4): 1026-1035. 
Meltzer, H. Y. (1994). "An overview of the mechanism of action of clozapine." J Clin Psychiatry 
55 Suppl B: 47-52. 
Merchenthaler, I. (1984). "Corticotropin releasing factor (CRF)-like immunoreactivity in the rat 
central nervous system. Extrahypothalamic distribution." Peptides 5 Suppl 1: 53-69. 
Mierau, J., F. J. Schneider, H. A. Ensinger, C. L. Chio, M. E. Lajiness and R. M. Huff (1995). 
"Pramipexole binding and activation of cloned and expressed dopamine D2, D3 and D4 
receptors." Eur J Pharmacol 290(1): 29-36. 
Miller, K. K., R. H. Perlis, G. I. Papakostas, D. Mischoulon, D. V. Losifescu, D. J. Brick and M. 
Fava (2009). "Low-dose transdermal testosterone augmentation therapy improves depression 
severity in women." CNS Spectr 14(12): 688-694. 
Miller, R., M. Wankerl, T. Stalder, C. Kirschbaum and N. Alexander (2013). "The serotonin 
transporter gene-linked polymorphic region (5-HTTLPR) and cortisol stress reactivity: a meta-
analysis." Mol Psychiatry 18(9): 1018-1024. 
Miner, L. H., H. P. Jedema, F. W. Moore, R. D. Blakely, A. A. Grace and S. R. Sesack (2006). 
"Chronic stress increases the plasmalemmal distribution of the norepinephrine transporter and 
the coexpression of tyrosine hydroxylase in norepinephrine axons in the prefrontal cortex." J 
Neurosci 26(5): 1571-1578. 
194 
 
Mitsushima, D., K. Yamada, K. Takase, T. Funabashi and F. Kimura (2006). "Sex differences in 
the basolateral amygdala: the extracellular levels of serotonin and dopamine, and their responses 
to restraint stress in rats." Eur J Neurosci 24(11): 3245-3254. 
Moncek, F., R. Duncko and D. Jezova (2003). "Repeated citalopram treatment but not stress 
exposure attenuates hypothalamic-pituitary-adrenocortical axis response to acute citalopram 
injection." Life Sci 72(12): 1353-1365. 
Moncrieff, J. (2007). "Are antidepressants as effective as claimed? No, they are not effective at 
all." Can J Psychiatry 52(2): 96-97; discussion 102. 
Moncrieff, J. and I. Kirsch (2015). "Empirically derived criteria cast doubt on the clinical 
significance of antidepressant-placebo differences." Contemp Clin Trials 43: 60-62. 
Monin, J. F. o. and M. G. Hinchey (2003). Understanding formal methods. London ; New York, 
Springer. 
Monti, J. M. (2010). "The role of dorsal raphe nucleus serotonergic and non-serotonergic 
neurons, and of their receptors, in regulating waking and rapid eye movement (REM) sleep." 
Sleep Med Rev 14(5): 319-327. 
Moore, C. R. and D. Price (1932). "Gonad hormone functions, and the reciprocal influence 
between gonads and hypophysis with its bearing on the problem of sex hormone antagonism." 
American Journal of Anatomy 50(1): 13-71. 
Morimoto, M., N. Morita, H. Ozawa, K. Yokoyama and M. Kawata (1996). "Distribution of 
glucocorticoid receptor immunoreactivity and mRNA in the rat brain: an immunohistochemical 
and in situ hybridization study." Neurosci Res 26(3): 235-269. 
Mountjoy, K. G., L. S. Robbins, M. T. Mortrud and R. D. Cone (1992). "The cloning of a family 
of genes that encode the melanocortin receptors." Science 257(5074): 1248-1251. 
Mozer, M. a. S., P (1989). Skeletonization: A Technique for Trimming the Fat from a Network 
via Relevance Assessment, University of Colorado, Boulder. 
Mueller-Eckhardt, G., G. Giers, A. Salama, D. J. Schendel, G. Fass and C. Mueller-Eckhardt 
(1988). "Major histocompatibility complex markers in patients with nomifensine-induced 
immune hemolytic anemia." Vox Sang 54(1): 59-61. 
Murphy, S. E., R. Norbury, U. O'Sullivan, P. J. Cowen and C. J. Harmer (2009). "Effect of a 
single dose of citalopram on amygdala response to emotional faces." Br J Psychiatry 194(6): 
535-540. 
Naudon, L., M. El Yacoubi, J. M. Vaugeois, I. Leroux-Nicollet and J. Costentin (2002). "A 
chronic treatment with fluoxetine decreases 5-HT(1A) receptors labeling in mice selected as a 
genetic model of helplessness." Brain Res 936(1-2): 68-75. 
Nemeroff, C. B. and M. J. Owens (2004). "Pharmacologic differences among the SSRIs: focus 
on monoamine transporters and the HPA axis." CNS Spectr 9(6 Suppl 4): 23-31. 
Nemeroff, C. B. and W. W. Vale (2005). "The neurobiology of depression: inroads to treatment 
and new drug discovery." J Clin Psychiatry 66 Suppl 7: 5-13. 
Nestler, E. J., M. Barrot, R. J. DiLeone, A. J. Eisch, S. J. Gold and L. M. Monteggia (2002). 
"Neurobiology of depression." Neuron 34(1): 13-25. 
Neumeister, A., M. Willeit, N. Praschak-Rieder, S. Asenbaum, J. Stastny, E. Hilger, W. Pirker, 
A. Konstantinidis and S. Kasper (2001). "Dopamine transporter availability in symptomatic 
depressed patients with seasonal affective disorder and healthy controls." Psychol Med 31(8): 
1467-1473. 
Newman-Tancredi, A., C. Chaput, L. Verriele and M. J. Millan (1996). "Clozapine is a partial 
agonist at cloned, human serotonin 5-HT1A receptors." Neuropharmacology 35(1): 119-121. 
195 
 
Newman-Tancredi, A., D. Cussac, Y. Quentric, M. Touzard, L. Verriele, N. Carpentier and M. J. 
Millan (2002). "Differential actions of antiparkinson agents at multiple classes of 
monoaminergic receptor. III. Agonist and antagonist properties at serotonin, 5-HT(1) and 5-
HT(2), receptor subtypes." J Pharmacol Exp Ther 303(2): 815-822. 
Nierenberg, A. A., L. A. Adler, E. Peselow, G. Zornberg and M. Rosenthal (1994). "Trazodone 
for antidepressant-associated insomnia." Am J Psychiatry 151(7): 1069-1072. 
Nikodemova, M., C. R. Diehl and G. Aguilera (2002). "Multiple sites of control of type-1 
corticotropin releasing hormone receptor levels in the pituitary." Arch Physiol Biochem 110(1-
2): 123-128. 
Nishitani, N., K. Nagayasu, N. Asaoka, M. Yamashiro, H. Shirakawa, T. Nakagawa and S. 
Kaneko (2014). "Raphe AMPA receptors and nicotinic acetylcholine receptors mediate 
ketamine-induced serotonin release in the rat prefrontal cortex." Int J Neuropsychopharmacol 
17(8): 1321-1326. 
Nocjar, C., B. L. Roth and E. A. Pehek (2002). "Localization of 5-HT(2A) receptors on 
dopamine cells in subnuclei of the midbrain A10 cell group." Neuroscience 111(1): 163-176. 
Nord, M., S. J. Finnema, C. Halldin and L. Farde (2013). "Effect of a single dose of escitalopram 
on serotonin concentration in the non-human and human primate brain." Int J 
Neuropsychopharmacol 16(7): 1577-1586. 
O'Reardon, J. P., M. P. Chopra, A. Bergan, R. Gallop, R. J. DeRubeis and P. Crits-Christoph 
(2004). "Response to tryptophan depletion in major depression treated with either cognitive 
therapy or selective serotonin reuptake inhibitor antidepressants." Biol Psychiatry 55(9): 957-
959. 
Odagaki, Y., R. Toyoshima and T. Yamauchi (2005). "Trazodone and its active metabolite m-
chlorophenylpiperazine as partial agonists at 5-HT1A receptors assessed by [35S]GTPgammaS 
binding." J Psychopharmacol 19(3): 235-241. 
Onur, O. A., H. Walter, T. E. Schlaepfer, A. K. Rehme, C. Schmidt, C. Keysers, W. Maier and 
R. Hurlemann (2009). "Noradrenergic enhancement of amygdala responses to fear." Soc Cogn 
Affect Neurosci 4(2): 119-126. 
Oosterhof, C. A., M. El Mansari and P. Blier (2015). "Asenapine alters the activity of 
monoaminergic systems following its subacute and long-term administration: An in vivo 
electrophysiological characterization." Eur Neuropsychopharmacol. 
Orengo, C. A., L. Fullerton and M. E. Kunik (2005). "Safety and efficacy of testosterone gel 1% 
augmentation in depressed men with partial response to antidepressant therapy." J Geriatr 
Psychiatry Neurol 18(1): 20-24. 
Ornstein, K., H. Milon, A. McRae-Degueurce, C. Alvarez, B. Berger and H. P. Wurzner (1987). 
"Biochemical and radioautographic evidence for dopaminergic afferents of the locus coeruleus 
originating in the ventral tegmental area." J Neural Transm 70(3-4): 183-191. 
Ostrowski, N. L., S. J. Lolait, D. J. Bradley, A. M. O'Carroll, M. J. Brownstein and W. S. Young, 
3rd (1992). "Distribution of V1a and V2 vasopressin receptor messenger ribonucleic acids in rat 
liver, kidney, pituitary and brain." Endocrinology 131(1): 533-535. 
Ou, X. M., K. Chen and J. C. Shih (2006). "Glucocorticoid and androgen activation of 
monoamine oxidase A is regulated differently by R1 and Sp1." J Biol Chem 281(30): 21512-
21525. 
Ozawa, H., T. Ito, I. Ochiai and M. Kawata (1999). "Cellular localization and distribution of 
glucocorticoid receptor immunoreactivity and the expression of glucocorticoid receptor 
196 
 
messenger RNA in rat pituitary gland. A combined double immunohistochemistry study and in 
situ hybridization histochemical analysis." Cell Tissue Res 295(2): 207-214. 
Page, M. E. and E. D. Abercrombie (1997). "An analysis of the effects of acute and chronic 
fluoxetine on extracellular norepinephrine in the rat hippocampus during stress." 
Neuropsychopharmacology 16(6): 419-425. 
Page, M. E., K. Brown and I. Lucki (2003). "Simultaneous analyses of the neurochemical and 
behavioral effects of the norepinephrine reuptake inhibitor reboxetine in a rat model of 
antidepressant action." Psychopharmacology (Berl) 165(2): 194-201. 
Page, M. E. and I. Lucki (2002). "Effects of acute and chronic reboxetine treatment on stress-
induced monoamine efflux in the rat frontal cortex." Neuropsychopharmacology 27(2): 237-247. 
Pan, L. and F. Gilbert (1992). "Activation of 5-HT1A receptor subtype in the paraventricular 
nuclei of the hypothalamus induces CRH and ACTH release in the rat." Neuroendocrinology 
56(6): 797-802. 
Papadimitriou, A. and K. N. Priftis (2009). "Regulation of the hypothalamic-pituitary-adrenal 
axis." Neuroimmunomodulation 16(5): 265-271. 
Papakostas, G. I., S. A. Montgomery, M. E. Thase, J. R. Katz, A. Krishen and V. L. Tucker 
(2007). "Comparing the rapidity of response during treatment of major depressive disorder with 
bupropion and the SSRIs: a pooled survival analysis of 7 double-blind, randomized clinical 
trials." J Clin Psychiatry 68(12): 1907-1912. 
Papakostas, G. I., J. C. Nelson, S. Kasper and H. J. Moller (2008). "A meta-analysis of clinical 
trials comparing reboxetine, a norepinephrine reuptake inhibitor, with selective serotonin 
reuptake inhibitors for the treatment of major depressive disorder." Eur Neuropsychopharmacol 
18(2): 122-127. 
Pariante, C. M. and S. L. Lightman (2008). "The HPA axis in major depression: classical 
theories and new developments." Trends Neurosci 31(9): 464-468. 
Pariante, C. M. and A. H. Miller (2001). "Glucocorticoid receptors in major depression: 
relevance to pathophysiology and treatment." Biol Psychiatry 49(5): 391-404. 
Parker, G. (2000). "Classifying depression: should paradigms lost be regained?" Am J Psychiatry 
157(8): 1195-1203. 
Parker, G., K. Roy, D. Hadzi-Pavlovic and F. Pedic (1992). "Psychotic (delusional) depression: a 
meta-analysis of physical treatments." J Affect Disord 24(1): 17-24. 
Parker, K. J., C. L. Buckmaster, A. F. Schatzberg and D. M. Lyons (2005). "Intranasal oxytocin 
administration attenuates the ACTH stress response in monkeys." Psychoneuroendocrinology 
30(9): 924-929. 
Patchev, V. K., S. Hayashi, C. Orikasa and O. F. Almeida (1995). "Implications of estrogen-
dependent brain organization for gender differences in hypothalamo-pituitary-adrenal 
regulation." FASEB J 9(5): 419-423. 
Patel, P. D., J. F. Lopez, D. M. Lyons, S. Burke, M. Wallace and A. F. Schatzberg (2000). 
"Glucocorticoid and mineralocorticoid receptor mRNA expression in squirrel monkey brain." J 
Psychiatr Res 34(6): 383-392. 
Patisaul, H. B., K. T. Burke, R. E. Hinkle, H. B. Adewale and D. Shea (2009). "Systemic 
administration of diarylpropionitrile (DPN) or phytoestrogens does not affect anxiety-related 
behaviors in gonadally intact male rats." Horm Behav 55(2): 319-328. 
Pazzagli, M., M. G. Giovannini and G. Pepeu (1999). "Trazodone increases extracellular 
serotonin levels in the frontal cortex of rats." Eur J Pharmacol 383(3): 249-257. 
197 
 
Pehrson, A. L. and C. Sanchez (2014). "Serotonergic modulation of glutamate neurotransmission 
as a strategy for treating depression and cognitive dysfunction." CNS Spectr 19(2): 121-133. 
Perez, S., M. Basile, D. C. Mash and E. J. Mufson (2002). "Galanin receptor over-expression 
within the amygdala in early Alzheimer's disease: an in vitro autoradiographic analysis." J Chem 
Neuroanat 24(2): 109-116. 
Perra, S., M. A. Clements, B. E. Bernier and H. Morikawa (2011). "In vivo ethanol experience 
increases D(2) autoinhibition in the ventral tegmental area." Neuropsychopharmacology 36(5): 
993-1002. 
Perry, B. D. and D. C. U'Prichard (1981). "[3H]rauwolscine (alpha-yohimbine): a specific 
antagonist radioligand for brain alpha 2-adrenergic receptors." Eur J Pharmacol 76(4): 461-464. 
Perry, D., R. Sperling, R. Katz, D. Berry, D. Dilts, D. Hanna, S. Salloway, J. Q. Trojanowski, C. 
Bountra, M. Krams, J. Luthman, S. Potkin, V. Gribkoff, R. Temple, Y. Wang, M. C. Carrillo, D. 
Stephenson, H. Snyder, E. Liu, T. Ware, J. McKew, F. O. Fields, L. J. Bain and C. Bens (2015). 
"Building a roadmap for developing combination therapies for Alzheimer's disease." Expert Rev 
Neurother 15(3): 327-333. 
Pessia, M., Z. G. Jiang, R. A. North and S. W. Johnson (1994). "Actions of 5-hydroxytryptamine 
on ventral tegmental area neurons of the rat in vitro." Brain Res 654(2): 324-330. 
Petit-Demouliere, B., F. Chenu and M. Bourin (2005). "Forced swimming test in mice: a review 
of antidepressant activity." Psychopharmacology (Berl) 177(3): 245-255. 
Petraglia, F., P. Florio, A. Gallinelli, A. A. De Micheroux, A. Ferrari, D. De Vita, L. Aguzzoli, 
A. D. Genazzani and C. Di Carlo (1994). "Secretion and putative role of activin and CRF in 
human parturition." Ann N Y Acad Sci 734: 380-386. 
Petralia, R. S. and R. J. Wenthold (1992). "Light and electron immunocytochemical localization 
of AMPA-selective glutamate receptors in the rat brain." J Comp Neurol 318(3): 329-354. 
Pfaus, J. G., A. Jakob, S. P. Kleopoulos, R. B. Gibbs and D. W. Pfaff (1994). "Sexual stimulation 
induces Fos immunoreactivity within GnRH neurons of the female rat preoptic area: interaction 
with steroid hormones." Neuroendocrinology 60(3): 283-290. 
Piacentini, M. F., R. Clinckers, R. Meeusen, S. Sarre, G. Ebinger and Y. Michotte (2003). 
"Effect of bupropion on hippocampal neurotransmitters and on peripheral hormonal 
concentrations in the rat." J Appl Physiol (1985) 95(2): 652-656. 
Pieribone, V. A., Z. Q. Xu, X. Zhang, S. Grillner, T. Bartfai and T. Hokfelt (1995). "Galanin 
induces a hyperpolarization of norepinephrine-containing locus coeruleus neurons in the 
brainstem slice." Neuroscience 64(4): 861-874. 
Pietrzak, R. H., J. D. Gallezot, Y. S. Ding, S. Henry, M. N. Potenza, S. M. Southwick, J. H. 
Krystal, R. E. Carson and A. Neumeister (2013). "Association of posttraumatic stress disorder 
with reduced in vivo norepinephrine transporter availability in the locus coeruleus." JAMA 
Psychiatry 70(11): 1199-1205. 
Pilowsky, L. S., G. F. Busatto, M. Taylor, D. C. Costa, T. Sharma, T. Sigmundsson, P. J. Ell, V. 
Nohria and R. W. Kerwin (1996). "Dopamine D2 receptor occupancy in vivo by the novel 
atypical antipsychotic olanzapine--a 123I IBZM single photon emission tomography (SPET) 
study." Psychopharmacology (Berl) 124(1-2): 148-153. 
Pineda, F. J. (1987). "Generalization of back-propagation to recurrent neural networks." Phys 
Rev Lett 59(19): 2229-2232. 
Pirot, S., R. Godbout, J. Mantz, J. P. Tassin, J. Glowinski and A. M. Thierry (1992). "Inhibitory 
effects of ventral tegmental area stimulation on the activity of prefrontal cortical neurons: 
198 
 
evidence for the involvement of both dopaminergic and GABAergic components." Neuroscience 
49(4): 857-865. 
Plenge, P. and E. T. Mellerup (2003). "Pindolol and the acceleration of the antidepressant 
response." J Affect Disord 75(3): 285-289. 
Primus, R. J., A. Thurkauf, J. Xu, E. Yevich, S. McInerney, K. Shaw, J. F. Tallman and D. W. 
Gallagher (1997). "II. Localization and characterization of dopamine D4 binding sites in rat and 
human brain by use of the novel, D4 receptor-selective ligand [3H]NGD 94-1." J Pharmacol Exp 
Ther 282(2): 1020-1027. 
Prisco, S., S. Pagannone and E. Esposito (1994). "Serotonin-dopamine interaction in the rat 
ventral tegmental area: an electrophysiological study in vivo." J Pharmacol Exp Ther 271(1): 83-
90. 
Puig, M. V., F. Artigas and P. Celada (2005). "Modulation of the activity of pyramidal neurons 
in rat prefrontal cortex by raphe stimulation in vivo: involvement of serotonin and GABA." 
Cereb Cortex 15(1): 1-14. 
Puig, M. V., N. Santana, P. Celada, G. Mengod and F. Artigas (2004). "In vivo excitation of 
GABA interneurons in the medial prefrontal cortex through 5-HT3 receptors." Cereb Cortex 
14(12): 1365-1375. 
Puig, M. V., A. Watakabe, M. Ushimaru, T. Yamamori and Y. Kawaguchi (2010). "Serotonin 
modulates fast-spiking interneuron and synchronous activity in the rat prefrontal cortex through 
5-HT1A and 5-HT2A receptors." J Neurosci 30(6): 2211-2222. 
Qin, S., E. J. Hermans, H. J. van Marle, J. Luo and G. Fernandez (2009). "Acute psychological 
stress reduces working memory-related activity in the dorsolateral prefrontal cortex." Biol 
Psychiatry 66(1): 25-32. 
Rainbow, T. C., B. Parsons and B. B. Wolfe (1984). "Quantitative autoradiography of beta 1- 
and beta 2-adrenergic receptors in rat brain." Proc Natl Acad Sci U S A 81(5): 1585-1589. 
Rainer, Q., H. T. Nguyen, G. Quesseveur, A. M. Gardier, D. J. David and B. P. Guiard (2012). 
"Functional status of somatodendritic serotonin 1A autoreceptor after long-term treatment with 
fluoxetine in a mouse model of anxiety/depression based on repeated corticosterone 
administration." Mol Pharmacol 81(2): 106-112. 
Ratka, A., W. Sutanto, M. Bloemers and E. R. de Kloet (1989). "On the role of brain 
mineralocorticoid (type I) and glucocorticoid (type II) receptors in neuroendocrine regulation." 
Neuroendocrinology 50(2): 117-123. 
Razoux, F., R. Garcia and I. Lena (2007). "Ketamine, at a dose that disrupts motor behavior and 
latent inhibition, enhances prefrontal cortex synaptic efficacy and glutamate release in the 
nucleus accumbens." Neuropsychopharmacology 32(3): 719-727. 
Remick, R. A. and C. Froese (1990). "Monoamine oxidase inhibitors: clinical review." Can Fam 
Physician 36: 1151-1155. 
Renoldi, G. and R. W. Invernizzi (2006). "Blockade of tachykinin NK1 receptors attenuates 
stress-induced rise of extracellular noradrenaline and dopamine in the rat and gerbil medial 
prefrontal cortex." J Neurosci Res 84(5): 961-968. 
Reul, J. M., A. Gesing, S. Droste, I. S. Stec, A. Weber, C. Bachmann, A. Bilang-Bleuel, F. 
Holsboer and A. C. Linthorst (2000). "The brain mineralocorticoid receptor: greedy for ligand, 
mysterious in function." Eur J Pharmacol 405(1-3): 235-249. 
Reyes, B. A., D. A. Bangasser, R. J. Valentino and E. J. Van Bockstaele (2014). "Using high 
resolution imaging to determine trafficking of corticotropin-releasing factor receptors in 
noradrenergic neurons of the rat locus coeruleus." Life Sci 112(1-2): 2-9. 
199 
 
Reyes, B. A., R. J. Valentino and E. J. Van Bockstaele (2008). "Stress-induced intracellular 
trafficking of corticotropin-releasing factor receptors in rat locus coeruleus neurons." 
Endocrinology 149(1): 122-130. 
Reyes, B. A., R. J. Valentino, G. Xu and E. J. Van Bockstaele (2005). "Hypothalamic projections 
to locus coeruleus neurons in rat brain." Eur J Neurosci 22(1): 93-106. 
Reynolds, A. R., M. A. Saunders, H. W. Brewton, S. R. Winchester, I. S. Elgumati and M. A. 
Prendergast (2015). "Acute oral administration of the novel, competitive and selective 
glucocorticoid receptor antagonist ORG 34517 reduces the severity of ethanol withdrawal and 
related hypothalamic-pituitary-adrenal axis activation." Drug Alcohol Depend 154: 100-104. 
Reznikov, L. R., C. A. Grillo, G. G. Piroli, R. K. Pasumarthi, L. P. Reagan and J. Fadel (2007). 
"Acute stress-mediated increases in extracellular glutamate levels in the rat amygdala: 
differential effects of antidepressant treatment." Eur J Neurosci 25(10): 3109-3114. 
Rigby, M., R. O'Donnell and N. M. Rupniak (2005). "Species differences in tachykinin receptor 
distribution: further evidence that the substance P (NK1) receptor predominates in human brain." 
J Comp Neurol 490(4): 335-353. 
Ripoll, N., D. J. David, E. Dailly, M. Hascoet and M. Bourin (2003). "Antidepressant-like effects 
in various mice strains in the tail suspension test." Behav Brain Res 143(2): 193-200. 
Rivier, C. (1993). "Female rats release more corticosterone than males in response to alcohol: 
influence of circulating sex steroids and possible consequences for blood alcohol levels." 
Alcohol Clin Exp Res 17(4): 854-859. 
Roberto, M., P. Schweitzer, S. G. Madamba, D. G. Stouffer, L. H. Parsons and G. R. Siggins 
(2004). "Acute and chronic ethanol alter glutamatergic transmission in rat central amygdala: an 
in vitro and in vivo analysis." J Neurosci 24(7): 1594-1603. 
Robichaud, M. and G. Debonnel (2005). "Oestrogen and testosterone modulate the firing activity 
of dorsal raphe nucleus serotonergic neurones in both male and female rats." J Neuroendocrinol 
17(3): 179-185. 
Rocha, B. A., R. Fleischer, J. M. Schaeffer, S. P. Rohrer and G. J. Hickey (2005). "17 Beta-
estradiol-induced antidepressant-like effect in the forced swim test is absent in estrogen receptor-
beta knockout (BERKO) mice." Psychopharmacology (Berl) 179(3): 637-643. 
Rodaros, D., D. A. Caruana, S. Amir and J. Stewart (2007). "Corticotropin-releasing factor 
projections from limbic forebrain and paraventricular nucleus of the hypothalamus to the region 
of the ventral tegmental area." Neuroscience 150(1): 8-13. 
Rogers, J., L. J. Martin, A. G. Comuzzie, J. J. Mann, S. B. Manuck, M. Leland and J. R. Kaplan 
(2004). "Genetics of monoamine metabolites in baboons: overlapping sets of genes influence 
levels of 5-hydroxyindolacetic acid, 3-hydroxy-4-methoxyphenylglycol, and homovanillic acid." 
Biol Psychiatry 55(7): 739-744. 
Roland, B. L. and P. E. Sawchenko (1993). "Local origins of some GABAergic projections to the 
paraventricular and supraoptic nuclei of the hypothalamus in the rat." J Comp Neurol 332(1): 
123-143. 
Romero, L., P. Celada, R. Martin-Ruiz, L. Diaz-Mataix, M. Mourelle, J. Delgadillo, I. Hervas 
and F. Artigas (2003). "Modulation of serotonergic function in rat brain by VN2222, a serotonin 
reuptake inhibitor and 5-HT1A receptor agonist." Neuropsychopharmacology 28(3): 445-456. 
Rood, B. D. and S. G. Beck (2014). "Vasopressin indirectly excites dorsal raphe serotonin 
neurons through activation of the vasopressin1A receptor." Neuroscience 260: 205-216. 
200 
 
Root, D. H., C. A. Mejias-Aponte, S. Zhang, H. L. Wang, A. F. Hoffman, C. R. Lupica and M. 
Morales (2014). "Single rodent mesohabenular axons release glutamate and GABA." Nat 
Neurosci 17(11): 1543-1551. 
Rosario, E. R., L. Chang, F. Z. Stanczyk and C. J. Pike (2004). "Age-related testosterone 
depletion and the development of Alzheimer disease." JAMA 292(12): 1431-1432. 
Roseboom, P. H. and N. H. Kalin (2000). "Neuropharmacology of venlafaxine." Depress 
Anxiety 12 Suppl 1: 20-29. 
Rosenkranz, J. A. and A. A. Grace (2002). "Cellular mechanisms of infralimbic and prelimbic 
prefrontal cortical inhibition and dopaminergic modulation of basolateral amygdala neurons in 
vivo." J Neurosci 22(1): 324-337. 
Ross, R. A. and U. B. Kaiser (2016). "Reproductive endocrinology: The emotional cost of 
contraception." Nat Rev Endocrinol 13(1): 7-9. 
Roth, B. D., J "PDSP Ki Database." University of North Carolina at Chapel Hill and the United 
States National Institute of Mental Health(Psychoactive Drug Screening Program). 
Rothman, R. B., A. Mele, A. A. Reid, H. C. Akunne, N. Greig, A. Thurkauf, B. R. de Costa, K. 
C. Rice and A. Pert (1991). "GBR12909 antagonizes the ability of cocaine to elevate 
extracellular levels of dopamine." Pharmacol Biochem Behav 40(2): 387-397. 
Rovin, M. L., K. A. Boss-Williams, R. S. Alisch, J. C. Ritchie, D. Weinshenker, C. H. West and 
J. M. Weiss (2012). "Influence of chronic administration of antidepressant drugs on mRNA for 
galanin, galanin receptors, and tyrosine hydroxylase in catecholaminergic and serotonergic cell-
body regions in rat brain." Neuropeptides 46(2): 81-91. 
Rowbotham, M. C., R. T. Jones, N. L. Benowitz and P. Jacob, 3rd (1984). "Trazodone-oral 
cocaine interactions." Arch Gen Psychiatry 41(9): 895-899. 
Royland, J. E., L. J. Weber and M. Fitzpatrick (1994). "Testes size and testosterone levels in a 
model for weightlessness." Life Sci 54(8): 545-554. 
Rozeske, R. R., A. K. Evans, M. G. Frank, L. R. Watkins, C. A. Lowry and S. F. Maier (2011). 
"Uncontrollable, but not controllable, stress desensitizes 5-HT1A receptors in the dorsal raphe 
nucleus." J Neurosci 31(40): 14107-14115. 
Rubinow, D. R., P. J. Schmidt and C. A. Roca (1998). "Estrogen-serotonin interactions: 
implications for affective regulation." Biol Psychiatry 44(9): 839-850. 
Rubio, G., L. San, F. Lopez-Munoz and C. Alamo (2004). "Reboxetine adjunct for partial or 
nonresponders to antidepressant treatment." J Affect Disord 81(1): 67-72. 
Rudnick, G., S. S. Steiner-Mordoch, H. Fishkes, Y. Stern-Bach and S. Schuldiner (1990). 
"Energetics of reserpine binding and occlusion by the chromaffin granule biogenic amine 
transporter." Biochemistry 29(3): 603-608. 
Ruhe, H. G., S. J. Khoenkhoen, K. W. Ottenhof, M. W. Koeter, R. J. Mocking and A. H. Schene 
(2015). "Longitudinal effects of the SSRI paroxetine on salivary cortisol in Major Depressive 
Disorder." Psychoneuroendocrinology 52: 261-271. 
Rumelhart, D. (1988). Learning and Generalization. Proc. IEEE Int. Conf. Neural Networks, San 
Diego. 
Rush, A. J., D. E. Giles, M. A. Schlesser, P. J. Orsulak, C. R. Parker, Jr., J. E. Weissenburger, G. 
T. Crowley, M. Khatami and N. Vasavada (1996). "The dexamethasone suppression test in 
patients with mood disorders." J Clin Psychiatry 57(10): 470-484. 
Rush, A. J., M. H. Trivedi, S. R. Wisniewski, A. A. Nierenberg, J. W. Stewart, D. Warden, G. 
Niederehe, M. E. Thase, P. W. Lavori, B. D. Lebowitz, P. J. McGrath, J. F. Rosenbaum, H. A. 
Sackeim, D. J. Kupfer, J. Luther and M. Fava (2006). "Acute and longer-term outcomes in 
201 
 
depressed outpatients requiring one or several treatment steps: a STAR*D report." Am J 
Psychiatry 163(11): 1905-1917. 
Russo-Neustadt, A. A., H. Alejandre, C. Garcia, A. S. Ivy and M. J. Chen (2004). "Hippocampal 
brain-derived neurotrophic factor expression following treatment with reboxetine, citalopram, 
and physical exercise." Neuropsychopharmacology 29(12): 2189-2199. 
Rutter, J. J., C. Gundlah and S. B. Auerbach (1994). "Increase in extracellular serotonin 
produced by uptake inhibitors is enhanced after chronic treatment with fluoxetine." Neurosci Lett 
171(1-2): 183-186. 
Saez, J. M., A. M. Morera, F. Haour and D. Evain (1977). "Effects of in vivo administration of 
dexamethasone, corticotropin and human chorionic gonadotropin on steroidogenesis and protein 
and DNA synthesis of testicular interstitial cells in prepuberal rats." Endocrinology 101(4): 
1256-1263. 
Sakanaka, M., T. Shibasaki and K. Lederis (1986). "Distribution and efferent projections of 
corticotropin-releasing factor-like immunoreactivity in the rat amygdaloid complex." Brain Res 
382(2): 213-238. 
Samanin, R., S. Bernasconi and S. Garattini (1975). "The effect of nomifensine on the depletion 
of brain serotonin and catecholamines induced respectively by fenfluramine and 6-
hydroxydopamine in rats." Eur J Pharmacol 34(2): 377-380. 
Samuels, E. R. and E. Szabadi (2008). "Functional neuroanatomy of the noradrenergic locus 
coeruleus: its roles in the regulation of arousal and autonomic function part II: physiological and 
pharmacological manipulations and pathological alterations of locus coeruleus activity in 
humans." Curr Neuropharmacol 6(3): 254-285. 
Sanchez, C., P. B. Bergqvist, L. T. Brennum, S. Gupta, S. Hogg, A. Larsen and O. Wiborg 
(2003). "Escitalopram, the S-(+)-enantiomer of citalopram, is a selective serotonin reuptake 
inhibitor with potent effects in animal models predictive of antidepressant and anxiolytic 
activities." Psychopharmacology (Berl) 167(4): 353-362. 
Santana, N., A. Bortolozzi, J. Serrats, G. Mengod and F. Artigas (2004). "Expression of 
serotonin1A and serotonin2A receptors in pyramidal and GABAergic neurons of the rat 
prefrontal cortex." Cereb Cortex 14(10): 1100-1109. 
Santarelli, L., G. Gobbi, P. C. Debs, E. T. Sibille, P. Blier, R. Hen and M. J. Heath (2001). 
"Genetic and pharmacological disruption of neurokinin 1 receptor function decreases anxiety-
related behaviors and increases serotonergic function." Proc Natl Acad Sci U S A 98(4): 1912-
1917. 
Sapolsky, R. M. (2000). "Stress hormones: good and bad." Neurobiol Dis 7(5): 540-542. 
Schacht, U. and W. Heptner (1974). "Effect of nomifensine (HOE 984), a new antidepressant, on 
uptake of noradrenaline and serotonin and on release of noradrenaline in rat brain 
synaptosomes." Biochem Pharmacol 23(24): 3413-3422. 
Scherman, D. and J. P. Henry (1984). "Reserpine binding to bovine chromaffin granule 
membranes. Characterization and comparison with dihydrotetrabenazine binding." Mol 
Pharmacol 25(1): 113-122. 
Schildkraut, J. J. (1965). "The catecholamine hypothesis of affective disorders: a review of 
supporting evidence." Am J Psychiatry 122(5): 509-522. 
Schlosser, R., H. Wetzel, H. Dorr, W. Rossbach, C. Hiemke and O. Benkert (2000). "Effects of 
subchronic paroxetine administration on night-time endocrinological profiles in healthy male 
volunteers." Psychoneuroendocrinology 25(4): 377-388. 
202 
 
Schott, D. A., J. Nicolai, J. E. de Vries, I. M. Keularts, M. E. Rubio-Gozalbo and W. J. Gerver 
(2010). "Disorder in the serotonergic system due to tryptophan hydroxylation impairment: a 
cause of hypothalamic syndrome?" Horm Res Paediatr 73(1): 68-73. 
Schotte, A., P. F. Janssen, A. A. Megens and J. E. Leysen (1993). "Occupancy of central 
neurotransmitter receptors by risperidone, clozapine and haloperidol, measured ex vivo by 
quantitative autoradiography." Brain Res 631(2): 191-202. 
Schule, C., T. Baghai, S. Schmidbauer, M. Bidlingmaier, C. J. Strasburger and G. Laakmann 
(2004). "Reboxetine acutely stimulates cortisol, ACTH, growth hormone and prolactin secretion 
in healthy male subjects." Psychoneuroendocrinology 29(2): 185-200. 
Schulz, D. J., J. M. Goaillard and E. E. Marder (2007). "Quantitative expression profiling of 
identified neurons reveals cell-specific constraints on highly variable levels of gene expression." 
Proc Natl Acad Sci U S A 104(32): 13187-13191. 
Schwall, R. H., E. Szonyi, A. J. Mason and K. Nikolics (1988). "Activin stimulates secretion of 
follicle-stimulating hormone from pituitary cells desensitized to gonadotropin-releasing 
hormone." Biochem Biophys Res Commun 151(3): 1099-1104. 
Schwartz, N. B. and S. N. Justo (1977). "Acute changes in serum gonadotrophins and steroids 
following orchidectomy in the rat: role of the adrenal gland." Endocrinology 100(6): 1550-1556. 
Scuvee-Moreau, J. J. and A. E. Dresse (1979). "Effect of various antidepressant drugs on the 
spontaneous firing rate of locus coeruleus and dorsal raphe neurons of the rat." Eur J Pharmacol 
57(2-3): 219-225. 
Seale, J. V., S. A. Wood, H. C. Atkinson, E. Bate, S. L. Lightman, C. D. Ingram, D. S. Jessop 
and M. S. Harbuz (2004). "Gonadectomy reverses the sexually diergic patterns of circadian and 
stress-induced hypothalamic-pituitary-adrenal axis activity in male and female rats." J 
Neuroendocrinol 16(6): 516-524. 
Seckl, J. R. and G. Fink (1992). "Antidepressants increase glucocorticoid and mineralocorticoid 
receptor mRNA expression in rat hippocampus in vivo." Neuroendocrinology 55(6): 621-626. 
Segee, B. a. C., M (1991). "Fault Tolerance of Pruned Multilayer Networks." 
Seiden, G. and A. Brodish (1971). "Physiological evidence for 'short-loop' feedback effects of 
ACTH on hypothalamic CRF." Neuroendocrinology 8(3): 154-164. 
Sepede, G., M. Corbo, F. Fiori and G. Martinotti (2012). "Reboxetine in clinical practice: a 
review." Clin Ter 163(4): e255-262. 
Sernia, C. and W. G. Thomas (1994). "A novel inhibitory role for glucocorticoids in the 
secretion of angiotensinogen by C6 glioma cells." J Neurochem 62(4): 1296-1301. 
Seutin, V., P. Verbanck, L. Massotte and A. Dresse (1989). "Galanin decreases the activity of 
locus coeruleus neurons in vitro." Eur J Pharmacol 164(2): 373-376. 
Sevcik, J., E. P. Finta and P. Illes (1993). "Galanin receptors inhibit the spontaneous firing of 
locus coeruleus neurones and interact with mu-opioid receptors." Eur J Pharmacol 230(2): 223-
230. 
Shacham, S., D. Harris, H. Ben-Shlomo, I. Cohen, D. Bonfil, F. Przedecki, H. Lewy, I. E. 
Ashkenazi, R. Seger and Z. Naor (2001). "Mechanism of GnRH receptor signaling on 
gonadotropin release and gene expression in pituitary gonadotrophs." Vitam Horm 63: 63-90. 
Shahid, M., G. B. Walker, S. H. Zorn and E. H. Wong (2009). "Asenapine: a novel 
psychopharmacologic agent with a unique human receptor signature." J Psychopharmacol 23(1): 
65-73. 
Shang, T., L. Zhao, H. Li and Z. H. Liu (2003). "[Concentration of follistatin in maternal serum 
at term and its expression in placenta]." Zhonghua Fu Chan Ke Za Zhi 38(7): 390-393. 
203 
 
Shapiro, D. A., S. Renock, E. Arrington, L. A. Chiodo, L. X. Liu, D. R. Sibley, B. L. Roth and R. 
Mailman (2003). "Aripiprazole, a novel atypical antipsychotic drug with a unique and robust 
pharmacology." Neuropsychopharmacology 28(8): 1400-1411. 
Shea, A., C. Walsh, H. Macmillan and M. Steiner (2005). "Child maltreatment and HPA axis 
dysregulation: relationship to major depressive disorder and post traumatic stress disorder in 
females." Psychoneuroendocrinology 30(2): 162-178. 
Shikanai, H., T. Yoshida, K. Konno, M. Yamasaki, T. Izumi, Y. Ohmura, M. Watanabe and M. 
Yoshioka (2012). "Distinct neurochemical and functional properties of GAD67-containing 5-HT 
neurons in the rat dorsal raphe nucleus." J Neurosci 32(41): 14415-14426. 
Shrier, M., J. E. Diaz and N. Tsarouhas (2000). "Cardiotoxicity associated with bupropion 
overdose." Ann Emerg Med 35(1): 100. 
Shughrue, P. J., M. V. Lane and I. Merchenthaler (1997). "Comparative distribution of estrogen 
receptor-alpha and -beta mRNA in the rat central nervous system." J Comp Neurol 388(4): 507-
525. 
Siegelmann, H. T. and E. D. Sontag (1991). "Turing Computability with Neural Nets." Applied 
Mathematics Letters 4(6): 77-80. 
Sietsma, J. and R. J. F. Dow (1991). "Creating Artificial Neural Networks That Generalize." 
Neural Networks 4(1): 67-79. 
Sillaber, I., M. Panhuysen, M. S. Henniger, F. Ohl, C. Kuhne, B. Putz, T. Pohl, J. M. Deussing, 
M. Paez-Pereda and F. Holsboer (2008). "Profiling of behavioral changes and hippocampal gene 
expression in mice chronically treated with the SSRI paroxetine." Psychopharmacology (Berl) 
200(4): 557-572. 
Silverstone, P. H., M. D. Lalies and A. L. Hudson (2012). "Quetiapine and Buspirone Both 
Elevate Cortical Levels of Noradrenaline and Dopamine In vivo, but Do Not have Synergistic 
Effects." Front Psychiatry 3: 82. 
Singewald, N., G. G. Chicchi, C. C. Thurner, K. L. Tsao, M. Spetea, H. Schmidhammer, H. K. 
Sreepathi, F. Ferraguti, G. M. Singewald and K. Ebner (2008). "Modulation of basal and stress-
induced amygdaloid substance P release by the potent and selective NK1 receptor antagonist L-
822429." J Neurochem 106(6): 2476-2488. 
Singh, S. (2000). "Chemistry, design, and structure-activity relationship of cocaine antagonists." 
Chem Rev 100(3): 925-1024. 
Soiza-Reilly, M. and K. G. Commons (2011). "Glutamatergic drive of the dorsal raphe nucleus." 
J Chem Neuroanat 41(4): 247-255. 
Solomon, M. B. and J. P. Herman (2009). "Sex differences in psychopathology: of gonads, 
adrenals and mental illness." Physiol Behav 97(2): 250-258. 
Souery, D., G. I. Papakostas and M. H. Trivedi (2006). "Treatment-resistant depression." J Clin 
Psychiatry 67 Suppl 6: 16-22. 
Souto, M., J. M. Monti and H. Altier (1979). "Effects of clozapine on the activity of central 
dopaminergic and noradrenergic neurons." Pharmacol Biochem Behav 10(1): 5-9. 
Spannuth, B. M., M. W. Hale, A. K. Evans, J. L. Lukkes, S. Campeau and C. A. Lowry (2011). 
"Investigation of a central nucleus of the amygdala/dorsal raphe nucleus serotonergic circuit 
implicated in fear-potentiated startle." Neuroscience 179: 104-119. 
Sparta, D. R., F. W. Hopf, S. L. Gibb, S. L. Cho, G. D. Stuber, R. O. Messing, D. Ron and A. 
Bonci (2013). "Binge ethanol-drinking potentiates corticotropin releasing factor R1 receptor 
activity in the ventral tegmental area." Alcohol Clin Exp Res 37(10): 1680-1687. 
204 
 
Spiga, F., L. R. Harrison, S. A. Wood, H. C. Atkinson, C. P. MacSweeney, F. Thomson, M. 
Craighead, M. Grassie and S. L. Lightman (2007). "Effect of the glucocorticoid receptor 
antagonist Org 34850 on basal and stress-induced corticosterone secretion." J Neuroendocrinol 
19(11): 891-900. 
Spiga, F., L. R. Harrison, S. A. Wood, C. P. MacSweeney, F. J. Thomson, M. Craighead, M. 
Grassie and S. L. Lightman (2008). "Effect of the glucocorticoid receptor antagonist Org 34850 
on fast and delayed feedback of corticosterone release." J Endocrinol 196(2): 323-330. 
Spiker, D. G., J. C. Weiss, R. S. Dealy, S. J. Griffin, I. Hanin, J. F. Neil, J. M. Perel, A. J. Rossi 
and P. H. Soloff (1985). "The pharmacological treatment of delusional depression." Am J 
Psychiatry 142(4): 430-436. 
Sprouse, J. S., L. S. Reynolds, J. P. Braselton, H. Rollema and S. H. Zorn (1999). "Comparison 
of the novel antipsychotic ziprasidone with clozapine and olanzapine: inhibition of dorsal raphe 
cell firing and the role of 5-HT1A receptor activation." Neuropsychopharmacology 21(5): 622-
631. 
Stahl, S. M. (2009). "Mechanism of action of trazodone: a multifunctional drug." CNS Spectr 
14(10): 536-546. 
Stahl, S. M. (2009). Stahls Essential Psychopharmacology Prescribers Guide. New York, NY, 
Cambridge University Press. 
Stahl, S. M., J. F. Pradko, B. R. Haight, J. G. Modell, C. B. Rockett and S. Learned-Coughlin 
(2004). "A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and 
Dopamine Reuptake Inhibitor." Prim Care Companion J Clin Psychiatry 6(4): 159-166. 
Stanford, I. M. and M. G. Lacey (1996). "Differential actions of serotonin, mediated by 5-HT1B 
and 5-HT2C receptors, on GABA-mediated synaptic input to rat substantia nigra pars reticulata 
neurons in vitro." J Neurosci 16(23): 7566-7573. 
Stein, L. a. O., S. (1960). Accelerated Recovery from Reserpine Depression by Monoamine 
Oxidase Inhibitors, Nature. 
Steiner, M., E. Dunn and L. Born (2003). "Hormones and mood: from menarche to menopause 
and beyond." J Affect Disord 74(1): 67-83. 
Stene, M., N. Panagiotis, M. L. Tuck, J. R. Sowers, D. Mayes and G. Berg (1980). "Plasma 
norepinephrine levels are influenced by sodium intake, glucocorticoid administration, and 
circadian changes in normal man." J Clin Endocrinol Metab 51(6): 1340-1345. 
Stewart, J. W., P. J. McGrath, C. Blondeau, D. A. Deliyannides, D. Hellerstein, S. Norris, J. 
Amat, D. J. Pilowsky, P. Tessier, L. Laberge, D. O'Shea, Y. Chen, A. Withers, R. Bergeron and 
P. Blier (2014). "Combination antidepressant therapy for major depressive disorder: speed and 
probability of remission." J Psychiatr Res 52: 7-14. 
Stone, J. M., C. Dietrich, R. Edden, M. A. Mehta, S. De Simoni, L. J. Reed, J. H. Krystal, D. 
Nutt and G. J. Barker (2012). "Ketamine effects on brain GABA and glutamate levels with 1H-
MRS: relationship to ketamine-induced psychopathology." Mol Psychiatry 17(7): 664-665. 
Stout, S. C., M. J. Owens and C. B. Nemeroff (2002). "Regulation of corticotropin-releasing 
factor neuronal systems and hypothalamic-pituitary-adrenal axis activity by stress and chronic 
antidepressant treatment." J Pharmacol Exp Ther 300(3): 1085-1092. 
Strine, T. W., A. H. Mokdad, L. S. Balluz, O. Gonzalez, R. Crider, J. T. Berry and K. Kroenke 
(2008). "Depression and anxiety in the United States: findings from the 2006 Behavioral Risk 
Factor Surveillance System." Psychiatr Serv 59(12): 1383-1390. 
205 
 
Stuber, G. D., T. S. Hnasko, J. P. Britt, R. H. Edwards and A. Bonci (2010). "Dopaminergic 
terminals in the nucleus accumbens but not the dorsal striatum corelease glutamate." J Neurosci 
30(24): 8229-8233. 
Succu, S., F. Sanna, T. Melis, A. Boi, A. Argiolas and M. R. Melis (2007). "Stimulation of 
dopamine receptors in the paraventricular nucleus of the hypothalamus of male rats induces 
penile erection and increases extra-cellular dopamine in the nucleus accumbens: Involvement of 
central oxytocin." Neuropharmacology 52(3): 1034-1043. 
Summer, B. E. and G. Fink (1995). "Estrogen increases the density of 5-hydroxytryptamine(2A) 
receptors in cerebral cortex and nucleus accumbens in the female rat." J Steroid Biochem Mol 
Biol 54(1-2): 15-20. 
Summers, C. H., J. L. Kampshoff, P. J. Ronan, C. A. Lowry, A. A. Prestbo, W. J. Korzan and K. 
J. Renner (2003). "Monoaminergic activity in subregions of raphe nuclei elicited by prior stress 
and the neuropeptide corticotropin-releasing factor." J Neuroendocrinol 15(12): 1122-1133. 
Svensson, T. H., B. S. Bunney and G. K. Aghajanian (1975). "Inhibition of both noradrenergic 
and serotonergic neurons in brain by the alpha-adrenergic agonist clonidine." Brain Res 92(2): 
291-306. 
Szabo, S. T. and P. Blier (2001). "Effect of the selective noradrenergic reuptake inhibitor 
reboxetine on the firing activity of noradrenaline and serotonin neurons." Eur J Neurosci 13(11): 
2077-2087. 
Szabo, S. T. and P. Blier (2001). "Functional and pharmacological characterization of the 
modulatory role of serotonin on the firing activity of locus coeruleus norepinephrine neurons." 
Brain Res 922(1): 9-20. 
Szabo, S. T. and P. Blier (2002). "Effects of serotonin (5-hydroxytryptamine, 5-HT) reuptake 
inhibition plus 5-HT(2A) receptor antagonism on the firing activity of norepinephrine neurons." 
J Pharmacol Exp Ther 302(3): 983-991. 
Takahashi, H., N. Yahata, M. Koeda, A. Takano, K. Asai, T. Suhara and Y. Okubo (2005). 
"Effects of dopaminergic and serotonergic manipulation on emotional processing: a 
pharmacological fMRI study." Neuroimage 27(4): 991-1001. 
Talley, E. M., D. L. Rosin, A. Lee, P. G. Guyenet and K. R. Lynch (1996). "Distribution of alpha 
2A-adrenergic receptor-like immunoreactivity in the rat central nervous system." J Comp Neurol 
372(1): 111-134. 
Tan, H., P. Zhong and Z. Yan (2004). "Corticotropin-releasing factor and acute stress prolongs 
serotonergic regulation of GABA transmission in prefrontal cortical pyramidal neurons." J 
Neurosci 24(21): 5000-5008. 
Tassone, A., G. Madeo, T. Schirinzi, D. Vita, F. Puglisi, G. Ponterio, F. Borsini, A. Pisani and P. 
Bonsi (2011). "Activation of 5-HT6 receptors inhibits corticostriatal glutamatergic 
transmission." Neuropharmacology 61(4): 632-637. 
Tatemoto, K., A. Rokaeus, H. Jornvall, T. J. McDonald and V. Mutt (1983). "Galanin - a novel 
biologically active peptide from porcine intestine." FEBS Lett 164(1): 124-128. 
Tatsumi, M., K. Groshan, R. D. Blakely and E. Richelson (1997). "Pharmacological profile of 
antidepressants and related compounds at human monoamine transporters." Eur J Pharmacol 
340(2-3): 249-258. 
Taylor, A. L., J. M. Goaillard and E. Marder (2009). "How multiple conductances determine 
electrophysiological properties in a multicompartment model." J Neurosci 29(17): 5573-5586. 
Thase, M. E., B. R. Haight, N. Richard, C. B. Rockett, M. Mitton, J. G. Modell, S. VanMeter, A. 
E. Harriett and Y. Wang (2005). "Remission rates following antidepressant therapy with 
206 
 
bupropion or selective serotonin reuptake inhibitors: a meta-analysis of original data from 7 
randomized controlled trials." J Clin Psychiatry 66(8): 974-981. 
Thierry, A. M., M. Fekete and J. Glowinski (1968). "Effects of stress on the metabolism of 
noradrenaline, dopamine and serotonin (5HT) in the central nervous system of the rat. (II). 
Modifications of serotonin metabolism." Eur J Pharmacol 4(4): 384-389. 
Thomas R, d. A. R. (1990). "Biological Feedback." CRC press. 
Thorn, G. W., P. H. Forsham, T. F. Frawley, S. R. Hill, Jr., M. Roche, D. Staehelin and D. L. 
Wilson (1950). "The clinical usefulness of ACTH and cortisone." N Engl J Med 242(22): 865-
872. 
TOCRIS GBR 12909 dihydrochloride. T. a. b. brand. 
Tooney, P. A., G. G. Au and L. A. Chahl (2000). "Localisation of tachykinin NK1 and NK3 
receptors in the human prefrontal and visual cortex." Neurosci Lett 283(3): 185-188. 
Trivedi, M. H., M. Fava, S. R. Wisniewski, M. E. Thase, F. Quitkin, D. Warden, L. Ritz, A. A. 
Nierenberg, B. D. Lebowitz, M. M. Biggs, J. F. Luther, K. Shores-Wilson, A. J. Rush and S. D. 
S. Team (2006). "Medication augmentation after the failure of SSRIs for depression." N Engl J 
Med 354(12): 1243-1252. 
Trulson, M. E. and D. W. Preussler (1984). "Dopamine-containing ventral tegmental area 
neurons in freely moving cats: activity during the sleep-waking cycle and effects of stress." Exp 
Neurol 83(2): 367-377. 
Tsubota, S., N. Adachi, J. Chen, T. Yorozuya, T. Nagaro and T. Arai (1999). "Dexamethasone 
changes brain monoamine metabolism and aggravates ischemic neuronal damage in rats." 
Anesthesiology 90(2): 515-523. 
Tsuda, K., H. Yokoo and M. Goldstein (1989). "Neuropeptide Y and galanin in norepinephrine 
release in hypothalamic slices." Hypertension 14(1): 81-86. 
Turner, E. H., A. M. Matthews, E. Linardatos, R. A. Tell and R. Rosenthal (2008). "Selective 
publication of antidepressant trials and its influence on apparent efficacy." N Engl J Med 358(3): 
252-260. 
Turrigiano, G. (2012). "Homeostatic synaptic plasticity: local and global mechanisms for 
stabilizing neuronal function." Cold Spring Harb Perspect Biol 4(1): a005736. 
Turrigiano, G. G. (1999). "Homeostatic plasticity in neuronal networks: the more things change, 
the more they stay the same." Trends Neurosci 22(5): 221-227. 
Turrigiano, G. G. (2008). "The self-tuning neuron: synaptic scaling of excitatory synapses." Cell 
135(3): 422-435. 
Turrigiano, G. G., K. R. Leslie, N. S. Desai, L. C. Rutherford and S. B. Nelson (1998). "Activity-
dependent scaling of quantal amplitude in neocortical neurons." Nature 391(6670): 892-896. 
Turrigiano, G. G. and S. B. Nelson (2000). "Hebb and homeostasis in neuronal plasticity." Curr 
Opin Neurobiol 10(3): 358-364. 
Unnerstall, J. R., T. A. Kopajtic and M. J. Kuhar (1984). "Distribution of alpha 2 agonist binding 
sites in the rat and human central nervous system: analysis of some functional, anatomic 
correlates of the pharmacologic effects of clonidine and related adrenergic agents." Brain Res 
319(1): 69-101. 
Unno, N., W. X. Wu, X. Y. Ding, C. Li, W. K. Hing and P. W. Nathanielsz (1998). "The effects 
of fetal adrenalectomy at 110 days gestational age on AVP and CRH mRNA expression in the 
hypothalamic paraventricular nucleus of the ovine fetus." Brain Res Dev Brain Res 106(1-2): 
119-128. 
207 
 
Valentino, R. J. and S. L. Foote (1988). "Corticotropin-releasing hormone increases tonic but not 
sensory-evoked activity of noradrenergic locus coeruleus neurons in unanesthetized rats." J 
Neurosci 8(3): 1016-1025. 
Valentino, R. J., S. L. Foote and M. E. Page (1993). "The locus coeruleus as a site for integrating 
corticotropin-releasing factor and noradrenergic mediation of stress responses." Ann N Y Acad 
Sci 697: 173-188. 
Van Bockstaele, E. J. and V. M. Pickel (1995). "GABA-containing neurons in the ventral 
tegmental area project to the nucleus accumbens in rat brain." Brain Res 682(1-2): 215-221. 
Van de Kar, L. D., R. A. Piechowski, P. A. Rittenhouse and T. S. Gray (1991). "Amygdaloid 
lesions: differential effect on conditioned stress and immobilization-induced increases in 
corticosterone and renin secretion." Neuroendocrinology 54(2): 89-95. 
Van Pett, K., V. Viau, J. C. Bittencourt, R. K. Chan, H. Y. Li, C. Arias, G. S. Prins, M. Perrin, 
W. Vale and P. E. Sawchenko (2000). "Distribution of mRNAs encoding CRF receptors in brain 
and pituitary of rat and mouse." J Comp Neurol 428(2): 191-212. 
VanderMaelen, C. P., G. K. Matheson, R. C. Wilderman and L. A. Patterson (1986). "Inhibition 
of serotonergic dorsal raphe neurons by systemic and iontophoretic administration of buspirone, 
a non-benzodiazepine anxiolytic drug." Eur J Pharmacol 129(1-2): 123-130. 
Veith, R. C., J. D. Best and J. B. Halter (1984). "Dose-dependent suppression of norepinephrine 
appearance rate in plasma by clonidine in man." J Clin Endocrinol Metab 59(1): 151-155. 
Vernikos-Danellis, J. (1965). "Effect of Stress, Adrenalectomy, Hypophysectomy and 
Hydrocortisone on the Corticotropin-Releasing Activity of Rat Median Eminence." 
Endocrinology 76: 122-126. 
Viau, V., B. Bingham, J. Davis, P. Lee and M. Wong (2005). "Gender and puberty interact on 
the stress-induced activation of parvocellular neurosecretory neurons and corticotropin-releasing 
hormone messenger ribonucleic acid expression in the rat." Endocrinology 146(1): 137-146. 
Viau, V. and M. J. Meaney (1996). "The inhibitory effect of testosterone on hypothalamic-
pituitary-adrenal responses to stress is mediated by the medial preoptic area." J Neurosci 16(5): 
1866-1876. 
Vincent, M. Y. and L. Jacobson (2014). "Glucocorticoid receptor deletion from the dorsal raphe 
nucleus of mice reduces dysphoria-like behavior and impairs hypothalamic-pituitary-
adrenocortical axis feedback inhibition." Eur J Neurosci 39(10): 1671-1681. 
Vitay, J. and F. H. Hamker (2014). "Timing and expectation of reward: a neuro-computational 
model of the afferents to the ventral tegmental area." Front Neurorobot 8: 4. 
Vollenweider, F. X. and M. Kometer (2010). "The neurobiology of psychedelic drugs: 
implications for the treatment of mood disorders." Nat Rev Neurosci 11(9): 642-651. 
Vollrath, L. and H. A. Welker (1988). "Day-to-day variation in pineal serotonin N-
acetyltransferase activity in stressed and non-stressed male Sprague-Dawley rats." Life Sci 
42(22): 2223-2229. 
Waldmeier, P. C. (1982). "Effects of antidepressant drugs on dopamine uptake and metabolism." 
J Pharm Pharmacol 34(6): 391-394. 
Walf, A. A. and C. A. Frye (2010). "Estradiol reduces anxiety- and depression-like behavior of 
aged female mice." Physiol Behav 99(2): 169-174. 
Wanat, M. J., F. W. Hopf, G. D. Stuber, P. E. Phillips and A. Bonci (2008). "Corticotropin-
releasing factor increases mouse ventral tegmental area dopamine neuron firing through a protein 
kinase C-dependent enhancement of Ih." J Physiol 586(8): 2157-2170. 
208 
 
Wander, T. J., A. Nelson, H. Okazaki and E. Richelson (1986). "Antagonism by antidepressants 
of serotonin S1 and S2 receptors of normal human brain in vitro." Eur J Pharmacol 132(2-3): 
115-121. 
Wang, B., Z. B. You, K. C. Rice and R. A. Wise (2007). "Stress-induced relapse to cocaine 
seeking: roles for the CRF(2) receptor and CRF-binding protein in the ventral tegmental area of 
the rat." Psychopharmacology (Berl) 193(2): 283-294. 
Wang, P., H. Li, S. Barde, M. D. Zhang, J. Sun, T. Wang, P. Zhang, H. Luo, Y. Wang, Y. Yang, 
C. Wang, P. Svenningsson, E. Theodorsson, T. G. Hokfelt and Z. Q. Xu (2016). "Depression-like 
behavior in rat: Involvement of galanin receptor subtype 1 in the ventral periaqueductal gray." 
Proc Natl Acad Sci U S A 113(32): E4726-4735. 
Washburn, M. and H. C. Moises (1989). "Electrophysiological correlates of presynaptic alpha 2-
receptor-mediated inhibition of norepinephrine release at locus coeruleus synapses in dentate 
gyrus." J Neurosci 9(6): 2131-2140. 
Waters, R. P., M. Rivalan, D. A. Bangasser, J. M. Deussing, M. Ising, S. K. Wood, F. Holsboer 
and C. H. Summers (2015). "Evidence for the role of corticotropin-releasing factor in major 
depressive disorder." Neurosci Biobehav Rev. 
Weder, N., H. Zhang, K. Jensen, B. Z. Yang, A. Simen, A. Jackowski, D. Lipschitz, H. Douglas-
Palumberi, M. Ge, F. Perepletchikova, K. O'Loughlin, J. J. Hudziak, J. Gelernter and J. Kaufman 
(2014). "Child abuse, depression, and methylation in genes involved with stress, neural 
plasticity, and brain circuitry." J Am Acad Child Adolesc Psychiatry 53(4): 417-424 e415. 
Weisler, R. H., J. A. Johnston, C. G. Lineberry, B. Samara, R. J. Branconnier and A. A. Billow 
(1994). "Comparison of bupropion and trazodone for the treatment of major depression." J Clin 
Psychopharmacol 14(3): 170-179. 
Weissman, M. M., R. C. Bland, G. J. Canino, C. Faravelli, S. Greenwald, H. G. Hwu, P. R. 
Joyce, E. G. Karam, C. K. Lee, J. Lellouch, J. P. Lepine, S. C. Newman, M. Rubio-Stipec, J. E. 
Wells, P. J. Wickramaratne, H. Wittchen and E. K. Yeh (1996). "Cross-national epidemiology of 
major depression and bipolar disorder." JAMA 276(4): 293-299. 
Wellington, K. and C. M. Perry (2001). "Venlafaxine extended-release: a review of its use in the 
management of major depression." CNS Drugs 15(8): 643-669. 
Werkman, T. R., J. E. Olijslagers, B. Perlstein, A. H. Jansen, A. C. McCreary, C. G. Kruse and 
W. J. Wadman (2004). "Quetiapine increases the firing rate of rat substantia nigra and ventral 
tegmental area dopamine neurons in vitro." Eur J Pharmacol 506(1): 47-53. 
Wieczorek, I., C. Schulz, H. Jarry and H. Lehnert (2001). "The effects of the selective serotonin 
reuptake-inhibitor fluvoxamine on body weight in Zucker rats are mediated by corticotropin-
releasing hormone." Int J Obes Relat Metab Disord 25(10): 1566-1569. 
Wong, M. L., M. A. Kling, P. J. Munson, S. Listwak, J. Licinio, P. Prolo, B. Karp, I. E. 
McCutcheon, T. D. Geracioti, Jr., M. D. DeBellis, K. C. Rice, D. S. Goldstein, J. D. Veldhuis, G. 
P. Chrousos, E. H. Oldfield, S. M. McCann and P. W. Gold (2000). "Pronounced and sustained 
central hypernoradrenergic function in major depression with melancholic features: relation to 
hypercortisolism and corticotropin-releasing hormone." Proc Natl Acad Sci U S A 97(1): 325-
330. 
Wood, S. K., X. Y. Zhang, B. A. Reyes, C. S. Lee, E. J. Van Bockstaele and R. J. Valentino 
(2013). "Cellular adaptations of dorsal raphe serotonin neurons associated with the development 
of active coping in response to social stress." Biol Psychiatry 73(11): 1087-1094. 
209 
 
Wynn, P. C., J. P. Harwood, K. J. Catt and G. Aguilera (1985). "Regulation of corticotropin-
releasing factor (CRF) receptors in the rat pituitary gland: effects of adrenalectomy on CRF 
receptors and corticotroph responses." Endocrinology 116(4): 1653-1659. 
Xia, Y. and J. E. Wikberg (1996). "Localization of ACTH receptor mRNA by in situ 
hybridization in mouse adrenal gland." Cell Tissue Res 286(1): 63-68. 
Xu, T. and S. C. Pandey (2000). "Cellular localization of serotonin(2A) (5HT(2A)) receptors in 
the rat brain." Brain Res Bull 51(6): 499-505. 
Xu, Z. Q., X. Zhang, V. A. Pieribone, S. Grillner and T. Hokfelt (1998). "Galanin-5-
hydroxytryptamine interactions: electrophysiological, immunohistochemical and in situ 
hybridization studies on rat dorsal raphe neurons with a note on galanin R1 and R2 receptors." 
Neuroscience 87(1): 79-94. 
Yamashita, H., M. Kasai and K. Inenaga (1991). "Effects of corticotropin-releasing factor on 
neurons in the hypothalamic paraventricular nucleus in vitro." Brain Res Bull 27(3-4): 321-325. 
Yang, G., J. Koistinaho, S. H. Zhu and A. Hervonen (1989). "Induction of c-fos-like protein in 
the rat adrenal cortex by acute stress--immunocytochemical evidence." Mol Cell Endocrinol 
66(2): 163-170. 
Yang, G. A., J. Koistinaho, M. Iadarola, Z. Shenhua and A. Hervonen (1990). "Administration of 
adrenocorticotropic hormone (ACTH) enhances Fos expression in the rat adrenal cortex." Regul 
Pept 30(1): 21-31. 
Yang, Y. K., T. L. Yeh, W. J. Yao, I. H. Lee, P. S. Chen, N. T. Chiu and R. B. Lu (2008). 
"Greater availability of dopamine transporters in patients with major depression--a dual-isotope 
SPECT study." Psychiatry Res 162(3): 230-235. 
Yau, J. L., J. Noble, C. Hibberd and J. R. Seckl (2001). "Short-term administration of fluoxetine 
and venlafaxine decreases corticosteroid receptor mRNA expression in the rat hippocampus." 
Neurosci Lett 306(3): 161-164. 
Yoshida, M., Y. Takayanagi, K. Inoue, T. Kimura, L. J. Young, T. Onaka and K. Nishimori 
(2009). "Evidence that oxytocin exerts anxiolytic effects via oxytocin receptor expressed in 
serotonergic neurons in mice." J Neurosci 29(7): 2259-2271. 
Yoshitake, T., R. Iizuka, S. Yoshitake, P. Weikop, W. E. Muller, S. O. Ogren and J. Kehr (2004). 
"Hypericum perforatum L (St John's wort) preferentially increases extracellular dopamine levels 
in the rat prefrontal cortex." Br J Pharmacol 142(3): 414-418. 
Yoshitake, T., I. Reenila, S. O. Ogren, T. Hokfelt and J. Kehr (2003). "Galanin attenuates basal 
and antidepressant drug-induced increase of extracellular serotonin and noradrenaline levels in 
the rat hippocampus." Neurosci Lett 339(3): 239-242. 
Young, E. A., S. G. Kornstein, S. M. Marcus, A. T. Harvey, D. Warden, S. R. Wisniewski, G. K. 
Balasubramani, M. Fava, M. H. Trivedi and A. John Rush (2009). "Sex differences in response 
to citalopram: a STAR*D report." J Psychiatr Res 43(5): 503-511. 
Zhang, D., S. Yang, G. Z. Jin, B. S. Bunney and W. X. Shi (2008). "Oscillatory firing of 
dopamine neurons: differences between cells in the substantia nigra and ventral tegmental area." 
Synapse 62(3): 169-175. 
Zimmermann, E. and V. Critchlow (1967). "Effects of diurnal variation in plasma corticosterone 
levels on adrenocortical response to stress." Proc Soc Exp Biol Med 125(2): 658-663. 
Zisook, S., A. J. Rush, B. R. Haight, D. C. Clines and C. B. Rockett (2006). "Use of bupropion in 
combination with serotonin reuptake inhibitors." Biol Psychiatry 59(3): 203-210. 
210 
 
Zocchi, A., D. Fabbri and C. A. Heidbreder (2005). "Aripiprazole increases dopamine but not 
noradrenaline and serotonin levels in the mouse prefrontal cortex." Neurosci Lett 387(3): 157-
161. 
 
